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391 Foreword 
Health research with  developing  countries  has  been part of the European Commission's research 
agenda under its  regular research budget for  almost  15  years. 
It is  currently  part  of  the  specific  RTD  Programme  in  the  field  of  Cooperation  with  Third 
Countries  and  International  Organizations  (INCO):  activity  II  of the  Framework  Programme  IV 
(1994-1998)  (see  annex). 
The  selection  of  research  areas  is  based  on  existing  and  newly  identified  health  needs  in 
developing  countries  and  on the  capacity to  cope  with  these  needs  through research. 
This  document  presents  the  "parasitology"  component  of  the  health  sector  under  the  !NCO-
developing countries programme (INCO-DC)  and its  predecessor STD-3  (1991-1994). It combines 
summaries  of completed  contracts  for  STD3  and  a  catalogue  of ongoing  and  new  contracts  of 
STD3  and INCO-DC,  1st and 2nd call. Other health research areas including work on the tools for 
prevention  and  control  of  viral,  bacterial  and  non-communicable  diseases  and  health  systems 
research are  presented in other volumes. 
The parasitic diseases remain  a major health problem in many  developing  countries.  While there 
have  been  notable  successes  in  the  fight  against  parasitic  diseases  in  recent  times,  for  example 
Chagas'  disease  vector  control  in Latin America  and  Onchocerciasis  control  in  West  Africa,  the 
general  situation  has  not  improved  and  in  some  cases  has  deteriorated.  Science  has  offered  the 
technical ability to  have  a major input to  a wider variety of health needs  in developing countries 
and  the  parasitology  research  reported  here  has  focused  on  attempts  to  better  understand  the 
biology of disease  and  to  provide the  tools  for  successful interventions including vaccines,  drugs 
and  diagnostic  products. 
Through  the  STD  and  INCO-DC  programmes  particular  emphasis  is  given  to  the  process  of 
partnership-building  in  science.  Capacity  and  capability  development  for  all  teams  involved  (in 
developing  countries  as  well  as  in  the  EU)  is  the  key  to  this  process. 
Scientific  cooperation  being  an  integral  part  of the  EU  research  policy  is  therefore  an  essential 
instrument in  support of the development policy  of the  EU. 
The  specific  objectives  and  the  operational  modalities  are  dealt  with  in  annex  1  and  in  the 
information packages  which  are  produced to  accompany  each  'call for  proposals'. 
Address: 
European Commission 
Health research with Developing  Countries 
DG  XII/B-4 Rue  de  Ia  Loi,  200 
1049  Brussels 
Belgium 
Tel:  +32.2.295.91.72 
Fax:  +32.2.296.62.52 
E-mail:  marc.de-bruycker@dg12.cec.be 
R.  Gerold 
Director 8 
The INCO-DC Workprogramme: 
Field of Parasitology: part of health related research 
Research on the tools for prevention and the fight against the predominant 
diseases 
Vaccines 
Vaccines  are  cost-effective tools for disease control.  Research  on  vaccines  in 
the programme should be concentrated on  selection, evaluation and delivery of 
antigens,  with  the  objective  of  designing  vaccines  applicable  for  DC's.  For 
vaccines against diseases with a significant impact in  Europe,  emphasis will  be 
on  aspects  specific  to  DC's.  With  regard  to  the  evaluation  of  antigens, 
emphasis will  be  put on  immunological  mechanisms underlying experimentally 
induced  protection.  Research  on  the  non-targeted effects of vaccines will  also 
be  taken  into consideration. 
Drugs 
Emphasis will be put on targeted drug design and targeted drug delivery, based 
on  the  fundamental  understanding of biological  functions  of  pathogens and  of 
disease  mechanisms.  Research  on  drugs,  including  bioactive  natural  com-
pounds  is  eligible  when  focused  on  drugs  for  predominant  diseases  in  DC's 
when  non-toxic efficient treatments are  unavailable. 
Diagnostic products 
This research  should make an  initial distinction between  1) the development of 
diagnostic products as research tools, or 2) the development of diagnostic tools 
for  routine  health  care.  Application  of  high  technology  approaches  to  design 
robust  and  simple  diagnostic  tools  for  routine  health  care  will  be  given  due 
attention.  The  relevance  for  practical  case  management  of  the  read-out  of 
routine  diagnostic tools  should  be  adequately addressed. 
For  each  project  concerning  the  design  and  the  development  of  vaccines, 
drugs  and/or  diagnostics  products,  the  feasibility  of  introducing  affordable 
products  envisaged  should  be  pre-evaluated. 
Research on the biology of the diseases 
Biology 
The  understanding of the  processes  and  biological  interactions  is  a source  of 
new  techniques  and  tools  for  the  control  of  disease.  Research  on  genome 
structure  and  regulation  of  gene  expression  is  eligible  if  it  supports  the 
investigation of defined biological mechanisms aiming at the control of disease causing  pathogens.  Metabolic  pathways  that  differ  between  the  human  host 
and  the  pathogen  may  be  addressed  as  a  source  for  targeted  interventions. 
Immunological  studies  should  concentrate  on  the  biological  function  of  anti-
genic  molecules  and  the  mechanisms  leading  to  protection  against  disease. 
Studies  on  the  genetics  of  vectors  are  supported  as  tools  that  allow  under-
standing of the physiological processes of the vectors,  and vectorial interaction 
with  the  pathogenic  agent  and  the  host.  Studies  of  intervention  based  on 
vectorial  biology are eligible provided that monitoring is envisaged on  a longer 
term  and  on  a sustainable  basis. 
Pre-clinical models 
A model  may be  used for different purposes. Where a model  is  proposed as  a 
screen  in  a  development  process,  the  relevance  of  the  particular  model  for 
human  disease  has  to  be  established.  In  vitro  and  in  vivo  models  for  human 
disease  will  be  the  subject  of  studies  aimed  at  refinement,  replacement  and 
reduction  of animal  experimentation. 
9 STD-3 (1991-1994) 
Under  the  3rd  Framework  Programme,  the  predecessor  of  the  INCO-DC  pro-
gramme,  the  STD-3  programme  (Life  Sciences  and  Technologies  for  Developing 
Countries:  1991-1994,  area  Health),  resulted  in  140  health  related  STD-3  con-
tracts. Of these 69 were on  Parasitology.  283 scientific teams from  185 institutes, 
involving  50  countries  received  European  Commission  support  for  this  specific 
subtopic  totaling  19.8  Million  ECU.  This  represented  about  51.3°/o  of  the  total 
health  research  related  budget of this  EC  RTD  programme  (Figure). 
INCO-DC (1994-1998) 
Under the  4th  Framework  Programme,  the  INCO-DC  programme  (sector  health) 
has,  as  a  result  of the  first  and  second  call  in  1995  and  in  1996,  selected  48 
projects  related  to  Parasitology involving  52  countries.  A  budget  of  19.18  Million 
ECU  (so far 46.7°/o  of the contribution to the health sector of INCO-DC)  has been 
in  support of 177 teams from  153 institutes dealing with this component of health 
research  (Figure). 
The evaluation process related to the 3rd Call for Proposals of 1997 has selected 
another group of 20  Parasitology projects with an  estimated budget of 8.68 Million 
ECU,  to  be  operational  in  1998. 
Trends 
From  STD-3 to  INCO-DC,  more  high  quality proposals  have been  selected.  New 
equitable  partnerships  have  been  initiated  and  ongoing  collaboration  has  been 
reinforced. The increased awareness of the worsening malaria situation has led to 
the demand for increased efforts to deal with the problem. The challenge has been 
taken up by the scientific community and the INCO-DC Programme has responded 
to this  by allocating  increased  levels  of support to  malaria  projects,  at the  same 
time  maintaining  its  investment in  other areas of  health  research. 
10 PARASITOLOGY RESEARCH
COUNTRIES,  TEAMS, BUDGBT
STD 3 INCO-Irc (bt & 2nd call)
60
tt
6)
€so
En
fr f
=30 o
I
bzo
L
Q' E El0 a z
0
300
v,
tr
E zso
; 52W ta
.fi r5o
t-
:  loo
.t
550 z
0
20
l8
l6
l4
=12 Hro
6
4
2
COI.INTRIES  INVOLVED
IMediterrarcan
BSub-saharan  Africa
trIatin America
IASIA
IEU
BUDGET
11Presentatioa of EC supported joint research projects (1991-1996) 
STD3/INCO-DC: 1st and 2nd Call •  • ~;·  - :.  .':  •  .  • "  v.  - . .  •  '  ~  ~  ~·  • :  :  :  .  :  .  .;.  •• :· 
•·· .. ··•·  /'.to,,;~of.~~.~JC>k'lt~~·(f9$~~~}( 
.  ·J·NI"\A  .. n~  ·'1:~ ...:•:.:.t.~A·,r,.~  ....  ·  ~  · 
....  ,  =··  :·:,·;:·::\·.  ·:  ~:(.'  -~·  rAI'"·(•'tu·vm~;  ..  =. 
Areas of interest: 
1.  Malaria 
Vector 
TS3*CT910032 
TS3*CT920  101 
TS3*CT920044 
TS3*CT920139 
TS3*CT930236 
IC18*CT960030 
IC18CT970211 
IC1BCT970244 
Genome 
TS3*CT920103 
IC18*CT960052 
IC18*CT960066 
IC18*CT960071 
IC18CT970217 
Behavioral studies of Anopheles gambiae and Culex 
quinquefasciatus for the development of odour-baited traps, I. 
Behavioral studies of Anopheles gambiae and Culex 
quinquefasciatus for the development of odor-baited traps, II. 
Identification of a promoter specifically transcribed in the gut 
cells of Anopheles mosquitoes for the expression of 
antiparasitic agents, I. 
Identification of a promoter, specifically transcribed in the gut 
cells of Anopheles mosquitoes for the expression of 
antiparasitic agents, II. 
Network for field research on afrotropical malaria vectors. 
Studies on mosquito vectors in West Africa, aimed at malaria 
epidemiology and control. 
Identification and characterisation of malaria vectors in South 
East Asia: a prerequisite for appropriate vector control. 
Development and field applications of molecular probes for 
the study of afrotropical malaria vectors. 
Plasmodium genome - structure and dynamics. 
Regulation of development in malaria parasites. 
Analysis of var genes from  P.  vivax and P.  falciparum. 
Plasmodial chromatin: structure and function. 
Molecular mechanisms of Plasmodium falciparum sexual 
development: an integrated approach. 
Vaccines and Immunology 
TS3*CT920053 
(see also 940346) 
Malaria pre-erythrocytic stages (MPES) European network 
antigens target of immune responses capable of inhibiting P. 
falciparum pre-erythrocytic development. 
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TS3*CT920068  Malaria asexual blood stage European network (MAS), II.  56 
TS3*CT920116  Regulation of sexual development in malaria parasites and  'i! 
the design of logical intervention strategies.  58 
l: 
TS3*CT920138  Malaria asexual blood stage European network (MAS), I.  62 
TS3*CT920147  Malaria asexual blood stage European network (MAS), Ill.  64 
TS3*CT930228  Natural and artificially induced immunity against Plasmodium 
liver stages.  68 
TS3*CT930229  Regulation of sexual development in malarial parasites and 
the design of logical intervention strategies.  70 
TS3*CT940272  Studies on humoral and cellular immune responses in 
humans to previously defined malaria vaccine candidates.  74 
TS3*CT940317  Identification of malaria vaccine candidates by passive 
transfer in infected individuals of antibodies with defined 
specificities.  78 
TS3*CT940345  Assessment of immune responses induced in primates 
immunized with lipopeptides derived from  P.  falciparum 
MPES antigens.  82 
TS3*CT940346  Malaria pre-erythrocytic stages (MPES) European network 
(see also 920053)  antigens target of immune responses capable of inhibiting P. 
falciparum pre-erythrocytic development.  84 
IC1B*CT950015  The African Malaria Vaccine Testing Network.  90 
IC18*CT950016  Selection of P.  falciparum genes for MPES vaccine 
development.  92 
IC18*CT950019  Evaluation and delivery of Thrombospondin Related 
Anonymous Protein (TRAP) immunogens for the 
development of malaria vaccine.  94 
IC18*CT950020  A concerted European approach towards the development of 
malaria vaccines.  96 
IC1B*CT950021  Pre-clinical study of the immunogenicity of MSP3 and GLURP 
TWO P.  falciparum antigens targeted by protective antibodies.  100 
IC18*CT950022  The application of transfection technology to malaria vaccine 
development.  102 
IC18*CT960125  Concerted action in support of high quality Non-Human 
Primate (NHP} breeding and biomedical research in  NHP 
source countries.  104 
IC18CT970238  Immunity to genetically characterised malaria infections. A 
comparison between longitudinal studies in a West and an 
East African village experiencing different intensities of 
transmission.  106 
IC1BCT970242  Mathematical models of the immunological and clinical 
epidemiology of Plasmodium falciparum malaria.  108 
16 Transmission 
TS3*CT920045  Plasmodium vivax malaria in man: anti-disease and 
transmission blocking immunity.  112 
TS3*CT920063  The biological and epidemiological significance of 
transmission blocking immunity and transmission reducing 
factors in endemic falciparum malaria. Human factors that 
influence infection of mosquitoes.  114 
IC1B*CT950018  The development and potential of midgut antigens as 
vaccine agents for novel mosquito and malaria control.  118 
Drugs 
TS3*CT920084  The development of a pharmacological model for anti-
malarials which inter1ere with phospholipid metabolism.  120 
TS3*CT920145  Identification of Plasmodium falciparum proteases and their 
implications for the membrane organization the infected red 
cell. Design of high affinity receptors.  124 
TS3*CT930224  Epidemiology of drug resistance in  Plasmodium falciparum.  128 
TS3*CT940297  DNA polymerases of malaria parasites: targets of choice, both 
for treatment of the disease and for control of the infection.  130 
IC1B*CT960056  Phospholipid metabolism, a novel target for antimalarial 
drugs: development of the pharmacological model.  134 
IC1B*CT960074  Development of novel drugs against malaria.  138 
IC1BCT970223  Development of inhibitors of malarial and trypanosoma! 
dihydrofolate reductase as antiparasitic agents through 
combinatorial chemistry.  140 
IC1BCT970227  Detection of Plasmodium falciparum resistant to antifolate 
and sulphonamide drugs, and assessment of the efficacy of 
drug treatment using molecular methods.  142 
Intervention 
TS3*CT920070  Community based malaria control under the guidance of 
health services: intervention study in Ecuador and Colombia.  144 
TS3*CT920083  The consequences of malarial infection in pregnant women 
and their infants.  146 
TS3*CT930225  Epidemiology and control of malaria in the province of 
Ratchaburi, Thailand.  148 
TS3*CT930251  Three years controlled trial of lambda-cyhalothrin 
impregnated bed nets and maloprim/placebo 
chemosuppression in control of malaria in children living in a 
holoendemic area of Sierra Leone.  150 
IC18CT970210  Delayed child mortality and insecticide-impregnated 
materials: theoretic fantasy or harsh reality?  152 
17 Contract number TS3*CT91 0032 
BEHAVIORAL  STUDIES  OF  ANOPHELES GAMBIAE AND  CULEX QUINQUEFASCIA-
TUS  FOR  THE  DEVELOPMENT OF ODOUR-BAITED TRAPS,  1 
Period: 
Co-ordinator: 
Objectives 
April  1,  1992- March 31,  1995 
WAGENINGEN AGRICULTURAL UNIVERSITY, 
DEPARTMENT OF ENTOMOLOGY, 
Wageningen, The Netherlands (W. TAKKEN) 
•  To  study the  principal  cues that mosquitoes  use  to  identify a human  host. 
•  To  analyze  how these  cues  guide  mosquitoes to  the  host. 
•  To  determine the  effects of  insecticides on  host seeking  behaviour. 
Activities 
The  target  insect will  be  An.  gambiae but work on  other malaria  mosquitoes and  on  Cx. 
quinquefasciatus will  be  included. 
Host seeking in experimental huts 
The  rate  of  entry  and  exit  and  movements  of  mosquitoes  into  the  huts  is  monitored  by 
video,  electric  nets  and/or  infra-red  sensors.  The  temperature,  humidity  and  air currants 
are  recorded  at  various  points  within  the  hut  on  a  data  logger.  These  data  are  then 
correlated  with  the  movement patterns  of the  mosquitoes to  elucidate  the  mechanism  of 
host  location.  For  these  experiments  two  pairs  of  field  assistants  are  chosen  so  that  in 
each  case  one  man  is  relatively  attractive  and  the  other  unattractive,  as  determined  by 
previous  landing  catches.  Only the  legs  of the  men  are  exposed,  so  that the  approach, 
landing  and  biting  behaviour of the  mosquitoes  can  be  recorded  on  video.  The  men  will 
otherwise  be  protected  by  bed  nets  and  offered  anti-malaria  prophylaxis  under  medical 
supervision. 
Landing catch 
To  determine  how  accurately  landing-catchers  reflect  the  true  biting  behaviour  and· host 
preference of undisturbed mosquitoes, the  men  will  conduct a routine  landing-catch in  the 
experimental  hut,  instead  of  allowing the  mosquitoes to feed  freely. 
18 Contract number TS3*CT91 0032 
Attractiveness of human odours 
The  two field  assistants will  sleep  outdoors  in  tents and  their odours will  be  pumped  into 
the experimental huts with  fans and  plastic lay-flat tubing. The odour will  be  released from 
the  end  of the tubing where the  assistants would  normally lie,  at  an  airflow rate  similar to 
that created by convection currents. An  electric net will  be  placed over the opening  of the 
tube  to  collect  mosquitoes as  they arrive  at the odour source. 
Identification of attractive odours 
Skin  emanations  and  expired  air  will  be  trapped  on  solid  adsorbents.  Successive 
fractionation should make  it  possible to start identifying components  in  the active fractions 
by standard spectroscopic techniques.  In parallel with this, the possibilities for electrophysi-
ological  recording from antennae of  An.  gambiae will  be  investigated, using both  EAG  and 
single cell technique. The behavioral effect (activation,  orientation and  landing) of the most 
promising  candidate  odours  and  combinations  of  odours  will  be  analyzed  first  in  the 
laboratory windtunnel  and  then  in  the  field. 
Several types of traps,  baited with candidate host odours will be tested in the experimental 
huts.  Paired  studies  using  human-landing  catches,  light-trap ·catches  and  odour-baited 
traps will  be  made,  in  order to  assess the  relative  attractiveness of odour baits compared 
to  the  other sampling  methods. 
Insecticides  currently  in  use  for  the  treatment  of  bed-nets  or  as  residual  on  indoor 
resting  sites  of  mosquitoes,  will  be  tested  for  their  effect  on  house  entry  and  host-
seeking  behaviour  of  An.  gambiae and  Cx.  quinquefasciatus.  As  soon  as  the  behaviour 
in  the  laboratory  is  known,  this  work  will  be  repeated  in  experiments  with  huts  in  the 
field. 
Results 
Host seeking in  experimental huts 
Field studies with the odour-baited entry trap (OBET) continued  in  1994 and  1995, both  in 
Burkina  Faso  and  in  Tanzania.  Also,  experiments  were  done  in  tent-traps.  In  both  study 
areas it was found that An. gambiae s.s. expresses differences in  attractiveness for human 
hosts,  based  on  odours only.  These  differences are consistent in  time  and  are  expressed 
both  at  the  individual  level  and  within  a  group.  A  study  to  reveal  the  nature  of  these 
differences  suggested  that  these  are  primarily  due  to  the  concentration  of  C02  in  the 
exhaled  breath. 
19 Contract number TS3*CT91 0032 
A dose  response  relationship  for  the  attraction  to  C02  was  found  for  several  mosquito 
species,  being  clearest for Mansonia uniformis and  An.  gambiae s.l.,  through  in  the  latter 
species  this  relationship  did  not  hold  beyond  the  natural  emission  rate  of  C02 .  Further-
more,  the  Burkina  Faso  studies showed  that about 30°/o  of the  attraction  of An.  gambiae 
to  humans was caused by C02  and the  remaining attraction was caused by body odours. 
A similar study in Tanzania found that only Bo/o  of the attraction to humans was caused by 
C02  which  was  not  increased  by  higher levels  of C02  output.  Both  studies  showed  that 
breath  odours  (other than  C02)  did  not contain  important attractants for An.  gambiae s.l. 
and  that  human  body  odours  must  account for  the  high  degree  of  anthropophily  in  this 
species.  A newly developed  odour-baited  electric-grid trap,  designed  to  intercept mosqui-
toes  flying  outdoors,  proved  successful  in  collecting  several  mosquito  species,  including 
An.  gambiae and  Culex quinquefasciatus. 
Identification of attractive odours 
Previously we  reported  that An.  gambiae s.s.  was  attracted to  the  odours of  human  feet, 
and  that  these  could  be  (partially)  removed  by  washing  with  bactericidal  soap.  Further 
studies  on  the  identification  of  attractive  odours  demonstrated  that  An.  gambiae  s.s.  is 
attracted to the emanations of Limburger cheese.  These  resemble  human  foot odour,  and 
caused a strong attraction both  derived from  natural cheese as well  as after extractions in 
acid. Chemical analysis showed that the active fractions consisted mostly of low-chain fatty 
acids. The acid fraction and a synthetic mixture of fatty acids, based on the composition of 
natural  fatty  acids  in  cheese,  based  on  the  composition  of  natural  fatty  acids  in  cheese, 
were  attractive  at  very  low  concentrations.  The  original  extract  was  repellent.  Electro-
antennogramme  recordings  with  fatty  acids  showed  a  high  activity for  individual  compo-
nents  which  was  dose-related.  Chemical  analysis  of  human  sweat,  obtained  from  volun-
teers in  Burkina Faso and Tanzania,  showed that human sweat contains similar fatty acids 
as  found  in  cheese  emanations.  A preliminary  field  study  with  the  fatty  acid  mixture  in 
Tanzania  did  not  confirm  the  laboratory  results,  but  this  may  have  been  caused  by 
inadequate  release  methodology of the  fatty  acids. 
Effect of insecticides on  host seeking behaviour 
These  studies  have  not  been  undertaken  due  to  lack  of  time  and  facilities,  given  the 
priorities set within  the  total  study. 
20 Contract number TS3*CT91 0032 
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BEHAVIORAL  STUDIES  OF ANOPHELES GAMBIAE AND  CULEX QUINQUEFASCIA-
TUS  FOR  THE  DEVELOPMENT OF ODOR-BAITED TRAPS, 2 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1992 - June 30,  1996 
UNIVERSITA 01  ROMA "LA SAPIENZA", INST.  01 
PARASSITOLOGIA, Roma,  Italy (M.  COLUZZI) 
•  To  study the  principal  cues  that mosquitoes  use  to  identify a human  host. 
•  To  analyze  how these  cues  guide  mosquitoes to the  host. 
•  To  determine the  effects  of  insecticides on  host seeking  behavior. 
Activities 
This project is complementary to the project under contract number ST3CT91 0032 and the 
two  projects are  fully integrated. 
The testing of host-seeking behavior will be  done both  on  single mosquitoes as well as on 
groups  of  mosquitoes  subjected  to  alternative stimuli  in  the  windtunnel.  This  should  also 
include the  study of the  effect of mechanical  barriers  in  the  approach  to  the  stimuli  in  an 
attempt to  determine behavioral  differences related  to  endophily.  Marking with  fluorescent 
powder will  be  utilized when  comparing different strains or carriers of different karyotypes 
by  mass  released  in  the  windtunnel. 
It  is  expected  that  strain  differences  are  experimentally  established  and  they  will  be 
crossed  and  backcrossed  for  the  genetic  analysis  of  the  specific  responses  and  these 
analyses can  eventually proceed  up  to  gene mapping,  depending on  the  results.  The  link 
with  ISTPAR on  genome mapping of Anopheles gambiae is  expected to  contribute to  this 
aspect of the  work. 
Depending on the outcome of these experiments these strains will  also be used  in  genetic 
analysis of the  selected behavioral differences. The candidate  material  is  from  Anopheles 
arabiensis  populations  showing  obvious  differences  in  the  field  for  both  the  degree  of 
anthropophily  and  endophily.  Other candidate  strains  already  available  are  various  alter-
native  chromosomal  variants  obtained  from  polymorphic  populations  of  Anopheles gam-
biae such  as  the  alternative  homokaryotypes 2L+  and  2La-. 
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Results 
Field  studies  were  conducted  in  Burkina  Faso.  In  a  two-choice  experiment,  using 
odor-baited  entry  traps  (OBETs),  placed  side  by  side  outside  a  rural  village,  where 
populations  of  An.  gambiae  5.1.  are  abundant  during  the  rainy  season,  traps  baited  with 
human odor or odors from  a calf,  have shown consistent differences in  catch composition. 
For the  human  trap the  ratios were  52°/o  An.  arabien5i5 to  48°/o  An.  gambiae s.s.,  for the 
calf-trap the ratios were 92°/o An. arabien5i5 to 8°/o  An. gambiae 5.5  ..  These results confirm 
the very high degree of anthropophily of both An.  arabien5i5 and An. gambiae 5.5.  in West 
Africa,  and  show  that  odors  other  than  C02  contribute  to  the  determination  of  that 
preference. They also confirm our previous field observations on odor-mediated differences 
in  behaviour between these two species.  In  a related field  study in  Tanzania  it  was found 
that during the  rainy  season  An.  arabien5i5 was  also  highly attracted to  human  odour,  to 
the same degree as An.  gambiae 5.5 ..  In  the  latter study it was also found,  as  in  Burkina 
Faso,  that other odours than C02  contribute to the attraction to  human hosts.  However,  in 
Tanzania  the  role  of C02  was  of  less  importance  than  in  Burkina  Faso.  The  differences 
found  underline  the  heterogenetic variance  in  host-seeking  behaviour within  members  of 
the  An.  gambiae  complex,  which  may  be  related  to  host  availability  and  geographical 
separation. 
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IDENTIFICATION OF A PROMOTER SPECIFICALLY TRANSCRIBED IN THE GUT CELLS 
OF ANOPHELES MOSQUITOES FOR THE EXPRESSION OF ANTIPARASITIC AGENTS, I 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1992 - September 30,  1995 
UNIVERSITA Dl  ROMA "LA SAPIENZA", 
INST.  Dl  PARASSITOLOGIA 
Roma, Italy (A.  GRISANTI) 
We  propose  to  perform  a  series  of  experiments  aimed  at  the  identification  of  mosquito 
promoter/enhancer sequences specific for the cells of the intestinal  lineage of Anopheles. 
The  candidate  genes  for  conferring  a  non-vectorial  phenotype  (anti-gamete/ookinete 
specific  immunoglobulin),  against  malaria  (both  human  and  mouse)  will  be  targeted  for 
expression  in  mosquito intestinal cells  by  means of a  DNA vector containing the  specific 
promoter sequence.  The  experimental  objectives include: 
•  identification of  mosquito genes that are  specifically transcribed  in  the gut cells; 
•  identification  of the  upstream· regulatory  DNA sequences  that  drive  gut  specific  tran-
scription; 
•  transfection of mosquito cell lines with DNA constructs containing a reporter gene under 
the  control  of the selected promoter sequences; 
•  development of a suitable in  vitro and a laboratory scale assay to determine the tissue 
specificity of the  selected  promoter; 
•  cloning of the coding sequences for the binding region of Plasmodium gamete/ookinete 
antibodies.  The  gut  specific  promoter  will  be  used  to  develop  transgenic  and  trans-
planted  mosquitoes  secreting  in  the  midgut  transmission  blocking  antibodies.  The 
transmission  blocking  activity of the  antibody produced  in  the  mosquito  midgut will  be 
assayed  in  the  human  P.  falciparum and  in  the  mouse  P.  berghei models. 
Activities 
Identification of a promoter sequence specifically transcribed in Anopheles gambiae: gut cells 
The genes specifically expressed in the gut cell of the Anopheles will be isolated from a A.gt 11 
eDNA expression library with the help of an antiserum raised against the secretory protein of 
the gut. The 5' non transcribed promoter region will be isolated from a genomic library using 
specific eDNA clones. Also the coding sequences of the Aedes trypsin gene will be used to 
screen the Anopheles genomic library to search for the corresponding promoter. The transcrip-
tion start site will be identified by primer extension and 81- mapping and the promoter region 
will be subcloned. The promoter will be functionally defined by deletion mapping and in vivo 
assay. In addition the putative regulatory transcription sequences will be tested for interaction, 
in gel shift electrophoresis, with protein from An. gambiae nuclear extract. 
Cloning of the heavy (H)  and light (L) chains of gametocyte monoclonal antibody 
with blocking activity 
Mouse hybridomas screening antibodies that both react with gamete/ookinete antigens and 
have transmission blocking activity will be collected from several laboratories. It is our intention 
to use antibodies against both P.  falciparum and P.  berghei antigens. The variable domains of 
the heavy and light chains will be amplified from eDNA generated from the secreting cells. 
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The  coding  sequences  of  the  variable  regions  H  and  L  will  be  cloned  in  a  eucaryotic 
expression  vector  within  the  invariant  regions  of  the  y  and  K  chain  respectively  and 
expressed in  NSO cells,  (Orlandi et al  1989). As control the transmission blocking function 
of the  recombination antibody will  be tested in  the supernatant of transformed NSO cells. 
In vivo activity of the putative An.  gambiae gut specific promoter 
The upstream sequences of the gut specific transcribed gene will  be tested on  mosquito-
derived  cell  lines  for  the  ability  to  induce  specific  transcription  and  expression.  Both  a 
reporter  gene  (luciferase)  and  the  cloned  gamete/ookinete  antibody  sequence  will  be 
cloned in a vector, containing long genomic eDNA sequences of An. gambiae, downstream 
of the putative promoter. 
Expected outcome 
If the product of the transgene is  able to  interfere with  virus and parasite  replication,  the 
resulting mosquitoes should display a non-permissive phenotype for disease transmission. 
The  identification  of  a  gut promoter would  be  particularly  relevant  for the  generation  of 
transgenic mosquitoes to be used in  the genetic control of the wild type trains.  In  fact,  to 
be successful the product of the transgene should not impair the environmental fitness, the 
fertility  and  the  behavior  of  the  mosquitoes.  This  would  be  better  achieved  if  the 
expression of the transgene is  restricted,  by a  specific promoter,  to the organ  (gut)  were 
most parasites and viruses undergo replication. 
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IDENTIFICATION  OF  A  PROMOTER,  SPECIFICALLY  TRANSCRIBED  IN  THE  GUT 
CELLS OF  ANOPHELES  MOSQUITOES  FOR  THE  EXPRESSION  OF ANTIPARASITIC 
AGENTS,  II 
Period:  January 1,  1993- December 31,  1995 
Co-ordinator:  UNIVERSITA Dl  ROMA "LA SAPIENZA", 
INST.  Dl  PARASSITOLOGIA,  Roma,  Italy (A. GRISANTI) 
Objectives 
•  To determine the exact place and time of expression of genes that are expressed in the 
gut  of  the  mosquito  Anopheles  gambiae,  using  the  heterologous  in  vivo  system  of 
Drosophila melanogaster. 
•  To  map  on  the genome of Anopheles gambiae a set of molecular landmarks consisting 
of  anonymous cDNAs to  sequence  expressed  in  the  gut  of  this  mosquitoes. 
Activities 
This  project  is  complementary  to  the  project  under contract  number TS3*CT91 0044  and 
the  two  projects are  fully  integrated. 
The  study  of  Drosophila  genetics  during  the  last  decade  has  led  to  development  of 
several techniques that are of the  utmost importance in  the  study of this organism. These 
techniques  include  both  the  stable  germline  transformation  (using  P-element  and  hobo 
based  vectors)  as  well  as  analysis  of  the  transit  expression  in  somatic  tissues,  that  is 
investigated  after  the  injection  of  specific  constructs  into  early  embryos.  In  addition, 
several  more  experimental  procedures  are  now  available,  that  allow  the  study  the 
expression  of specific genes throughout the different developmental  stages of the fruit fly. 
Thus,  in  situ  hybridization  and  immunochemical  stains  make  the  visualisation  of  gene 
products  (mANA  and  protein)  feasible  in  both  whole  mount~ and  sections  through  the 
animals. 
As  the  above  mentioned  methods  are  not  yet  available  for  mosquitoes  (in  particular 
germline  transformation)  the  temporal  and  spatial  pattern  of  expression  of  sequences 
that  are  presumed  to  be  active  in  the  digestive  tract  of  An.  gambiae  will  be  studied 
using  the  available  techniques  in  Drosophila.  Once  these  genes  have  been  isolated 
and  their  putative  "control"  regions  have  been  identified  through  "classical"  molecular 
analysis,  their  pattern  of  expression  will  be  investigated  in  Drosophila.  The  idea  is  to 
dissect the  cis-control  tract,  so  that  potentially  useful  elements  can  be  identified  for  the 
future  construction  of  chimeric  plasmids  to  be  expressed,  in  the  midgut  of  the 
mosquito. 
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The  rationale  for  the  cross-species  experiments  that  are  proposed  is  the  fact  that  it  has 
been  previously  shown  that  control  regions  of  specific  genes  can  be  recognised  by  the 
regulatory  proteins  of  animals  that  are  separated  even  by  several  hundred  millions  of 
years of evolution.  Here 5'-non-transcribed sequences of the mosquito genes will  be fused 
to  appropriate marker genes  (e.g.  the  lacZ gene from  E.  coli)  and  the  expression  pattern 
will  be  established  in  Drosophila  after  germ  line  transformation,  using  P-element  based 
vectors.  Similarly,  the same  or analogous constructs will  be  used for transient expression 
experiments.  By  using  chimeric  plasmids  encompassing  different  upstream  segments  of 
genes  to  be  analyzed  the  necessary  and  sufficient  cis-controlling  sequences  will  be 
determined. For this,  in both of these lines of investigation, serial sections as well as whole 
mounts  of  Drosophila  will  be  examined  throughout  the  course  of  development  of  the 
animal. 
Identification of Anopheles genes expressed in the gut upon blood feeding 
Serine proteases are among the enzymes which  play a crucial  role  during the digestion of 
the  blood  meal  in  the  gut  of  mosquitoes.  Experimental  evidence  indicates  that  trypsin 
activity  can  be  recovered  in  the  gut  of  Anopheles  mosquitoes  a  few  hours  after  blood 
feeding.  We  thought  that  the  analysis  of  the  genomic  organization  of  the  trypsin  genes 
may  lead  to  the  isolation  of  a  gut-specific,  inducible  promoter  for  the  expression  of 
anti-parasitic agents  in  transgenic  mosquitoes. 
According  to  the  objectives  of  the  proposal,  we  have  performed  a series  of  experiments 
aimed  at  identifying  Anopheles  gambiae  trypsin  genes  and  at  studying  their  genomic 
organization. 
eDNA cloning and sequence analysis 
The  PCR  product  obtained  with  the  primers  deduced  from  conserved  trypsin  se-
quences  was  used  as  probe  to  search  for  full  length  eDNA  clones  in  a  i\gt11 
expression  library  developed  using  eDNA  generated  from  mANA  of  blood  fed  A. 
gambiae.  The  inserts  of  a  number  of  positive  i\gt11  plaques  were  cloned  in  the  EcoRI 
site  of  the  pDS56/RBSII,  6xHis/E- polynker.  Two  types  of  clones  were  identified 
according  to  the  restriction  pattern  of  the  two  previously  cloned  PCR  fragments. 
Sequence  analysis  of  full  length  eDNA  clones  of  each  type,  Antryp1  and  Antryp2, 
showed  that  they  encompassed  the  respective  partial  sequences  of  the  cloned  PCR 
products.  Antryp1  and  Antryp2  revealed  open  reading  frames  (G/C-content  of  60°/o  and 
59°/o  for  Antryp1  and  Antryp2  respectively),  coding  for  a  polypeptide  of  274  and  277 
amino  acids  respectively.  The  analysis  of  the  translated  product  of  Antryp1  and 
Antryp2  indicated  that  both  clones  encode  for  two  distinct  polypeptide  showing  75% 
homology  at  the  amino  acid  level.  Moreover,  both  polypeptides  are  highly  homologous 
to  known  trypsin  sequences. 
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Genomic organization of the Anopheles gambiae trypsin genes 
To  determine  the  genomic  sequences  of  Antryp1  and  Antryp2,  a  genomic  A.  gambiae 
XEMBL3A library was screened with the same probe that was used for the  isolation of the 
Xgt11  clones.  Several  overlapping  XEMBL3A  clones  were  obtained,  two  of  them,  Ty  3.3 
and Ty 4.1  containing both trypsin sequences. Hybridisation experiments carried out on the 
genomic  clones  and  on  A.  gambiae  DNA  digested  with  a  set  of  restriction  enzymes 
revealed  several  bands  that  could  not  be  explained  by  the  presence  of  Antryp1  and 
Antryp2  only.  We  have  sub  cloned  and  sequenced  the  internal  BamHI  fragments  of  the 
genomic  subclone,  containing  Antryp1  and  Antryp2,  confirmed  the  respective  eDNA 
sequences and  indicated that the coding sequences of both  genes were not interrupted by 
any  intron.  Moreover,  five  additional  trypsin  related  genes  were  found  in  proximity  Qf 
Antryp1  and Antryp2,  also these  genes did  not contain  any intron.  Contiguity and  relative 
orientation was confirmed by further restriction fine  mapping of the  genomic clones TY3.3 
and  TY  4.1  which  was  in  accordance  with  the  results  obtained  by  Southern  analysis  of 
genomic  clones.  In  addition,  contiguity  was  proven  by  PCR  performed  on  TY3.3  using 
specific  primer pairs,  followed  by digestion  of the  PCR  products  with  restriction  enzymes 
specific for each  fragment. 
Blood meal induced expression of the trypsin genes Antryp1  and Antryp2 
The  expression  of  the  trypsin  genes  in  the  mosquito was  assessed  by  Northern  analysis 
using  total  RNA  extracted  from  female  mosquitoes  at  different  time  points  after  blood 
feeding.  As  control,  RNA from  male  mosquitoes,  fourth  instar larvae,  pupae  and  non-fed 
female  mosquitoes  were  analyzed.  As  probes  the  oligonucleotides  pTy1-S  and  PTy2-S 
that  have  unique  sequences  specific for Antryp1  and  Antryp2  respectively  were  used.  To 
reduce  the  possibility  of  cross  hybridisation  of  the  probes  on  similar  sequences,  Ty1-S 
and  pTy2-S  were  derived from  one  of the  most polymorphic regions of the  trypsin  genes. 
In  Nothern  blot,  both  probes  hybridized  with  a  RNA  species  migrating  around  1  kb  with 
an  estimated  transcript  length  of  about  950  bases.  Adult  females  and  to  some  degree 
pupae,  showed  a  small  amount  of  Antryp1  transcript.  After  blood  feeding,  in  female 
mosquitoes  transcription  of  Antryp1  steadily  increased  and  reached  its  peak  after  24h. 
The  amount  of  Antryp1  mANA  was  decreased  40h  after  the  blood  meal.  Antryp2 
transcripts could  be  shown  only in  female  mosquitoes  between  8 h and  24  h after blood 
feeding.  The  amount  of  transcript  induced  is  at  the  detection  limit  of  end  labelled 
oligomers  in  Northern  analysis.  Induction  of  the  Antryp2  gene  could  be  demonstrated 
much  clearer in  amplification  experiments  using  as  template  eDNA generated from  blood 
fed  mosquitoes.  Under  this  experimental  condition  it  was  possible  to  demonstrate  that 
Antryp2  is  expressed  only  in  female  mosquitoes  and  that  its  induction  is  tightly  control-
led. 
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NETWORK FOR  FIELD  RESEARCH  ON  AFROTROPICAL MALARIA VECTORS 
Period: 
Co-ordinator: 
Objectives 
General objectives 
October 1  , 1993 - September 30,  1996 
UNIVERSITA Dl  ROMA "LA SAPIENZA", 
INST.  Dl  PARASSITOLOGIA 
Roma,  Italy (M.  COLUZZI) 
•  To  improve  the  knowledge  of  malaria  vectors  and  transmission  in  subsaharan  Africa  by 
introducing new methods (genetic, molecular, immunological) for the study of the vector and 
the  parasite  in  the  vector. 
•  To  predict and monitor variations in  the malaria vector system related to ecological changes 
induced by  urbanization,  desalinization,  deforestation  and  irrigation  of arid  areas.  : 
•  To  obtain  and  assist African  scientists  in  improving  research  capabilities applied to  malaria 
entomology and  vector control. 
Specific objectives 
•  To  evaluate  the  influence  of  salt  vs.  fresh  water  environments  in  the  frequency  of  An. 
gambiae and  An.  me/as and  their chromosomal  variants  in  West African  coast  localities. 
•  To  determine  the  redistribution,  bionomics,  population  and  vector  status  of  the  newly 
described  Mopti  chromosomal  form  of An.  gambiae and  of  its  inversion  karyotypes. 
•  To  determine  the  population  structure  and  bionomics  of  An.  funestus  with  particular 
reference to  intrapopulation  genetic heterogeneities. 
•  To  evaluate the  role  of An.  pharoensis and  An.  rufipes in  the transmission  of  P.  falciparum 
and  to analyze  sibling  species within  these taxa. 
•  To  implement large-scale use of molecular probes for the identification of sibling species on 
the  An. gambiae complex in  malaria epidemiology studies. 
Activities 
The  present  project  implemented  research  and  training  activities  already  in  progress  within 
STD1  and  STD2  programs  coordinated  by  ISTPAR-Rome.  These  activities  were  focused  on 
specific research  objectives emerged from  previous results while the training was expanded to 
Portuguese-speaking countries via the  participation  in  the  network of the  IHMT of Lisbon. The 
DC  partners  co-participants  in  the  proposal  were  laboratories  in  Mali  (Departement 
d'Epidemiologie  des  Affections  Parasitaires,  "DEAP"),  in  Madagascar  (Etablissement 
d'Enseignement Superieur des Entomologiques,  "OCCGE"),  where good  research  facilities are 
available  together  with  experienced African  leadership  trained  under STD1  and  STD2.  How-
ever,  other African  countries were  involved,  namely: 
*  Burkina Faso, where the "Centre National de Lutte centre le Paludisme" (CNLP) financed by 
Italian  Cooperation was  a focal  point for research  and  training. 
*  Guinea-Bissau, Sao-Tome and Cabo Verde, where IHMT implemented research and training. 
Moreover, the network collaborated with various groups working in field research on Afrotropical 
malaria vectors,  particularly with  ORSTOM-Institut Pasteur in  Senegal. 
Results 
All  the  above specific objectives were  pursued and  further progress towards the achievement 
of the  general  objectives were  obtained  as  follows: 
Research  on  influence  of  salt vs.  fresh  water environments was  carried  out  in  Guinea-Bissau 
by  IHMT and  ISTPAR. 
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Different  seasonal  and  spatial  distributions  of  An.  me/as  and  of  An.  gambiae  Bissau  and 
Savanna  chromosomal  forms  were  recorded  and  their  relative  contribution  to  P.  falciparum 
inoculation  rates  was  evaluated. The  importance of 2Rn  inversion polymorphism  in  An.  me/as 
in  relation  to  the  distance  from  the  sea  has  been  confirmed.  This  chromosomal  variation 
appears  adaptive for tide-dependent larval  breeding  places. 
Ecological  genetic  studies  were  carried  out by  DEAP  and  ISTPAR  on  the  chromosomal  form 
Mopti  of  An.  gambiae  in  Mali  in  samples  from  a  16-locality transect.  The  2R  polymorphism 
showed wide variation and  highly significant correlation with  both  temporal and spatial climatic 
differences.  Mosquitoes homokaryotypic for 2Rbc were found  to  be the actual dry season  and 
arid  area breeders.  Only the chromosomal form  Mopti fully exploits the breeding opportunities 
during the dry season and is able to displace by competitive exclusion the other taxa of the An. 
gambiae complex,  namely An.  arabiensis and  An.  gambiae Savanna. 
Investigations in  Burkina Faso carried out by ISTPAR and CNLP have brought the discovery of 
sibling species within the taxon An.  funestus,  the most important malaria vector in Africa South 
of  the  Sahara  after  An.  gambiae.  The  standard  arrangement  of  the  polytene  complement 
prevails  in  one  of  the  taxa  while  the  other  was  found  to  be  highly  polymorphic.  The  latter, 
characterized by a higher vectorial capacity,  was the only one present in  Madagascar where it 
hibernates at the larval stage on the  Plateaux (Antananarivo area). Both taxa were identified in 
Senegal  and  in  Mali. 
Various samples of An. pharoensis were examined and CSP positive specimens were detected 
in Burkina Faso. The evaluation of the vector role of this species requires further investigations. 
The  large  scale  use  of  polytene  chromosome  analysis  and  of available  diagnostic  molecular 
probes for the study of malaria vectors was successfully implemented and specific training was 
provided  by ISTPAR for  a total  of 16  months/man.  Three trainees  were  from  IHMT,  two  from 
DEAP,  one  from  EESS and  one  from  OCCGE. 
Partners 
Universita di  Roma "La Sapienza" 
lnst. di  Parassitologia 
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Rua da Junqueira 96 
1300 Lisbon,  Portugal 
Ecole Nationale de Medecine et de Pharmacie 
Dept. d'Epidem. des Affections Parasitaires 
P.O.  Box 1805 
Bamako, Mali 
Etablissement d'Enseignement Superieur des 
Sciences 
Lab.  d'Entomologie, Fac. des Sciences 
B.P.  906 
101  Antananarivo, Madagascar 
Centre de Recherches Entomologiques de 
Cotonou, OCCGE 
B.P. 062604 
Cotonou, Benin 
M.  Coluzzi 
Tel:  +39/6/445.57.80 
Fax: +39/6/499.1 0.348 
V.  Do Rosario 
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M. Akogbeto 
Tel:  +229/33.08.25 
31 Contract number IC18*CT960030 
STUDIES  ON  MOSQUITO  VECTORS  IN  WEST AFRICA, AIMED AT  MALARIA EPIDE-
MIOLOGY AND  CONTROL 
Period:  December 1  , 1996 - November 30,  1999 
Co-ordinator:  CENTRO DE MALARIA E OUTRAS DOENCAS TROPICAIS (IHMT}, 
Lisbon, Portugal (V.E.  DO ROSARIO) 
Objectives 
+ To  determine  the  distribution,  bionomics,  population  structure  and  vectorial  capacity  of 
malaria vectores  in  S.Tome  and  Equatorial  Guinea. 
+ To  implement the  large  scale  use  of  molecular  probes  for  the  identification  of  anopheline 
sibling  species. 
+ To  identify human  parasite species  in  mosquitoes  by  PCR  using  different methods of  DNA 
extraction. 
+  To  perform  longitudinal studies on  the population  dynamics of mosquito vectors  in  associa-
tion  to  interventions. 
Activities 
*  Collections will be carried out by teams already trained, in both islands, and under supervised 
visits. These will take place, twice a year for the initial collection of data, followed by regular 
samplings throughout the year, aimed at studies of distribution and bionomics. 
Locations  of  collections  will  be  made  preferably,  in  relation  to  a)  intervention  sites  e.g. 
drainage and  local  use of mosquito bed  nets vs controls;  b)  randomly determined locations. 
These  are  being  discussed  at this stage. 
Population structure will  be assessed by specific inversion kayotype studies as well as PCR 
classification. 
During  the  first  year,  training  on  these  and  other  required  techniques  will  take  place  at 
Lisbon  and  Rome.  Implementation  in  the  field  of  these  techniques  and  establishment  of 
functional  laboratories  in  the  field  will  take  place  in  the  first year. 
*  Validation  of  field  sampling  methods,  including  CDC  miniature  light  traps,  indoor  resting 
collections,  exit  window  traps  and  human  landing  collections,  for  estimating  entomological 
inoculation  rates  (EIR},  for  the  different  vector  species,  will  be  undertaken  and  the  most 
reliable  and  cost  effective  method  will  be  adopted  for long  term  studies. 
Vectorial  capacity will  be  further  evaluated  by  standardized  ELISA assays  for NANP Ag. 
Whenever  required,  age  grading  studies  will  take  place,  after  analysis  of  the  first  years 
results. 
*  PCR  methodology will  be  applied  mainly for comparative  studies from  regions  within  each 
island and these will aim specifically to the Anopheles gambiae complex of vectors. 
PCR  studies  aimed  at  identifying  human  malaria  parasites  will  take  place  in  order  to 
evaluate transmission  of the  4 existing  malaria parasites  in  both  islands. These  are  carried 
out from  both  oocysts and  salivary glands,  from. naturally fed  mosquitoes,  collected from  a) 
patients with  identified gametocytes by optical  microscopy,  b)  from  a random  sample of the 
population. 
PCR  studies for the  identification  of human  malaria parasites  require  preliminary laboratory 
assays  in  order  to  improve  DNA  extraction  from  parasites  and  thereby  reduce  technical 
difficulties  due  to  excessive  mosquito  material.  These  studies  will  be  initiated  in  the 
laboratory  in  Lisbon. 
*  Interventions are  planned,  locally,  aimed  at  malaria control.  These  include the  utilization  of 
impregnated  bed  nets  (Sao  Tome  and  Equatorial  Guinea),  and  drainage  of  some  areas  in 
Sao Tome  where  malaria is  highly prevalent.  Both  are  being  implemented now and  studies 
on  the  dynamics  of  vector  populations  will  be  carried  out  according  to  methodologies 
described  above. 
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Expected outcome 
=:::)  Training of personnel from SaoTome e Principe and Equatorial Guinea, in  Lisbon (PCR) and 
Rome  (Cytogenetics). 
=:::)Workshop  in  Equatorial  Guinea,  on  the project aims and  methodologies will  take  place in 
March/April  1997.  · 
=:::)  Local  laboratories,  fully  equiped,  able  to  carry  out  studies  on  vector  identification  by 
cytogenetics and  DNA extractions. 
=:::)  Determination  of  the  best  mosquito  collection  methods  to  apply  in  the  field  will  be 
determined  and  applied  within  a  standardized  work  programme.  Longitudinal  time  series 
analysis of (daily)  collections from  individual  houses will  be completed after 2-3 years. 
=:::)  Identification  of malaria vectors  and  parasites  by  PCR  and  cytogenetics,  on  both  islands, 
after 18 months. 
=:::)  Mapping  of  collection  sites  and  vector  distribution  by  GPS  (Global  Positioning  System) 
established within  the first year. 
=:::)  Integration of epidemiological morbidity data with entomological information by the second year. 
=:::)  Integration with  parallel  studies on  drug  resistance  in  Sao Tome  and  Equatorial  Guinea. 
=:::)The  relative risk of malaria transmission,  by time of night,  area,  season and vector species 
will  be  determined. 
=:::)  Appropriate  vector  control  strategies,  based  on  the  assessment  of  these  risks,  will  be 
defined and  implemented in  defined sites. 
Partners 
Centro de Malaria e Outras Doencas Trap. 
Rua da Junqueria, 96 
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IDENTIFICATION  AND  CHARACTERISATION  OF  MALARIA  VECTORS  IN  SOUTH 
EAST ASIA: A  PREREQUISITE FOR  APPROPRIATE VECTOR  CONTROL 
Period: 
Co-ordinator: 
Objectives 
General  objectives 
December 1,  1997 - November 30, 2000 
INSTITUTE OF TROPICAL MEDICINE, Dept. of Parasitology, 
Antwerp,  Belgium (M.  COOSEMANS) 
+  To  develop in  Southeast Asia appropriate vector control measures based on the correct 
identification  of  the  vector  species  involved  in  malaria  transmission  and  on  their 
behaviour  in  order  to  reduce  malaria  incidence  in  populations  at  high  risk  and  to 
prevent malaria epidemics by early detection  and  control. 
Measurable specific objectives 
+ To  elucidate the epidemiological  relevance of heterogeneities in  vector populations and 
the  sibling  species  of  malaria  vectors  in  different  physico-geographical  regions  of 
Southeast Asia. 
+ To  develop · improved  methods  for  vector  species  identification  and  to  obtain  clear 
criteria that  can  be  used  to  define  malaria  risk  areas;  this  will  help  in  the  choice  and 
implementation  of preventive  measures. 
+ To study the practical implications of the genetically defined sibling species in  relation to 
vector behaviour,  vectorial  capacity. 
+  Capacity  building  by  exchange  of  technologies  and  collaborative  training  in  research 
methodology. 
Activities 
The  study will  be  performed  in  three  physico-geographical  regions  of  Vietnam  (northern, 
central  and  southern),  in  Laos  and  in  Cambodia. 
Baseline ecological and  malaria epidemiological  data will  be  collected for each  study site. 
Mosquitoes  (adults  and  larvae)  will  be  collected  in  each  study  site  applying  multiple 
collection  methods  during the  first year of the  project. 
Different experimental procedures to analyse the field samples will be applied: morphology, 
isozyme electrophoresis,  RAPD-PCR,  PCR-RFLP and  ELISA. 
Isozyme  electrophoresis will  be  applied  to  morphologically identified forms  (morphotypes) 
in order to confirm species identification, and to discriminate individual members of species 
complexes.  This  technique  will  provide  information  on  the  extent  of  genetic  variation 
between  and  within  different  populations.  This  will  allow  us  to  detect  intrinsic  barriers  to 
gene flow by the demonstration of a lack of heterozygotes. The enzymatic markers will  be 
tested  for  their  ability  to  distinguish  potential  cryptic  species  and  subsequently  used  to 
investigate species  relationships  relevant to vector biology and  transmission. 
Molecular techniques will  be  applied  for the  development of simple  and  reliable  tools for 
species identification; e.g.  screening of RAPD-PCR primers;  amplification of variable rONA 
regions  and  RFLP  analysis.  The  molecular  markers  will  be  tested  for  their  ability  to 
distinguish cryptic species  identified  by  isozyme  electrophoresis. 
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Expected outcome 
The project will assess the species status of the three major malaria vectors in  Southeast 
Asia and will  evaluate the  role  of the individual species in  malaria transmission. This will 
lead  to considerable  improvement of the  vector control  activities  by focusing  the  control 
measures  on  the  efficient  vectors  with  the  appropriate  tools  and  in  relation  to  their 
behaviour.  Moreover,  a  better evaluation  of the  intervention,  using  the  new identification 
methods,  is  an  additional  benefit.  It  would  also  be  possible  to  estimate  the  risk  of 
environmental changes on vector distribution. 
Partners 
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DEVELOPMENT  AND  FIELD  APPLICATIONS  OF  MOLECULAR  PROBES  FOR  THE 
STUDY OF AFROTROPICAL MALARIA VECTORS 
Period: 
Co-ordinator: 
Objectives 
December 1,  1997 - May 31, 2001 
FOUNDATION FOR RESEARCH & TECHNOLOGY HELLAS, 
lnst. of Molecular Biology & Biotechnology, 
Heraklion, Greece (C.  LOUIS) 
•  The  development of rONA-based  molecular markers  for  each  of the  taxonomic  units 
shown within  An.  gambiae s.s.  and An.  funestus s.s. 
•  The evaluation of the new diagnostic tools on field-collected material typed by polytene 
chromosome analysis. 
•  The physical isolation and cloning of the  DNA surrounding the breakpoints of inversion 
2La. 
•  The sequence determination of specific DNA segments linked to 2La and their use in 
the  karyotype  identification  of  field-collected  malaria  vectors  and  in  phylogenetic 
studies. 
Activities 
This proposal  focuses on  the  molecular analysis of the Anopheles gambiae and the An. 
funestus complexes, the malaria vector system in  Sub-Saharan Africa. The sibling species 
in  the complexes are defined by the presence or absence of specific inversions detected 
on polytene chromosomes. Furthermore, there are indications that additional taxa carrying 
typical sets of polymorphic chromosomal inversions and characterized by variable degrees 
of intergradation, are members of these complexes. The long term goal is to undertake an 
in  depth study of the genetic structure and dynamics of field  populations of An.  gambiae 
and An.  funestus and to attempt to correlate specific recognizable genetic polymorphisms 
with vector biology,  in  order to provide a better description of this powerful vector system 
and to obtain  reliable  data towards  its  monitoring and control. 
We  propose  to  undertake  a  molecular  genetic  analysis  of the  inversion  polymorphisms 
using molecular probes. The primary objective of the present study is the development of 
specific  PCR-based  diagnostics  based  on  both  rDNA  (for  both  An.  gambiae  and  An. 
funestus)  and  cloned  inversion  breakpoints  for the 2La  inversion  of  An.  gambiae.  As  a 
parallel objective, we wish to analyze the phylogenetic relationship of chromosomal forms 
of An. gambiae and to obtain information on the monophyletic origin of the inversions and 
on  introgression and gene flow among different inversions. 
Expected outcome 
=>The development of rONA-based  molecular markers  for  each  of  the  taxonomic  units 
shown within  An.  gambiae s.s.  and An.  funestus s.s. 
=> The evaluation of the new diagnostic tools on field-collected material typed by polytene 
chromosome analysis. 
=> The physical isolation and cloning of the DNA surrounding the breakpoints of inversion 2La. 
=> The sequence determination of specific DNA segments linked to 2La and their use in the 
karyotype identification of field-collected malaria vectors and in phylogenetic studies. 
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PLASMODIUM  GENOME - STRUCTURE AND  DYNAMICS 
Period: 
Co-ordinator: 
Objectives 
October 1,  1992 - March 31,  1995 
UNIVERSITY OF EDINBURGH,  INST.  OF CELL, 
ANIMAL AND  POPULATION BIOLOGY, 
Edinburgh, United Kingdom  (D.  WALLIKER) 
The  overall  objective  of the  project  has  been  to  understand  the  mechanisms  which  give 
rise  to  the  genetic  diversity  seen  in  populations  of  malaria  parasites.  The  project  has 
involved  field  studies  on  the  most  important  species  affecting  humans,  Plasmodium 
falciparum,  to determine the extent of polymorphism of certain  genes among the parasites 
of  small  communities  and  to  examine  the  role  of  cross-mating  between  parasites  in 
generating this diversity.  In the laboratory, studies on  the organization of the genome have 
been  carried  out  with  both  P.  falciparum  and  the  rodent  malaria  model  P.  berghei,  with 
particular  emphasis  on  the  organization  of  repetitive  DNA  elements  and  their  role  in 
generating  chromosomal  re-arrangements. 
Activities 
Genetic polymorphism in natural  P.  falciparum populations 
Much  work  in  recent  years  has  established that there  is  considerable  genetic diversity in 
populations  of  P.  falciparum,  even  among  the  parasites  of  small  communities.  Certain 
genes, notably those encoding antigens, exist in such populations as a complexity of allelic 
variants,  and  many patients contain  mixed  infections of more than  one parasite clone. The 
significance of these findings for control  measures, especially those based on  vaccination, 
has  yet to  be  established. 
The  work  undertaken  during  this  project  has  been  to  examine  the  diversity  of  three  P. 
falciparum genes among parasites in villages in  Papua New Guinea (PNG). The objectives 
were  (i)  to  determine  whether  there  were  differences  between  the  frequencies  of  allelic 
variants  of  these  genes  among  the  parasite  populations  of  different  villages  in  a  single 
region  (ii)  to  investigate  what  changes  occur  in  these  antigens  during  the  course  of  an 
infection  in  individual  patients,  and  (iii)  to  determine  the  frequency  of  crossing  between 
different parasite clones  during  mosquito transmission. 
Diversity of antigen genes in blood infections 
Methods  based  on  the  polymerase  chain  reaction  (PCR)  have  been  devised  to  identify 
alleles of merozoite surface proteins MSP-1  and  MSP-2.  we  have concentrated most effort 
on  MSP-2 because this antigen is expected to form  part of a malaria subunit vaccine to be 
tested  in  this  area  in  the  near future. 
Results 
A survey of the  MSP-2 alleles of 304  people living  in  the  Wosera  region  of PNG  revealed 
38  alleles which  could  be  discriminated by this technique,  33  of which  have  proved  to  be 
novel  alleles.  Twelve  alleles have also  been  sequenced,  six of which  have  been  found  to 
belong to the so-called "FC27" allelic family of this antigen,  and  six to the "3D7" family. All 
sequence  data  are  to  be  analyzed  with  respect  to  genetic  distance,  structure,  and 
periodicities  of  the  repeats,  in  order  to  trace  how  genomic  re-arrangements  may  have 
occurred  during the  evolution  of this  group  of  alleles. 
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Information  on  parasite  prevalence  as  measured  by  PCR  in  these  individuals  was 
compared  with  prevalence  as  measured  by  microscopy.  An  important  result  of  this 
comparison,  which  could  be  important for  mathematical  models  of  malaria transmission, 
was  that  no  difference  in  parasite  prevalence  was  found .between  children  (48o/o)  and 
adults  (47o/o),  whereas  by  microscopy parasites were detected only in  23°/o  of adults and 
32°/o of children.  Furthermore, in  more than 50°/o  of all samples positive for P.  vivax and  P. 
malariae,  an  underlying  P.  falciparum  infection was detected  by  PCR. 
The  data  on  MSP-2  genotypes  were  combined  with  immunological  and  epidemiological 
data collected from  the  same individuals at the same time.  214 adults were  analyzed for 
antibody  and  T-cell  response  against  three  different  MSP-2  antigen  preparations.  No 
correlation  between  antibody or T-cell  response  and  parasite  genotype was detected. An 
attempt  was  also  made  to  determine  whether  there  was  any  differential  distribution  of 
MSP-2 genotypes in  symptomatic and asymptomatic patients infected with  P.  falciparum in 
case a control study of 227 individuals. Parasites of FC27 genotype were twice as likely to 
be found  in  symptomatic as  in  asymptomatic people. 
The  overall  conclusion  of  this  work  was  that  crossing  between  parasites  was  clearly 
occurring,  although  at  a  lower  frequency  than  might  be  expected  from  the  number  of 
multiclonal  infections.  This  suggested  that  only  a  limited  number of the  clones  detected 
among the blood infections were producing gametocytes infective to mosquitoes. However, 
it was of interest that no linkage disequilibrium could be detected among the genes studied 
in  the blood  infections. Thus the comparatively low degree of crossing  in  this  region  was 
nonetheless sufficient to  produce linkage equilibrium  in  the  population  of blood  parasites. 
Karyotype polymorphism 
Correlation between chromosome size polymorphisms and the presence or absence 
of specific functions 
Deletions  resulting  in  measurable  changes  in  the  sizes  of  chromosomes  of  malaria 
parasites,  detectable  by  pulsed  field  gradient  gel  electrophoresis  (PFG),  are  frequently 
seen in  parasites maintained under both  in vitro and in  vivo conditions.  In  some instances, 
it has been possible to correlate such changes,  notably those involving terminal deletions, 
with  the  loss  of apparently dispensable functions.  For example,  a  deletion  polymorphism 
affecting chromosome 9 of  P.  falciparum  has been  described,  the shorter vision  of which 
involved  a  terminal  deletion  which  was  associated  with  loss  of  cytoadherence  and  poor 
gametocyte production. 
This phenomenon has been investigated in  more detail by comparing a number of isogenic 
cloned lines of  P.  falciparum differing  in  their gametocyte production. These lines were as 
follows:  (i)  seven  clones  lacking  gametocytes  which  had  been  derived  from  the  307 
gametocyte-producing clone, (ii) clones HB3sel4 (possessing an intact chromosome 9) and 
clone  HB3  (short  chromosome  9),  and  (iii)  clone  1776sel8  (intact  chromosome  9)  and 
clone C10  (short chromosome 9). 
With  regard  to  (i),  no  obvious size  differences were observed  between  chromosome 9 of 
any of the seven  clones and  of the  parent 307 clone;  thus,  in  this  instance,  the function 
impairment  (lack  of  gametocytes)  could  not  be  correlated  with  major  deletion  or  re-
arrangement events. With  regard to the HB3 series of clones,  it appeared that the fraction 
of  parasites  bearing  a  deleted  form  of  chromosome  9  rapidly  outgrew  the  remaining 
parasites in  the cultures.  Intact chromosomes are found  in  the fraction  of parasites which 
develop into gametocytes. 
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These studies also made use of a gene (Pfg27) expressed early in gametocyte development. 
Expression of this gene could not be detected in the various gametocyte-less clones studied, in 
those  with  deletions  in  chromosome  9,  or  in  three  of  the  3D7  derivatives  with  intact 
chromosomes. This indicated that these clones were affected very early in their gametocyte 
development. A structural analysis of the genomic DNA region 5' to the Pfg27 gene revealed 
that a sequence of 1  0-15kb adjacent to the Pfg27 promoter is highly polymorphic in the 3D7, 
HB3sel4 and C10 clones. Some of these polymorphisms might be  related to an anomalous 
production of Pfg27 transcripts in  asexual parasites seen in clones C1 0 and 1776sel8. The 
region upstream of Pfg27 has also been analyzed in two of the gametocyte-less derivatives of 
3D7. A comparison  with the parent clones showed that no  major structural  alteration  had 
occurred in this region during the loss of gametocyte production. 
Subtelomeric structures 
Evidence  is  accumulating  that  genes  determining  essential  functions  in  Plasmodium  are 
safely placed in the central regions of chromosomes, while genes determining dispensable 
functions under non-selective conditions are located in  the distal regions of chromosomes, 
which  are  subject to frequent deletions or re-arrangements. 
It is well-known that subtelomeric regions of chromosomes are  unstable, but the structural 
basis of their high  degree of polymorphisms is  not understood.  Species-specific repetitive 
units  are  often  maintained  at  the  ends  of  several  chromosomes,  and  are  believed  to 
enhance the  occurrence of inter-chromosomal  recombination  events.  Results  obtained  by 
the Rome group under a previous STD contract showed that in  P.  berghei these subtelom-
eric repeated sequences are regularly intercalated with telomere-related sequences. 
The  organization  of  the  subtelomoeric  structure  present  on  many  P.  falciparum  chromo-
somal  ends thus appears to  be  substantially different from  the  one  present in  P.  berghei. 
In  particular,  there  is  no  evidence  of  internal  telomeric  stretches  in  P.  falciparum. 
Homologous  recombination  would  not  appear to  be  particularly  favored  along  the  rep20 
region,  where  homology between  21-bp  units  is  limited  to  not  more  than  8-9  contiguous 
base pairs.  Exchanges of subtelomeric sequences between non-homologous  P.  falciparum 
chromosomes  might  be  predicted  to  occur  more  frequently  in  other  portions  of  the 
sub-telomeric structure,  where  long  regions  of  homology are  present. 
However, exchanges in non-repetitious regions would have no detectable effect on chromo-
some size.  From the available evidence,  it can  be  stated with confidence that rep20  is  not 
involved  in  fundamental  functions  such  as chromosome  replication  or chromatid  segrega-
tion, since the whole region can  be lost without serious impairment in cell viability. 
Diversification of telomeric tracts in  P.  berghei 
Telomeric  sequences  in  Plasmodium  result  from  the  irregular  alternation  of  two  basic 
repeats TTTAGGG  and TTCAGGG. The length of the telomeric structure,  i.e.  the  number 
of  telomeric  heptanucleotide  repeats,  appears  to  be  constant  during  mitotic  parasite 
propagation.  By  sequencing  sibling  telomeric  clones  derived  from  a  P.  berghei chromo-
somal  extremity,  it  was  shown  previously  that  their  proximal  portions  start  with  identical 
sequences of the two types of repeats, and that sequence divergence occurs from variable 
breakpoints.  The  results  suggested  that  frequent  terminal  deletions  followed  by  random 
distributive  addition  of the  two  repeat  versions  is  responsible  for telomere  turnover,  in  a 
mechanism  of telomere  length  regulation. 
These studies have been  extended  under the present contract.  The breakpoint frequency 
distribution  has been  studied  in  a new set of sibling telomeric clones.  The results confirm 
the  suggested  hypothesis  and  show  that  90°/o  of  the  telomeric  structure  is  subject  to 
events causing  abrupt changes  in  the  sequence of telomeric  repeats. 
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This  indicates  that,  in  the  dynamic  equilibrium  governing  steady-stage  telomere  length, 
shortening cannot be due to incomplete replication.  Rather,  terminal deletions appear to be 
quite frequent events,  their frequency  rapidly  increasing  in  the outward  direction over the 
entire telomeric tract. 
Summary and conclusion 
New information  has  been  obtained on  the diversity and  frequencies of alleles of antigen 
genes in natural populations of P.  falciparum in Papua New Guinea. An important result from 
this  field  study  has  been  the  determination  of  the  frequency  of  cross-mating  between 
parasite clones in wild-caught mosquitoes; this has implications for predicting how parasites 
in  nature  may  respond  to  control  measures based  on  chemotherapy  and  vaccination.  In 
addition,  the  laboratory  studies  on  P.  berghei  have  provided  new  information  on  the 
organization of sub-telomeric regions of chromosomes. This will undoubtedly lead to some 
understanding  of  the  genetic  mechanisms  by  which  genome  re-arrangements  occur  in 
malaria parasites.  Subjects which  remain  unfinished include the isolation of candidates for 
transposable elements, and details of the process of recombination at meiosis. 
In  the  course  of  this  project,  all  major  techniques  of  molecular  genetics  have  been 
introduced  to  the  Madang  laboratory  of  the  PNG  Institute  of  Medical  Research.  A 
laboratory  technician  from  Papua  New  Guinea  has  been  trained  in  basic  molecular 
biological  techniques,  i.e.  methods  of  DNA isolation,  Southern  blotting  and  hybridisation, 
molecular cloning,  phage and  plasmid  mini-preparations, and  restriction  mapping.  Visits of 
the  partners to  each  other's laboratories have  taken  place,  and  solid  research  collabora-
tions  established. 
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REGULATION  OF  DEVELOPMENT IN  MALARIA PARASITES 
Period: 
Co-ordinator: 
Objectives 
January 1,  1997 - December 31,  1999 
UNIVERSITY OF LEIDEN, DEPT. OF PARASITOLOGY, 
Leiden, The Netherlands (C.J. JANSE) 
+  The investigation of the  regulation  of parasite development through  studies on  1)  gene 
promotor  structure,  strength  and  stage  specificity  and  on  2)  function  of  the  proteins 
encoded  by the  genes  under the  control  of these  promoters. 
•  The  genes of study are:  P.  falciparum,  Glycophorin binding protein (GBP)  130,  Na+/H+ 
transport  protein;  from  P.  berghei,  PBS21,  pb87,  rRNA  units  (A-D),  150  family,  crk2, 
EF-1 a;  from  P.  vivax,  crk2,  EF-1 a,  rRNA. 
•  Development  of  plasmid  systems  based  upon  the  Tet  repressor  which  will  allow  the 
inducible  expression  of cloned  genes  in  different species  of  Plasmodium. 
+ Where  feasible,  to  develop  resources  to facilitate  the  isolation  and  characterisation  of 
genes encoding proteins with  a specific role  in  development during gametocytogenesis 
and  throughout the  mosquito phase of the  life  cycle  in  P.  vivax and  P.  berghei. 
Activities 
*  Where appropriate, to clone and complete the full characterisation of the named genes, 
their sequence,  expression  and comparative  structures. 
*  Studying the structure and function  of promoters of transcription of RNA polymerases  I 
and  II  in  both  P.  berghei and  P.  falciparum  using  stable  and  transient  transfection 
technologies. 
*  Investigating the species specificity of promoter structure through an  investigation of the 
ability of defined promoter regions of genes isolated from  P.  vivax to  accurately control 
transcription  in  P.  berghei. 
*  Developing  plasmid  systems  based  upon  the  Tet  repressor  which  will  allow  the 
inducible expression  of cloned  genes  in  different species of  Plasmodium. 
*  Initiating  a  study  of  structure/function  relationships  of  specific  parasite  structures 
through  gene mutagenesis,  replacement,  over-expression and/or knock out to establish 
the  role  of the  protein. 
*  Studying the control  of gene expression  in  P.  berghei at the post-transcriptional level  in 
female  gametocytes  using  the  Pbs21  (female  gametocyte  specific),  150  gene  family 
(variant 3'  UTA)  and  pb87 (nuclear protein  gene)  as  paradigms. 
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*  Where  feasible  developing  resources  to  facilitate  the  isolation  and  characterisation  of 
genes  encoding  proteins with  a  specific  role  in  development during  gamecytogenesis 
and throughout the mosquito phase  of the  life cycle  in  P.  vivax and  P.  berghei. 
*  To  continue to  expand the  investigation  of the  relationship  between  genome organisa-
tion  and  sexual  development. 
Expected outcome 
~  The programme should provide a functional analysis of the genes under study and thus 
provide  insights into their role  during the complex development cycle of  Plasmodium. 
~  An  insight  will  be  gained  into  the  functional  structure  of  stage  specific  promoters  of 
gene transcription. This can  be  expected to  include an  identification of those elements 
which  dictate stage- and  sex-specificity and  those which  direct basal  transcription. 
~  The study will provide reagents and materials, which are essential for further studies on 
the  sexual  development of Plasmodium. 
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ANALYSIS OF  VAR GENES FROM  P.  VIVAX AND P.  FALCIPARUM 
Period: 
Co-ordinator: 
Objectives 
January,  1 1997 - June, 30 1999 
ZENTRUM FUR INFEKTIONSFORSCHUNG, UNIV. WURZBURG, 
WOrzburg,  Germany (M.  LANZER) 
•  to  determine the  genomic organization  of  var genes in  P.  falciparum 
•  to  examine the  mechanism  of differential  var gene  expression  in  P.  fa/ciparum 
•  to  examine the adhesive  phenotypes of specific  var gene  variants 
•  to  clone  var gene  homologous genes from  P.  vivax 
•  to  study the genomic organization  of  var gene  homologues  in  P.  vivax 
Activities 
*  Production  of a  P.  vivax YAC  library and the  assortment into contigs.  A representative 
YAC  library for  P.  vivax will  be  constructed.  The  DNA  material  will  be  obtained  from 
patients and  from  primates  infected  with  an  Indian  isolate of  P.  vivax. 
*  Assortment of  P.  vivax YAC  clones into chromosomal  contig  maps.  Chromosomal YAC 
contig  maps  will  be  generated  using  a  'top down' approach  based  on  advanced  filter 
hybridization strategies.  YAC  filters will  be  screened with  random  eDNA clones from  P. 
vivax. 
*  Isolation of P.  vivax var genes. The UNIEBP primers developed to amplify P.  falciparum 
var genes  will  be  used  to  identify  and  clone  homologous  genes  from  P.  vivax.  The 
production of full-length  gene sequences from  P.  vivax will  be  useful for comparison to 
the  P.  falciparum  var genes,  particularly for functional  comparison  as it is believed that 
P.  vivax-infected  erythrocytes do  not adhere to  host endothelium. 
*  Production  of  a  3D7  clone  tree  and  cloning  of  expressed  var genes.  To  study  the 
mechanism  of  var gene switching  in  P.  falciparum,  a clone tree from  the  P.  falciparum 
isolate 3D7 will  be  generated by limiting dilution. The  resulting  clones will  be  analyzed 
for antigenic similarity  using  the  mixed  agglutination  reaction  with  hyperimmune  sera. 
Using RT-PCR, the expressed  var gene will be identified and sequenced. The sequence 
will  be  correlated  with  the  adhesive properties of this variant. 
*  Mapping a resetting  locus in  P.  falciparum.  Using the existing progeny from the genetic 
cross between  the  resetting  clone  Dd2  and the  non-resetting clone  HB3 we  will  follow 
the  segregation  of  the  resetting  phenotype  in  this  cross  and  determine  a  candidate 
locus.  This candidate  locus will  be  screened for the  possible expression  of  var genes, 
to explore the  possibility that  rossetting  is  mediated  by  a particular  var gene variant. 
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*  Genomic analysis of var genes.  Using  existing,  and yet to be constructed,  YAC  contig 
maps of  P.  falciparum and  P.  vivax chromosomes,  the genomic location and organiza-
tion  of the  var gene family will  be  studied  in  both  P.  vivax and  P.  falciparum. 
*  Analysis  of  var genes  in  field  samples  (P.  vivax and  P.  falciparum).  To  determine the 
degree of var gene variability in field populations, longitudinal studies will be carried out 
in  Brazil  and  India.  The  expressed  var gene  variants  will  be  determined  by  RT/PCR 
amplification using the UNIEBP oligonucleotides as primers. The resulting fragments will 
be cloned and sequenced. This will  generate a data set of expressed  var genes within 
given  spatial  and temporal  locations. 
Expected outcome 
=::)  The study will provide a better understanding of the mechanisms of differential var gene 
expression. 
=::)The  study will  correlate defined adhesive properties with  particular  var gene variants 
=::)The  study will  show the  diversity of  var gene variants  in  the  field. 
=::)The study will provide tools,  such as YAC  libraries and chromosomal contig maps,  that 
will  be  useful  in  other areas of malaria research. 
=::)  The study will  explore the existence of  var genes in  P.  vivax. 
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PLASMODIAL CHROMATIN:  STRUCTURE AND  FUNCTION 
Period: 
Co-ordinator: 
Objectives 
January, 1 1997 - June, 30  1999 
ZENTRUM FUR INFEKTIONSFORSCHUNG, UNIV. WURZBURG, 
Wurzburg,  Germany (M.  LANZER) 
•  to  identify  P.  falciparum centromere  sequences 
•  to  analyze  spatial  and  temporal  chromatin  changes  and  their  effect  on  transcriptional 
activity  in  P.  falciparum 
•  to  develop  an  in  vitro plasmodial  telomerase  assay 
•  to  identify and  clone the  P.  falciparum telomerase  including  its  RNA subunit 
•  to  characterize  subtelomeric domains  in  P.  vivax 
•  to  identify and  clone  non-histone  nuclear proteins 
•  to  identify origins of replication 
Activities 
*  Development  of  an  in  vitro  P.  falciparum  telomerase  assay.  An  in  vitro  assay  for 
plasmodial  telomerase  activity  will  be  established.  Different  oligonucleotides  will  be 
tested  for function  as  templates for the  plasmodial  telomerase.  The  effect of  inhibitors 
on  in  vitro telomerase  activity and  in  vivo parasite viability will  be  tested. 
*  Cloning  of  the  plasmodial  telomerase.  The  gene  encoding  the  protein  subunit  of  the 
plasmodial  telomerase  will  be  cloned  a)  using  a  structural  approach,  based  on 
conserved  telomerase  sequences,  b)  by  screening  a  P.  falciparum  expression  library 
with  antibodies  to  the  Tetrahymena  telomerase.  The  RNA  subunit  of  the  plasmodial 
telomerase will  be  cloned  by screening  a genomic  P.  falciparum libraries with  oligonu-
cleotide  complementary to  plasmodial  telomeres. 
*  Studies on  plasmodial  replication.  Electron-microscopic studies will  be  conducted  using 
decondensed chromatin  to  determine areas where  replication  had  initiated.  In  addition, 
two-dimensional gel  electrophoresis as described by Brewer and  Fangman will be  used 
to  visualize  replication  intermediates. 
*  Identification  of  functional  centromere  sequences.  Centromeric  sequences  will  be 
identified  using  a  functional,  transfection  based  approach.  A  wild-type  P.  falciparum 
strain  will  be  transfected  with  a  P.  falciparum  library  cloned  in  a  vector,  which 
contains  a  selectable  marker.  Repeated  rounds  of  selection  and  plasmid  recovery, 
followed  by  re-transformation,  will  be  employed  to  enrich  for  sequences  containing  a 
plasmodial  centromere.  Centromeres  will  be  further  dissected  by  deletion  analysis. 
Protein  binding  motifs  will  be  tested  in  gel  retardation  assays,  using  nuclear 
proteins. 
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*  Spatial  and  temporal  changes  of  plasmodial  chromatin.  The  chromatin  structure  of 
telomeric  repeat  sequences,  subtelomeric  regions,  internal  chromosome  domains  and 
the transition  between  these different domains will  be  investigated. The  possible effect 
of chromatin changes on the transcriptional activity of developmentally expressed genes 
will  be  investigated. 
*  Characterizing  protein  components  of  plasmodial  chromatin.  Monoclonal  antibodies 
against  NAP  (Nucleosome  Assembly  Protein)  will  be  used  in  immunofluorescence 
studies  to  examine  the  association  of  this  protein  with  the  nuclear  material.  In  vitro 
reconstitution  experiments  are  planned  to  test  the  activity  of  the  NAP  protein  in 
chromatin  assembly. 
Expected outcome 
:::::}  The study aims at characterizing those structural aspects of plasmodial  chromatin that 
are relevant to the multiple functions in  which  chromatin  is  involved,  such as transcrip-
tion,  replication,  segregation,  chromosomal  stability  versus  (possibly  programmed) 
rearrangements. 
~The  study will  aid  in  identifying  new targets for rational  drug  design. 
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DEVELOPMENT  OF  INHIBITORS  OF  MALARIAL  AND  TRVPANOSOMAL  DIHVDRO-
FOLATE  REDUCTASE  AS  ANTIPARASITIC  AGENTS  THROUGH  COMBINATORIAL 
CHEMISTRY 
Period: 
Co-ordinator: 
Objectives 
November 1,  1997 - October 31,  1999 
INSEAM, Paris, France (C.  DOERIG) 
•  To  elucidate  the  molecular  mechanisms  regulating  sexual  differentiation  and  game-
togenesis  in  the  human  malaria parasite  Plasmodium falciparum. 
•  To  identify  potential  anti-malarial  compounds  based  on  chemical  inhibitors  of  protein 
kinases  involved  in  the  regulation  of parasite growth  and/or development. 
Activities 
The  regulation  of  P.  falciparum  sexual  development  requires  the  tight  coordination  of 
several  cellular and  biochemical  processes,  such  as  the  control  of cell  cycle  progression 
and  of  initiation  of  DNA  synthesis,  differential  morphogenesis,  and  stage-specific  gene 
transcription.  These  processes  are  likely  to  be  coordinated  via  signal  transduction  path-
ways  that  are  activated  by  the  (as  yet  unknown)  stimuli  triggering  differentiation.  The 
strategy we  will  follow to  approach  this  problem  will  consist of the  integration  of  different 
lines  of investigations: 
*  Comparativ e biochemical  and  molecular biology studies  using wild-type  parasites and 
mutant parasite  lines  which  have  lost the  ability to  undergo  sexual  development. 
*  Identification and characterisation of signal transduction pathways potentially involved in 
the  sexual  development of the  parasite. 
*  Study of the  interface between  the  control  of  initiation  of DNA synthesis and  upstream 
signal  transduction  pathways  in  the  context  of  gametocytogenesis  (cell  cycle  arrest, 
inhibition of  DNA synthesis) and gametogenesis (sudden  release from  cell  cycle arrest, 
active  DNA synthesis). 
*  Study  of  gametocyte-specific  transcription  and  its  interface  with  upstream  signal 
transduction  pathways,  using  the  promoter  of  the  early  gametocytogenesis  marker 
antigen  Pfg25/27 as  a model. 
*  Screening of protein kinase inhibitors as potential antimalarials. Available data on  signal 
transduction and cell cycle control  in  P.  falciparum indicate that many genes involved  in 
these processes are conserved  in  the  parasite;  these include cyclin-dependant kinases 
(CDKs),  several  homologues  of  which  have  been  identified  in  P.  falciparum.  The 
possibility that these enzymes may  represent targets for new chemotherapeutic agents 
will  be investigated. The IC50 of several hundred derivatives of CDK chemical inhibitors 
will  be  determined  on  parasite  cultures,  human  cells  lines,  and  in  vitro kinase  assays 
with  purified  CDKs  from  both  sources.  The  purpose  of  these  experiment  is  to  identify 
compounds  inhibiting preferentially the  parasite's (versus the  host's)  CDKs,  as  the  first 
step towards the development of novel  antimalarials. 
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Expected outcome 
The studies on the molecular mechanisms of Plasmodium differentiation are likely to bring 
a  considerable  increase  in  our understanding  of the  basic  biology  of the  parasite.  It  is 
reasonable to expect that the results of the proposed work will  include the identification of 
components  of  regulatory  networks  that  are  vital  to the  parasite,  and  hence  will  be  of 
significance in  the context of novel drug design. 
Our attempt to identify parasite-specific CDK inhibitors is an example of the exploitation of 
results from fundamental studies towards drug development. Although the outcome of such 
screening approaches is difficult to predict, prospects are promising in the present case, as 
some  of the  compounds  that will  be  tested  have  already  been  shown  to.  have  different 
IC50s on  CDKs from  different organisms. 
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MALARIA PRE-ERYTHROCYTIC STAGES (MPES)  EUROPEAN  NETWORK ANTIGENS 
TARGET OF  IMMUNE  RESPONSES  CAPABLE OF INHIBITING  P.  FALCIPARUM PRE-
ERYTHROCYTIC  DEVELOPMENT 
Period: 
Co-ordinator: 
Objectives 
August 1,  1992 - July 31,  1994 
January 1,  1995 - December 31,  1997 
INSTITUT PASTEUR,  DEPT.  PARASITOLOGIE BIOMEDICALE 
Paris, France (P.  DRUILHE) 
+  Development  of  the  immunology  of  MPES  with  the  aim  of  developing  an  effective 
MPES vaccine. 
+ Acquisition  of  an  improved  knowledge  of the  biology of MPES. 
+  Improved  coordination  and  exchanges  within  and  between  European  and  Developing 
Country teams. 
Activities 
The  European  malaria  pre-erythrocytic  stages  network  is  aimed  at  elucidating  the  basic 
biology of,  as  well  as  developing control  means against,  human  malaria.  It includes: 
*  Molecular biology studies of pre-erythrocytic antigens from  mostly  P.  falciparum and  P. 
berghei,  and  in  part  P.  reichenowi (identification,  characterisation,  production  of  genes 
and antigens:  LSA 1  , a major 200 kDa molecule expressed in  liver stages; SALSA,  a 70 
kDa antigen shared  between  sporozoite and  liver stages;  LSA3-729,  a pre-erythrocytic 
stage specific molecule expressed  in  sporozoites and  liver stages;  DG21,  a sporozoite 
specific  78  kDa  molecule).  Antigenic  features  of  these  molecules,  conservation  of 
epitopes  amongst  isolates,  epitope  mapping;  immunogenicity in  animals,  characterisa-
tion  and  prevalence  of  immune  responses  in  humans  and  in  animals  (mice  and 
primates),  identification  amongst the  remaining  series  of  cloned  pre-erythrocytic  stage 
molecules of those that deserve further detailed studies. 
*  Improvement of the  reproducibility  of  liver infections  in  Aotus  monkeys.  Immunisation, 
and  sporozoites challenges,  of chimpanzees and Aotus  with  P.  falciparum antigens,  of 
mice  and  Thammomys  with  P.  berghei,  P.  yoelii  antigens.  Analysis  of  the  immune 
responses  developed  by  immunised  animals  and  of  the  type  of defence  mechanisms 
operating.  Comparison  of  the  type  of  immunity  induced  by  antigens  and  by  whole 
parasites  (i.e.  irradiated sporozoites)  in  natural versus  artificial  hosts. 
*  Analysis of naturally occurring immunity to MPES in field conditions, of the mechanisms 
regulating  parasite  loads  at  the  MPES  level,  and  of the  main  antigens  inducing  such 
mechanisms.  Analysis  of  the  artificial  immunity  induced  by  injection  of  y-irradiated 
sporozoites,  and  of the  mechanisms and  antigens  responsible for such  an  immunity. 
*  Studies of the mode of action and the respective importance of antibodies, antibody-cell 
cooperation,  lymphocyte  cytotoxicity  and  cytokines  using  P.  falciparum  and  human 
hepatocytes,  under in  vitro conditions  or  in  vivo in  SCID  mice. 
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Expected outcome 
Our  main  goal  is  the  development  of  an  effective  means  of  vaccination.  Additionally  the 
project could  provide: 
=> An  improved  understanding  of  the  human  P.  falciparum  relationship  at  MPES  level, 
mainly through  an  analysis of existing  regulatory mechanisms developed against those 
stages by exposed individuals and their epidemiological consequences in various areas 
differing  in  their vectorial  capacity. 
=>  Improved cohesion  of  European  research  in  epidemiology and  diagnostics in  concerta-
tion with Developing Countries enabling a sustainable research strengthening in malaria 
endemic areas. 
Results (so far) 
In general, the malaria pre-erythrocytic stage network has provided a tremendous increase 
in  the  output  of  studies  on  the  molecular biology,  immunology and  cell  biology of human 
malaria liver stages. 
Molecular biology 
4  out  of  4  of  the  new  P.  falciparum  molecules  being  studied  namely  STARP,  SALSA, 
LSA-1 , LSA-3  have  been  characterized  in  terms  of  their  full  length  DNA  sequence  and 
stage  specific  expression,  and  we  have  initiated  the  study  of  three  new  MPES  genes, 
DG  64,  DG  6F  and  DG  571,  two  of  them  in  collaboration  with  Nijmegen  and  BPRC. 
Immunological  studies  with  isolates  of  P.  falciparum at  the  sporozoite  stage  have  shown 
the  consistent expression  of  those  genes  and  comparison  of sequence  data  for  areas  of 
immunological  interest  of  LSA-1  and  LSA-3,  have  shown  a  remarkable  degree  of 
conservation,  in  contrast to  many other  P.  falciparum antigens.  Homologs of those  genes 
have  been  found  in  the  ape  parasite  P.  reichnowi and  for  some  of  them  the  sequence 
(e.g.  STARP)  determined.  Immunological  and  genetic  screening  of  other  plasmodial 
species  led  to  identification  of  an  equivalent  of  LSA-3  in  the  rodent  species  P.  yoelii 
which  in  particular share  8- and T-cell  epitopes with the  P.  falciparum gene and  open  the 
possibility  of  performing  immunization  and  challenges  with  the  rodent  species  in  labora-
tory  animals. 
For  immunization  purposes,  the  genes  have  been  cloned  in  various  types  of  vectors, 
expressed  in  prokaryotic,  eukaryotic  cells  and  naked  DNA vectors.  For  instance,  a very 
large  range  of  recombinant  expression  systems  are  now  available  for LSA-3  as  a model 
system. 
This,  together  with  the  large  number  of  lipopeptides  derived  from  the  above  molecules, 
provides a very  large  range  of  immunization  systems. 
51 Contract number TS3*CT920053 and  TS3*CT940346 
Experimental models 
One  of the  strengths of the  network lies  in  the  wide  range  of  model  systems available: 
The  primates  facilities  are  unique,  particularly  in  BPRC-TNO,  in  Cali  (Columbia)  and  in 
CIRMF  (Gabon)  by  their  having  chimpanzees  and  Aotus  colonies,  the  connected 
excellent  research  laboratory  facilities  and  the  malarial  expertise  of  the  corresponding 
teams. 
Chimpanzees at BPRC have been fully MHC-Ciass-1  and  Class-11  typed.  In  addition,  steps 
have  been  taken  to  develop  a  novel  model  in  Burma,  the  gibbon,  as  an  experimental 
system  for erythrocytic and  liver stages. 
The  IMTPL in  Belgium  has developed a colony of Thamnomys which  provided the means 
to  compare  host parasite  interactions in  natural  versus  artificial  hosts.  The  unique  set  up 
in  Nijmegen  has  provided  a  continuous  production  of  large  numbers  of  P.  falciparum 
sporozoites  for  immunological  studies  and  for  challenges.  In  addition  2  insectaries  were 
developed  in  Columbia  for  P.  falciparum  and  P.  vivax,  one  in  IMTPL for  P.  berghei and 
another one  in  Paris for  P.  yoelii.  Despite the  enormous difficulties of this model,  the  liver 
stage cultures of  P.  falciparum have  been  performed on  a discontinuous but regular basis 
in  Paris and  used to assess in vitro defence mechanisms towards  P.  falciparum sporozoite 
and  liver stages. 
Many  efforts  have  been  devoted  to  develop  a  SCID  mouse  model  enabling  support  in 
vivo  for  the  P.  falciparum  liver  stage  development  in  human  hepatocytes.  Satisfactory 
progress  has  been  made  in  this  direction  since  the  grafting  of functionally  active  human 
hepatocytes  has  been  successfully  performed  and  kept  for  up  to  four  months  in  this 
experimental  host..  However,  attempts to infect those  hepatocytes  in  vitro have  up  to  now 
been  unsuccessful. 
Field set ups 
Excellent field  facilities  have  been  developed  and  used  for  antigenicity studies  mostly  in 
Senegal,  in  Madagascar,  but also in  the  Congo,  in  Kenya,  in  Brazil,  in  Burma and  in  the 
Gambia.  The  contribution  of  those  centres  has  been  invaluable  for  the  identification  of 
epitopes for  B-cell,  forT-helper cells  and  for cytolytic T-cells. 
In  addition,  a novel type of field  study has  been  designed and  implemented to  investigate 
the  existence  of  naturally  occurring  anti-IMPES  immunity.  Some  individuals  appear  to 
develop a strong resistance to sporozoite challenge and the  correspondence between this 
and the immune responses developed to the molecules under study is expected to provide 
clues  about  which  molecules  induce  responses  which  contribute  to  protection  against 
MPES. 
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Antigenicity studies 
Using  peptides  and  recombinants  from  the  four  lead  molecules,  studies  in  five  endemic 
areas  have  identified  the  sequences  defining  B-cell  epitopes  and  have  showed  high  to 
very  high  sera-prevalences  to  them  (e.g.  97°/o  prevalence  to  LSA-3  repeats  in  Senegal 
spanning all age groups). Similarly T-helper cell  epitopes were mapped and  a correspond-
ence  between  the  level  of  malaria  transmission  and  the  proportion  of  T-cell  responders 
was observed (up to 85o/o T-cell responders to most peptides in the Congo). Many of those 
epitopes  were  also  found  to  be  able  to  stimulate  the  secretion  of  interferon  gamma,  the 
cytokine  known  to  be  the  most  potent  in  blocking  liver  stage  development.  One  LSA-3 
peptide induces the secretion of particularly high  concentrations of this cytokine.  Finally,  a 
very large number of  HLA class-1  restricted  CTL epitopes have  been  identified in  the four 
genes  under study:  6 in  LSA-1,  2 in  SALSA,  1 in  STARP  and  11  in  LSA-3. 
lmmunogenicity and vaccination studies 
Chimpanzee  and  Thamnomys  were  used  as  model  systems  to  analyze  the  protection 
induced per irradiated sporozoites and  the  immune responses  in  the  18  krad  chimpanzee 
paralleled those  recorded  in  human  volunteers immunized  in  the same  manner.  However, 
the  CDS  lymphocyte  depletion  planned  in  this  animal  could  not  be  performed.  Rodent 
modelling  revealed  an  inverse  relationship  between  the  susceptibility  of  the  host  to  the 
parasite  and  the  dose  of  irradiated  sporozoites  needed  to  achieve  protection,  i.e. 
protection  was  very  difficult  to  induce  in  Thamnomys  which  is  more  susceptible  than 
artificial  laboratory hosts. 
Using the four lead  molecules,  preliminary immunization attempts were performed in  mice 
of five  different H2  haplotypes with  many different synthetic  peptides  and  lipopeptides as 
well  as  recombinant proteins and  a large range of adjuvants.  One of the  most remarkable 
results was obtained with  lipopeptide which  proved able to  induce Th  and  CTL responses 
without adjuvant and to increase the immunogenicity to the point of apparently overcoming 
partially or totally the genetic restriction observed in  inbred mice. Therefore,  immunizations 
were  performed  in  chimpanzees  using  six  lipopeptides  injected  in  PBS  and  six  non 
lipopeptides injected in  montanide adjuvant,  or adsorbed on  microspheres.  By this means, 
T-helper  cell  responses  were  induced  to  all  twelve  peptides,  some  of  them  at  very  high 
level  (stimulation  indices> 80),  antibody  production  was  observed  towards  eleven  of  the 
twelve  peptides,  most of them  at very  high  levels. 
Moreover,  these  responses proved to  be  long  lasting and  to  be  specific to  parasite native 
proteins.  Finally,  CTL  responses  were  detected towards  six of  those  peptides.  Challenge 
studies  indicated  that  SALSA  and  mostly  LSA-3  held  the  best  promise  in  terms  of 
protection. 
A  large  number  of  immunization  schemes  were  used  in  mice  with  LSA-3  as  a  model 
system  to  assess  protection  against  P.  yoelii challenge. 
Results with QS21, titermax,  FCA or FIA were disappointing. To  date the best results were 
obtained  with  lipopeptide or with  microsphere  immunization which  have the  advantage of 
being  effective without adjuvant and  to  induce a full  range  of immune  responses. 
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In vitro study of defence mechanisms 
The  P.  falciparum  human  hepatocyte  in  vitro  system was used to  study defence mecha-
nisms. At very low concentration,  antibodies to  STARP and  LSA-3,  and also anti-SALSA 
antibodies strongly inhibited  P.  falciparum  sporozoite invasion.  lgM  from  irradiated sporo-
zoite  volunteers  proved  more· efficient  than  lgG  antibodies.  Several  attempts  to  show 
whether CTL cells could lyse human or chimpanzee infected hepatocytes have been made 
so far without reaching  a conclusive result.  However the conditions necessary to achieve 
this goal have considerably improved.  For instance, a method enabling the raising of CTL 
malaria specific CTL lines from healthy volunteers, developed in  Oxford, increases greatly 
the chances of matching the  MHC Class-1  antigen from the effector cells with  that of the 
target  hepatocytes.  One  drug,  already  developed  and  used  clinically,  proved  to  be  very 
effective  in  vitro  upon  P.  falciparum  liver  stages  but  not  against  P.  yoelii  liver  stages. 
G-Oiigonucleotide primers derived from LSA-3 were used in  a PCR assay which proved to 
be  the  most  sensitive  diagnostics  mean  available  to  date  to  detect  very  low  grade  P. 
falciparum  blood  infection. 
In  total,  these  studies  have confirmed  the  potential  of the  molecules  under study,  which 
antigenicity and  immunogenicity as well  as conservation  among  isolates  appeared to  be 
remarkable.  The vaccination  schemes  employed  up to  now may not yet be optimal,  but 
have yielded very encouraging results,  and the conditions to assay the efficacy of further 
immunization schemes have greatly improved. 
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MALARIA ASEXUAL BLOOD STAGE  EUROPEAN  NETWORK (MAS),  II 
Period: 
Co-ordinator: 
Objectives 
October 1,  1992- September 30,  1995 
MAX PLANCK INSTITUT FOR IMMUNBIOLOGIE 
Breigau, Germany (J.  LANGHORNE) 
•  The overall  objective of this part of the  malaria asexual blood stage European  Network 
(MAS)  is to acquire some insight into the immune response to the asexual blood stage 
of malaria  parasites with  special  emphasis on  Plasmodium falciparum. 
•  To  integrate  studies  on  the  analysis  of  the  asexual  blood  stage  antigens  MSA-1, 
MSA-2,  PF83  and  GLURP. 
Activities 
The  specific activities of this  project are: 
Year 1 
To  determine  the  phenotype  and  function  of T cells  from  immune  individuals  before  and 
after stimulation  in  vitro  with  whole  P.  falciparum  infected  erythrocytes.  1  0-20  individuals 
from  each  of the  following  age  groups  0-5,  6-10,  11-14,  15-19,  20+  will  be  monitored  in 
Benin  on  two  separate occasions over the one year period.  Isolation and  cloning of 1  0  P. 
falciparum samples from  Benin.  PCR analysis of variability (MSA  1,  MSA-2), cataloguing of 
patients  (Malaria-specific antibody  responses,  different isotypes  and  specificities). 
aJ3T cell  responses of ten  immune adults in  Benin to SDS-PAGE separated proteins of  P. 
falciparum.  Basic epidemiological  survey of the  chosen  area  in  Benin.  From  the  selected 
immune individuals from ten  Benin function of T cells responding to  MSA-1 , MSA-2,  PF83 
and  GLURP. 
Year 2 
Further  analysis  of  phenotype  and  function  of  responding  T  cells  obtained  from  Benin. 
Extension  to  examination  of limited  numbers of samples  (5  to  10  in  different age groups, 
twice  a year)  from  Mozambique  and  Zimbabwe.  Analysis  of  variability  of  cloned  isolates 
(10-20  each  from  Benin,  Mozambique and  Zimbabwe). 
Analysis  of  Variability  of  three  to  five  selected  P.  falciparum  clones  in  vivo  in  Aotus 
monkeys. 
Further  characterization  of  malaria-specific  antibody  responses  and  titre  and  aJ3T  cell 
responses  of  the  same  immune  individuals  in  Benin  compared  with  1  0  individuals  in 
Mozambique and  Zimbabwe  in  cooperation  with  SSI  and  TNO. 
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Year 3 
Further T cell  analysis of the  remaining samples from  all  three areas in  Africa,  evaluation 
of antibodies and T cells in  longitudinal studies.  Evaluation of variability of MSA-1 , MSA-2, 
PF84  (in  collaboration  with TNO)  and  GLURP (in  collaboration  with  SSI)  over the 3 year 
period  in  all  areas. 
Expected outcome 
The network activity,  possibly with inclusion of new partners, will enhance the understand-
ing of asexual blood stage putative vaccine candidates. The elucidation of the mechanisms 
operating  at  the  asexual  blood  stage  P.  falciparum  antigens  through  the  analysis  of 
immune-responses developed against the stage by individuals living in  endemic areas may 
further help  in  the choice  of candidate  molecules for a vaccine against  P.  falciparum. 
Partners 
Max Planck Institute fur lmmunbiologie 
Stubeweg 51 
7800 Breigau (Freiburg) 
Germany 
Guys Hospital 
Dept. of Immunology 
London Bridge 
SE1  9RT London 
United Kingdom 
Universite Nationale de Benin 
Dept. Biochimie et Biologie Cellulaire 
B.P.  040320 
Cotonou 
Benin 
Centre National Hospitalier et Univ.  Cotonou 
Labo. de Parasitologie 
B.P.  7025 
Cotonou 
Benin 
J. Langhorne 
Tel:  +49n61/510.85.33 
Fax: +49n61/51 0.82.21 
E-mail: j.langhorne@ ic.ac.uk 
G.H. Mitchell 
Tel:  +44/171/955.44.21 
Fax: +44/171/357.75.63 
E-mail: ghm57@ miranda.umds.ac.uk 
A. Sanni 
Tel:  +229/30.1 0.24 
Fax: +229/30.1 0.24 
B.C. Sadeler 
Tel: +229/30.14.78 
Fax: +229/30.1 0.24 
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REGULATION  OF  SEXUAL  DEVELOPMENT  IN  MALARIA  PARASITES  AND  THE 
DESIGN  OF  LOGICAL INTERVENTION  STRATEGIES 
Period: 
Co-ordinator: 
Objectives 
September 1,  1992- December 31,  1993 
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE 
London,  United Kingdom (R.E. SINDEN), 
Through  collaborative  studies  and  associated  training  programmes,  the  project  aimed  to 
investigate  the  genetic-,  molecular-,  and  biological  regulation  of  sexual  development  of 
Plasmodium.  Through  the  information  gained  logical  intervention  strategies  would  be 
investigated. 
Activities 
Through  mutual  exchanges of personnel  and  reagents between the  participating  laborato-
ries  we  have  integrated the  particular expertise  of  each  laboratory  in  a series  of  studies, 
many  of  which  have  been  published.  The  diverse  methodologies  used  have  been 
described  in  these  publications and  are  therefore  not  repeated  here. 
Results 
Genetic regulation of sexual development 
By comparing the chromosomal  location of a large number of genes in  different strains of 
the  four  rodent  species,  our  data  indicated  that  there  is  very  little  gene  re-assortment 
between  non-homologous  chromosomes.  The  different  chromosomes  appear  to  form 
stable  linkage  groups  of  specific  genes  in  all  species.  We  have  initiated  a collaboration 
with  the  University of  Sao  Paulo  to  investigate  the  genome  organization  of  P.  vivax.  We 
tested small filters  (Piasmodipur;  Euro-Diagnostica, The  Netherlands) for removal  of white 
blood cells (wbc)  from  P.  vivax infected blood.  These filters effectively removed  wbc  while 
the  different  developmental  stages  of  the  parasites  were  not  trapped  in  the  filters.  The 
older blood  stages  of  P.  vivax (trophozoites,  schizonts  and  gametocytes)  could  easily  be 
separated  using  Nycodenz  density  gradient  centrifugation  from  uninfected  erythrocytes. 
These parasites have been successfully used for separation of the chromosomes in pulsed 
field  gel  electrophoresis. 
To  elucidate the  mechanism(s)  responsible  for chromosome  size  polymorphism  occurring 
during  mitotic  multiplication  of  Plasmodium  parasites  and  the  possible  correspondence 
between  the  appearance  of  karyotype  variants  and  the  loss  in  the  ability  to  undergo 
gametocyte  differentiation.  We  characterised  a  gametocyte-defective  clone  (HPE)  of  P. 
berghei which  emerged  during  asexual  multiplication  of  the  gametocyte  producer  clone 
8417HP.  It  exhibits  a large  subtelomeric  deletion  of  chromosome  5.  In  P.  falciparum the 
effect  of  a terminal  deletion  on  chromosome  9 (reported  to  be  associated  with  impaired 
gametocyte production) on stage specific control of gene expression in sexual differentiation 
was investigated. Differences in the sexual/asexual pattern of expression of the gametocyte-
specific  gene  Pfg27  were  found  both  at  the  level  of  the  protein  and  of  mRNA  species 
between the line harbouring the deleted chromosome 9,  its parental line 1776 and line 3D7. 
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There  is  evidence that all  genes known  so  far which  are  involved in  sexual  differentiation 
and  expressed  almost  exclusively  during  and  after  gametocytogenesis  are  clustered  on 
chromosome  5 of rodent  parasites.  These  genes are  -tubulin-1,  Pbs21,  C-type  rRNA and 
two  other characterized  genes. 
To  provide  evidence  of  the  genetic  diversity  of  the  "Pbs21  gene"  within  other  rodent 
malaria species,  attempts were  made  to  clone the  equivalent gene from  different species. 
The  P.  yoelii  equivalent  was  cloned  and  sequenced.  Screening  of  two  lg11  genomic 
libraries of  P.  vivax with  Pbs21  probes resulted  in  a number of positive clones between  1 
and  6 kb  in  size  but  none  of these  appear to  be  the  Pbs21  homologue. 
Molecular regulation of sexual development 
To  select  novel  P.  berghei genes  specifically  expressed  in  sexual  forms,  we  devised  a 
subtraction  strategy  using  gametocyte-producer  and  gametocyte-less  clones.  A  labelled 
eDNA  enriched  for  sequences  selectively  expressed  in  the  gametocyte-producer  clone 
8417HP  was  obtained  after subtraction  with  a large  excess  of  mANA prepared  from  the 
non-producer  clone  K173  and  used  to  screen  a  P.  berghei genomic  library.  Among  the 
positive clones, a novel gene which maps to chromosome 5 at a subtelomeric position was 
selected. 
Northern  analysis  using  stage  specific  RNA preparations from  pure  cultured  sexual  forms 
demonstrated  that  production  of  the  Pbs21  transcript  was  initiated  in  gametocytes  yet 
translation  is  evident  only  after  gametogenesis  and  the  transcript  is  considered  to  be 
translationally  repressed.  Preliminary evidence  indicates that the  start site  of transcription 
lies  - 350nt  upstream  of  the  translational  start  site  and  that  processing  of the  transcript 
occurs at the 3' end of the mRNA molecule. To find  regulatory elements for the expression 
of  Pbs21  two  larger eDNA clones  (1.1  and  1.25 kb)  encoding the  Pbs21  gene have  been 
sequenced,  639bp  of the  region  upstream  the  Pbs21  gene  have  been  described. 
In  situ detection  of  mRNA was  used  to  analyze  the  expression  pattern  of  mRNAs  for  a 
number  of  sexual  stage  specific  transmission-blocking  antigens,  including  Pbs21,  Psf25, 
Pfs28  and  Pfs230,  throughout  gametocytogenesis  of  P.  berghei and  P.  falciparum.  The 
initiation  of transcription  of these  mRNAs occurs  in  a staged  series following  commitment 
to  sexual  development.  Pbs21,  Pfs25,  and  Pfs28  mRNAs  accumulate  in  gametocytes  in 
the absence of detectable translation products (collaboration with  NIH,  Bethesda) suggest-
ing  that  post-transcription  mechanisms  operate  to  regulate  the  translation  of  the  protein 
(see  above). 
We  have developed probes which  allow the demonstration of transcriptional activity of the 
two  classes of  rRNA gene  in  the  highly developed  model  available  in  the  laboratory.  The 
probes  detect  the  external  transcribed  spacer  (ETS)  of  the  two  types  of  rRNA  unit  and 
demonstrate not only transcription but also the degree of conservation between the genes 
comprising  the  two  types  of  rONA  unit. 
To  identify cdc2  products in  P.  berghei extracts,  immunoblot assays were conducted using 
a · commercial  monoclonal  antibody  directed  against  the  highly  conserved  domain 
PSTAIRE.  A protein  of 30kDa was  detected  in  young  trophozoites  only.  We  were  able  to 
amplify a 1 kb  fragment  of a gene,  showing  a high  homology to  cdc2,  in  5  Plasmodium-
species:  P.  knowlesi,  P.  berghei,  P.  vinckei,  P.  chabaudi and P.  yoelii. 
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These  fragments  were  cloned  and  sequenced.  In  cooperation  with  the  University  of  Sao 
Paulo,  Brazil,  the  same  fragment  of  the  P.  vivax  gene  was  also  cloned  and  its 
DNA-sequence determined.  In  the  1 kb  fragment of all  species  under study,  three  introns 
are  present  at  conserved  loci.  By  comparing  these  introns  with  respect  to  a  number  of 
characteristics,  we  were  able  to  draw  some  conclusions  on  intron-organisation  and 
evolution  within  the  genus  Plasmodium. 
Biology of sexual regulation 
Mechanisms of transmission blockade in infected hosts. The natural decline of infectivity of 
gametocytes  three  days  post  infection  is  not  antibody  mediated  since  it  could  be 
demonstrated  that  the  pattern  of  infectivity  was  exactly  the  same  i.n  severe  combined 
immunodeficient  mice  (scid)  as  in  their  intact  Balb/c  congenic  partners.  The  resulting 
inhibition  of the  parasites'  sexual  cycle within  the  mosquito occurs within  one  hour of the 
mosquito feed.  To  date,  there  is  no  significant evidence that nitric oxide or its  derivatives 
are  involved  in  the  blockade  of either  P.  berghei or  P.  vinckei infections. 
Studies  were  carried  out  to  test  cryopreservation  efficacy  of  sexual  stages  of  P.  vivax 
malaria parasite from blood from patients. Zygotes were obtained in  vitro and unfrozen and 
cryopreserved  blood  infectivity was  tested  by  An.  albimanus infections.  The  proportion  or 
recovery was  similar to  that obtained  in  cryopreserved  asexual  stages of the  parasite. 
Development of logical intervention strategies 
Studies  on  the  expression  and  immunogenicity  of  recombinant  Pbs21  expressed  in  a 
baculovirus system  revealed  that: 
=>  Expression  of  the  recombinant  protein  in  insect  larvae  results  in  higher  yields  than 
expression  in  in  vitro systems. 
=> The  protein  is  indistinguishable  from  native  protein  by  means  of  conformation-
dependent antibodies. 
=>  Deletion  of  the  putative  signal  sequence  prevented  protein  expression  on  the  cell 
surface. 
=> Transmission-blocking activity induced by the full  length protein in  mice was higher than 
90°/o. 
We  have evidence that the protein has either a novel type of GPI  anchor or is an  acylated 
membrane  protein.  Neither  PIPLC  treatment  nor  nitrous  acid  deamination  had  any effect 
on  the  molecule but with  hydroxylamine treatment cleavage of the  membrane anchor was 
obtained. 
Infected blood erythrocytes obtained from  P.  vivax-infected patients, in their original plasma 
or  plasma  obtained  from  uninfected  normal  donors,  were  offered  to  An.  albimanus and 
transmission blocking activity was  estimated by comparison of the  infection  rates obtained 
with  the 2 preparations.  Protein extracts were prepared from  purified  P.  vivax gametocytes 
and used for immunoblot assays of sera with transmission blocking activity. Several protein 
bands were  identified. The  most frequently observed  were  protein  bands of  113,  1  03,  94, 
85,  68,  47,  41,  37  and  31  Kda. 
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Partners 
Imperial College of Science, Technology & 
Medicine 
Dept. of Biology 
Prince Consort Road 
South Kensington 
London SW7 288 
United Kingdom 
Rijksuniversiteit Leiden 
Dept. of Parasitology 
Postbus 9605 
2300 RC  Leiden 
The Netherlands 
lstituto Superiore di Sanita 
Labo. di Biologia Cellulare 
Viale Regina Elena 299 
00161  Rome 
Italy 
Centro de lnvestigacion del Paudismo 
Dept. of lmmunoparasitology 
Apartado Postal 537 
Tapachula 30700, Chiapas 
Mexico 
R.E. Sinden 
Tel:  +44/171/594.54.24 
Fax: +44/171 /594.54.24 
E-mail: r.sinden@ bio.ic.ac.uk 
C.Janse 
Tel:  +31/7/127.68.42 
Fax: +31/7/127.68.50 
M. Ponzi 
Tel:  +39/6/444.02.  70 
Fax: +39/6/444.00.18 
M.H. Rodriguez 
Tel:  +96/26.22.19 
Fax: +96/26.57.82 
E-mail: nrodriguez@ hotmail.com 
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MALARIA ASEXUAL BLOOD STAGE  EUROPEAN  NETWORK {MAS),  I 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1992 - September 30,  1995 
STATENS SERUM  INSTITUT,  DEPT OF PARASITOLOGY, 
Copenhagen, Denmark (B.  HOGH) 
+  The overall objective of the malaria asexual blood stage European Network (MAS)  is to 
acquire  a comprehensive  insight  in  some  of  the  basic  questions of the  biology of  the 
asexual  blood  stage  of  malaria  parasites  with  special  emphasis  on  Plasmodium 
falciparum. 
+ To  integrate  studies  on  the  analysis  of  the  asexual  blood  stage  antigens  MSA-1 , 
MSA-2,  Pf83  and  GLURP. 
Activities 
The  specific activities of this  project are: 
Year 1 
Production  of  prokaryote  expressed  GLURP  and  GLURP  fragments  in  E.  coli,  and 
eucaryote  expression  of  the  entire  GLURP  antigen  in  vaccinia  virus.  Map  potential 
protective  immunogenic  epitopes  of  GLURP  in  mice  and  rabbits.  Assess  the  protective 
immunogenicity  of  GLURP  in  Aotus  monkeys.  lmmunisations  will  follow  the  current 
protocol  at  WRAIR.  An  evaluation  of  GLURP  produced  in  E.  coli and  encapsulated  in 
liposomes with  lipid A,  and  GLURP recombinant vaccinia virus will  be  performed by SSI  in 
collaboration  with  WRAI R. 
Examine  the  expression  of  GLURP  in  liverstage  parasites.  Anti-GLURP  peptide  sera  will 
be  used  for  IFAT  and  immunoelectron  microscopy of  cryosections  of  liverstage  parasites 
taken  from  chimpanzees  infected with  P.  falciparum will  be  performed  by  SSI  in  collabo-
ration  with  TNO. 
Prepare  for  field  studies  in  Mozambique  and  Zimbabwe,  collect  baseline  parasitological 
and  entomological  data  and  establish  techniques  for  field  studies:  ELISA,  PCR  etc.  for 
both  molecular biological  and  immunological  studies will  be  performed  by  SSI  in  collabo-
ration  with  TNO  and  MPI  (begin  T cell  analysis,  spot  ELISA for  cytokine  production  and 
PBL phenotype before and  after stimulation with  antigens,  PCR analysis of antigen where 
necessary). 
Year 2 
Continue  the  activities  initiated  during  year  one.  Perform  field  studies  - parasite 
immunology and  entomology  in  Mozambique  and  Zimbabwe,  with  established  techniques 
performed  by  local  researchers  in  collaboration  with  SSI,  TNO  and  MPI. 
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Year 3 
To  correlate  human  immune  responses  to  GLURP  with  exposure,  age  and  disease  in 
longitudinal  epidemiology  studies  pertormed  by  local  researchers  in  Mozambique  and 
Zimbabwe in collaboration with SSI, TNO and MPI. Assess the conservation of the putative 
protective immunogenic epitopes of GLURP. 
Rounding  off  the  field  and  laboratory work.  Statistical  evaluation  and  presentation  of the 
results  in  relevant peer-reviewed journals.  Planning  new research. 
Expected outcome 
It  is  hoped that the network activity,  possibly with  inclusion of new partners,  will  enhance 
the  understanding of asexual  blood stage putative vaccine candidates. The elucidation of 
the  mechanisms operating at the asexual  blood  stage  P.  falciparum antigens through the 
analysis of immune responses developed against the stage by individuals living in endemic 
areas  may  further  help  in  the  choice  of  candidate  molecules  for  a  vaccine  against  P. 
falciparum. 
Partners 
Statens Serum lnstitut 
Dept. of Parasitology 
Artillerivej 5 
2300 Copenhagen 
Denmark 
Biomedical Primate Research Centre BPRC 
Dept. of Parasitology 
P.O.  Box 5815 
2280 HV Rijswijk 
The Netherlands 
Universita di Camerino 
Dipt. di  Biologia Molecolare, Cellulare, 
Ani male 
Via F.  Camerini 2 
62032 Camerino 
Italy 
Institute Nacional de Saude, MOZ 
Dept. of Blood Parasitology 
CP 264 
Maputo 
Mozambique 
Ministry of Health, Zimbabwe 
Blair Research Institute 
P.O.  Box 8105 
Harare 
Zimbabwe 
B.Hogh 
Tel:  +45/32.68.32.68 
Fax: +45/32.68.38.68 
A. Thomas 
Tel:  +31/1/584.25.38 
Fax: +31/1/584.39.86 
F.  Esposito 
Tel:  +39n/374.07.38 
Fax: +39n/374.07.64 
R.  Gama Vaz 
Tel:  +258/1 /42.03.68 
Fax: +258/1 /32.1 03 
S. Chandiwana 
Tel:  +263/470.39.19 
Fax: +263/479.24.80 
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MALARIA ASEXUAL BLOOD STAGE  EUROPEAN  NETWORK {MAS),  Ill 
Period: 
Co-ordinator: 
Objectives 
February 1  , 1993 - January 31 , 1996 
BIOMEDICAL PRIMATE RESEARCH CENTRE BPRC, 
DEPT.  OF PARASITOLOGY, 
Rijkswijk, The Netherlands (A. THOMAS) 
•  The overall objective of the  malaria asexual  blod  stage  European  Network (MAS)  is  to 
acquire a comprehensive insight into some of the  basic questions of the biology of the 
asexual  blood  stage  of  malaria  parasites  with  special  emphasis  on  Plasmodium 
falciparum. 
•  To  integrate  studies  on  the  analysis  of  the  asexual  blood  stage  antigens  MSP-1, 
MSP-2,  PF83/AMA-1  and  GLURP. 
Activities 
Year1 
Express  full  length  recombinant  PF83/  AMA-1  and  clone  and  express  full  length  recom-
binant  PV66/  AMA-1 ,  and  develop  mid/large  scale  expression  cultures.  Begin  rodent 
PF83/  AMA-1  immunisation  for cross  protection  studies. Assess  non-immune and  immune 
adult serum  reactivities with  PF83/AMA-1  to  establish  baseline  values. 
Year 2 
Purify PF83/  AMA-1  from  expression cultures in  amounts sufficient for 1)  seroepidemiologi-
cal  study,  2)  for  T-cell  lymphoproliferative  assay  in  endemic  areas  and  for  Aotus 
immunisation  trial.  Develop  a  similar  strategy  for  PV66/  AMA-1  and  develop  truncated 
constructs for  both  PF83  and  PV66  that  may  be  expressed  at  higher  levels.  Begin  mAb 
production  vs AMA-1  constructs. Assess  naturally occuring variation  in  PF83 and  analyse 
P.  reichenowi AMA-1  sequence. 
Year 3 
Continue  biochemical  and  immunological  characterization  of  AMA-1  molecular  family. 
Analyse  mAb  activity  against  parasite  development.  Determine  utility  of  Pichia  pastoris 
expression for PV66. 
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Results 
The  European  network  for  asexual  blood  stage  vaccine  development  has  followed  an 
integrated approach  and  has  benefited  significantly from  the  inclusion  of enthusiastic and 
productive  developing country partnerships.  Within  this  contract diverse  approaches  have 
been  followed  to  develop  an  understanding  of AMA-1  as  a vaccine  candidate  molecule. 
The work has  reinforced the candidacy of the  P.  falciparum 83  kDa AMA-1  molecule as  a 
target for parasite inhibitory responses,  by showing that despite the difference in molecular 
weight,  both 83 and 66  kDa forms of AMA-1  are similarly targeted by antibodies that block 
parasite  multiplication.  Purified  recombinant  PF83/AMA-1  was  highly  immunogenic,  and 
induced  parasite  inhibitory  responses. 
One  of  the  most  important  findings  was  that  a  new  yeast  expression  system,  Pichia 
pastoris,  is  ideally suited to very high  level  expression of the  P.  vivax form  of AMA-1 , and 
that  such  material  is  correctly  folded  and  immunogenic.  Discussions  surrounding  the 
generation  of  clinical  grade  PV66  have  been  initiated.  The  prospects  for  P.  falciparum 
AMA-1  expression  in  this  efficient  system  are  also  promising.  A transcriptionally  active 
block to  P.  falciparum AMA-1  expression has been  identified and the gene mutagenised to 
try to  overcome the  problem. 
Because AMA-1  is  so  highly constrained  in  its conformation,  any deviation from  a "native" 
type  structure  may  have  significant  negative  consequences.  All  eucaryotic  expression 
systems are  likely to  glycosylate,  often  very  heavily,  at  sites  within  the  gene that are  not 
normally glycosylated. All  potential N-glycosylation sites were identified, and conservatively 
removed  by mutagenesis (AMA-1  does not appear to  be glycosylated in the parasite). This 
has  been  completed  for  P.  falciparum,  P.  vivax and  P.  knowlesi AMA-1  molecules.  As  a 
result  a  highly  homogeneous  product  is  now  produced  in  the  expression  systems.  The 
folding of the mutagenised recombinant AMA-1  molecules is equivalent to the "native" form 
of the molecule. Similar levels of PV66 expression were obtained for both molecular forms, 
and  comparative  studies  are  underway. 
Initial  work  with  a  naked  DNA  system,  using  mutagenised  AMA-1  variants,  suggest  that 
expression  of AMA-1  can  be  achieved.  Given  the  immunogenicity of AMA-1  that we  have 
also shown, it suggests that even at low level expression DNA vaccination may be of great 
value  for AMA-1. 
Using  the  most  effective  recombinant  systems  that  we  have  so  far  identified  for  P. 
falciparum  AMA-1  and  P.  vivax AMA-1  (baculovirus  and  yeast  respectively),  we  have 
devised  purification  regimes  to  provide  material  for  a wide  range  of  studies.  AMA-1  has 
been  prepared  for  ELISA  (and  made  available  to  many  groups  worldwide),  for  T-cell 
studies  and  for immunisation  studies. 
Evidence  that  P.  falciparum AMA-1  could  be  functionally  blocked  came  from  studies  on 
mAbs  to  the  molecule.  Two  mAbs  were  identified  that  inhibited  red  cell  invasion  by  the 
merozoite.  Sera  from  endemic  regions  contained  antibody  specificities  that  strongly 
competed with the binding of these mAbs to AMA-1  immunisation of rats and mice induced 
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polyclonal  antibodies  that  also  blocked  parasite  multiplication.  During  the  immunisation 
studies  a  variety  of  adjuvants  and  immunising  doses  were  compared.  There  was  clear 
evidence that even  without  adjuvant the  molecule was  higlhy immunogenic. 
An  immunisation study using an Aotus  monkey challenge  model  has been  completed and 
is  being  evaluated. 
One  of  the  most  intriguing  studies  has  analysed  the  molecular fate  of AMA-1.  This  has 
produced the first evidence for malaria parasites of a processing dependant re-localisation 
of  antigen.  Furthermore,  the  molecular  characteristics  of  AMA-1,  and  the  timing  of  the 
processing  serve to  link the  molecule  intimately with  red  cell  invasion. 
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Partners 
Biomedical Primate Research Centre BPRC 
Dept. of Parasitology 
P.O.  Box 5815 
2280 HV Rijswijk 
The Netherlands 
Rijksuniversiteit Leiden 
Dept. of Parasitology 
Postbus 9605 
2300 RC  Leiden 
The Netherlands 
Statens Seruminstitut 
Dept. of Parasitology 
Artillerivej 5 
2300 Copenhagen 
Denmark 
lnstituto Nacional de Saude, Moz. 
Dept. of Immunology 
CP 264 
Maputo 
Mozambique 
University of lbadan 
Dept. of Zoology 
lbadan 
Nigeria 
Max Planck lnstitut fur lmmunbiologie 
Stubeweg 51 
7800 Breigau (Freiburg) 
Germany 
A. Thomas 
Tel:  +31/1/584.25.38 
Fax: +31/1/584.39.86 
E-mail: thomas@itri.avg.mbc.tno.nl 
A.  Waters 
Tel:  +31/7/127.68.58 
Fax: +31/7/127.68.50 
E-mail: Waters@rullf2.1eidenuniv.nl 
B.Hogh 
Tel:  +45/31.95.28.17 
Fax: +45/31.95.58.22 
J.  Barreto 
M. Nwagwu 
E-mail: library@ kdl.ui.edu.ng 
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NATURAL AND  ARTIFICIALLY  INDUCED  IMMUNITY AGAINST  PLASMODIUM  LIVER 
STAGES 
Period: 
Co-ordinator: 
Objectives 
September 1  , 1993 - August 31 , 1996 
GROUPE HOSPITALIER PITIE-SALPETRIERE, 
Paris,  France (D.  MAZIER) 
•  To  analyze  the  immune  response  induced  by "known"  multi-stage  epitopes  expressed 
during the  hepatic phase of  malaria parasite development. 
•  To  identify "new"  epitopes expressed  on  the  surface  of  infected  hepatocytes. 
•  To  gain an  insight into immune regulation between the hepatic and  the other stages of 
infection,  with  an  emphasis on  the development of cerebral  malaria. 
Activities 
1.  Studies will  concern: 
*  T-cell  epitopes of the  non-repetitive part of the CS  protein  (P.  falciparum,  P.  yoelii and 
P.  berghe1). 
*  Heat-shock like epitopes  (P.  falciparum). 
*  Merozoite surface  proteins  MSP1  (P.  falciparum and  P.  yoelil). 
Work will  be  focused  on: 
*  MHC-restricted cytotoxicity mediated  by  CD4+ and  CDS+  T cells. 
*  Antibody dependent cellular cytotoxicity (ADCC). 
Immunizations will  be  performed  using the epitopes alone or coupled together in  Multiple 
Antigen  Peptide systems (MAPs).  In  vitro studies carried out in  parallel with those  in vivo 
will  utilize  hepatocytes  and  other  liver  cells  from  the  same  host  in  order  to  make 
comparisons  as  valid  as  possible  between  both  in  vivo  and  in  vitro  infections,  and  the 
human  and  animal  studies in  culture. 
2.  The  natural  peptide fragments  of  P.  fa/ciparum,  P.  vivax and  P.  yoelii antigens  will  be 
isolated  by acid  extraction and  extracts will  be  fractionated  by reverse-phase  HPLC. 
Individual  peptide fractions will  be  tested: 
*  For their ability to  react with  sera from  immunized and  protected  animals or with  sera 
from  humans  living  in  endemic areas. 
*  For  their  ability  to  stimulate  splenic  T  cells  obtained  from  the  same  animals  or 
peripheral T lymphocytes from  humans. 
In positive fractions, peptide structure will be determined by microsequencing. Peptides will 
then be synthesized. DNA probes will be synthesized from the primary structure of isolated 
peptides,  amplified by the  PCR  method and  the genes coding for these proteins localized 
in  a  DNA  library.  The  peptides  will  then  be  analyzed  for their  immunogenicity  and  their 
potential  role  in  protection. 
3.  We  shall  investigate  whether  interference  with  hepatic  stage  development  modulates 
subsequent cerebral  malaria complications. 
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The role  of cytokine regulation  will  be analyzed  in  humans in  endemic areas by following 
changes in cytokine profiles and pattern of reinfection. We shall interpret these data using 
rodent  malaria  infections  in  the  natural  hosts  and  in  mice  with  different  haplotypes  and 
backgrounds. 
Expected outcome 
=>A better knowledge of the plasmodial antigens that could induce protection against the 
hepatic stages. 
=>A better  understanding  of  the  host-parasite  interaction,  specially  the  parasite  mecha-
nisms of escape from  the  immune  response,  to aid  in  development of a vaccine. 
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REGULATION  OF  SEXUAL  DEVELOPMENT  IN  MALARIAL  PARASITES  AND  THE 
DESIGN  OF LOGICAL INTERVENTION  STRATEGIES 
Period: 
Co-ordinator: 
Objectives 
January 1,  1994 - March 31,  1996 
IMPERIAL COLLEGE OF SCIENCES, TECHNOLOGY & MEDICINE, 
DEPT.  OF BIOLOGY,  London,  United Kingdom (R.  SINDEN) 
Through  collaborative  studies  and  associated  training  programmes,  the  proJect  aimed  to 
investigate  the  genetic,  molecular  and  biological  regulation  of  sexual  development  of 
Plasmodium.  Though  the  information  gained  logical  intervention  strategies  would  be 
investigated. 
Activities 
Through  mutual exchanges of personnel  and  reagents between the participating laborato-
ries  we  have  integrated the  particular expertise  of  each  laboratory in  a series of  studies, 
many  of  which  have  been  published.  The  diverse  methodologies  used  have  been 
described  in  these  publications and  are  therefore  not  repeated  here. 
Results 
Expression and immunogenicity of recombinant transmission-blocking antigens 
A preliminary  comparative  study  assessing  the  immunogenicity  of  full  length  Pbs21  and 
Pbs21  lacking the anchor region  has shown that antibodies reactive to native Pbs21  were 
induced in  both  groups of immunized mice,  however pronounced differences in the titre of 
antibody  responses  in  Western  blot  analyses and  in  the  transmission-blocking  activity of 
immune  sera were observed. 
Three  recombinant  baculovirus  containing  the  full  length  coding  region  of  Pfs28,  the  P. 
falciparum homologue of Pbs21,  were purified and patterns of protein expression  in  insect 
cells  was  determined  by  Western  blot  analysis,  and  optimal  conditions  for  antigen 
production were determined. The immunogenicity of the recombinant protein will  be tested 
in  immunization  experiments  and  compared  to  recombinant  Pfs28  expressed  in  yeast 
(obtained  from  NIH,  Bethesda). 
A  plasmid  for  DNA  vaccination  containing  the  Pfs28  gene  was  constructed.  Plasmid 
mediated  protein  expression  will  be  tested  using  a mammalian  cell  system. 
A novel  P.  berghei sexual stage specific protein was identified.  Native protein was purified 
by  electroelution.  Preliminary  data  suggest  that the  protein  is  expressed  in  zygotes  and 
ookinetes starting approximately 6 h after activation of gametocytes. Immune sera against 
the  protein  and  monoclonal  antibodies are currently being  developed to further character-
ize  the  protein  and  to screen  an  ookinete specific eDNA library. 
rRNA regulation 
In situ hybridization confocal  laser scanning microscope studies on  the  regulation  of rRNA 
during sexual  development are  described elsewhere  in  the  report. 
The  identification  of proteins that are  phosphorylated/dephosphorylated. 
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The phosphorylating and  H1  kinase activities of extract preparations of  P.  chabaudi and  P. 
berghei parasites  were  analyzed  along  the  erythrocytic  cycle.  In  experiments  using  P. 
berghei extracts, histone was intensively labelled in young trophozoite extracts; this activity 
decreased  in  mature trophozoites  and  disappeared  in  schizonts.  Labelling  of  non-histone 
proteins  was  parasite  stage  specific:  a  band  of  >200  kDa  was  phosphorylated  in  young 
trophozoites,  a band  of 45kDa was  labelled  in  mature trophozoites and  a 40  kDa protein 
was  phosphorylated  in  schizonts.  Quantitative  analysis  of 
32P-ATP  incorporation  was 
carried  out in  P.  chabaudi.  Major histone  kinase  activity occurs  in  mature trophozoites.  In 
the  absence  of  histone,  no  incorporation  of 
32P- was  detected  in  schizonts.  When  H1 
histone  was  added,  stimulation  of  the  phosphorylation  occurred  in  all  asexual  parasite 
stage  extracts.  Experiments  to  study  phosphorylation  in  P.  berghei sexual  stages  have 
produced contradictory results  mainly because of asexual stage contaminations.  We  have 
standardized  purification  techniques  for  micro- and  macro- gametes,  zygotes  and  ooki-
netes  and  are  currently using  these  preparations. 
cdc-2  like  kinase  activity;  and  expression  of  cyclin  during  the  different  phases  of  the 
parasite  life  cycle.  The  peptide  sequence  reported  for  a  highly  conserved  region  of  the 
cyclin molecule of several species, between positions 201  and 335, named the "cyclin box" 
and  the  codon  usage  of  P.  falciparum  were  used  for  PeR-amplification  of  P.  chabaudi 
DNA.  The products obtained were cloned  in  the Small site of pBiuescript plasmid for their 
characterization.  The  sequencing  and  analysis  of  the  inserts  obtained  are  in  progress. 
Preliminary comparisons of the 400 bp band  indicated sequence homology with  human G 
protein coupled  receptor;  human  gene  1  AC;  and  several  anonymous sequences of the  P. 
falciparum  genome  (including  genomic  clone  0433).  The  amino  acid  sequence  shared 
homology  with  yeast  cell  division  control  protein  1  0  (20°/o  in  a  38  aa  strand);  mouse 
tyrosine receptor FLT4  (66°/o  in  a 10 aa strand),  a putative serine/threonine kinase R107.4 
(83°/o  in  a 6 aa strand) and a similar degree of homology (40°/o  in  18 aa strands) with zinc 
fingers  of  rat,  mouse and  human.  We  are  currently sequencing the other clones. 
Molecular karyotype changes related to gametocytogenesis in  P.  berghei 
and in  P.  falciparum 
In  P.  berghei  several  sexual-specific  genes  have  been  characterized,  which  map  to 
chromosome  5.  Moreover,  rearrangements  which  affect  this  chromosome  correlate  with 
defects in  the  gametocytogenesis.  Its  structural  organization  has been  studied  in  detail  in 
collaboration  with  the  University of  Leiden.  A long-range  map  of chromosome  5 from  the 
gametocyte-producer clone  8417HP,  taken  as  a  reference  clone,  has  been  constructed 
and  genes  hybridizing  to  it  positioned.  Subtelomeric  portions  of  this  chromosome  have 
been studied in  more detail. They are characterized by the presence of a region, extending 
60  kb  at  most,  shared  by  both  the  extremities  and  symmetrically  located.  This  region  is 
involved  is  most  large-scale  rearrangements  affecting this chromosome. 
In  P.  falciparum  the  role  of  the  terminal  portion  of  chromosome  9  in  gametocyte 
differentiation  has  been  investigated.  By  analyzing  a  synchronous  parasite  population  of 
line  HB3,  heterogeneous  for  the  size  of  chromosome  9,  it  was  shown  that  the  small 
fraction  of full-length  chromosome  9  was  preferentially  retained  in  those  parasites devel-
oping  into  gametocytes.  Studies  on  isogeneic  parasite  lines  (derived  from  isolate  1776) 
differing for the  size  of chromosome  9 demonstrated that parasites  harboring the deleted 
forms  do  not  enter the  earliest detectable  step  of sexual  differentiation.  This  suggests  a 
role of functions encoded in  that region of chromosome 9 in  the regulation of early events 
of sexual  differentiation. 
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Regulation of sexual/asexual gene expression 
A novel gene family,  which maps to the terminal portions of  P.  berghei chromosome 5 (one 
member  was  selected  by  subtraction  procedures),  has  been  characterized.  It  contains 
three  partially homologous genes which  share the  N-terminus of the  deduced  proteins. 
The  genomic region  of  one  of  these  three  genes  is  involved  in  large  scale  subtelomeric 
rearrangements  observed  in  two  characterized  gametocyte-defective mutants. 
A  P.  berghei  gene  (pb87)  conserved  within  the  Plasmodium  genus  is  also  being 
characterized The coding  sequence exhibits significant blocks of similarity with  a class of 
nucleosome assembly proteins.  The  nuclear localization  of  pb87 gene  product  has  been 
demonstrated both  in  P.  berghei and  P.  falciparum using specific monoclonal antibodies. A 
significant difference in the size of the corresponding transcripts has been  observed when 
comparing  sexual  and  asexual  parasites.  lntrons  have  been  detected  positively  and  a 
possible  mechanism  of  alternative splicing  is  under investigation. 
In  order  to  describe  the  promoter  of  Pfg27  gene  of  P.  falciparum  and  its  regulation,  a 
structural  and  functional  analysis  was  undertaken  on  the  genomic  region  upstream  the 
gene which  is active in  early stages of gametocytogenesis. Northern blot analysis,  RNAse 
protection  and  nuclear "run-off''  experiments  on  sexual  and  asexual  stages  permits  us  to 
state  that  the  expression  of  this  gene  occurs  at  the  level  of  transcription  initiation.  The 
gene is transcribed in the first 2 to 3 days of sexual differentiation, while it stops afterward. 
Genetic transformation 
This  work has  included: 
~  The successful development of a drug selectable system for the genetic transformation 
of the  rodent  malaria parasite,  Plasmodium berghei,  based  upon  the donation  of drug 
resistance  to  the  antimalarial  drug  pyrimethamine.  A copy  of  the  homologous  dhrf/ts 
gene  containing  a  Ser/Asn110  mutation  has  been  engineered  into  E.  coli  plasmids 
creating  transfection  vectors.  A  series  of  vectors  have  been  constructed  that  are 
designed to  integrate  in  a site  specific fashion  into the  parasite genome. 
~The  use  of  the  system  to  transform  and  select transformed  parasites  that  maintained 
the vectors as  episomes. The further characterization of the biological  properties of the 
plasmid  DNA maintained  in  the transformed  parasites. 
~  The successful and site specific introduction of foreign DNA into subtelomeric regions of 
three  P.  berghei chromosomes demonstrating that subtelomeric structures can  support 
expression  of  RNA polymerase  II  transcribed  genes. 
Gene mapping 
Collaborative studies revealed  that the  location and  linkage of genes on  chromosomes of 
rodent  malaria  parasites  are  highly  conserved.  The  link  between  chromosome  5  and 
sexual development has been  investigated.  In  different non-gametocyte producing parasite 
clones a specific rearrangement in the subtelomeric regions of this chromosome has been 
observed  and  genes  involved  in  sexual  development  appear  to  cluster  on  this  chromo-
some.  In  one  of  our collaborations a  long  range  restriction  map  of the  chromosome  has 
been  produced  and  the  size  reduction  shown  to  consistently involve  rearrangements  in  a 
single region  of the chromosome. A YAC  library of a gametocyte producing parasite clone 
has been  produced and to date YACs covering 60o/o  of chromosome 5 have been isolated. 
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Gene expression 
The cloning and mapping of the 5' regions of model genes has resulted in  identification of 
the  promoter  regions  of  both  A-type  rRNA  genes  and  the  Pbs21  gene.  The  latter  was 
shown  by  in  situ mANA hybridization  on  bloodstage  parasites  to  be  transcribed  only  in 
female  gametocytes.  Transient  transfection  technology  for  the  functional  analysis  of the 
structure of these promoters is  under development. 
The precise pattern of expression of the stage specific rRNA genes has been determined 
throughout most of the  P.  berghei life cycle  (collaborations with  Imperial College). 
In collaboration with University of Sao Paulo, the cell cycle gene crk2 has been cloned and 
characterized  from  a  number of different malaria species  (P.  berghei,  P.  knowlesi and  P. 
vivax)  as  have  the  genes  encoding  the  ribosome  associated  EF-1  alpha  protein.  The 
genetic and biochemical characterization of crk2 is in  hand. This collaboration also initiated 
studies on the organization of the genome of P.  vivax involving a 6 week visit of a student 
from  USP. 
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STUDIES  ON  HUMORAL  AND  CELLULAR  IMMUNE  RESPONSES  IN  HUMANS  TO 
PREVIOUSLY  DEFINED  MALARIA VACCINE  CANDIDATES 
Period:  August 1,  1994 - July 31,  1997 
Co-ordinator:  INSTITUT PASTEUR,  Paris,  France (L.  PEREIRA DASILVA) 
Objectives 
Identification  of  B  and  T  cell  epitopes  present  in  recombinant  P  falciparum  antigens 
recognised  by  the  human  immune  system  in  relation  to  naturally  acquired  protective 
immunity; search for human genetic factors (in  particular HLA)  involved in the development 
of  immunity to  malaria infection. 
Activitie$ and Results 
Field studies on anti-disease and anti-parasite premunition 
Our  analysis  of  the  protective  role  of  parasite  antigens  is  based  essentially  on  the 
comparative  studies  of  immune  responses  in  protected  and  susceptible  individuals  ex-
posed  to  malaria  infection.  This  is  performed  by  a  longitudinal  clinical-parasitological 
survey with  a permanent follow-up  of human  populations from  endemic areas of Senegal 
and  Brazil:  a)  inhabitants  of  two  villages  (Dielmo  and  N'Diop)  in  the  holo- and  hyper-
endemic area in  Senegal and b) the Candeias, Urupa and  Porto Chuelo sites in  Rondonia, 
Brazil  (hypoendemic  malaria with  epidemic episodes). 
Previous studies from  various research  groups (including our own)  have  been  done using 
the  criteria  of  age  to  define  the  development  of  premunition.  However,  the  field  studies 
developed  by  our  groups  in  Senegal  and  Brazil,  in  the  last  year  show  the  limitation  of 
these simplified criteria. The following recent results illustrate these limitations and  make a 
case  for a more  precise  definition of premunition. 
Our  longitudinal  survey  allows  a comparative  clinical  and  parasitological  analysis  of  the 
populations  from  N'Diop  and  Dielmo  villages,  which  are  situated  only  5  km  apart  in  the 
Side  Saloum  area  of  Senegal.  The  presence  of  a  permanent  stream  running  through 
Dielmo  provides permanent breeding  sites for Anopheles mosquitoes and  an  intense and 
perennial  malaria transmission  (around 200 infective bites per person  per year).  In  N'Diop 
transmission occurs intensively only in the  rain  season  (around 20 infective bites per year 
concentrated  in  the  four months  rainy  period). 
The  annual  incidence of  malaria attacks  as  well  as  parasite  index differs considerably  in 
both  villages:  adults  from  N'Diop  present  a  higher  number  of  malaria  attacks;  children 
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under 5 years  old  from  Dielmo present twice as  many malaria attacks than  children  from 
N'Diop. However,  in N'Diop children over 5 continue to present a high frequency of malaria 
attacks  until  they are  12  - 14 years  old. 
Another interesting  observation  concerns the  evolution  of  clinical  immunity:  it is  accepted 
that premunition is characterised by a decrease in the number of malaria attacks. We tried 
to  verify  if  this  age  dependent  immunity  corresponds  also  to  a  decrease  in  intensity  of 
symptoms  in  immune adults.  However,  detailed studies of  symptoms and  quantified signs 
(temperature,  sudoresis,  vomiting)  indicates that  the  only clear difference  is  found  in  the 
duration  of the  symptoms. 
Other  observations  concern  the  non-specificity  of  clinical  immunity  conferred  by  malaria 
parasites.  In  Dielmo it is observed that clinical attacks by P malariae are quite rare  in spite 
of  the  high  prevalence  of  parasites of this  species  in  the  blood  of children.  In  Rondonia, 
Brazil,  where  clear  premunition  was  not  observed  in  various  cross-sectional  surveys. 
Interference  between  P falciparum and  P vivax infections  is  also observed. 
In  the  light  of  these  and  other  observations,  the  immune  status  (level  of  clinical  and 
anti-parasite  immunity)  is  now  defined  individually,  in  relation  to  the  evolution  of  the 
infection  in  the  child  or  in  the  adult  (asymptomatic  or  symptomatic;  stable  or  unstable 
parasitemia)  in  the  periods  preceding  and  succeeding  the  time  when  samples  of  sera 
and/or cells  are taken  for analysis. 
HLA typing 
Following  previous  analysis  of  HLA,  class  I antigens typing  of  Dielmo  habitants  we  have 
performed analysis of HLA-A,  B,  C,  DR and  DQ in  116 habitants of Dielmo from the Serere 
ethnic  groups.  No  statistically  significant  differences  were  observed  in  the  frequency  or 
distribution  of  the  25  different  alleles  identified  in  the  Dielmo  Serere  in  relation  to  the 
results  described  by  other  authors  concerning  the  Mandinka  groups  from  Senegal  and 
Serere  and  the  Mandinka groups of the  Gambia. 
Immunological studies in the endemic areas 
In  the  last  year  we  have  concentrated  our  studies  in  Dielmo  on  characterisation  of  the 
isotope specific antibody  responses  against total  and  specific  P falciparum antigens. 
This was justified by previous results showing the protective antibodies are not neutralising 
antibodies,  but  are  cytophilic  antibodies  (bind  to  Fe  receptors  of  macrophages).  The 
anti-parasite activity depending on  mechanisms of ADCI  and/or opsonization/phagocytosis. 
Serum  samples from  three cross-sectional  surveys  in  the  Dielmo village (145  habitants of 
all  age  groups)  were  used  for  analysis  of  antibody  isotypes.  In  a  first  approach,  total 
antigen  of  P falciparum was  used  for  measuring  total  anti-malarial  antibodies  of  the  lgM 
and  lgG  class  and  of  lgG  sub-classes  in  a  ELISA  assay.  Adults  had  higher  levels  of 
specific antibodies than  children.  With  lgM,  lgG2 and  lgG3  accounting  for the  difference. 
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Differences in  antibody levels were significant for lgG1,  lgG2,  lgG3 and  lgG4 between the 
lowest  and  the  highest transmission  seasons  (while  infective  bites/person/night  increased 
around 20 fold).  No  particular isotype distribution pattern could  be found to  be  associated 
with  any given  parasitemia level. The  relationship between the OD values of each  isotype 
and  the  risk  of  clinical  malaria  attack  (in  the  period  following  the  serum  sampling  was 
tested  using  a Poisson  regression  model.  Only the  lgG3 OD  increases were found  to  be 
associated  with  a  significant  reduced  risk  of  malaria  attack.  These  seroepidemiological 
data suggest that, whereas the total  lgG specific activity is not indicative of any given level 
of  protection  against  malaria,  the  level  of  lgG3  was  significantly  associated  with  the 
relative  susceptibility  to  clinical  malaria  attacks.  The  analysis  of  antigen  specific  lgG3 
levels  is  underway.  Preliminary  data  indicate  an  increase  in  anti  R45  and  anti  MSP-3 
antibodies of the  lgG3  isotope in  individuals with  reduced  risk of malaria attacks.  Studies 
are  also  in  progress  on  the  measurement of antibodies against the  different fragments  of 
the  C terminal  part of the  MSP-1  antigens concerning the 42  Kd  and  19  Kd  processing of 
products.  MSP-1 isolated  and  characterised  by  the  MAC  laboratory. 
The Rondonia samples show an  increase in the level of antibodies against EB200 (Pf332) 
and  Pf72  antigens  as  a function  of  age  and  exposure  to  malaria  infection.  However,  no 
correlation  could  be  observed  with  any  premunition.  lsotype  analyses  are  now  in 
progress. 
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IDENTIFICATION  OF  MALARIA VACCINE  CANDIDATES  BY  PASSIVE  TRANSFER  IN 
INFECTED INDIVIDUALS OF ANTIBODIES WITH  DEFINED  SPECIFICITIES 
Period: 
Co-ordinator: 
Objectives 
November 1  , 1994 - October 31 , 1997 
INSTITUT PASTEUR,  DEPT.  PARASITOLOGIE BIOMEDICALE 
Paris,  France (P.  DRUILHE) 
We  propose  here  a  novel  approach  to  vaccine  design  based  on  the  study  of  human-
parasite  interaction  both  for the  selection  of  molecules and  the evaluation  of  results,  that 
is an approach  in which the clinical and parasitological response of infected humans is the 
main  screen. 
Our objectives are: 
•  To  identify  the  target  antigens  of  acquired  immunity  ("premunition")  for  vaccination 
purposes. 
•  To  produce  and  evaluate  therapeutic antibodies. 
Activities 
*  Isolation  of  antibodies  with  well-defined  specificities  by  affinity-purification  of  human 
immune lgG  on  relevant peptides and  assessment of their "in  vivo efficiency by passive 
transfer in  recrudescent asymptomatic  P.  falciparum cases. 
*  Further  epidemiological  studies  by  means  of  in  vitro cell-antibody  cooperation  assays 
(ADCI)  in  order: 
- to  confirm  the  relevance  of  the  target  antigens  already  selected  and  to  identify 
cross-reactive  epitopes,  if any; 
- to  define  if there  are  other antigens targeted  by  host defense  mechanisms. 
*  Development of an  immuno-deficient mouse model  receptive to  human malaria in order 
to further our understanding of  host defense mechanisms and  relevant target antigens. 
*  Development  of  the  technology  of  recombinant  human  antibodies  specific  to  P. 
falciparum  antigens  as  a  means  of  producing  large  amounts  of  identical  antibody 
specificity(ies) which  may prove to  be  effective by passive transfer and  which  could  be 
used  for clinical  treatment. 
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Expected outcome 
The  present  project  is  expected  to  supply  a  novel  means  of  assessing  new  vaccine 
candidates  in  order to  speed  up  the  development of a malaria vaccine. 
In  view  of  the  lack  of  a  model  established  as  being  relevant  to  the  human-P.falciparum 
immune  relationship,  this  approach  to  vaccine  design  is  based  on  the  study  of 
human-parasite  interaction  both  for  the  selection  of  molecules  and  the  evaluation  of 
results,  is  therefore  clinical  and  parasitological  responses  of  infected  humans  are  the 
main  screen. 
Results 
The first objective has progressed according to plan 
=>The relevance  of MSP-3 as  a target of  protective antibodies was  confirmed  by  means 
of ADCI  studies. 
=>  In  addition,  we  have  now  identified  two  additional  targets  of  the  Monocyte-
dependent  Antibody-mediated  inhibitory  mechanism  (ADCI).  One  of  them  is  the 
GLURP  molecule  expressed  at  the  merozoite  surface  level  in  which  not  less  than 
five  8-cell  epitopes  were  identified;  affinity  purified  antibodies  were  produced  and 
each  of  the  epitope  specific  antibodies  proved  able  to  exert  an  in  vitro  inhibition  of 
P.  falciparum  growth  in  ADCI  assay.  Another  target  is  the  SERP  molecule  which  is 
studied  in  collaboration  with  the  groups  of  D.  Camus,  in  Lille,  and  of  J.  lnselburg 
in  the  USA. 
=>  Previous  indications  of  potentially  cross  reactive  epitopes  between  two  of  the  above 
three  molecules  were  not confirmed  by  further  investigations. 
=>  A potential  fourth  target of ADCI  has  been  identified  in  MSP-1  through  a collaboration 
with  Dr.  A.  Holder and  E.  Riley.  One  EGF domain  would  be  the  target of ADCI  type of 
defence without direct effect of an1ibodies,  and  the  second  EGF  domain  would  be  the 
target of a direct effect of antibodies. However, the  initial results are only indicative and 
deserve to be  re-evaluated  with  a novel  batch  of human  lgG  which  has  been  recently 
prepared  (see  below). 
=>  Considerable  efforts  have  been  devoted  to  the  development  of  an  improved  and 
reliable  P.  falciparum-SCID  mouse  model.  This  model  has first of all  a potentially very 
large  number  of  applications  in  the  field  of  drug  and  vaccine  design.  Moreover,  it 
becomes  more  important  than  previously  in  view  of  the  severe  delays  that  the  novel 
French  legislation  for  blood  derived  products  has  imposed  on  a  part  of  our  project 
(see  below  8).  Compared  to  the  initial  protocol,  we  have  introduced  a  number  of 
modifications  to  the  scheme  of  additional  immunodulation  of  the  mouse  immune 
system. 
=> These  methods  have  enabled  us  to  reach  higher  parasitemia  up  to  38o/o  of  infected 
R8Cs.  However,  we  are  still  encountering  a  lack  of  reproductibility  in  the  results,  a 
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limitation to more extensive use of the model. We are therefore presently concentrating 
our work  on  means  to  improve  the  reproducibility.  Nevertheless,  preliminary  passive 
transfer experiments could be performed using whole human African  lgG from protected 
individuals and showed a total  absence of direct effect of clinically effective antibodies. 
Conversely,  we  have gathered evidence, though it now needs to  be confirmed, that the 
same antibodies become effective when  mice  are  grafted with  human  monocytes. 
~  We  have also performed systematic studies on  the  best technical conditions to perform 
on  a  large  scale,  and  ultimately  in  GMP  conditions,  the  affinity  purification  of  defined 
antibodies extracted from  whole African  lgG,  upon  insoluble peptide covalently coupled 
to  a  matrix.  One  of the  difficulties  is  that the  antibodies  of highest  affinity  cannot  be 
detached from  the affinity column  without denaturation.  However,  through  a systematic 
study  of  various  releasing  agents,  one  ensuring  the  best  compromise,  has  been 
identified for MSP-3. 
The second objective contains 2 distinct parts 
~The in  vivo  study  of  the  clinical  effect  of  defined  antibodies  is  suffering  considerable 
delay due to the major changes which were made to blood derived products regulations 
following  the  haemophilus  scandal  and  Ebola  virus  epidemic.  This  is  understandable, 
but  induced  unexpected delays  in  the  handling  of plasma of African  origin  by Western 
transfusion  centers.  Nevertheless  progress  could  be  made  so  that  the  new  pool  of 
African  malaria-immune plasma is  now ready,  and  that fractionation at bench  level,  but 
in  the same conditions used for GMP preparation,  can  now be  made and  will  serve at 
least for pre-clinical  steps  (e.g.  ADCI  and  SCID  work). 
~  The other part about recombinant antibodies carried on  in  collaboration with  Dr.  Dziegel 
has progressed well.  Lymphocytes RNAs were successfully extracted from  two pools of 
twenty African donors living in  a hyperendemic area of Senegal. The yield and integrity 
of RNA was  satisfactory and  allowed the successful preparation of two eDNA libraries. 
From  the first library,  the screening of malaria specific recombinant antibodies was first 
performed  using  GLURP  antigen  by  panning  of  filamentous  phages  and  led  to 
identification  positive  clones.  The  specificity of these  antibodies,  first  demonstrated  by 
ELISA,  was  confirmed  by Western-Blotting  as  well  as  by immunofluorescence studies. 
Further screening  of the  libraries with  MSP-3 antigens  is  now planned. 
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ASSESSMENT OF IMMUNE  RESPONSES INDUCED IN  PRIMATES  IMMUNIZED WITH 
LIPOPEPTIDES  DERIVED  FROM  P.  FALC/PARUM MPES ANTIGENS 
Period:  January 1  , 1995 - December 31 , 1998 
Co-ordinator:  INSTITUT PASTEUR, DEPARTEMENT PARASITOLOGIE BIOMEDICALE 
Paris,  France (P.  DRUILHE) 
Objectives 
•  To  construct  single  and  multiple  epitope  peptides  containing  a  lipid  moiety  using  the 
sequences already identified  in  LSA 1,  LSA3,  SALSA and  STARP  molecules. 
•  To  analyze the  immune  response  induced  in  primates by such  peptides. 
Activities 
The  immune  responses  induced  by  lipopeptides  in  mice,  chimpanzee  and  Aotus will  be 
analyzed  in  order,  firstly to  detect 8,  T and  CTL responses and secondly to  evaluate the 
possible  importance of CTL in  defence against human  malaria liver stages. 
Results 
~Additional epitopes  have  been  identified  by  elution  of  self-peptides  from  defined  HLA 
antigens  namely:  A2,  88,  827,  8W53,  835,  by  further  determination  of  amino-acids 
sequences of pooled  peptides and  identification  of critical  binding  residues,  by identifi-
cation in the sequence of MPES antigens of octamers and nonamers bearing the same 
motif, by synthesis and testing of these peptides in  an  HLA-assembly assay,  and finally 
by CTL assays performed in  malaria-exposed populations, for instance 11  CTL epitopes 
were  identified  in  the  LSA3  antigen. 
~  Larger peptides (16-34 AA)  including a lipid  moiety (Palmitoyi-Lysine)  introduced  using 
a simple and  single step procedure  have  been  synthesized  on  the  basis of the  above 
findings,  or of predictions  based  on  molecular analysis  (i.e.  flexible junction  areas)  for 
antigenic analysis and  mostly for immunization  purposes. 
~The  lipo-peptide LSA3-NR II, of 26 amino acids, derived from the Plasmodium falciparum 
LSA3 antigen was first employed for immunisation of mice and chimpanzees. 
Comparative immunisation  by this  peptide  with  and  without the  lipidic tail  shows tha-t: 
~  The  C-terminal  addition  of  a  palmitoyl  chain  can  dramatically  increase  Th  cell  re-
sponses  in  a wide  range  of  mice  MHC  Class-11  haplotypes,  to  the  extent  that  strong 
responses  were  induced  in  animals  otherwise  unable  to  respond  to  the  peptide  by 
classical  immunization,  (i.e.  with  Freund's adjuvant); 
~  The  increased  immunogenicity of the  lipopeptide  led  to  high  and  long  lasting  antibody 
production  without the  need to  use  powerful  adjuvants,  i.e.  with  a formulation  that can 
be  used  in  humans; 
~  8  and  T-cell  responses  induced  by  the  lipopeptide  were  reactive  with  native  protein 
epitopes; 
·- large  lipopeptides  can  be  endogenously  processed  to  associate  with  Class-1  and 
elicit CTL responses; 
~  the  lipopeptide was  safe  and  highly immunogenic  in  chimpanzees,  whose  immune 
system  is  similar to  the  human  system; 
- 8  and Th  responses were  induced  in  6 out of 6 immunized chimpanzees and  CTL 
were  detected in  5 of 6 chimpanzees with  diverse  MHC  background. 
Further studies were performed with 5 additional palmitoyl-lysine peptides derived from the 
SALSA,  the  LSA 1,  the  LSA3,  the STARP antigens in  mice,  in Actus and  in  Chimpanzees. 
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The  results  obtained  support  the  lipopeptide  based  approach  since  they  showed  that  a 
very simple immunogen formulation,  which can be used for vaccination in  humans,  is safe 
and  strongly  immunogenic:  in  chimpanzees  strong  T-lymphocyte  proliferative  responses 
were  recorded  to  each  of the  five  immunogens.  Interferon  gamma  secretion,  a  cytokine 
known to have the most potent effect upon  liver stage development, occurred in  response 
to  4  out  of  5  peptides.  High  to  very  high  antibody  titers  were  recorded  to  4  of  the 
immunizing  antigens  (1/5  does not define  a 8  cell  epitope,  as  shown  by epidemiological 
studies).  Moreover,  the  responses  induced  by  lipopeptides  injected  in  saline  without 
adjuvant  proved  to  be  long  lasting  since  they could  be  detected  up  to  ten  months  after 
immunization. The  relevance  of the  results obtained was  demonstrated by specific 8  and 
T  cell  responses  in  the  lipopeptide  immunized  animals  towards  native  proteins  on  the 
sporozoite surface of  P.  falciparum.  Similar results were  also obtained  in  Aotus monkeys. 
Finally,  in four out of six cases lipopeptides injected in  saline proved able to  induce a HLA 
class  I restricted,  CDS  dependent, cytolytic activity.  However,  the specific activity obtained 
in  this was in  general terms relatively low (in the range  12 to 25°/o  specific lysis), as is the 
case  in  people exposed to malaria in  the  field. 
Altogether these  results  suggest  that  relatively  large  synthetic  peptides,  carefully chosen 
from  critical  areas of large proteins,  and  incorporating a simple palmitoyl-lysine which  are 
simple to  produce and  purify under GMP conditions can  induce,  without adjuvant,  a wide 
range  of strong  and  long  lasting  immune  responses  in  genetically diverse populations. 
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MALARIA PRE-ERYTHROCYTIC STAGES (MPES) EUROPEAN NETWORK ANTIGENS 
TARGET OF IMMUNE RESPONSES CAPABLE OF INHIBITING  P.  FALCIPARUM PRE-
ERYTHROCYTIC DEVELOPMENT 
Period: 
Co-ordinator: 
Objectives 
January 1,  1995 - December 31,  1997 
INSTITUT PASTEUR, DEPT.  PARASITOLOGIE BIOMEDICALE 
Paris, France (P.  DRUILHE) 
•  Development  of  the  immunology  of  MPES  with  the  aim  of  developing  an  effective 
MPES vaccine. 
•  Acquisition  of an  improved  knowledge  of the biology of MPES. 
•  Improved  coordination  and  exchanges  within  and  between  European  and  Developing 
Country teams. 
Activities 
The  European  malaria  pre-erythrocytic  stages  network  is  aimed  at  elucidating  the  basic 
biology of,  as well  as developing control  means against,  human  malaria.  It includes: 
*  Molecular biology studies of pre-erythrocytic antigens from  mostly  P.  falciparum and  P. 
berghei,  and  in  part  P.  reichenowi (identification,  characterisation,  production  of genes 
and antigens: LSA  1, a major 200 kDa molecule expressed in  liver stages; SALSA, a 70 
kDa antigen  shared between sporozoite and  liver stages;  LSA3-729, a pre-erythrocytic 
stage specific molecule expressed in  sporozoites and liver stages;  DG21,  a sporozoite 
specific  78  kDa  molecule).  Antigenic  features  of  these  molecules,  conservation  of 
epitopes  amongst isolates,  epitope  mapping;  immunogenicity in  animals,  characterisa-
tion  and  prevalence  of  immune  responses  in  humans  and  in  animals  (mice  and 
primates),  identification  amongst the  remaining  series of cloned  pre-erythrocytic stage 
molecules of those that deserve further detailed studies. 
*  Improvement of the  reproducibility  of  liver infections  in  Aotus  monkeys.  Immunisation, 
and  sporozoites challenges,  of chimpanzees and Aotus with  P.  falciparum antigens,  of 
mice  and  Thammomys  with  P.  berghei,  P.  yoelii antigens.  Analysis  of  the  immune 
responses  developed  by immunised  animals and  of the  type  of defence  mechanisms 
operating.  Comparison  of  the  type  of  immunity  induced  by  antigens  and  by  whole 
parasites  (i.e.  irradiated sporozoites)  in  natural versus artificial  hosts. 
*  Analysis of naturally occurring immunity to MPES in field conditions, of the mechanisms 
regulating  parasite  loads  at the  MPES  level,  and  of the  main  antigens  inducing  such 
mechanisms.  Analysis  of  the  artificial  immunity  induced  by  injection  of  y-irradiated 
sporozoites,  and of the  mechanisms and antigens responsible for such  an  immunity. 
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*  Studies of the mode of action and the respective importance of antibodies, antibody-cell 
cooperation,  lymphocyte  cytotoxicity  and  cytokines  using  P.  falciparum  and  human 
hepatocytes,  under in  vitro conditions  or in  vivo in  SCID  mice. 
Expected outcome 
Our main  goal  is  the  development of  an  effective  means  of vaccination. 
Additionally the  project  cou~d provide: 
=>An  improved  understanding  of  the  human  P.  falciparum  relationship  at  MPES  level, 
mainly through  an  analysis of existing  regulatory mechanisms developed against those 
stages by exposed individuals and their epidemiological consequences in various areas 
differing  in  their vectorial  capacity. 
=>  Improved cohesion  of  European  research  in  epidemiology and  diagnostics in  concerta-
tion with  Developing Countries enabling a sustainable research strengthening in  malaria 
endemic areas. 
Results (so far) 
In general, the malaria pre-erythrocytic stage network has provided a tremendous increase 
in  the  output of  studies  on  the  molecular biology,  immunology and  cell  biology of  human 
malaria  liver stages. 
Molecular biology 
4  out  of  4  of  the  new  P.  falciparum  molecules  being  studied  namely  STARP,  SALSA, 
LSA-1,  LSA-3  have  been  characterized  in  terms  of  their  full  length  DNA  sequence  and 
stage specific expression,  and we  have initiated the study of three new MPES genes,  DG 
64,  DG  6F  and  DG  571,  two  of  them  in  collaboration  with  Nijmegen  and  BPRC. 
Immunological  studies  with  isolates  of  P.  falciparum  at sporozoite  stage  have  shown  the 
consistent  expression  of  those  genes  and  comparison  of  sequence  data  for  areas  of 
immunological  interest  of  LSA-1  and  LSA-3,  have  shown  a  remarkable  degree  of 
conservation,  in  contrast to  many other  P.  falciparum antigens.  Homologs of those  genes 
have been found  in the ape parasite  P.  reichnowi and for some of them the sequence (e.g. 
STARP)  determined.  Immunological and  genetic screening of other plasmodial species led 
to  identify an  equivalent of  LSA-3  in  the  rodent species  P.  yoelii which  in  particular share 
B- and  T-cell  epitopes  with  the  P.  falciparum  gene  and  open  the  possibility  tQ  perform 
immunization  and  challenges with  the  rodent  species  in  laboratory animals. 
For  immunization  purposes,  the  genes  have  been  cloned  in  various  types  of  vectors, 
expressed  in  prokaryotic,  eukaryotic  cells  and  naked  DNA vectors.  For  instance,  a very 
large  range  of  recombinant  expression  systems  are  now  available for  LSA-3  as  a model 
system.  This,  together  with  the  large  number  of  lipopeptides  derived  from  the  above 
molecules,  provides  a very  large  range  of  immunization  systems. 
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Experimental models 
One  of the  strengths of  the  network lies  in  the  wide  range  of model  systems available: 
The  primates  facilities  are  unique,  particularly  in  BPRC-TNO,  in  Cali  (Columbia)  and  in 
CIRMF (Gabon)  by their having chimpanzees· and Aotus colonies,  the connected excellent 
research  laboratory  facilities  and  the  malarial  expertise  of  the  corresponding  teams. 
Chimpanzees at BPRC  have been fully MHC-Ciass-1  and  Class-11  typed.  In  addition, steps 
have  been  taken  to  develop  a  novel  model  in  Burma,  the  gibbon,  as  an  experimental 
system  for  erythrocytic and  liver stages. 
The  IMTPL in  Belgium  has  developed  a colony  of Thamnomys which  provided  means  to 
compare  host  parasite  interactions  in  natural  versus  artificial  hosts. 
The  unique set ·up  in  Nijmegen has  provided a continuous production of large numbers of 
P.  falciparum  sporozoites  for  immunological  studies  and  for  challenges.  In  addition  2 
insectaries were developed in  Columbia for P.  falciparum and  P.  vivax, one in  IMTPL for  P. 
berghei and  another one  in  Paris for  P.  yoelii. 
Despite  the  enormous  difficulties  of  this  model,  the  liver  stage  cultures  of  P.  falciparum 
have been  performed on  a discontinuous but  regular basis in  Paris and  used to  assess in 
vitro defence  mechanisms towards  P.  falciparum sporozoite and  liver stages. 
Many  efforts  have  been  devoted  to  develop  a  SCID  mouse  model  enabling  support  in 
vivo  for  the  P.  falciparum  liver  stage  development  in  human  hepatocytes.  Satisfactory 
progress  has  been  made  in  this  direction  since  the  grafting  of functionally  active  human 
hepatocytes  has  been  successfully  performed  and  kept  for  up  to  four  months  in  this 
experimental  host.  However,  attempts to  infect those  hepatocytes  in  vitro have  up  to  now 
been  unsuccessful. 
Field set ups 
Excellent field  facilities  have  been  developed  and  used  for  antigenicity  studies  mostly  in 
Senegal,  in  Madagascar,  but also in  the  Congo,  in  Kenya,  in  Brazil,  in  Burma  and  in  the 
Gambia.  The  contribution  of  those  centres  has  been  invaluable  for  the  identification  of 
epitopes for B-cell,  for T-helper cells  and  for cytolytic T-cells. 
In  addition,  a novel type of field  study has  been  designed and  implemented to  investigate 
the  existence  of  naturally  occurring  anti-IMPES  immunity.  Some  individuals  appear  to 
develop a strong resistance to sporozoite challenge and the correspondence between this 
and the immune responses developed to the molecules under study is expected to provide 
clues  about  which  molecules  induce  responses  which  contribute  to  protection  against 
MPES. 
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Antigenicity studies 
Using  peptides  and  recombinants  from  the  four  lead  molecules,  studies  in  five  endemic 
areas  have  identified  the  sequences  defining  B-cell  epitopes  and  have  showed  high  to 
very  high  sera-prevalences  to  them  (e.g.  97o/o  prevalence  to  LSA-3  repeats  in  Senegal 
spanning all age groups).  Similarly T-helper cell epitopes were mapped and a correspond-
ence  between  the  level  of  malaria  transmission  and  the  proportion  of T-cell  responders 
was observed (up to 85°/o T-cell responders to most peptides in the Congo). Many of those 
epitopes were  also found  to  be  able to  stimulate  the  secretion  of interferon  gamma,  the 
cytokine  known  to  be  the  most potent in  blocking  liver stage development. 
One  LSA-3  peptide  induces  the  secretion  of  particularly  high  concentrations  of  this 
cytokine.  Finally,  a very  large  number of  HLA class-1  restricted  CTL epitopes  have  been 
identified  in  the four genes under study:  6 in  LSA-1,  2 in  SALSA,  1 in  STARP  and  11  in 
LSA-3. 
lmmunogenicity and vaccination studies 
Chimpanzees  and  Thamnomys  were  used  as  model  systems  to  analyze  the  protection 
induced per irradiated sporozoites and the  immune responses  in  the 18 krad chimpanzee 
paralleled those  recorded  in  human volunteers  immunized  in  the  same  manner. 
However,  the  COB  lymphocyte depletion  planned  in  this animal  could  not be  performed. 
Rodent modelling revealed an  inverse relationship between the susceptibility of the host to 
the  parasite  and  the  dose  of  irradiated  sporosoites  needed  to  achieve  protection,  i.e. 
protection  was  very  difficult  to  induce  in  Thamnomys  which  is  more  susceptible  than 
artificial  laboratory hosts. 
Using the four lead  molecules,  preliminary immunization attempts were performed in  mice 
of five  different H2  haplotypes with  many different synthetic peptides and  lipopeptides as 
well  as recombinant proteins and a large range of adjuvants. One of the most remarkable 
results  was  obtained  with  lipopeptide  which  proved  able  to  induce  without,  Th  and  CTL 
responses without adjuvant and to  increase the immunogenicity to the point of apparently 
overcoming  partially  or  totally  the  genetic  restriction  observed  in  bred  mice.  Therefore, 
immunizations were  performed  in  chimpanzee  using  six lipopeptides injected  in  PBS  and 
six non  lipopeptides injected  in  montanide adjuvant,  or adsorbed on  microspheres. 
By this means, T-helper cell  responses were induced to all twelve peptides, some of them 
at  very  high  level  (stimulation  indices >  80),  antibody  production  was  observed  towards 
eleven  of the twelve  peptides,  most of them  at very high  levels. 
Moreover, these  responses proved to be  long  lasting and to be specific to parasite native 
proteins.  Finally,  CTL responses  were  detected towards  six of those  peptides.  Challenge 
studies  indicated  that  SALSA  and  mostly  LSA-3  held  the  best  promise  in  terms  of 
protection. A large  number of immunization schemes were  used in  mice with  LSA-3 as  a 
model  system  to  assess protection against  P.  yoelii challenge. 
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Results with QS21, titermax,  FCA or FIA were disappointing. To  date the best results were 
obtained  with  lipopeptide or with  microsphere  immunization which  have the  advantage of 
being  effective without adjuvant and  to  induce a full  range  of  immune  responses. 
In vitro study of defence mechanisms 
The  P.  falciparum  human  hepatocyte  in  vitro system  was  used  to  study defence  mecha-
nisms.  At  very  low concentration,  antibodies to  STARP  and  LSA-3,  and  also  anti-SALSA 
antibodies  strongly inhibited  P.  falciparum sporozoite  invasion.  lgM  from  irradiated  sporo-
zoite  volunteers proved  more  efficient than  lgG  antibodies. 
Several  attempts  to  show  whether  CTL  cells  could  lyse  human  or  chimpanzee  infected 
hepatocytes  have  been  made  so  far  without  reaching  a  conclusive  result.  However the 
conditions  necessary  to  achieve  this  goal  have  considerably  improved.  For  instance,  a 
method  enabling  the  raising  of  CTL  malaria  specific  CTL  lines  from  healthy  volunteers, 
developed  in  Oxford,  increases greatly the  chances of matching the  MHC  Class-1  antigen 
from  the  effector cells  with  that  of the  target  hepatocytes.  One  drug,  already developed 
and  used clinically,  proved to be  very effective  in  vitro upon  P.  falciparum liver stages but 
not against  P.  yoelii liver stages. G-Oiigonucleotide primers derived from  LSA-3 were used 
in  a PCR assay which proved to be the most sensitive diagnostics mean available to date 
to  detect very low grade  P.  falciparum blood  infection. 
In  total,  these  studies  have  confirmed  the  potential  of the  molecules  under study,  which 
antigenicity and  immunogenicity as  well  as  conservation  among  isolates  appeared  to  be 
remarkable. 
The  vaccination  schemes  employed  up  to  now  may  not yet be  optimal,  but  have  yielded 
very .encouraging  results,  and the conditions to  assay the efficacy of further immunization 
schemes  have  greatly improved. 
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THE AFRICAN  MALARIA VACCINE TESTING  NETWORK 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1996 - June 30,  1998 
NATIONAL INSTITUTE FOR MEDICAL RESEARCH, 
Dares Salaam, Tanzania (W.  L.  KILAMA) 
To  establish an African  malaria vaccine testing network. To  facilitate coordinated  multicen-
tre  malaria vaccine studies. 
Activities 
*  Establish  a  secretariat  for  the  network  at  the  National  Institute  for  Medical  Research 
(NIMR)  in  Dar es  Salaam. 
*  Convene  meetings of the  network coordinating  committees. 
*  Familiarize the  coordinating committee with  potential field  study sites. 
*  Distribute questionnaires,  collate questionnaires and  publish  a database and  a booklet 
on African  institutions undertaking malaria vaccine  research  and  on  potential field  sites 
for malaria vaccine trials. 
*  Suggest  programmes  for  training  of  African  scientists  in  various  aspects  of  malaria 
vaccine trials,  such as good clinical practices,  good laboratory practices, data manage-
ment. 
Expected outcome 
Publishing of a database and a booklet on African  institutions undertaking malaria vaccine 
research  and  on  potential field  sites for malaria vaccine trials.  Evaluation of potential field 
sites  for  malaria  vaccine  trials.  Initiation  of  courses  relevant  to  malaria  vaccine  trials. 
Creation of a forum for exchange of experiences regarding operational/logistical difficulties, 
as  well  as for scientific discussions. 
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SELECTION  OF  P.  FALCIPARUM GENES FOR  MPES VACCINE  DEVELOPMENT 
Period:  January 1  , ·1996 - December 31,  1998 
Co-ordinator:  INSTITUTE PASTEUR, 810 MEDICAL PARASITOLOGY, 
Paris,  France (P.  DRUILHE) 
Objectives 
+  To  further investigate the vaccine potential  of SALSA,  STARP,  LSA1  and  LSA3. 
+ To  improve  our  understanding  of  the  mechanisms  mediating  protection  against  P. 
falciparum  MPES  in  humans. 
+ To  investigate  the  potential  of  10  novel  MPES  genes  and  to  choose  those  which 
deserve further characterization  and  immunogenicity studies. 
Activities 
*  Using the 4 lead antigens (Ags) SALSA, LSA  1,  STARP and LSA3, whose antigenicity is 
established,  we  will  employ a series of antigen-presentation  systems,  namely  lipopep-
tides,  multiple  antigen  lipopep-tides,  recombinant  Ags  adsorbed  to  microparticles, 
DNA-based  immunization,  in  order  to  optimize  the  conditions  under  which  defence 
mechanisms are induced in  chimps,  in Aotus against  P.  falciparum and  in  mice against 
P.  yoelii.  Where  necessary  improved  recombinant  expression  systems  will  also  be 
evaluated. 
*  Perform  analysis  of  B,  Th,  CTL  responses,  and  identify  antigens  targeted  by  mecha-
nisms effective under in vitro conditions,  so as to provide an  understanding of the basis 
of protection  and  therefore develop adapted formulations. 
*  Develop  improved  in  vivo  and  in  vitro  screening  systems  to  evaluate  the  4  lead  Ags. 
Compare  antigen  specific  immune  responses  in  humans  and  in  chimpanzees  immu-
nized with  irradiated sporozoites.  Analyze the  relationship  between  immune  responses 
and protective status in  individuals exposed in  endemic areas. Analyze  in  vitro with the 
human and  chimpanzee hepatocyte model the various effector mechanisms directed to 
these  antigens.  Immunize  and  challenge  chimpanzees,  Aotus  and  mice.  Additional 
studies  in  rodents,  in  immunocompromised  animals  reconstituted  with  human  hepato-
cytes,  and  in  exposed  populations,  are  aimed  at  supplying  an  understanding  of  the 
immunological  basis  of  protection  in  natural  host-parasite  combinations  (P.  berghei in 
Thamnomys,  P.  falciparum  in  humans and  human  hepatocytes)  and  particularly study-
ing  CTL activity. 
*  Employ  the  conditions  of  immunization  defined  in  the  above  steps  to  investigate  the 
potential  of a further  1  0 novel  antigens. 
*  Extend the "best" antigens and presentation systems,  identified in these studies,  mostly 
in  chimpanzees  and  Aotus,  to  a  larger  groups  of  Aotus  so  as  to  gather  statistically 
significant data. 
Expected outcome 
A strengthened network of EC  and  DC  partners,  with  a better understanding of the critical 
effector  mechanisms  that  protect  humans  against  P.  falciparum  pre-erythrocytic  stage 
parasites.  From  this improved  understanding  we  expect to  develop a rational  strategy for 
human  MPES vaccine  development. 
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EVALUATION  AND  DELIVERY  OF  THROMBOSPONDIN  RELATED  ANONYMOUS 
PROTEIN  {TRAP) IMMUNOGENS FOR THE DEVELOPMENT OF MALARIA VACCINE 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1996 - December 31 , 1998 
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND 
MEDICINE, INFECTION AND IMMUNITY SECTION, 
London,  United Kingdom (A.  GRISANTI) 
To  evaluate,  in  different  models,  the  ability  of  TRAP  derived  immunogens  to  elicit 
protective  immunity against a challenge with  Plasmodium sporozoites. 
Activities 
*  Selection of delivery systems for inducing humoral immunity and specific CTLs against 
TRAP.  Few  antigen  delivery  systems,  have  been  shown  to  induce  both  humoral 
immunity and specific CTLs,  these  include:  recombinant vaccinia viruses;  lipidic  adju-
vants;  naked  DNA;  listeriolysin  0  (LLO)  of  L.  monocytogenes.  We  will  compare  the 
relative  efficacy of these  delivery systems to  induce an  appropriate  immune  response 
against P.  berghei TRAP immunogens containing B cell,  Helper and CTL epitopes. Cell 
lines  will  stably  transfected  with  a  series  of  DNA vectors  inducing  the  expression  of 
progressively deleted  PbTRAP constructs. 
*  Analysis  of TRAP epitopes variability among  P.  falciparum  isolates.  Polymorphisms  of 
immunologically  relevant  epitopes  will  render  problematic  the  use  of  TRAP  for  the 
development of a vaccine. A total of one hundred blood samples will  be collected from 
different locations of endemic areas in  Mali  at different time  points during the  malaria 
transmission season. Parasite DNA will be extracted from bloodspots and amplified with 
combinations of primers generating sequences of immunologically relevant T and B cell 
epitopes permitting  direct DNA sequencing to  look for mutations. 
*  Cloning  of  TRAP  homologues  from,  P.  knowlesi,  P.  cynomo/!}1  and  P.  fragile.  There 
are  no  perfect  host  systems  that  can  be  used  to  model  P.  falciparum  infection  in 
humans.  Aotus  and  Saimiri  genera  are  variably  susceptible  to  blood  stage  infections 
from  a  limited  range  of  adapted  parasite  species,  a  challenge  model  with  Aotus  is 
limited  to  the  use  of  particular  monkey  subspecies  (Aotus  lemurinus)  and  to  a 
particular  parasite  strain  (P.  falciparum  St.  Lucia).  Specific  PCR  products  will  be 
generated  from  parasite  DNA using  primers. for  regions  of TRAP  that  are  conserved 
between  the  Plasmodium  species.  Labelled  PCR  products  will  be  used  as  probes  to 
screen  A.gt  1  0/A.gt  11  genomic  libraries  developed  from  DNA  of  P.  knowlesi,  P. 
cynomolgi and  P.  fragile. 
*  Evaluation  of experimental  induced  PfTRAP  immunity against  Plasmodium  sporozoite 
challenge.  The  TRAP  gene  from  the  St.  Lucia  strain  will  be  amplified  in  PCR 
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experiments,  cloned  and  sequenced. A cohort consisting  of  1  0 adult animals of either 
sex will  be  randomly assigned to  three experimental  groups of five animals each.  The 
two  groups  of  monkeys  will  be  immunized  with  constructs  generated  using  either St. 
Lucia TRAP or a polymorphic PfTRAP variant. After thorough analysis of humoral and 
cellular  responses  all  the  monkey  cohorts  will  be  challenged  with  20,000  St.  Lucia 
sporozoites.  Monkeys will  be  observed  daily for parasitemia. 
Expected outcome 
It  is  anticipated  that  these  experiments  will  allow  us  to  select  an  appropriate  delivery 
system for TRAP derived immunogens inducing both  humoral and cell  mediated cytotoxic 
immunity. This information will  provide the  rationale for developing an  experimental TRAP 
vaccine for human trials. 
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A  CONCERTED  EUROPEAN  APPROACH  TOWARDS  THE  DEVELOPMENT  OF  MA-
LARIA VACCINES 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1996 - June 30,  1998 
STATENS SERUM  INSTITUT, OFFICE OF  INT.  HEALTH, 
Copenhagen, Denmark (S. JEPSEN) 
To  promote  a coherent  approach  to  the  development  of  malaria  vaccines.  This  requires 
focused  interactions between  vaccine  industrialists and  scientists  in  Europe  and  develop-
ing  countries,  concerned  with  malaria  antigens  and  with  the  wider  fields  which  underpin 
malaria vaccine  development.  To  identify and  exploit existing  structures  and  resources to 
support  malaria  vaccine  develop-ment  and  to  create  fora  for  the  regular  exchange  of 
information  on  planned  work,  progress  and  results  germane  to  malaria  vaccines.  To 
provide  a channel  for expert advice on  malaria vaccine  research  and  development to the 
European  Commission,  as  well  as  to  other  national  and  international  authorities.  To 
develop  partnerships  amongst  academia,  the  Public  Sector  Vaccine  Institutes  and  the 
European  Vaccine  Enterprises  and  to  promote  interaction  amongst  those  engaged  in 
malaria vaccine  research  and  development  in  Europe  and  elsewhere. 
Activities 
*  The  primary  core  activity  of  this  concerted  action  will  be  a series  of  expert  meetings 
addressing different aspects of malaria vaccine development. These meetings will  bring 
together groups of the  INCO-DC  (and  former STD3)  contract holders,  other experts  in 
the fields which  underpin the science base of a malaria vaccine, and  representatives of 
vaccine  manufacturers.  The  industries  and  public  sector  institutes  invited  to  specific 
meetings  include:  SmithKiine  Beecham  (Belgium),  Pasteur  Merieux  (France),  Chi-ron/ 
BIOCINE  (Italy),  Hoffman  LaRoche  (Switzerland),  Swiss  Vaccine  and  Serum  Institute 
(Switzerland),  Statens  Seruminstitut  (Denmark)  and  RIVM  (The  Netherlands).  Liaison 
with  the  European  Vaccine  Manufactures  (EVM)  is  ensured. 
*  Assistance tools will  be  updated  and  made  operational: The  Malaria Antigen  Database 
(with  WHO/TOR,  USAID  and  NIAID),  The  compendium  of  in  vitro  and  smaller animal 
models  (with  COST/STD  and  EVM),  the  PVEN  document (with  PVEN)  and  the  "Atlas" 
and  guidelines for field  trials  (with AMVTN). 
Expected outcome 
Vaccines  are  the  most  cost-effective  approach  to  control  of  transmissible  diseases.  The 
benefit  of  this  CA  is  in  its  role  in  expediting  and  rationalising  progress  towards  malaria 
vaccine development and  production.  Continual  discussions with  representatives from  the 
malaria  endemic  countries  will  benefit  the  process  of  malaria  vaccine  development. 
Developing  countries  will  benefit  from  the  proposed  action,  and  also  from  the  networks 
(PVEN  and AMVTN)  which  will  enhance the  influence of the  Developing Country partners 
on  the  process  of vaccine  development. 
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Partners 
International Center for Genetic 
Engineering and Biotechnology 
Malaria Research Group 
P.O.  Box 10504, Aruna Asalf Ali Marg 
11 0067 New Delhi 
India 
Universita di  Roma "La Sapienza" 
Piazzale Aldo Moro 5 
1st.  di Parassitologia 
00185 Roma 
Italy 
Institute of Malariology 
Parasitology & Entomology 
BC 10.200 
Hanoi 
Vietnam 
lnstitut Pasteur Paris 
Dept. Parasitologie Biomedicale 
28 Rue du Dr.  Roux 
75724 Paris Cedex 15 
France 
Katholieke Universiteit Nijmegen 
University Hospital Nijmegen 
Dept. of Medical Parasitology 
P.O  Box 9101 
6500 HB Nijmegen 
The Netherlands 
Centro Nacional de Biotechnologia 
Canto Blanco Campus 
Universidad Autonoma 
28049 Madrid 
Spain 
Universidad del Valle 
Fundacion Centro de Primates 
A.A. 25360 
Cali 
Colombia 
Nat. Institute for Medical Research 
Div.  of Parasitology 
The Ridgeway Mill Hill 
London NW7 1  AA 
United Kingdom 
V.  S. Chauhan 
Tel:  +91/11/617.73.57 
Fax: +91/11/616.23.16 
E-mail: icgeb@del2.vsnl.net.in 
A. Crisanti 
Tel:  +39/6/49.91.46.47 
Fax: +39/6/49.91.46.44 
LeDinh Cong 
Tel:  +84/454.30.34 
Fax: +84/454.30.35 
P.  Druilhe 
Tel: +33/1/45.68.85.78 
Fax: +33/1 /45.68.86.40 
E-mail: druilhe@pasteur.fr 
W.  Eling 
Tel:  +31/80.61.36.63 
Fax: +31 /80.54.02.16 
E-mail: medpar-jm@  aznvx1.azn.nl 
M. Esteban 
Tel:  +34/1 /585.45.03 
Fax: +34/1 /585.45.06 
E-mail: mesteban@ samba.cnb.uam.es 
S. Herrera 
Tel:  +57/25.58.19.31/19.46 
Fax: +57/25.58.1 0.61 
E-mail: soheva@ mafalda.univalle.edu.co 
A.  Holder 
Tel:  +44/181/959.36.66/21.75 
Fax: +44/181/913.85.93 
E-mail: a-holder@ nimr.mrc.ac.uk 
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Statens Serum lnstitut 
Office of International Health 
5 Artillerivej 
2300 Copenhagen S 
Denmark 
Nat.  lnst. for Medical Research Tanzania 
P.O.  Box 9653 
Dar es Salaam 
Tanzania 
The Medical School Guys Hospital 
Dept. of Immunology 
London Bridge 
London SE1  9RT 
United Kingdom 
Netherlands Org. for Scientific Research 
131  Laan van Nieuw Oost lndie 
2509 AC The Hague 
The Netherlands 
lnstitut Pasteur 
Unite d'lmmunologie Mol. des Parasites 
28 Rue du Dr Roux 
75724 Paris Cedex 15 
France 
London School of Hygiene & Trop. Med. 
Dept. of Medical Parasitology 
Keppel Street 
London WC1 E 7HT 
United Kingdom 
Biomedical Primate Research Centre 
Dept. of Parasitology 
P.O.  Box 5815 
2280 HV Rijswijk 
The Netherlands 
WELLCOME Trust Centre for Human 
Genetics 
Oxford OX3 7BN 
United Kingdom 
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S. Jepsen - CONTACT POINT 
Tel: +45/32.68.31.88 
Fax: +45/32.68.32.28 
E-mail: sjepsen @cb.diag.ssi.dk 
W.  L.  Kilama 
Tel:  +255/513.07.70 
Fax: +255/513.06.60 
E-mail: wkilama@ costech.gn.apc.org 
G.H. Mitchell 
Tel:  +44/171/955.44.21 
Fax: 44/171/955.88.94 
E-mail: ghm57@ miranda.umds.ac.uk 
B.  Mons - CONTACT POINT 
Tel:  +31n0/344.07.48 
Fax: +31n0/344.08.49 
E-mail: barend@innet.nl 
P.  Dubois 
Tel:  +33/1/45.68.80.00 
Fax: +33/1/40.61.31.85 
E-mail: pdub@pasteur.fr 
G. Targett 
Tel:  +44/171/927.23.24 
Fax: +44/171/636.87.39 
E-mail: g.targett @lshtm.ac.uk 
A. Thomas 
Tel:  +31/15.84.25.38/30.13 
Fax: +31/15.84.39.86 
E-mail: thomas@bprc.nl 
A. Hill 
Tel:  +44/1865n4.00.26 
Fax: +44/1865n4.21.96 
E-mail: a.hill @well.ox.ac.uk Contract number IC18*CT950021 
PRE-CLINICAL  STUDY  OF  THE  IMMUNOGENICITV  OF  MPS3  AND  GLURP  TWO  P. 
FALCIPARUM ANTIGENS TARGETED  BY PROTECTIVE ANTIBODIES 
Period: 
Co-ordinator: 
Objectives 
January 1,  1996 - December 31,  1998 
STATES SERUMINSTITUT, KLINISK BIOKEMISK AFDELNING, 
Copenhagen, Denmark (S. JEPSEN) 
To  optimize  the  immunogenicity  of  MSP3  and  GLURP  by  using  several  antigen-
presentation systems in  a)  mice,  b)  Saimiri,  c) Aotus,  and d)  Chimpanzee.  To characterize 
the  antibodies  (fine  epitope  specificity,  isotype)  induced  by  the  various  protocols,  and 
analyze their biological effect in  defence mechanisms, a)  in vitro,  invasion and ADCI,  b)  in 
vivo by  passive  transfer  in  the  humanized  SCID  mouse  and  in  c)  primate.  Compare  the 
results  with  P.  falciparum  challenge  experiments  in  the  primates  immunized  with  MSP3 
and  GLURP.  Complete the  characterization  of the  B and  T cell  epitopes from  MSP3  and 
GLURP by epidemiological  field  studies. 
Activities 
*  Immunizing  mice  with  one  lipopeptide,  and  one  recombinant  from  MSP3  and  one 
peptide  and  one  recombinant  derived  from  GLURP  with  the  different  adjuvants.  The 
titer,  and  isotype  as  well  as  the  ADCI  effect  of  the  antibodies  obtained  will  be 
determined. 
*  Aouts  will  be  BCG  primed,  immunized  with  PPD-coupled  GLURP  and  MSP3  and 
subsequently challenged  with  P.  falciparum. 
*  ADCI  experiments  will  be  conducted  in  SCID  mice  harbouring  live  P.  fa/cuparum and 
human  monocytes by  passively transferring total  lgG  from  hyperimmune  individuals to 
confirm  the  model.  Anti-RO,  anti-R2,  and  anti-MSP3  and  other  antibodies  will  subse-
quently be  analyzed  in  the  SCID  mode. 
*  Epidemiological  studies with  MSP3b  and  RO,  and  R2  in  Dielmo. 
*  Mice  will  be  immunized  with  new  peptides  and  recombinant  proteins  derived  from 
MSP3 and  GLURP with  the  best performing adjuvant. The titer,  and  isotype and ADCI 
effect of the  antibodies  induced  by  new constructs  will  be  determined. 
*  Immunizing  Aotus  and  Saimiri  with  the  GLURP  and  MSP3  vaccine  formulation  that 
induced  antibodies  which  prove  to  be  efficient  in  ADCI.  The  humoral  and  cellular 
immune  responses  of the  monkeys  will  be  analyzed. 
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*  The antibody reactivity to epitopes identified in  MSP3 clone 256 and 256B and peptides 
derived from  GLURP will  be  analyzed  in  the population  of  Dielmo. 
*  Immunizing Aotus and Saimiri with antigens provided that they are superior to the initial 
constructs.  The  immunogenicity  of  the  best  performing  MSP3  and  GLURP  antigen 
formulation  will  be  determined  in  Chimpanzees. 
Expected outcome 
The  optimal  conditions  for  inducing  antibodies  against  MSP3  and  GLURP will  be  deter-
mined  and  functional  protection  assays  established.  Improved  understand  of the  critical 
epitopes  involved  in  the  production  of  protective  antibodies and  cross-reactivity to  MSP3 
and  GLURP. 
Partners 
Statens Seruminstitut 
Klinisk Biokemisk Afdeling 
Artillerivej 5 
2300 Copenhagen 
Denmark 
lnstitut Pasteur de Paris 
Dept. of Biomedical Parasitology 
28 Rue du Dr Roux 
75015 Paris 
France 
lnstitut Pasteur de Lilla 
Laboratoire de Chimie des Biomolecules -
URA CNRS 1309 
1 Rue du Prof. Calmette 
59019 Lilla 
France 
Fundacion Centro de Primates 
Universidad del Valle 
Institute de lmmunologia 
AA 2188 
Cali 
Colombia 
Fundacao Oswaldo Cruz 
Dept. of Immunology Manguinhos 
Av.  Brasil 4365 
Rio de Janeiro 
Brazil 
S.Jepsen 
Tel:  +45/32.68.32.68 
Fax:  +45/32.68.38.68 
E-mail: sjepsen@ cb.diag.ssi.dk 
P.  Druilhe 
Tel:  +33/1/45.68.80.00 
Fax: +33/1 /45.68.86.40 
E-mail: druilhe@ pasteur.fr 
H. Gras-Masse 
Tel:  +33/3/20.87.77.76 
Fax: +33/3/20.87.  73.77 
S.  Herrera 
Tel: +57/25.58.19.46 
Fax: +57/25.58.1 0.61 
E-mail: soheva@ mafalda.univalle.edu.co 
C.D. Ribeiro 
Tel:  +55/21/590.35.45 
Fax: +55/21/590.35.45 
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THE APPLICATION  OF TRANSFECTION  TECHNOLOGY TO  MALARIA VACCINE  DE-
VELOPMENT 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1996 - December 31 , 1998 
UNIVERSITY OF LEIDEN  (RUL),  DEPT.  OF PARASITOLOGY, 
Leiden, The Netherlands (A.P.  WATERS) 
To  develop  DNA  expression  vector  systems  that  will  facilitate  the  introduction  of  genes 
encoding  proteins  with  vaccine  potential  into  asexual  bloodstages  of  the  rodent  malaria 
parasite,  Plasmodium  berghei.  To  study  the  following  model  genes:  Apical  membrane 
antigen  (AMA)  - 1,  erythrocytic  vaccine  candidate  Pbs21  ookinete  surface  protein, 
transmission  blocking  candidate  Circumsporozoite  (CS)  protein,  pre-erythrocytic  vaccine 
candidate. To  clone and  modify these genes in  such  a way that they can  be expressed in 
recombinant  P.  berghei parasites with a view to analyzing the regulation of their expression 
and  manipulating  the  immune  response  to  these  proteins.  To  isolate  DNA  elements 
(promoters)  involved in  the control of the stage specific expression of the three  P.  berghei 
genes to permit the appropriate expression of recombinant genes upon  re-introduction into 
the parasite.  To  attempt to  knock ouf these genes  in  the  P.  berghei parasite genome and 
demonstrate  their  immediate  biological  function  and  essential  nature.  To  re-introduce 
modified  copies  or  analogues  of  the  genes  into  the  knock-out  mutants  to  1)  restore  2) 
modulate  3)  demonstrate the  conserved  nature  of the  function  of the  encoded  protein. 
Activities 
*  Appropriate  vectors  for the  expression  of  genes  introduced  by  genetic  transformation 
into  the  rodent  malaria,  P.  berghei,  will  be  developed  based  upon  the  available 
DHFR!TS  selectable  marker  which  donates  resistance  to  the  antimalarial  drug,  py-
rimethamine. 
*  Attempts will be made to develop new selectable markers and vectors for the disruption 
and  modulation  of genes. 
*  The  relatively new system for the transfection of malaria parasites will  be disseminated 
throughout the  partner groups. 
*  The  technology for the dissection of promoter structure will  be  developed and  dissemi-
nated. 
Expected outcome 
The  study  should  provide  a  case  example  of  the  utility  of  transfection  technology,  as 
applied to  malaria parasites,  to  investigate the  function  as  well  as the  immunological  and 
biochemical properties of conserved proteins of malaria parasites that are considered to be 
candidate components of vaccine formulations. An  insight will be gained into the functional 
structure of stage specific promoters of gene transcription. This can be expected to include 
an  identification of those elements which dictate stage and sex specificity and those which 
direct basal  transcription. 
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Partners 
University of Leiden (RUL) 
Dept. of Parasitology 
Postbus 9605 
2300 RC Leiden 
The Netherlands 
International Centre for Genetic Engineering 
and Biotechnology (ICGEB) Nil Campus 
Malaria Research Group 
Aruna Asag Ali Marg 
110067 New Delhi 
India 
Imperial College of Science (IC) 
Dept. of Biology 
Prince Consort Road 
London SW7 2BB 
United Kingdom 
Institute Nacional de Salud Publica 
Centro de lnvestigacione de Paludismo (CIP) 
Poniente 
4AAv Norte 
Y 17 Calle 
Tapechula 30700 
Mexico 
Biomedical Primate Research Centre (BPRC) 
Dept. of Parasitology 
Lange Kleiweg 157 
2280 GH Rijswijk 
The Netherlands 
A.P.  Waters 
Tel:  +31n15.27.68.58 
Fax: +31n15.27.68.50 
E-mail: Waters@ rullf2.1eidenuniv.nl 
V.S. Chauhan 
Tel:  +91/11/686.73.57 
Fax: +9111686.23.16 
E-mail: Chauhan@ icgeb.trieste.it 
R.E. Sinden 
Tel:  +44/171/594.54.25 
Fax: +44/171 /594.54.24 
E-mail: R.Sinden@ ic.ac.uk 
M.H. Rodriguez 
Tel: +52196.26.22.19 
Fax: +52/96.26.57.82 
E-mail: nrodriguez@ hotmail.com 
A.W. Thomas 
Tel:  +31/15.84.25.38 
Fax: +31/15.84.39.86 
E-mail: Thomas@bprc.nl 
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CONCERTED ACTION IN  SUPPORT OF HIGH QUALITY NON-HUMAN PRIMATE (NHP) 
BREEDING AND  BIOMEDICAL RESEARCH  IN  NHP SOURCE COUNTRIES 
Period: 
Co-ordinator: 
Objectives 
September 1  , 1996 - August 31 , 1999 
BIOMEDICAL PRIMATE RESEARCH CENTRE, 
DEPT.  OF PARASITOLOGY, Rijswijk, The Netherlands 
(A.  W. THOMAS) 
•  To  develop  an  organisational  and  communication  framework  between  European  and 
Developing  Country  primate  research  centres  within  which  improvements  in  the  capa-
bilities for  research  on  health  problems of  Developing  Countries  and  improvements  in 
animal  welfare  can  most effectively be  realised. 
•  To  identify the  areas  for  improvement that  can  most  benefit from  collaborative  efforts 
and  co-ordinate the  implementation  of such  efforts. 
Activities 
*  Estab lish  Regional  Networks and appropriate regional centres for Latin America, Africa 
and  Asia.  Each  regional  centre  will  inform  primate  centres  within  the  region  of  the 
establishment  of  PVEN  and  invite  applications  to  participate  in  the  network.  Each 
regional  centre  will,  together  with  the  PVEN  advisory  board,  select  5  - 6 appropriate 
members who will  form  the  initial core  membership of PVEN. A European co-ordinating 
centre will  be  established and  the  PVEN  regional  centres,  together with  this  European 
centre,  will  invite  independent  experts  to  join  an  external  advisory  board  for  the 
network. 
*  Hold  regional  meetings  at  which  the  opportunities  for  collaborative  development  of 
improved  Research  and  Reference  standards  will  be  identified.  Specifically the  Refer-
ence Programme (published in  PVEN Guidelines) will be used as a starting point for the 
evaluation  of critical  factors  in: 
- colony  health  and  management  including  virological,  bacteriological,  fungal  and 
parasitological  testing,  the  implementation  of  welfare  standards,  haematology  and 
clinical  chemistry  (normal  and  pathological  values). 
- colony characterisation  and  development including  MHC  typing,  DNA fingerprinting, 
genetic conservation  of  laboratory species,  in  and  out-breeding,  reproduction  tech-
nology. 
- research  fundamentals  including  cytokines,  hormones,  blood  groups,  MHC,  CD 
markers,  cellular immunology techniques,  non-invasive  monitoring. 
- knowledge  resources  including  computer databases. 
- training  including  exchange  of  staff  to  transfer  specific  technologies  and  the 
establishment of accepted standards of training  in  primate care  and  use  for animal 
handlers. 
*  Identify  the  most  appropriate  sources  for  expertise  and  ensure  such  expertise  is 
available to  primate centres,  through  support of travel,  organisation  of workshops,  etc. 
in  order to  assist  in  the  implementation  of collaborative  efforts. 
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Expected outcome 
=>  Clearly  identified  priorities  for  collaborative  development  of  research  and  reference 
capabilities. 
=>Management  and  communication  structures  that  allow  rapid  and  free  exchange  of 
information  between  primate centres. 
=> Co-ordination  of the  improvement  of  capabilities,  ensuring  that  duplication  of effort  is 
substantially reduced  and that optimal  use  of scarce  resources  is achieved. 
Partners 
Biomedical Primate Research Centre 
Department of Parasitology 
151  Lange Kleiweg 
2288 GJ Rijswijk 
The Netherlands 
Primate Centre 
Immunology Institute 
Universidad del Valle 
PO Box AA2188 
Calle 4B No 34.00 
Cali 
Colombia 
Institute of Primate Research 
National Museums of Kenya 
PO Box 24481 
Nairobi 
Kenya 
Guangdong Shunde Institute of Laboratory 
Animals 
Shunde Daliang 
Guangdong 
China 
United Medical and Dental Schools 
The Medical School 
Guy's Hospital 
London SE1  9RT 
United KinQdom 
Centre de Primatologie 
Fort Foch 
67207 Niederhausbergen 
France 
A.W. Thomas 
Tel:  +31/15/284.2538 
Fax: +31/15/284.3986 
E-mail: thomas@bprc.nl 
S. Hererra 
Tel:  +572/588.1946 
Fax: +572/588.1 061 
E-mail: soheva@mafalda.univalle.edu.co 
C.  Bambra 
Tel:  +254/288.2571 
Fax: +254/288.2546 
E-mail: ipr@ elci.gn.apc.org 
Q. Sheng Chen 
Tel:  +765/26.22.897 
Fax: +  765/26.20.415 
G. H. Mitchell 
Tel:  +44/171/955.4421 
Fax: +44/171 /955.8894 
E-mail: ghm57@ miranda.umds.ac.uk 
N. Herrenschmidt 
Tel:  +33/3/88.56.12.68 
Fax: +33/3/88.56.02.30 
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IMMUNITY TO GENETICALLY CHARACTERISED MALARIA INFECTIONS: A COMPARI-
SON  BETWEEN  LONGITUDINAL  STUDIES  IN  A  WEST  AND  AN  EAST  AFRICAN 
VILLAGE EXPERIENCING  DIFFERENT INTENSITIES OF TRANSMISSION 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1997 - September 30, 2000 
UNIVERSITY OF EDINBURGH, INSTITUTE OF CELL 
ANIMAL AND POPULATION BIOLOGY, 
Edinburgh, United Kingdom (D.E. ARNOT) 
To  compare  the  molecular  parasitology  and  immunology  of  antigenic  variation  in  P. 
falciparum  malaria  in  an  area  of  high  transmission  and  hyperendemic  malaria  (Ghana, 
West Africa)  with  that  in  an  area of  hypoendemic,  unstable  malaria  (Sudan,  East Africa) 
and to discover whether parasite strategies for immune evasion by antigenic variation vary 
under different transmission  conditions. 
Activities 
*  Cloning  and  sequence  PfEMP-1/var  genes  and  gene  fragments  from  African  P. 
falciparum  samples  to  obtain  reagents  and  develop  assays  for  the  analysis  of  the 
genetics  of  the  PfEMP-1/var system  and  to  test  whether  clonal  antigenic  variation 
associated  with  var gene  switching  allows  the  parasite  to  survive  in  the  host  during 
chronic  malaria  infections. 
*  Characterising  the  immunological  and  parasitological  events  associated  with  the 
acquisition  of  agglutinating  antibody  responses.  To  attempt  to  correlate  agglutination 
responses  in  human  infections  from  Sudan  and  Ghana  with  the  appearance  of 
specific  responses  to  defined  parasite  encoded  adhesion  molecules  such  as 
PfEMP-1  and  sequestrin.  Building  on  ongoing  research,  to  compare  the  acquisition 
of  agglutinating  antibody  responses  with  the  acquisition  of  antibody  responses 
against  variant  and  conserved  portions  of  major parasite  merozoite  antigens  such  as 
MSP-1. 
*  Strengthening  molecular  biology  and  immunology  research  on  malaria  in  the  African 
partner  institutions  and  to  train  junior scientists  in  the  European  partner  laboratories. 
To  promote  scientific  exchanges  between  malaria  researchers  in  East  and  West 
Africa. 
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Expected outcome 
By  the  end  of  the  study  we  will  have  basic  epidemiological  data  on  the  period  that 
individuals  remain  asymptomatically  infected  at  each  study site  and  quantitative  data on 
whether parasite  densities  fluctuate  or  remain  broadly stable  during  asymptomatic  infec-
tions  at  each  site.  The  length  and  densities of gametocytaemia will  also  be  known.  This 
epidemiological  data will  allow us  to  interpret the  results  of the concurrent immunological 
and  molecular  biological  studies  on  typing  the  PfEMP-1 /var genes  (using  RT-PCR  and 
human  phage display library generated antibodies)  in  the  parasites isolated from  sympto-
matic and  asymptomatic individuals. 
This will  allow us to assay if,  and  how frequently,  the parasite population in the monitored 
asymptomatic  infections  is  switching  PfEMP-1  expression  and  whether  asymptomatic 
individuals  infected  with  an  apparently  genetically  stable  population  of  parasites  show 
constant  responses  in  mixed  agglutination  assays  or whether these  vary  in  concert  with 
var gene  switches. 
Such  reagents  and  information  will  be  essential  for  further  studies  on  the  role  of  P. 
falciparum antigenic variation  in  pathogenesis. 
Partners 
University of Edinburgh 
Institute of Cell Animal and Population 
Biology 
West Mains Road 
Edinburgh EH9 3JT 
United Kingdom 
Faculty of Medicine 
Biochemistry Department 
University of Khartoum 
P.O.  Box 102 
Khartoum 
Sudan 
Noguchi Institute for Medical Research 
University of Ghana 
P.O.  Box 25 
Leg on 
Ghana 
Centre for Medical Parasitology 
University of Copenhagen, M7641 
Tagensvej 20, 
2200 Copenhagen N 
Denmark 
D.E. Arnot 
Tel/fax: +44/131/650.86.55 
E-mail: d.e.arnot@ed.ac.uk 
G. Satti 
Tel/fax: +249/11/77  .53.51 
E-mail: biochem@sud.healthnet.org 
K.  Koram 
Tel:  +223/21/50.03.74 
Fax:  +223/21/50.21.82 
E-mail Karam:  noguchi@ mantse.gh.com 
T. Theander 
Tel:  +45/35.32.  76.77 
Fax:  +45/35.32.78.51 
E-mail: theander@ biobase.dk 
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MATHEMATICAL  MODELS  OF  THE  IMMUNOLOGICAL  AND  CLINICAL  EPIDEMIOL-
OGY OF  PLASMODIUM  FALCIPARUM  MALARIA 
Period: 
Co-ordinator: 
Objectives 
September 1,  1997- August 31,  2000 
EBERHARD-KARLS-UNIVERSITY, DEPT. OF MEDICAL BIOMETRY, 
TObingen,  Germany (K.  DIETZ) 
•  Construct  mathematical  models  of  the  immunological  and  clinical  epidemiology  of 
Plasmodium falciparum  (P.f.)  malaria,  and  test the  model  predictions against observa-
tions collected  independently of this  project. 
•  Use  the  models for helping to: 
a)  calculate the expected  impact of interventions; 
b)  improve the  design  of field  intervention trials; 
c)  identify crucial  gaps  in  knowledge that constrain  (a)  and  (b). 
Activities 
*  Review of relevant biological,  clinical,  and  epidemiological  knowledge 
*  Specification  of observations to  be  used  as  modelling targets: 
a)  longitudinal  data  on  the  behaviour of  P.f.  infection  and  disease  in  individuals  after 
one  or more  experimental  inoculations; 
b)  longitudinal data on the behaviour of P.f.  infection and disease in  individuals naturally 
exposed  to  repeated  inoculation; 
c)  longitudinal  data on  the  transmission  of  P.f.  and  the  behaviour of  P.f.  infection  and 
disease  in  naturally exposed  populations. 
*  Formulation  (and  reformulation)  and  programming of the  models. 
*  Design,  performance and  evaluation  of simulations. 
The  evaluation  will  consist  primarily  of  the  formal  comparison  of  simulations  to 
observations.  The  comparisons  will  suggest  revisions  of the  models'  assumptions and 
parameters values,  until  an  acceptable fit is  obtained. 
*  Formulation  of  recommendations 
The practical implications of the work will be made explicit, leading to recommendations 
in  the following  areas:  (a)  planning of malaria control;  (b)  evaluation of malaria control 
programmes and  of field  trials;  (c)  epidemiological  research;  (d)  research  on  statistical 
methods. 
Expected outcome 
Better simulation  models will  help to  clarify the  following  issues: 
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1)  Optimal adaptation of control  strategies,  using currently available methods, to different 
epidemiological  and  socio-economic situations,  including  projections  of what could  be 
expected from  additional  resources; 
2)  Expected  benefits  from  new tools  likely  to  be  technically  feasible,  including  different 
kinds of vaccines; 
3)  Optimal development and evaluation strategy of such  new tools. 
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PLASMODIUM  VIVAX  MALARIA  IN  MAN:  ANTI-DISEASE  AND  TRANSMISSION 
BLOCKING IMMUNITY 
Period: 
Co-ordinator: 
Objectives 
November 1  , 1992 - October 31 , 1995 
UNIVERSITY OF EDINBURGH, INST.  OF CELL, ANIMAL AND 
POPULATION BIOLOGY,  Edinburgh, United Kingdom (R.  CARTER) 
•  To  study the  mechanisms of immunity to disease in  P.  vivax and  P.  falciparum malaria. 
•  To  study immunity to  transmission  of  P.  vivax malaria in  human  populations. 
Activities 
*  The  disease  characteristics  of  P.  vivax  and  P.  falciparum  infections  in  naive  (non-
endemic)  individuals and  in  individuals from  an  endemic population were  recorded and 
characterised.  Cellular and  physiological  responses were measured both  in  vivo and  in 
vitro in  response  to  malaria exo-antigens.  The  presence  of antibodies  in  convalescent 
serum  was assayed for ability to  block the  induction  of cytokines and  other factors by 
the  action  of  malarial  exo-antigens  on  human  blood  monocytes  in  vitro. 
*  The  phenomena of paroxysm  in  P.  vivax malaria was the  subject of special  investiga-
tions to define the cellular mechanisms and soluble mediators involved. Attempts were 
made to characterise and fractionate the parasite products associated with the induction 
of a paroxysm  including investigation of species-specific aspects of their function  using 
products from  blood  stage  parasites of the two  human  malaria parasite species found 
in  Sri  Lanka,  P.  vivax and  P.  falciparum. 
*  Target  antigens  of  transmission-blocking  immunity  against  P.  vivax were  studied  and 
characterised  by attempts to  clone  the  genes coding for these proteins.  Using a panel 
of  monoclonal  antibodies  against  P.  vivax gamete  surface  antigens  previously  devel-
oped in our laboratories, we screened eukaryotic recombinant DNA expression libraries. 
Results 
Disease  profiles  of  successive  infections  of  P.  vivax and/or  P.  falciparum were  studied  in 
an  endemic  population  in  the  south  of  Sri  Lanka.  A total  of  1  .  7  48  cases  of  diagnosed 
malaria  were  recorded  in  a  population  of  1.942  individuals  over a  period  of  18  months. 
Analysis  of these  infections  showed  that there  was  a tendency for successive  infections 
within a period of about six months to be of lower clinical severity. This was especially true 
of infections preceeded by a  P.  vivax infection;  prior infection with  P.  falciparum gave very 
little protection against  P.  vivax infections and only slight protection against homologous  P. 
falciparum. 
Ex vivo studies were carried out on  the changing properties of cells and soluble mediators 
before,  during and after a paroxysm of  P.  vivax malaria.  Using cytokine-specific antibodies 
112 Contract number TS3*CT920045 
to  neutralise  their  effects  on  cells  in  vitro,  we  have  now  shown  that  the  cytokines  TNF, 
GM-CSF  and  IL-2  are  all  critically  involved  in  events  taking  place  during  a  P.  vivax 
paroxysm.  By the same approach the cytokines IL-Ia and  IL-Ib,  IL-3,  IL-4,  IL-5,  IL-6,  IL-7, 
IL-8,  IL-9,  IL-10,  IFNy and  TGFJ3  have  no  detected activity during  such  a paroxysm.  The 
active  cytokines,  TNF,  GM-CSF  and  IL-2,  and  the  active  parasite  products  released  just 
before  a  paroxysm  have  been  shown  to  mediate  their  effects  through  the  presence  of 
monocytes;  a  role  for  T  cells  is  implicated  by  the  active  involvement  of  IL-2,  but  direct 
evidence for the  involvement ofT cells  has  not yet been  obtained. 
In  our  cell  assay,  which  mediates  inactivation  of  the  sexual  blood  stage  parasites  of  P. 
vivax,  the  active  parasites present  in  plasma during a paroxysm  have been  shown  to  be 
antigenically species-specific. 
A synthetic peptide was made representing a sequence of P.  vivax antigen present on both 
sexual  and  asexual  blood  stage  parasites.  This  peptide  is  recognised  by  a  monoclonal 
antibody, A  12, which  is capable of totally blocking the infectivity of  P.  vivax gametocytes to 
mosquitoes.  Antibodies  raised  against  this  peptide  also  induced  P.  vivax  transmission 
blocking antibodies. A gene  has  been  cloned  and sequenced whose  product contains the 
peptide  sequence  recognised  by  the  A  12  Mab;  it  is  not  known,  however,  if  this  gene 
encodes the  protein  which  is  the  target of the  transmission  blocking  activity of Mab A  12. 
A second gene has been cloned from a COS cell expression library of  P.  vivax by panning 
with  Mabs with transmission blocking activity against  P.  vivax.  The product of this gene is 
the  target of  a Mab,  G  13,  whose  epitope specificity is  distinct from  that of A  12. 
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THE  BIOLOGICAL  AND  EPIDEMIOLOGICAL  SIGNIFICANCE  OF  TRANSMISSION 
BLOCKING  IMMUNITY  AND  TRANSMISSION  REDUCING  FACTORS  IN  ENDEMIC 
FALCIPARUM  MALARIA. HUMAN FACTORS THAT INFLUENCE INFECTION OF MOS-
QUITOES 
Period: 
Co-ordinator: 
Objectives 
January 1,  1993- December 31,  1995 
KATHOLIEKE UNIVERSITEIT NIJMEGEN, DEPT. OF MEDICAL 
PARASITOLOGY, Nijmegen, The Netherlands (J.P.  VERHAVE) 
•  To  study epidemiologically and  experimentally the transmission  potential  of blood from 
gametocyte carriers. 
•  To  identify human  blood  factors that can  reduce  infection of mosquitoes. 
Activities 
*  Infectivity of gametocytes will be studied in the Yaounde region by selecting gametocyte 
carriers  and  studying  naturally and  experimentally infected  mosquitoes.  The  blood  will 
be  examined  locally for gametocyte  density,  in  vitro fertilisation  in  original  and  normal 
plasma-replaced blood and  gametocyte antibodies;  contents of mosquito stomachs will 
be examined for phagocytosis, percentages of zygotes and oocysts and their quantities. 
*  Mosquitoes fed  on  whole patient blood provide an  indicator for the overall transmission 
capacity of the individual gametocyte carrier. The difference between the mean  number 
of  oocysts  in  the  control  batch  of  mosquitoes  and  the  experimental  batch  provides 
information about the  presence of transmission  blocking factors  in  the  plasma sample. 
*  The  percentage  of white  blood  cells  containing  parasite  material  is  determined  in  the 
dissected  bloodmeal,  3  hours  after  ingesting,  using  the  monoclonal  antibody  against 
25kD protein,  conjugated with  FITC.  Numbers of fertilised macrogametes/ookinetes are 
counted  in  bloodmeals  after  12-24  hours,  using  the  FITC-Iabelled  the  anti-25kD 
monoclonal  antibody. 
*  Oocysts on  the  mosquito midguts are counted after one  week,  using  an  ordinary light 
microscope. 
*  Transmission-blocking  activity  will  be  studied  in  age-graded  populations  with  varying 
degrees of transmission-intensity,  and  longitudinally over the season. 
*  The  overall  transmission  blocking  capacity  can  be  split  into  the  various  stages  of 
development  within  the  mosquito  and  the  reducing  action  of  human  factors  can  be 
studied  in  detail.  Series  of data  will  be  built  up  on  female  gametocytes,  gametes  or 
zygotes,  retort forms,  ookinetes and  oocysts. 
*  Sera  collected  from  gametocyte  carriers  are  to  be  tested  for  antibodies,  particularly 
when their lgG shows blockage in the bioassay. The tests to be used are the anti-48/45 
ELISA,  and  the anti-230  kD  ELISA. 
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Results 
Achievements of transmission research up to October 1996 
Analysis  of  factors  determining  the  outcome  of  gametocyte-containing  blood  meals  by 
(reared)  Anopheles gambiae in  Yaounde,  Cameroon,  indicated that gametocyte density is 
related  to  mosquito-infection  and  to  numbers  of  oocysts.  Transmission  was  obtained  in 
about  50-75°/o  of  the  experimental  feeds.  Sex  ratios  did  not  correlate  with  mosquito-
infection.  Fever and  parasitaemia did  not influence success of mosquito-infection,  but the 
sickle trait did. 
Experimental  infections were carried out with  blood of some 350 gametocyte carriers,  with 
the  aim  of  identifying  natural  transmission-blocking  (TMB)  factors  in  the  blood  that 
determine  the  outcome  of  sporogonic  development.  A  comparison  was  made  between 
infections  with  blood  containing  autologous  plasma  and  blood  in  which  the  plasma  was 
replaced  with  that  from  a  donor  without  previous  malaria. exposure  or  prophylaxis. 
Replacement  resulted  in  a significant  increase  in  mosquito-infection,  especially when  the 
homologous plasma was washed away. This indicates that plasma factor(s) can reduce the 
transmission  capacity of gametocyte carriers to  mosquitoes. 
This reduction  is now being compared with  assays using cultured gametocytes of NF54 in 
Nijmegen  and  sera  from  the  same  gametocyte  carriers.  Inconsistencies  in  the  compari-
sons,  due  to  difference  in  procedures  and  in  levels  of  infection  in  nature  and  in  the 
laboratory  are  met  by  careful  washing  away  of  the  carriers'  plasma.  The  numbers  of 
mosquitoes  examined  must  be  large  enough  for  statistical  analyses.  The  value  of 
dissecting 50-1 00  mosquitoes  in  a batch  process is  being  assessed.  The  mosquito strain 
used  in  Yaounde  appeared  completely  susceptible to  NF54. 
Antibodies of sexual stages 
The  various  types  of  antibody  tests  for  sexual  stage  antibodies  are  correlated  with 
reduction  of  transmission.  Confirmation  has  been  obtained  of  the  TMB  action  of  an 
anti-Pfs25  mab,  using  the  blood  from  gametocyte  carriers;  the  percentage  mosquito-
infection was reduced 10 times. The mab,  based on  isolate NF54, acts against sporogonic 
stages of  all  isolates tested  in  Yaounde  carriers. 
Mabs anti-Pfs48/45 were used to develop a competition  ELISA (cELISA), to detect natural 
Pfs48/45 antibodies. Agreement between cELISA (5 epitopes) and TB activity in  Cameroo-
nian  gametocyte carriers was  about 75%.  In  healthy schoolchildren  it was  not significant. 
A specificity of  94°/o  was  found  and  a sensitivity of  44°/o:  a positive test  indicates TMB  in 
the  mosquito assay,  but a negative  result  does not exclude TMB.  Gametocytes generally 
express the  lie  epitope  (PCR-confirmed). 
Population  studies  in  rural  areas  with  different  transmission  intensity  resulted  in  low 
prevalence of Pfs48/45 using the cELISA, whereas,  some 66°/o of sera from  Cameroonian 
gametocyte  carriers  was  positive.  European  carriers  all  developed  TMB  and  epitope-
specific antibodies. 
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Also a cELISA demonstrating antibodies against Pfs230 has been developed. All sera from 
gametocyte  carriers  immunoprecipitated  Pfs230  and  blocked  transmission  by  50o/o.  How-
ever,  no  correlation  exists between  these  two  phenomena.  All  anti-Pfs230  mabs  of  lgG2 
isotypes  blocked  transmission  only  in  the  presence  of complement,  whereas  lgG1  mabs 
did  not.  The  hybridoma  cell  line  producing  non-blocking  mab  of  the  lgG1  isotype  was 
switched to isotypes lgG2b and  lgG2a. These switched mabs effectively blocked transmis-
sion  by  lysis of  macrogametes and  zygotes  in  the  presence  of  complement.  Using  these 
techniques we  have fulfilled our aim  to  identify the TMB activity of  Pfs230 ab;  the cELISA 
with  Pfs230  mab  did  not reveal  TMB  activity in  sera  from  gametocyte carriers. 
Isolates from  Yaounde-patients were  cultured,  along with  isolate NF54,  gametocytes have 
been  produced,  but infections were  not successful. 
Gametocytogenesis and gametogenesis 
Patients  with  high  asexual  parasitaemia  received  amodiaquine  or  sulfadoxine-
pyrimethamine  medication  and  returned  after one,  and  up  to  four weeks  for detection  of 
gametocyte  density,  infectivity and  antibodies.  Existing  parasitaemias were  gone,  as  well 
as  the  elevated  levels  of  acute  phase  protein  CAP.  Fansidar  treatment  induced  an 
increase  of  gametocyte  densities  after  one  week,  whilst  infection  often  failed.  From  2 
weeks  all  gametocytaemias  decreased  as  did  infection  success.  A  similar  wave  of 
circulating gametocytes was found  in  rural  Mengang,  after treatment with  chloroquine,  but 
mainly in  patients/carriers with  parasites  resistant to  chloroquine. 
Gametocyte-maturity  in  the  circulation  and  phagocytosis  in  the  bloodmeal  are  presently 
being  studied  in  terms  of  transmission  success.  Removal  of  WBC  increases  mosquito 
infections. 
Transmission in the field 
Progress  was  made  in  the  detection of sporogonic stages  inside the  mosquito,  using the 
anti-Pfs25 mab-FITC, both in the field and in the lab. A major reduction was found to occur 
directly  after  the  bloodmeal.  In  the  transition  from  macrogametes/zygotes  to  ookinetes 
about 60o/o are lost, the other 40°/o forming ookinetes to young oocysts. Thereafter the loss 
is ·minimal.  Research  is  now concentrated  on  major loss and  the  mechanisms  involved. 
Bloodfed mosquitoes were collected in  houses in  a rural village with  hyperendemic malaria 
and parasites in  gut-contents examined with  immunofluorescence on the spot.  12o/o of An. 
gambiae or An.  funestus mosquitoes contained  zygotes  or ookinetes over a period  of 24 
hours  after a bloodmeal.  Sporozoite  rate  was  5%.  The  gametocyte  index  was  38o/o  with 
8/f.ll  (counted  against 1000 WBC)  and  was  maximal  in  houses with  the  highest number of 
infected mosquitoes.  Gametocyte detection done with  QBC,  reveals about twice as  many 
gametocyte carriers.  Using fed  mosquitoes caught under bednets with gametocyte carriers, 
again  a significant correlation  was  found  between  gametocyte  density,  the  percentage  of 
infected  mosquitoes and  number of developing  parasites in  the  mosquito  midguts.  Timing 
of  developing  zygotes,  retort  forms  and  ookinetes  was  registered.  Only  carriers  who 
carried  over  300  gametocytes/111  gave  rise  to  young  oocysts  at  about  40h  after  the 
blood meal. 
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THE DEVELOPMENT AND POTENTIAL OF MIDGUT ANTIGENS AS VACCINE AGENTS 
FOR  NOVEL MOSQUITO AND MALARIA CONTROL 
Period: 
Co-ordinator: 
Objectives 
January 1,  1996 - March 31,  1997 
UNIVERSITY OF ABERDEEN, DEPT.  OF ZOOLOGY, 
Aberdeen, United Kingdom  (P.F.  BILLINGSLEY) 
To  establish that sera raised  against mosquito midgut can  interfere with  normal  mosquito 
biology.  To  demonstrate  that  anti-mosquito  antibody  at  physiological  titres  can  adversely 
affect  vector  longevity and  fertility.  To  demonstrate  that  anti-mosquito  antibody  at  physi-
ological  titres can  reduce  malaria transmission. 
Activities 
*  New colonies of mosquitoes,  Anopheles gambiae ss and  Anopheles tessellatus, will be 
established at two sites. These and established colonies will be  used as the sources of 
new  antigen  preparations  from  midgut-derived  tissues.  Screening  of  some  200-300 
monoclonal  antibodies  (MABs)  directed  against  An.  stephensi tissues  will  be  initiated 
early in  the  project,  and  continued  throughout. 
*  Newly  derived  sera,  previously  characterized  sera  and  MAbs  will  be  screened  by  a 
standardized  appro~ch for anti-mosquito (fecundity and  longevity) activity,  and for their 
effects  on  transmission  of  human  and  malarial  parasites.  Sera  and  MAbs  will  be 
characterized  by  I  FA and  Western  blot. 
*  Promising  antigen  preparations  will  be  further  refined  for  detailed  study,  including 
production  of  new  MAbs.  Mosquito  eDNA  libraries  will  be  prepared  and  screened  in 
preparation for production  of recombinant  antigen.  Preliminary sequencing  of identified 
antigen  eDNA may be  undertaken. 
*  Promising  antigen  preparations,  and  resulting  sera  and  MABs  will  be  subjected  to 
intense  screening  at  all  sites,  and  to  more  detailed  characterization  at  the  molecular 
level.  Studies will  include colony and  wild-caught mosquitoes. 
Expected outcome 
Promising antigen  preparations,  and  resulting sera and MABs will  be  subjected to  intense 
screening at all  sites,  and to more detailed characterization at the molecular level.  Studies 
will  include colony and  wild~caught mosquitoes. 
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THE  DEVELOPMENT  OF  A  PHARMACOLOGICAL  MODEL  FOR  ANTI-MALARIALS 
WHICH  INTERFERE WITH  PHOSPHOLIPID METABOLISM 
Period: 
Co-ordinator: 
Objectives 
January 1,  1993- December 31,  1995 
CNRS, URA 1856, INTERACTIONS MEMBRANAIRES 
(UNIV.  MONTP.  1), Montpellier, France (H.  VIAL) 
To  study novel  antimalarial  agents that act upon  phospholipid  metabolism  in  the  erythro-
cytic stages of malarial development, and to develop appropriate pharmacological models. 
Activities 
This project aims to find  new chemotherapeutic treatments (and eventually prophylactics) 
for malaria. Interruptions of phospholipid metabolism of erythrocytic stages of Plasmodium, 
which  is  essential for the synthesis of parasite membranes,  blocks parasite development. 
The most promising compound inhibits choline carrier,  a rate  limiting step in  phosphatidyl-
choline  synthesis,  a  major  phospholipid  in  Plasmodium.  Compounds  such  as  this  step 
could  be effective against parasites resistant to  existing antimalarials. 
•  Biochemical  characterization  of the  pharmacological  target,  to  find  the  causes  of  the 
hyperfunctioning of the choline carrier after malarial  infection. 
•  Synthesis of new molecules among the 3 hyperactive families to optimize the structural 
requirements. 
•  Determination  of  the  antimalarial  activity· of  the  compounds  in  a  broad  spectrum  of 
resistant strains in  vitro and  in  vivo,  and preclinical  evaluation  against  P.  falciparum in 
monkeys. 
•  Sub-cellular localization of the drugs and studies on  the bioavailability and metabolism 
of one or two  radiolabelled  lead  compounds. 
•  Determination of the ease or difficulty by which  parasites become resistant to the lead 
compounds  in  vivo and  in  vitro by drug  pressure. 
•  Research  into  the  possible  activities  of  the  compounds  against  the  non-erythrocytic 
stage of Plasmodium. 
Expected outcome 
This project should provide insights into the nature and site of the choline transporter and 
thus for the creation of new molecules that will inhibit plasmodial phospholipid metabolism. 
The  project  further  expects  to  establish  the  therapeutic  doses  needed  to  block  the 
multiplication  of  Plasmodia  and  to  further  develop  such  drugs  that  have  a  maximum 
therapeutic index. 
Results 
Choline  entry  in  the  infected  erythrocytes  involves  an  asymmetric  cyclic  carrier  whose 
functioning  is  hyperactivated after Plasmodium infection.  Choline transport in  the erythro-
cytes  is  not  sodium-dependent  nor  stereospecific  as  demonstrated  using  methylcholine 
stereoisomers. 
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Choline transport  in  the  infected  erythrocyte  possesses  characteristics  quite distinct from 
that of the nervous system  allowing discrimination between  the antimalarial  activity and  a 
possible toxic effect. 
The  synthesis  of  choline  analogues  has  focused  on  quaternary  ammonium  salts  whose 
structures have been optimized leading to 1  0 compounds possessing IC50 ranging around 
1  o-
9 M and acting via an inhibition of de novo PC biosynthesis. In this quaternary ammonium 
series (first generation of active compounds), the lead compound G25 (IC50 = 0.6 nM) was 
highly efficient in vitro against 55  P.  falciparum polypharmacoresistant isolates with an  IC50 
also in the nanomolar range.  No cross resistance in vitro was observed between G25 and 5 
other classical antimalarials (chloroquine, quinine, mefloquine, halofantrine and artemether). 
In  vitro,  G25 was also active on  P.  berghei,  but IC50 was about 50-fold  higher than  on  P. 
falciparum. It was very specific to mature parasites (trophozoites) with specific ultrastructural 
alterations of the endoplasmic reticulum as determined in vitro against  P.  falciparum and  P. 
berghei, and also in vivo against P.  chabaudi-infected mice. This specificity corresponds to 
the most intense phase of phospholipid biosynthesis activity during the parasite cycle, thus 
corroborating the mechanism of action. 
When tested on the asexual stages of  P.  berghei in vitro,  no quantitative effect of the drug 
was evident on  the numbers of parasites that underwent exflagellation,  or on  the process 
of  exflagellation  and  gamete  release,  and  no  morphological  alterations  upon  the  male  or 
female gametes could  be  discerned.  By contrast,  between  1  o-
7  and  1  o-a  M,  a reduction  in 
ookinete  numbers  (probably  due  to  an  enhanced  fragility  rather  than  to  an  inhibition  of 
fertilization) and  motility was observed, along with an  inhibition in the clustering of pigment 
within  the  ookinete  resulting  in  generalized  morphological  abnormalities. 
The  in  vivo antimalarial activity (ED50) against  P.  chabaudi was 0.05 mg/kg, and a slightly 
lower  ED50  was  obtained  with  P.  vinckei  petteri,  as  assessed  when  the  drug  was 
intraperitoneally administered in the 4 day suppressive test. On  the other hand,  P.  berghei 
was  revealed  as  less sensitive  (3  - to  20-fold,  depending on  the  P.  berghei-strain)  in  vitro 
when  compared  to  P.  falciparum.  P.  yoelii also  appeared  less  susceptible to  G25.  In  the 
infected mouse model,  an  intrinsically lower sensitivity of  P.  berghei (also demonstrated in 
vitro)  or  P.  yoelii to  G25 was  demonstrated compared to  P.  chabaudi or  P.  vinckei petteri. 
This  difference  in  activity could  result  from  intrinsically  lower sensitivity of the  P.  berghei 
strain  to  G25,  from  invasion  preference  for  mature  or immature  red  blood  cells  of  every 
strain  or  from  their  degree  of  synchrony.  In  vivo,  G25  was  curative  when  administered 
twice a day subcutaneously to  P.  chabaudi-infected mice,  provided the treatment lasted for 
at least 8 consecutive days.  It succeeded in  completely inhibiting parasitemias as  high as 
11.2o/o without any decrease in  its therapeutic index (LD50/ED50),  indicating that it is thus 
not  necessary to  increase  doses to  reduce  parasitemia even  for severe  infections. 
When  administered  intramuscularly  twice  a  day  at  0.2  mg/kg  to  P.  falciparum-infected 
Aotus monkeys,  G25 also fully succeeded in  curing parasitemia as  high as 20o/o  revealing 
that  it  is  as  effective  as  sulfadoxine  +  pyrimethamine  (alone  or  in  combination  with 
quinine). As low as 0.030mg/kg G25 were sufficient to completely clear parasitemia without 
recrudescence  after 60  days as  checked  by  PCR. 
Keeping  in  mind  that  the  Maximal  Tolerable  Dose  for  the  monkey  ranges  around  1.5 
mg/kg, one can assume that Therapeutic index in the  P.  falciparum-infected Aotus monkey 
is  higher than  50,  revealing  the  very high  efficiency of G25  in  vivo against  P.  falciparum. 
Development  of  this  pharmacological  model  has  thus  been  fully  validated  with  the 
malaria-infected-mouse  and  -monkey  models.  Nevertheless,  the  very  low  permeability to 
the  intestinal  barrier hinders a further development of such  compounds for a widespread 
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use  in  uncomplicated malaria.  Transition to  a human  preclinical  investigation  has  required 
the  synthesis  of  molecules  which  would  be  better  tolerated  and  absorbed.  For  this 
purpose,  a new chemical  strategy was  developed. 
New  compounds  which  were  bioisosteric analogues  of  the  very  potent  leader compound 
G25  were thus synthesized to  improve oral  absorption  and  tolerance.  In  these series,  the 
quaternary ammonium  group  present  in  G25  was  replaced  by a basic bioisosteric  group, 
which  is  mainly  protonated  at  physiological  pH.  Among  them,  10  new  molecules,  were 
highly active in vitro against  P.  falciparum (IC50  in the nanomolar range)  their antimalarial 
activity  being  achieved  by  a  mechanism  of  action  involving  de  novo  PC  biosynthesis 
inhibition.  In  these  series,  MS1  was  designed  as  the  lead  compound  of  the  second 
generation of active compounds (IC50 =  0.5 nM). They revealed better absorption (by 7 to 
22-fold)  and  were also better tolerated  (by  15 to 20 fold)  than  G25.  They also possess  in 
vivo antimalarial activity in  the  P.  vinckei petteri system  (therapeutic index was  6 at best). 
This  low  in  vivo  antimalarial  activity  against  P.  vinckei or  P.  berghei results  from  a  low 
susceptibility of  the  murine  parasite  (as  already  observed  in  vitro  with  P.  berghe1)  rather 
than  from  unfavorable pharmacokinetics of these  compounds  (as  demonstrated with  G25 
of  MS1)  as  evidenced  by  ex vivo  tests  (performed  in  vitro  against  P.  falciparum  in  the 
presence of the serum of mice to which drug was  administered).  Indeed,  considering slow 
blood  clearance  (t1/2  elimination  =  10  h),  a  relatively  high  value  of  CO  (200-fold  higher 
than  in  vitro  IC50  against  P.  falciparum  after  administration  at  LD50/3)  and  linear 
pharmacokinetics,  MS 1 also  revealed  activity  in  vivo  against  P.  falciparum-infected  mon-
keys  (as  G25),  suggesting  that therapeutic  index for  MS1  could  be  higher than  50  even 
with  only  one  daily  dose  and  also  in  the  oral  mode.  The  next  experiments  will  test  this 
compound  in  vivo against  P.  falciparum in  the  infected Aotus  monkey. 
G25  and  MS 1  , tested  for  genotoxicity  using  the  Ames  test,  did  not show  any  mutagenic 
activity  (with  or  without  metabolic  activation).  Additional  compounds  are  currently  being 
synthesized  not  to  improve  the  antimalarial  activity  which  is  already  good  enough 
(nanomolar  range)  but  rather  to  obtain  compounds  with  better  tolerance  and  oral 
absorption. Some of them already are potential candidates for preclinical studies that could 
be  planned  within  the  next 2 years. 
Another part of the biochemical section was aimed at anticipating and circumventing possible 
resistances which could be set up by the parasite when the supply of choline is blocked by 
pharmacological interference. This notably consisted in evaluating rate limiting steps in crucial 
pathways and also in detecting potential vital pathways (absent from the host). 
CTP:  phosphocholine  cytidylyltransferase  (CCT)  (EC  2.7.7.15)  is  the  rate-limiting  and 
regulatory  enzyme  in  de  novo PC  synthesis. 
The  structural  gene  encoding  for  CCT  was  isolated  from  P.  falciparum  using  PCR  to 
amplify  genomic  DNA  with  degenerate  primers  constructed  on  the  basis  of  conserved 
regions  identified within yeast and  rat  liver CCT molecules,  and  using the  PCR  product to 
screen  a genomic  library.  The  P.  falciparum  CCT  gene  encodes  a protein  of  370  amino 
acids (42.6 kDa)  and displays 41-43°/o homology to CCT molecules of the other organisms 
cloned to date. The central domain of CCT homologues, proposed as the catalytic domain 
of  the  CTP-transfer  reaction,  shows  68-72o/o  homology  among  P.  falciparum,  human,  rat 
liver,  and  yeast  enzymes.  This  gene  is  present  in  a  single  copy  and  located  on 
chromosome  3 of the  parasite. 
The  molecular  analysis  of  this  gene  will  provide  the  mechanisms  of  transcriptional  (or 
translational)  regulation  of  the  enzyme  which  regulates  PC  biosynthesis  in  Plasmodium. 
This  will  help  to  understand  the  mechanism  of  an  even:tual  resistance  of  Plasmodium 
against original  antimalarials acting  by  inhibition  of  this  metabolic pathway. 
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IDENTIFICATION OF PLASMODIUM FALCIPARUM PROTEASES AND THEIR IMPLICA-
TIONS  FOR  THE  MEMBRANE ORGANIZATION  THE  INFECTED  RED  CELL.  DESIGN 
OF  HIGH  AFFINITY RECEPTORS 
Period: 
Co-ordinator: 
Objectives 
January 1,  1993- December.31, 1995 
MUSEUM NATIONAL D'HISTOIRE NATURELLE, 
LABORATOIRE DE BIOLOGIE PARASITAIRE ET 
CHIMIOTHERAPIE, Paris,  France (J.  SCHREVEL) 
•  To  study the proteinases of  P.  falciparum's asexual  stage,  MPEI  (Merozoite  Proteinase 
for  Erythrocyte  Invasion),  and  Pf37,  involved  in  the  reinvasion  process  step  of 
erythrocytes by  merozoites. 
•  To  study the  cytoadherence  of  P.  falciparum infected erythrocytes. 
Activities 
MPEI 
MPEI  active fraction was purified from  schizont stages of  P.  falciparum in  vitro cultures by 
its neutral  cysteine protease activity,  able to  cleave the  Gluconoyi-BLGK-AEC fluorogenic 
substrate.  Several  specific  inhibitors,  based  on  the  VLGK  peptidic  sequence,  were 
synthesised and  tested  on  the  in  vitro invasion.  They exhibited  an  IC50 at the  mM  level. 
Cloning of the MPEI gene was thus undertaken to provide material for determination of the 
three dimensional structure of the active site. A polyclonal antibody was raised against the 
purified MPEI fraction (containing proteins of 105, 97,  68 and 38 kDa),  and used to screen 
two  P.  falciparum  genomic  expression  libraries.  Two  novel  single  copy  genes  were 
isolated,  partially sequenced and  analyzed. 
Pf37 
The specific sites of cleavage of the human  spectrin  by Pf37 protease have been  located 
within  the  different  tryptic  domains  of the  spectrin  a-subunit,  using  polyclonal  antibodies 
specific for the different domains. Recombinant peptides of different regions of the a-subunit 
were produced, and used in enzymatic assays with preparations of pre-purified Pf37. 
Cytoadherence 
The  characterization  of the  proteins from  the  "virus-like" vesicles from  in  vitro cultured  P. 
falciparum have been established by metabolic labeling with  35S-methionine, and Western 
blotting  using  polyclonal  and  monoclonal  antibodies  against  membrane  and  cytoskeleton 
components of the  erythrocyte. 
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The  vesicles  have  been  visualized  by  immunofluorescent  probes  and  related  to  cyto-
adherence as  a function  of  the  K+  or K- phenotype. 
Results 
Proteinases and erythrocyte invasion 
MPEI 
Partial  sequences and  analysis of the two cloned genes indicated that one (  1626 bp open 
reading  frame)  encodes  a protein  with  31°/o  asparagine  residues,  found  in  both  repeated 
hexamers and  in  non-repeated  regions.  This gene corresponds to a novel  asparagine-rich 
protein  of  P.  falciparum.  The  second  gene  (1510  bp  ORF)  encodes a protein  with  highly 
significant  homologies  to  Zn-metallopeptidases.  The  27  amino-acids  sequence  of  the 
active  site  unambiguously places  it into the  M1  family of Zn-metallopeptidase.  This  novel 
gene  is  the  first cloned  P.  falciparum aminopeptidase. 
Antibodies  raised  against  recombinant  forms,  or  synthetic  peptides,  of  both  homologous 
asparagine-rich  and  Zn-metallopeptidase molecules,  yielded  specific whole  parasite  label-
ling  of  the  parasite  in  immunofluorescence  assays.  These  antibodies  recognize  peptides 
migrating as  the  MPEI's in  one  dimensional  SDS-PAGE,  and  immunoprecipitate the same 
peptides.  More,  aminopeptidases  activities  were  found  in  schizont  extracts:  one  of  them 
co-purified  with  the  MPEI  cysteine  protease. 
Pf37 
Pre-purified  fractions  of  the  Pf337  were  shown  to  cut  within  two  distinct  regions  of  the 
a-subunit  of  human  spectrin.  One  of  the  regions  corresponds  to  the  Src  homology  Ill 
(SH3)  motif,  with  a secondary structure different from  the  rest of the  polypeptide  made  of 
successive  triple  a  helices.  Enzymatic  assays,  using  recombinant  peptides  of  different 
segments of the human a-chain as substrate for Pf37, demonstrated that only recombinant 
SH3  was cleaved  by the  enzyr.1e,  at three close sites.  Identification of the amino-acids at 
these  cleavage  sites  is  now  i:1  progress  by  determination  of  the  precise  mass  of  the 
hydrolyzed  fragments  by  mass  SJ:ectrometry  and  comparison  with  the theoretical  masses 
deduced  from  the  amino-acid  sequence  of  the  recombinant  SH3.  Furthermore,  we  could 
show  that the  SH3  motif  from  a non-erythroid  spectrin,  i.e.  fodrin,  was  insensitive  to  the 
Plasmodium  spectrinase  activity.  The  results  will  allow  us  to  design  pseudo-peptides  as 
specific  inhibitors of the  spectrinase activity. 
Characterization of vesicle-like structures from  P.  falciparum in vitro cultures 
The  virus-like  vesicles  obtained  from  in  vitro  P.  falciparum  cultures  were  analyzed  by 
comparison  with  normal  red  blood  cell  (RBC)  cultures.  The  phenotypes  of  P.  falciparum 
strains used were  K+  (FcB1/Colombia) and  K-(FcR3/The Gambia). To  identify the parasite 
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origin  of  proteins,  the  infected  ABC  were  radiolabelled  with  355-methionine  and  the 
erythrocyte  membrane  proteins  were  studied  by  Western  blotting.  The  results  were  as 
follows: 
=>Virus-like vesicles were observed in vitro in both normal and infected  P.  falciparum ABC 
cultures  maintained  under the  classic  conditions. 
=>  Parasite proteins were detected in  the vesicles released from the  P.  falciparum infected 
ABC  in  contrast to  the  normal  ABC. 
=> The  erythrocyte  proteins  of  vesicles  correspond  to  the  intramembranous  proteins 
(modified  band  11.1  glycophorin).  All  erythrocyte  proteins  associated  with  the  cytoskel-
eton  were  observed  (spectrin,  ankyrin,  protein  4.1  actin). 
=>Up to  now,  no  specific  pattern  of  parasite  proteins  was  associated  with  the  K+  or  .K-
phenotype of the  strains.  · 
Expected outcome 
This  approach  may  lead  to  the  development  of  antimalarial  drugs.  Because  numerous 
proteases  activities  have  been  shown  to  be  essential  for  the  survival  of  Plasmodium 
falciparum,  our  aim  is  to  block  specifically  one  or  several  of  these  activities,  by  using 
specific  compounds  structurally  analogous  to  the  substrates  of  the  proteases.  Such  a 
strategy  requires  a  detailed  knowledge  of  the  active  site  of  the  protease,  in  order  to 
identify  its  best  substrate.  In  this  context,  we  have  obtained  promising  results  with 
protease  inhibitors which  can  more  easily reach  their targets  during  host cell  invasion,  in 
contrast to  intracellular proteinases  involved  in  the  haemoglobin  breakdown. 
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EPIDEMIOLOGY OF  DRUG  RESISTANCE  IN  PLASMODIUM FALCIPARUM 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1993 - September 30,  1996 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, 
DEPT.  OF MEDICAL PARASITOLOGY 
London, United Kingdom (D.  WARHUST) 
•  To  evaluate drug sensitivity of P.  falciparum malaria in  100 patients in  the  Prabies area 
of  Guinea-Bissau  and  in  the  Banjarnegara  area  of  Indonesia  by  the  WHO  in  vivo 
(chloroquine)  and  in  vitro tests  (over the period  1993-95). 
•  To  characterise  the  rRNA  genes  of  the  DNA .  samples  obtained  by  probe  and  PCR 
studies. 
•  The training  in  malaria culture,  drug-sensitivity testing,  and  molecular biological  proce-
dures of scientists from  countries with  endemic malaria,  transfer of technology to their 
laboratories and  to enhance their research  potential. 
Activities 
*  To collect dry blood spots and frozen blood samples from the patients for restriction and 
probe  studies  and  polymerase  chain  reaction  (PCR)  investigation  on  drug  resistance-
related  genes. 
*  To  cryopreserve  material  for subsequent  recovery  into culture  and  to  establish  clones 
from  selected  cultured  isolates,  in  particular,  from  up  to  50  which  have  recrudesced 
after chloroquine treatment. 
*  To  carry  out  restriction  and  PCR  studies,  and  evaluation  of  drug  sensitivities  on  the 
continuously cultured clones for comparison with results in vivo and in  vitro on the fresh 
isolates. 
Expected outcome 
Workers from  endemic areas will  be trained  in  malariology,  and the  use of molecular and 
pharmacological  approaches to study drug-resistance. There  will  be  enhanced collabora-
tion  within  and outside the  EC  in  malariology.  The expertise and  understanding of all  the 
collaborating countries will  be  enhanced. 
Knowledge  of  the  way  in  which  malaria  parasites  become  resistant  will  enable  the 
development of  imported  and  novel  drug  entities to  attack  malaria  morbidity,  reduce  the 
population  reservoir for the  parasite's transmission  and  reduce  the  overall  impact of this 
highly important vector borne  disease. 
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Valuable data on the drug response of falciparum malaria in the endemic areas concerned 
will also be obtained during the project, which will help iri deciding the approach to malaria 
treatment in  these areas. 
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DNA POLYMERASES  OF  MALARIA PARASITES:  TARGETS  OF  CHOICE,  BOTH  FOR 
TREATMENT OF  THE  DISEASE AND  FOR  CONTROL OF  THE  INFECTION 
Period: 
Co-ordinator: 
Objectives 
January 1,  1995 - December 31,  1996 
INSTITUTE OF INFECTIOUS DISEASES AND IMMUNOLOGY, 
DEPT.  OF PARASITOLOGY & TROPICAL VETERINARY MEDICINE 
Utrecht, The Netherlands (J.P. OVERDULVE) 
•  To  study  DNA  replication  enzymes  of  malaria  parasites  as  potential  targets  for  new 
antimalarials and  to  identify,  sequence  and  characterize their genes. 
+  To  search for specific inhibitors of these enzymes as candidates of such anti-malarials, 
and  to  study their pharmacokinetics,  target specificity and  applicability. 
•  To  study  means  - either  by  use  of  such  inhibitors  or  by  manipulation  of  the  target 
genes  - to  lower  the  pathogenicity  of  a  Plasmodium  infection  or  the  virulence  of  a 
Plasmodium  strain  so  as  to  promote  the  chance  of  development  of  protective 
immunity  by  the  host. 
•  To  strengthen  the  capacity  in  this  particular field  of  research  in  Thailand. 
Activities 
*  Synthesis  of  a  number  of  derivatives  of  the  potent  (but  rather  toxic)  anti-plasmodial 
nucleotide  analog  HPMPA as  well  as  their  diphosphates  (analogs  of  HPMP  App,  the 
intracellularly phosphorylated  and  presumed  actual  inhibitor). 
*  Determination  of  the  inhibitory effect  of these  derivatives against malaria  parasites  (P. 
falciparum)  in  culture.  If active, the inhibitory effect will  be  examined against  P.  berghei 
and/or  P.  vinckei  in  mice.  The  activity  of  diphosphate  derivatives  will  be  assessed 
against a number of plasmodial  replication  enzymes  in  vitro.  These  plasmodial  replica-
tion  enzymes will  be  produced as  native enzymes by purification from  parasite cultures 
and/or as  heterologous expression  products of  their genes. 
*  Study  of  pharmacokinetics  and  metabolism  of  compounds  that  show  antimalarial 
activity by  HPLC  analysis,  and  identification  of  the  active  metabolite(s)  and  the  actual 
target(s). 
*  Identification  of  the  enzyme  responsible  for  intracellular  phosphorylation  to  the 
diphosphate  form  and  analysis  of  the  kinetics  of  this  activation  of  HPMPA  and 
congeners. 
130 Contract number TS3*CT940297 
As  a corollary of this  research  investigations will  be  started to  induce protective immunity 
in  rodents by parasites "attenuated" either by direct use of plasmodial  replication inhibitors 
or by manipulation  of target enzyme  genes. 
Expected outcome 
=>  Identification  of  the  target(s)  and  mechanisms(s)  of  action  of  (deaza)  HPMPA  and 
related  compounds. 
=>  Sufficient  insight  into  structure/function  relationship  of this  class  of  putative  replication 
inhibitors  to  allow  a  rational  search  for  and  future  synthesis  of  effective  and  suitable 
antiplasmodial  inhibitor(s). 
=>  Increased  knowledge of the  replication  machinery of malaria parasites and  its underly-
ing  genes  to  permit  manipulation  of  this  machinery  in  order  to  decrease  malaria 
pathogenicity and/or parasite virulence. 
=>  Strengthening  of  the  research  capacity  in  this  particular field  of  research  of the  Thai 
research  partner  so  as  to  increase  their  role  as  a  center  of  excellence  for  malaria 
research  in  the  South Asian  Region. 
Results so far 
Target and mechanism of action of HPMPA 
The  targets  of  HPMPA  at  the  parasite  stage  level  are  asexually  multiplying  forms 
(schizonts) in erythrocytes and- even more sensitive- liver cells.  Microgametogenesis and 
meiosis  in  ookinetes are  insensitive. 
Liver stages of P.  berghei in  mice are all  killed by sustained release of a total dose of only 
0.45mg/mouse  during  the  first  two  days of sporozoite-induced  infection.  Recovered  mice 
were partially immune against sporozoite challenge:  survival time increased by a factor of 
about 2.5  and  cerebral  malaria,  normally causing  death  within  9 days  in  control  animals 
was  absent. 
In erythrocytes the effect of HPMPA is apparent at the late schizogony stage: schizonts are 
arrested  at about the  6-nucleated stage. 
At the  molecular level pharmacokinetics studies,  using  HPLC,  on  P.  falciparum cultures of 
wild-type and  resistant mutants incubated with  HPMPA showed that HPMPA was incorpo-
rated  into  the  DNA  at  a  ratio  of  about  1  in  20,000  and  1  in  70,000  adenosines, 
respectively,  with 60°/o of the incorporated HPMPA label consisting of HPMPAp, suggesting 
defective  DNA repair caused  by  HPMPA and  interruption  of DNA synthesis after incorpo-
ration  of  HPMPA. 
Molecular studies  on  mutant clones  of  P.  falciparum with  different levels  of  resistance  to 
HPMPA focusing on the possible role  of DNA polymerases as targets of HPMPA,  revealed 
that  resistance  is  associated with  a single  mutation  at a specific site. 
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This  mutation  results  in  a  substitution  of  a  valine  which  is  highly  conserved  in  DNA 
polymerase  ~ enzymes  of  different  eukaryotic  origin  as  well  as  in  herpes  virus  homo-
logues.  It is  located  in  the  3'-5' exonuclease,  proof-reading domain  in  the  N-terminal  half 
of the DNA polymerase  ~ and in  the  DNA polymerase a gene, which are both  responsible 
for DNA polymerase activity. 
Three other independent clones of a total  of 16,  with  resistance  up to  12 times the  wild-
type  sensitivity,  showed  a single  mutation at the  same site when  543  nucleotides around 
this site were  sequenced. 
From  the  location  of  the  substitution  we  conclude  that  HPMPA-induced  arrest  of  DNA 
replication  does  not result from  direct inhibition of the  polymerase activity of the  enzyme. 
Instead,  incorporation of HPMPA,  inducing e.g.  chain termination or distortion of the  DNA, 
can  be considered as its mode of action, and increased proof-reading capacity of the DNA 
polymerase  ~ exonuclease activity by substitution of a highly conserved valine as inducing 
resistance to  HPMPA. 
Structure/function relationship of nucleos(t)ide analogs 
A total of 68 analogs were investigated for anti-plasmodial activity in  P.  falciparum cultures. 
From  the  results  it can  be  concluded  that 3.chemical entities  seem  to  be  imperative for 
anti-plasmodial  activity:  a purine  base,  a  hydroxyl  group in  the  acyclic side  chain,  and  a 
phosphonate group terminating this chain. 
Genes of the replication machinery of malaria parasites 
The  49  kDa  primase  subunit of the  DNA polymerase  a  complex,  sequenced  previously, 
has been  expressed in  large quantities as a fusion  product with an  N-terminal His-tag. An 
indirect  primase  activity  assay  with  the  purified  renaturated  enzyme  showed  that  this 
subunit  alone  is  able  to  synthesize  RNA  precursors  de  novo,  in  contrast  to  the  mouse 
homologue which has been reported to be only active after heterodimer formation with the 
58kDa subunit. 
A similar approach has been followed with respect to the C-terminal polymerase domain of 
the DNA polymerase a gene, with similar results except that enzymatic activity has not yet 
been established. Also constructs containing the N-terminal exonuclease domain of the pol 
a  gene,  with  and without an  N-terminal  His-tag,  have  been  made,  as  well  as  a construct 
containing the whole  pol~ gene without a His-tag. Expression of the whole pol  ~gene  has 
not yet yielded  positive results  and  is  now studied at the  mRNA level. 
The  whole  topoisomerase  II  gene  after  sequencing  has  been  inserted  in  a  Bacoluvirus 
transfer vector and  expression  experiments have  been  started. 
The  DNA polymerase a  enzyme  of  P.  falciparum has  been  further purified  by FPLC  and 
micro N-terminal amino acid  sequencing  of the  putative enzyme,  a purification  product of 
150kDa (SDS-PAGE),  has  been  performed. 
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Strengthening of the research capacity of the DC research partner 
A  second  PhD  student  from  the  DC  partner's  laboratory  has,  after a  training  period  of 
almost 2 years in  the laboratory of the coordinator, returned to her home laboratory and is 
continuing plasmodial  DNA polymerase and topoisomerase  research  there. 
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PHOSPHOLIPID  METABOLISM,  A  NOVEL  TARGET  FOR  ANTIMALARIAL  DRUGS: 
DEVELOPMENT OF THE  PHARMACOLOGICAL MODEL 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1996 - October 1  , 1999 
UNIVERSITE MONTPELLIER II,  DEPT.  BIOLOGIE ET SANTE 
Montpellier, France {J.  SCHREVEL) 
The main objective of the project is the development of new antimalarial drugs that interact 
with  the  malarial  parasite  phospholipid  metabolism  and  could  provide  a  solution  to  P. 
falciparum polychemoresistant malaria. 
Although  there  is  no  indication  of  potential  resistance  to  date,  we  believe  that  we  must 
actively  initiate  studies  concerning  mechq.nisms  that  could  be  involved  in  potential 
acquisition  of  resistance  to  the  effectors.  This  molecular  approach  is  worth  immediate 
investigation  since  precise  mechanisms  can  be  expected  from  the  suspected  drug  site. 
Results could lead to the knowledge of a whole set of metabolic pathways vital for parasite 
growth. 
The main  objectives will  be  to synthesize new series of original and  potentially alternative 
compounds aimed at improving tolerance and  oral  absorption.  Identification,  isolation and 
characterization  of the pharmacological  target. 
To  carry  out  thorough  antimalarial  activity  studies  including  chemosensitivity,  therapeutic 
index after in  vivo oral formulations in  P.  falciparum-infected  monkeys,  and against others 
stages  {non  erythrocytic)  or species  {e.g.  P.  vivax). 
To  describe  the  pharmacokinetic  properties  and  toxic  evaluation  of  lead  compounds  will 
also  be  studied. 
Experimental  induction  of  resistances,  characterisation  of  effector-resistant  P.  falciparum 
malaria  and  alternative  to  resistance.  In  case  of  resistance,  combinations  with  other 
current approaches would  be  studied. 
Activities 
*  Chemical  synthesis  of  compounds  aimed  at  improving  tolerance  and  oral  absorption. 
This includes compounds with new cationic heads that could be  used if the current lead 
compounds  may  prove  to  have  unacceptable  drawbacks,  and  also  the  synthesis  of 
prodrugs  with  the  aim  of  improving  oral  absorption  and,  eventually  to  promote  the 
development a new generation  of effectors. 
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*  Identification and characterisation of the pharmacological target. Affinity chromatography 
using  a  column  of immobilized  effectors  is  proposed.  If  necessary,  chemists  will  also 
synthesise  photoreactive  lead  compound  derivatives.  Pharmacological  target  cloning 
should allow  its complete characterisation,  determination of the active site  and  help  in 
the design of new effectors. 
*  It  is  of  utmost  interest  to  study  the  mechanisms  of  regulation  of  PL  biosynthesis 
pathways  in  Plasmodium.  More  than  just  a  problem  of  metabolic  regulation,  this 
program concerns mechanisms which  could be  involved in  resistance that the parasite 
could  develop when  the  supply of  choline  is  blocked  due  to  pharmacological  interfer-
ence.  Biochemical  and  genetical  approaches  will  be  used  as  a  powerful  tool  for the 
elucidation of metabolic regulations as well as the biological significance of the different 
metabolic pathways  in  Plasmodium.  We  will  be  particularly concerned  by the  metabo-
lites and activities of COP-choline pathway which synthesizes de novo PC.  Additionally, 
we  will  focus  on  PS  Decarboxylase  activity  which  also  provides  Plasmodium  for  an 
important part of  PC. 
*  Antimalarial activity,  pharmacokinetics and toxic evaluation of lead compounds. The first 
priority tasks will  be  (1)  in  vitro and in  vivo evaluation of antimalarial activity against  P. 
falciparum blood stages.  (2)  4 to  5 lead compounds will  be  tested  in  the  P.  falciparum 
I SCID mouse model  , (3)  therapeutic index of various formulations (intramuscular and 
oral  modes)  of  2-3  compounds  in  Aotus  monkeys  infected  with  P.  falciparum.  Blood 
samples will  also  be  collected  to perform  bio-assays of the  seric compounds. 
*  Activity  of  2-3  lead  compounds against  P.  falciparum  isolates  with  various  degrees of 
resistance will  be  determined. 
*  To  evaluate  antimalarial  activity  against  P.  vivax/P.  cynomolgi blood  stages.  (2-4  lead 
compounds).  According  to  results,  to  evaluate  against  P.  cynomolgi in  rhesus  monkey 
and  against  P.  vivax  in  Saimiri  monkey  for  comparison  with  P.  falciparum/Aotus 
results. 
*  To  test  the  activity  of  the  lead  compounds  against  the  non-erythrocytic  stages  of 
Plasmodium. 
*  To  determine  pharmacokinetics  properties  of  lead  compounds  (ex  vivo  tests),  and  to 
determine toxicity of lead  compounds. 
*  Resistance mechanism and alternative to resistance. This includes the in vitro induction 
of  resistance  against  choline  analogs,  the  characterisation  of  effector-resistant  P. 
falciparum  malaria  (pharmacological  target  and  lipid  metabolism),  and  examination  of 
genes  associated  with  resistance  to  standard  antimalarial  drugs Alternatives  to  resist-
ance would include combined action of PL metabolism inhibitors with known antimalarial 
drugs. 
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Expected outcome 
The work content is totally devoted to the establishment of a new pharmacological  model. 
Although  the  outcome of  fundamental  and  experimental  research  can  never be  known  in 
advance,  the  numerous complementary experimental  approaches that are  planned  within 
the  different  partner  laboratories,  should  allow  to  reach  the  proposed  objectives.  It  is 
anticipated  that some  of  our  research  effort will  lead  to  potential  industrial  or pharmaco-
logical  outcomes. 
Concerning  malaria,  by  now,  the  most  urgent need  concerns  a first-line oral  substitute to 
chloroquine.  That  is  one  of  the  reasons  we  want  to  achieve  an  oral  formulation  of  our 
compounds,  rather than  risking  the  development of a non-oral  administerable compound. 
The  target  could  be  a  common  one  between  different  parasites.  However,  until  now, 
significant  inhibition  at  concentrations  lower that  1  mg/1  has  not  been  observed  for  any 
other  parasites  except  Babesia.  On  the  other  hand,  the  susceptibility  of  the  protozoan 
parasite  Babesia,  that  also  invades  erythrocytes  but  is  not  sensitive  to  haemoglobin 
degradation-related  lysomotropic  agents,  is  interesting  as  it  confirms  the  absence  of 
cross-resistance  of the  PL metabolism  pharmacological  effectors with  the  current lysomo-
tropic antimalarial  agents. 
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DEVELOPMENT OF NOVEL DRUGS AGAINST MALARIA 
Period: 
Co-ordinator: 
Objectives 
November 1  , 1996 - October 31 , 1999 
STATENS SERUM INSTITUT,  DEPT.  OF CLINICAL 
MICROBIOLOGY, Copenhagen, Denmark (A.  KHARAZMI) 
The  general  objective  of  this  research  proposal  is  to  select  an  appropriate  candidate 
compound  from  a  group  of  oxygenated  chalcones  with  novel  activity  against  malaria 
parasites for further development into  a new antimalarial  drug. 
The  specific objectives  are: 
•  To  develop  an  optimal  method  for  the  synthesis  of  necessary  amounts  of  the 
appropriate compounds. 
•  To  determine the  purity,  physicochemical  properties and  stability of these  compounds. 
•  To  examine  the  in  vitro  activity  of  these  compounds  against  different  strains  at 
erythrocytic and  liver stages  of  human  malaria parasite  Plasmodium  falciparum. 
•  To  investigate the  structure-activity relationship  of these  compounds. 
•  To  test  the  activity  of  selected  compounds  on  the  parasite  isolates  from  the  blood 
samples from  malaria patients  in  Colombia. 
•  To  carry  out  in  vivo  studies  to  determine  the  most  appropriate  formulation  for 
administration  of these  compounds. 
•  To  select  the  most  appropriate  compound(s),  based  on  their  in  vitro activity  and  test 
them  against  P.  berghei and  P.  yoelii in  murine  models  and  against  P.  falciparum  in 
Aotus  monkeys. 
•  To  investigate the  mechanism  of action  of these compounds  on  parasite  mitochondria. 
•  To  perform studies on  absorption,  tissue distribution,  pharmacokinetics,  and  pharmaco-
dynamics  in  rats,  dogs  and  monkeys. 
Activities 
*  Development  of  optimal  synthesis  methods.  A study taking  advantage  of  the  method-
ology developed for Quantitative Structure-Activity Relationships (QSAR)  will  be  utilized 
to  disclose the optimum structure for the antimalarial activity.  Based on  the outcome of 
the  QSAR  analysis  new  types  of  compounds  will  be  prepared  and  evaluated.  A 
procedure for  large  scale  synthesis  of the  selected  compounds  will  be  developed. 
*  In  vitro studies against blood stage  Plasmodium falciparum.  The  effect of a wide  range 
of  compounds  on  different chloroquine  sensitive  and  resistant  strains  of  P.  falciparum 
will  be  tested  using  conventional  methods.  Fifty  P.  falciparum  isolates  collected  in  an 
endemic  region  of  Colombia will  also  be  studied. 
*  In  vivo studies  in  murine  models.  The  appropriate compound(s)  for the  in  vivo studies 
will  be  selected  based  on  their  in  vitro  activity  against  P.  falciparum.  Several  mouse 
models  of  P.  yoelii  and  P.  berghei  infection  will  be  used  in  these  studies.  The 
compounds  will  be  administered  by  different  routes  and  dosages and  at different time 
periods  to  infected  animals.  Levels  of  parasitemia  in  Giemsa-stained  smears  and 
survival  of  animals  will  be  assessed. 
*  Studies on  the  liver stage  of  P.  falciparum.  The  activity against pre-erythrocytic stages 
will  be  tested  using  in  vitro assays with  different  P.  falciparum and  in  vivo in  mice  with 
P.  yoelii or P.  berghei. The  in vivo studies will  include i.v.  inoculation of sporozoites into 
mice.  The  effect  of  various  compounds  will  be  examined  by  either  i.p.  or  oral 
administration  of selected  compounds. 
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*  In  vivo studies  in Aotus  monkeys.  The  monkeys will  be  infected and  once parasitemia 
reaches  1.0°/o  they  will  be  treated  with  the  test  compound  by  giving  an  oral  dose  of 
each compound for different time periods.  Parasitemia will  be  determined daily by thick 
smears and  whenever necessary by PCR. 
*  Studies on  the  mechanism of action. The effect of these compounds on  the ultrastruc-
ture by  EM  and on  the function of mitochondria will  be carried out.  The effect of these 
compounds on  some  of the  enzymes of the  respiratory chain  in  mitochondria such  as 
fumarate  reductase  will  also be  examined. 
*  Formulation  studies.  These  studies  will  include  preparations  based  on  aqueous  solu-
tions  by  addition  of  solubility  promoting  substances  e.g.  polyalcohol,  glycolether  and 
glycolesters  or  solubilizing  agents.  Investigation  of  preparations  based  on  particulate 
drug  delivery systems e.g.  oil/water emulsion will  also  be  undertaken. 
Expected outcome 
The most important expected outcome of this study will  be  identification of an  appropriate 
oxygenated chalcone for phase  1 studies. 
::::} This  study  will  demonstrate  the  structural  requirements  for  optimal  selectivity  and 
activity for chalcones as antiprotozoal  drugs. 
::::} This  study  will  show  the  activity  of  these  compounds  against  different  strains  of  P. 
falciparum  in  vitro and  their activity against different species of  Plasmodium in  several 
animal  models. 
::::}  This  study  will  provide  insights  into  the  mechanism  of  action  of  the  selected  com-
pound(s). 
::::}  This  study  will  identify  the  appropriate  formulation  for  in  vivo  administration  of  the 
selected  compound(s) 
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DEVELOPMENT  OF  INHIBITORS  OF  MALARIAL AND  TRYPANOSOMAL  DIHYDRO· 
FOLATE  REDUCTASE  AS  ANTIPARASITIC  AGENTS  THROUGH  COMBINATORIAL 
CHEMISTRY 
Period: 
Co-ordinator: 
Objectives 
October 1, 1997- September 30, 2000 
NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT 
AGENCY,  Bangkok, Thailand (Y.  YUTHAVONG) 
•  To  test  the  validity  of  the  combinatorial  synthesis  approach  to  antiparasitic  drug 
development,  based on  the  inhibition of the  parasite dihydrofolate reductase domain of 
the  bifunctional  enzyme  dihydrofolate  reductase-thymidylate  synthase  (DHFR-TS),  and 
to  develop new drug candidates  especially against malaria from  this  approach. 
•  To  understand the relation between structure and function of the parasitic enzymes, the 
basis  for  differential  inhibition  of the  enzymes  by  candidate  agents,  and  the  basis  for 
development of  resistance. 
Activities 
Selected  libraries  of  2,4-diaminopyrimidines  and  dihydrotriazines  which  include  known 
inhibitors  of  malarial  dihydrofolate  reductase  will  be  created  and  screened  against 
recombinant  parasite  and  host  enzymes.  Libraries  will  be  made  both  in  solution  and  on 
solid  supports.  The  second  type  of  libraries  will  also  be  encoded  with  appropriate 
molecular tags for easy identification  of  structures.  In  the  first type  of  libraries,  screening 
will  be  made  against  the  enzyme,  either  in  free  form  or  linked  to  an  appropriate  solid 
support,  while  in  the  second  type,  screening  of  the  resin-bound  libraries  will  be  made 
against the  enzyme  linked to  an  appropriate fluorescent  molecule. 
Enzyme-bound  drug candidates  can  be  separated from  the  other compounds  by centrifu-
gal dialysis after addition of the enzyme. Alternatively,  resin-bound enzyme can  be used to 
trap the drug candidates.  Identification of bound inhibitors from the first type of libraries will 
be  made  after extraction  into  organic solvent  by  high-performance  liquid  chromatography 
coupled  with  mass  spectrometry  and  other  analytical  methods.  Identification  of  bound 
inhibitors from the second type of libraries will be made,  using a confocal laser microscope 
with  a micromanipulator and  an  adapted fluorescent activated cell  sorter. 
After  identification  of  these  compounds,  they  can  be  synthesized  in  solution  in  bulk  for 
further  studies.  This  is  important  in  order  to  ensure  that  the  binding  observed  in  the 
screening  was  not  influenced  by  linking  to  solid  supports  or  synergistic  or  antagonistic 
interaction of the  molecules in  the  mixture. The characteristics of enzyme inhibition will  be 
studied  in  solution  to  ensure  that tight-binding  components  are  indeed  good  inhibitors of 
enzyme  activity.  Emphasis  will  be  made  on  discovery  of  compounds  which  effectively 
inhibit mutant enzymes from  drug-resistant parasites. 
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Testing  of  inhibition  of  P.  falciparum  in  culture  will  also  be  done  as  well  as  testing  of 
enzyme inhibition. After identification of promising candidate molecules, focused  sublibrar-
ies will be  made to cover various structural possibilities related to the  identified molecules. 
In  parallel,  molecular  modelling  of  the  dihydrofolate  reductase  of  the  malarial  and 
trypanosoma!  enzyme  will  be  made,  using  information  from  known  structures  of  the 
Leishmania!  enzyme  as  well  as  bacterial  and  mammalian  enzymes.  Site-directed  muta-
genesis  of  the  malarial  enzyme  will  allow  us  to  create  a  number  of  enzymes  with 
mutations  at  sites  that  are  suspected  to  be  important  for  binding  of  substrates  and 
inhibitors. This will allow us to establish a model of binding between the inhibitors and the 
enzyme,  further  allowing  optimisation  of  the  inhibitor  structures  to  obtain  better  drug 
candidates for both the wild-type enzyme and the mutant enzymes arising from resistance. 
Expected outcome 
=::)The  validity  of  using  combinatorial  libraries  for  development of  antifolate  antimalarials 
will  be  tested. 
=::)  Combinatorial libraries based on  2,4-diaminopyrimidines and dihydrotriazines in solution 
or on  solid supports will  be  made,  as  will  milligram quantities of recombinant wild-type 
and  mutant malarial  dihydrofolate  reductases  ready for screening. 
=::)Appropriate  screening  methodologies  for  combinatorial  libraries  against  the  malarial 
enzyme  will  be  established. 
=::)  Better understanding  of  inhibitor binding to the  enzyme will  be  achieved. 
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DETECTION  OF  PLASMODIUM  FALCIPARUM  RESISTANT  TO  ANTIFOLATE  AND 
SULPHONAMIDE DRUGS, AND ASSESSMENT OF THE  EFFICACY OF DRUG  TREAT-
MENT USING  MOLECULAR  METHODS 
Period: 
Co-ordinator: 
Objectives 
November 1  , 1997 - April 30,  2001 
ROYAL TROPICAL INSTITUTE, 
Amsterdam, The Netherlands (L. OSKAM) 
To  evaluate molecular methods for the detection of antifolate and  sulphonamide  resistant 
malaria parasites,  and to  apply these  methods to  an  epidemiological  investigation  of the 
prevalence  of genes conferring  resistance  in  populations  of  Plasmodium falciparum.  The 
ultimate  aim  of the  work is  to  contribute towards  a  rational  use  of such  drugs  in  control 
strategies against the  disease. 
Activities 
*  To  evaluate  the  sensitivity  and  specificity  of  a  molecular  assay  - mutation  specific 
polymerase  chain  reaction  (MS-PCR)  and  in  situ PCR  - for the  detection  of antifolate 
(pyrimethamine)  and  sulphonamide  (sulfadoxine)  resistant  mutants  of  Plasmodium 
falciparum. 
*  To  evaluate the technique of semi-quantitative nucleic acid sequence based amplifica-
tion  (Q  NASBA)  for  the  detection  of  low  levels  of  malaria  parasites  and  for  the 
determining of the efficacy of drug-treatment. 
*  To  apply  these  assays  for  epidemiological  monitoring  of  drug-resistant  mutants  of  P. 
falciparum  in  different  drug-treatment  regimens  by  parasitological  and  clinical  criteria 
and  by the analysis of the  kinetics  and  degree of parasite clearance  by  NASBA. 
*  To  increase and  improve the local  research  capacity by providing training  in  molecular 
detection  methods  for  the  epidemiological  and  diagnostic  investigation  of  drug-
resistance  of  P.  falciparum. 
Expected outcome 
The  results  will  show  the  prevalence  of  antifolate  and  sulfadoxine  resistant  malaria 
parasites in  malaria patients in  Kenya and Zimbabwe. The prevalence of resistant strains 
is  expected to be  high  in  Kenya and  low in  Zimbabwe.  In  Kenya,  MS-PCR will  be applied 
on  samples collected during the second and third year of the study and  in  Zimbabwe the 
method will  be  applied  on  samples collected  in  the first,  second  and  third  year.  This will 
show whether the  prevalence  changes  in  times  and  whether chains  harbouring  different 
mutations will  arise. 
In  situ PCR  will  provide  insight in  the  prevalence of mixed  infections. 
The  NASBA  results  will  provide  information  on  the  treatment  efficacy  of  antifolates  and 
sulphonamides. 
Information  will  be  obtained  on  the  relative  sensitivities  of  the  different  assays  in 
determining drug-treayment efficacy. 
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COMMUNITY  BASED  MALARIA  CONTROL  UNDER  THE  GUIDANCE  OF  HEALTH 
SERVICES:  INTERVENTION  STUDY IN  ECUADOR AND  COLOMBIA 
Period: 
Co-ordinator: 
Objectives 
January 1,  1993 - August 31,  1994 
UNIVERSITAT HEIDELBERG, INST. FOR TROPENHYGIENE & 
OEFF. GESUNDHEITSWESEN, Heidelberg, Germany (A. KROEGER) 
•  To  describe the  epidemiology of malaria in  the study areas. 
•  To  measure the  impact of several  community based interventions of malaria control  on 
the  incidence of malaria attacks and  on  case  management. 
•  To identify factors which favour or hinder the protective efficacy of specific interventions. 
•  To  measure different cost aspects  of such  a programme 
Activities 
*  After  the  baseline  study  on  malaria  incidence  and  a  KAP  study  in  3  study  areas  of 
Ecuador and Colombia regarding self-diagnosis and self-treatment of malaria, the study 
communities were  divided randomly into intervention communities and  control  commu-
nities  respectively (randomised community trial). 
*  Training of trainers: the project teams trained staff members of the local health services. 
They learned  how to  carry out workshops  with  health-promoters and  volunteers of the 
malarial  control  programmes  and  how  to  use  the  training  materials.  All  aspects  of 
community based malaria control were dealt with, with special emphasis on  rational  use 
of antimalarial  drugs,  protection  with  mosquito  nets  as  well  as  draining  of water from 
breeding  places.  The  newly trained  staff carried  out a series  of training  workshops  in 
the  intervention  areas with  community  representatives  and  community volunteers.  The 
research  team  observed  these activities and  established a mapping of vector breeding 
places  as  well  as  a regular counting of larval  densities. 
*  After  8  months  of  intervention  the  research  team  repeated  the  measurements  again 
both  in the intervention and control areas assessing the malaria incidence and people's 
KAP  regarding  malaria prevention  and  treatment. 
*  Before  and  after  the  intervention,  health  services'  staff  (particularly  malaria  field 
workers)  were  observed  when  carrying  out  workshops  and  when  doing  community 
health  actions,  particularly DDT residual  spraying. 
*  During the activities described above, costs were monitored to enable calculation of the 
overall  costs  of the  programme. 
Results 
Between the 3 study areas on the Pacific Coast (2  in the Esmeraldas Province of Ecuador, 
1 in the Chocs of Colombia) there was a considerable variation concerning socio-economic 
characteristics  of  the  populations,  accessibility  of  health  services  and  ethnomedical 
practices.  The  demographic  structure,  housing  and  malaria  control  through  vertical  pro-
grammes were  similar.  Main  malaria vectors were: 
*  A.  albinaus in  Ecuador and  A.  nuneztovari in  Colombia. The monthly incidence rates of 
malaria episodes during the  wet season  was 3.5%  in  Columbia and  7.0%  in  Ecuador. 
The  main  parasite  was  P.  falciparum  (92°/o  in  Colombia,  86°/o  in  the  North  Coast  of 
Ecuador).  The  remainder  was  P.  vivax.  Transmission  occurred  principally  inside  or 
around the  houses.  Users of impregnated bed  nets had the same incidence of malaria 
episodes as  non-users of bed  nets. 
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*  The  impregnation  of bed  nets with  lambdacyhalothrin  showed  a high  (71°/o)  protective 
efficacy against clinical malaria attacks in Colombia. The study in Borbon (North Coast of 
Ecuador)  showed  that  intensive  residual  spraying  with  DDT  had  the  same  protective 
efficacy against malaria episodes as the impregnation of bed nets with permethrin; however, 
the costs of the DDT programme were 3.5 times higher than those of the impregnation 
programme. It was observed that residual spraying activities estrange malaria workers from 
the  communities  while  bed  net  impregnation  enhances  joint  community  actions  and 
improves  the  communication  between  health  services  and  local  dwellers.  In- Mulsne 
(Ecuador)  the  protective  efficacy  of  bed  net  impregnation  was  not  enhanced  by  the 
additional breeding of larvivorous fish in all large mosquito breeding places. 
A  set  of  limiting  and  favourable  factors  for  a  community  based  programme  of  bed  net 
impregnation  was  identified. 
The  educational  programme  in  Ecuador  had  the  following  impact  (expressed  as  o/o 
increase  of  correct  knowledge  and  practice):  improvement  of  correct  knowledge  about 
malaria  transmission  (30°/o),  symptoms  (25°/o)  and  the  correct  doses  of  chloroquine  for 
adults  (25.
0/o);  the  respective  values  in  Colombia  were  28°/o,  38°/o  and  48°/o.  The  correct 
doses  of  chloroquine  taken  during  a  clinical  malaria  attack  was  improved  by  20°/o  in 
Ecuador and  by 46o/o  in  Colombia.  The  factors  related  to  it were  analyzed. 
The  community  interventions  on  mosquito  breeding  places  had  no  clear effect  on  vector 
densities and  malaria incidence rates,  mainly because it was  not possible to drain and fill 
them  up  all  and/or because Anopheles  mosquitoes flew  in  from  the  surrounding  areas. 
The cost calculations showed that if is feasible to carry out an  impregnation programme on 
a large  scale. 
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THE  CONSEQUENCES  OF  MALARIAL  INFECTION  IN  PREGNANT  WOMEN  AND 
THEIR  INFANTS 
Period: 
Co-ordinator: 
January 1,  1993- December 31,  1995 
LIVERPOOL SCHOOL OF TROPICAL MEDICINE 
Liverpool, United Kingdom  (B.  BRABIN) 
This  research  proposal  had  the  general  aim  of  describing  the  prevalence  and  pattern  of 
malaria and  anaemia in  mothers and  their infants in  a rural  area of Malawi  where malaria 
transmission  is  endemic,  in  order to  establish a basis for developing sustainable interven-
tions  which  would  be  targeted  at those  in  most  need. 
Objectives 
•  To  quantify the  prevalence  and  pattern  of  malaria  and  anaemia  in  mothers  and  their 
infants  living  in  a malaria endemic area. 
•  To  investigate  whether  birth  haemoglobin  relates  to  the  development  of  anaemia  in 
infants. 
•  To  investigate the association between fetal  anaemia,  maternal  iron  status and  malaria 
in  pregnancy. 
•  To  quantify  the  contribution  of  maternal  anaemia  and  iron  status  to  fetal  growth 
retardation  and  low  bi rthweight. 
Additional  objectives  related  to  a technical  amendment were: 
•  To  determine the  HIV  status of recruited  women. 
•  To determine the HIV status of babies recruited in the cohort study and born to mothers 
in  the  Malaria  Pregnancy study. 
This  work gave  a high  priority to  training  components for young  scientists and  laboratory 
technicians from  Malawi  and  Europe. 
Activities 
Case control study 
Pregnant  women  attending  the  selected  health  centers  were  screened,  after  informed 
consent, at their first and further antenatal visits and at delivery. The women were enrolled 
at  random  and  were  matched for parity and  week  of delivery. 
The  women  were  screened  for  haemoglobin,  hematocrit  free  erythrocyte  protoporphyrin 
and  haemoglobin  electrophoresis.  A blood  film  was  made  regularly  for  hematology  and 
malaria  microscopy.  Cord  blood  obtained  at  delivery was  screened  for  haemoglobin  and 
malaria.  The  placenta  was  weighed  and  a  smear  was  taken  for  malaria.  From  the 
newborn, birthweight, length and heel circumference were measured and the Ballard score 
was  used  to  assess  the  gestational  age  of  the  newborn.  The  HIV  status  and  vitamin  A 
status of the  mother was  assessed. 
Linear  regression  analysis  was  used  to  identify  iron  status,  anaemia  or  malaria  experi-
enced during pregnancy, as a risk factor for low birth  haemoglobin, low birthweight or fetal 
growth  retardation. 
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Cohort study 
From  the  case  control  study· information  was  obtained  to  identify cohorts for the  longitu-
dinal  study.  The cohort was  selected by cord  haemoglobin forming  one  group with  an  Hb 
>  14 g/dl and a control group with an  Hb >  16g/dl. Babies were matched by sex,  birthweight 
and  maternal  parity and  were  enrolled throughout the  wet and  dry season. 
Morbidity  surveys  were  completed  monthly to  assess  illness  episodes  in  the  two  weeks 
prior  to  each  study  visit.  A  blood  film  for  malaria  microscopy  and  for  haemoglobin 
estimation  was  taken  at  2,  4,  6,  9 and  12  months.  At  2,  6 and  12  months  infants were 
assessed  medically for  growth  and  haematologically  for  hematocrit  and  free  erythrocyte 
protoporphyrin and a malaria smear was made.  Hb electrophoresis were done on  the 6 or 
12  month  samples.  Sera was  also screened for H  IV  seropositivity. 
Results 
The prevalence of P.  falciparum malaria was high in the Shire Valley and the current policy 
of promoting  1 routine  dose of sulphadoxine-pyrimethamine during  pregnancy for malaria 
control was not significantly reducing parasitemia at delivery, especially in the wet season. 
Cord haemoglobin values indicated that fetal anaemia was a common problem and related 
to  maternal  haemoglobin  at  delivery  and  was  affected  by  seasonal  changes.  Cord 
haemoglobin  was  related  to  placental  parasite  density and  associated  with  an  increased 
prevalence  of  infant  anaemia  as  well  as  increased  infant  mortality.  The  HIV  status  of 
women was significantly associated with malaria prevalence in  pregnancy and reduced the 
protection  provided  by  parity  specific  immunity.  Infant  mortality  was  3  times  higher  for 
babies of HIV+ women  and  6 times higher if these mothers also had  malaria at booking. 
This  increased  risk  occurred  despite  evidence  that vertical  transmission  of  HIV  was  not 
increased  with  maternal  malaria.  Malaria  in  pregnancy  was  associated  with  significantly 
increased  risk  of  infant  mortality  in  HIV+  mothers.  The  high  level  of  illiteracy  in  this 
population indicated a need to develop health interventions for malaria control in pregnancy 
which  are  based  on  literacy  programmes  since  illiterate  women  were  less  likely  to  use 
antenatal care facilities.  Maternal anaemia at delivery was significantly associated with low 
birthweight in  primiparae and  multiparae with  a two-fold increase in  low birthweight in  first 
pregnancies if mothers were anaemic and  up to a four-fold  increase with  severe maternal 
anaemia. Analysis of how this is confounded by other maternal characteristics is on-going. 
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EPIDEMIOLOGY AND CONTROL OF MALARIA IN  THE PROVINCE OF RATCHABURI, 
THAILAND 
Period: 
Co-ordinator: 
Objectives 
April 1,  1994- September 30,  1996 
ASSOCIATION SANTE SUD, DIVISION DES PROJETS 
Marseille, France (M. SALICETTI) 
•  Through  an  epidemiological  study  to  determine  the  behavioral  and  environmental 
factors  which  influence  the  transmission  of  malaria  in  the  village  in  the  province  of 
Ratchaburi. 
•  To  measure  the  prevalence,  distribution  and  seasonal  variations  in  the  incidence  of 
malaria infection  in  1  000  inhabitants  of 7  hamlets of a  village  in  the  district of Suam 
Phung. 
•  To  evaluate the efficacy of the recommended anti-malarial treatments. 
•  To  identify the Anopheline species  in  the  village  and to try to  establish  a  relationship 
between  entomological  parameters and  malariometric indices. 
•  To  define and validate new parasitological  diagnostic methods. 
•  To  evaluate  the  clinical,  parasitological  and  entomological  impacts  of  the  use  of 
deltamethrin  impregnated bednets. 
Activities 
The preliminary phase of the work (April  - June 1991) consisted of creating a team which 
completed a demographic survey of the hamlets of the village and installed a health center 
which  would carry out the epidemiological  studies and  diagnose cases of malaria. At the 
same time a questionnaire on the behavior of the population was administered so that the 
consequences for malaria infection could  be examined. 
The  second  phase  of the  work (July  1994 - June  1995) was a  period  of monitoring  and 
characterization of endemic malaria in  the population before the third  phase,  (July 1995 -
June  1996) when  deltamethrin  impregnated  mosquito nets were provided to 450  inhabit-
ants, the whole population of hamlet G and to most of the population of two other hamlets 
(A and  B).  During  these two phases blood  samples were taken  for thick and  thin  smear 
preparation  from  all  1000 inhabitants for active  case  detection.  The same parasitological 
examinations  were  made  for  any  febrile  illness.  In  some  cases  the  GBC®  and  PAR-
ASIGHT® diagnostic tests were  used. 
Surveillance after treatment with mefloquine (750 mg in  a single dose) for P.  falciparum or 
with  chloroquine  (1500mg  chloroquine for 3  days and  15  mg  primaquine  per day for  14 
days)  for  P.  vivax as continued for 14 days. 
Tests for chemoresistance of P.  falciparum were carried out in  1994, 1995 and 1996 by the 
Rieckmann  test and  a  radio-immunoassay. 
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Entomological  studies  were  completed  each  month  (including  vectorial  capacity,  parity, 
exophily,  endophily). 
Results 
The preliminary results from  phase two indicated a mean  incidence of 1.9 episodes.  1  000 
inhabitants  per  day  or  693.5  episodes/1 000  inhabitants  per  year.  There  was  variation 
among  the  hamlets and incidence was  highest during the  rains,  from  May to September. 
Males  had  twice  as  many  episodes  as  females  (912.5  episodes/1 000  men  per  annum 
versus 474.5 episodes/1000 women  per annum).  Four species of malaria were described 
P.  falciparum  (48°/o)  P.  vivax (45°/o)  P.  malariae (6.2o/o)  and  P.  ovale (0.8%).  Chloroquine 
resistance  of  P.  falciparum  in  vitro was evaluated  in  1994 and  1995 as  1  00°/o  (6  isolates 
tested)  and  46.4°/o  (28  isolates  tested).  Tests  for  resistance  to  quinine  and  mefloquine 
were carried  out at the  same time.  No  resistance was detected. 
The efficacy of mefloquine was confirmed in vitro by examination of 10°/o of post-treatment 
recrudescences.  P.  vivax showed no in vitro resistance.  Entomological studies revealed the 
presence of A.  durus,  A.  minimus and  A.  maculatus. 
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THREE  YEARS  CONTROLLED  TRIAL  OF  LAMBDA-CYHALOTHRIN  IMPREGNATED 
BED  NETS  AND  MALOPRIMIPLACEBO  CHEMOSUPPRESSION  IN  CONTROL  OF 
MALARIA IN  CHILDREN  LIVING  IN  A HOLOENDEMIC AREA OF  SIERRA LEONE 
Period: 
Co-ordinator: 
Objectives 
January 1 , 1994 - December 31 , 1995 
STATENS SERUMINSTITUT, DIVISION OF 
BIOTECHNOLOGY, LAB. OF PARASITOLOGY, 
Copenhagen, Denmark (E.  PETERSEN) 
•  Determine  the  efficacy  of  lambda-cyhalothrin  impregnated  bed  nets  and 
dapsone/pyrimethamine  fortnightly  chemosuppression,  singly  and  in  combination  on 
malaria morbidity in  children  living  under stable continuous  malaria transmission. 
•  Determine  the  impact  on  the  Anopheles  population  of  village  wide  application  of 
impregnated  bed  nets. 
Summary 
*  Most previous intervention studies have looked only at the effect of the intervention over 
no  more  than  a 12 month  period,  which  is  not sufficient to  demonstrate any long  term 
effect on  the  population. 
*  There was a clear difference between the dapsone/pyrimethamine singly and combined 
with  impregnated  mosquito  nets  during  the  first  12  months  of  the  study,  but  this 
difference  disappeared  during  the  second  intervention  year  and  first  half  of  the  third 
year. 
*  Malaria episodes per 1000 child  weeks  at  risk  was  in  the  first and  second intervention 
year in the control group 37.7 and 49.9 respectively;  in the group receiving impregnated 
bed nets alone 19.2 and  18.  7;  in the group receiving fortnightly dapsone/pyrimethamine 
22.2 and  41.4 and  in  the  group  receiving  both  impregnated  bed  nets  and  fortnightly 
dapsone/pyrimethamine  1  0. 7  and  14.8. 
*  This  gave  protective  efficacy  relative  to  the  control  group  of  the  lambda-cyhalothrin 
impregnated bed  nets alone of 49o/o  and  62°/o  in  the first and  second  intervention year; 
of fortnightly dapsone/pyrimethamine of 42o/o  and  18% in  the first and  second  interven-
tion  year  and  in  the  group  receiving  both  impregnated  bed  nets  and  fortnightly 
dapsone/pyrimethamine  of  72o/o  and  70%,  in  the  first  and  second  intervention  year 
respectively. 
*  The  decreased  efficacy of dapsone/pyrimethamine alone  and  the  minimal  difference in 
protective  efficacy  between  the  net  and  net  plus  dapsone/pyrimethamine  strongly 
suggests that dapsone/pyrimethamine was  much  less effective during the second year. 
The  only explanation  for this  decrease  in  efficacy  is  an  increase  in  drug  resistance  to 
dapsone,  pyrimethamine  or both. 
*  The development of resistance to dapsone, pyrimethamine or both was confirmed by  in 
vivo  susceptibility  testing  performed  pre-intervention  and  post-intervention.  The  initial 
response  to  a  prophylactic  dose  of  dapsone/pyrimethamine  was  the  same  in  1992 
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(pre-intervention)  and  1995  (post  intervention)  measured  by  the  parasite  rate  7  days 
after drug administration. However, the long lasting reduction  in  parasitemia had almost 
disappeared  in  1995,  when  parasite  rates  were  back  to  initial  values  after  2  weeks 
compared  to  6 weeks  in  the  pre-intervention  study. 
*  Comparing the geometric mean  parasitemia in  children who  remained  parasite positive 
at  each  examination  during  the  in  vivo  assay,  children  who  in  1992  were  parasite 
positive at day 2 had  a very low parasite density,  which  increased to  background  level 
at  day  14.  In  1995,  there  was  no  significant  change  in  parasite  density  after  drug 
administration,  showing  that  the  reduction  was  achieved  in  1992  in  ctiildren  parasite 
positive at day 7 had  vanished after three years of continuous dapsone/pyrimethamine 
administration. 
*  Sickle  cell  trait,  HbAS,  was  found  in  18.3°/o  HbF  in  1.8°/o  and  HvC  in  0.9o/o  of  the 
children. 
*  A  higher  proportion  of  blood-fed  Anopheline  mosquitoes  were  caught  resting  in  net 
villages,  which  suggests  that  the  presence  of  the  nets  in  the  rooms  drives  away 
blood-fed  mosquitoes to  their outdoor resting  site. 
*  We  found  no  evidence  of  decreased  susceptibility  to  lambda-cyhalothrin  during  the 
study period. 
*  Impregnated  bed  nets  significantly  reduced  indoor  resting  density  of,  and  exit  trap 
collections  of  Anopheline  mosquitoes,  but  did  not  have  any  effect  on  human  bait 
catching  and  light traps  catching. 
*  The  parity  rates  of  Anopheline  mosquitoes  were  significantly  reduced  in  villages  with 
impregnated  nets. 
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DELAYED CHILD MORTALITY AND INSECTICIDE-IMPREGNATED MATERIALS: THEO-
RETIC  FANTASY OR  HARSH  REALITY? 
Period: 
Co-ordinator: 
Objectives 
October 1,  1997 - January 31,  2001 
UNIVERSITY OF CAMERINO,  DEPT.  OF MOLECULAR, 
CELL & ANIMAL BIOLOGY Camerino,  Italy (F.  ESPOSITO) 
To  investigate the  impact of  insecticide  impregnated  curtains  (IIC)  on  child  mortality over 
the  period  3 to  5 years  following  their introduction. 
Specific objectives: 
a)  determining whether,  after an  initial reduction  in  child  mortality following the introduction 
of  IIC,  there  is  a  subsequent  increase  in  child  mortality  ("delayed"  mortality)  in  the  age 
range  6-59  months; 
b)  documenting changes over the medium term  in the ability of children's immune systems 
to  inhibit the  invasion  of  red  blood  cells  by  malaria  parasites; 
c)  documenting  changes  in  the  prevalence  of  malaria  episodes  and  in  the  profile  of 
parasitological  parameters  of  malaria  infection  in  children  aged  6-59  months  living  in 
villages  protected  by  IIC; 
d)  documenting changes  in  the  intensity of transmission,  in  the  biting/resting behaviour of 
malaria vectors,  in  their susceptibility to  permethrin  and  in  the  genetic composition  of the 
population  following  the  introduction  of  IIC; 
e)  training  one  Burkinabe  graduate  to  the  level  of  MSc  (epidemiology/statistics),  one  to 
PhD  level  in  entomology,  one  to  PhD  level  in  immunology,  and  one  to  MSc  level  in 
molecular biology. 
Activities 
Child mortality. The primary outcome measure in this study will be all-cause child  mortality. 
This  variable  will  be  measured  by  yearly  re-census.  At  this  moment in  time  the  following 
mortality data are  available: 
Time  period  Treatment group A  Treatment  Group  B 
1993-94  Mortality in  the  absence  IIC  (45.4%o)  Mortality in  the absence of IIC  (44.0%o) 
1994-95  Mortality during  1st year of  IIC  (27  .5%o)  Mortality in  the absence of IIC  (37 .3%o) 
1995-96  Mortality during 2nd  year of  IIC  (38.0%o)  Mortality in  the absence of IIC  (39.9%o) 
Complementary activities concern: 
Children's  immune  status.  As  no  marker  of  protective  immunity  has  been  identified  thus 
far,  we  shall  measure  in  vitro the  ability  of  children's  sera  to  inhibit  parasite  invasion  of 
erythrocytes  in  combination  with  a monocyte cell  line. 
Child  morbidity.  Cross-sectional  surveys  in  48  villages  (24  in  each  group)  will  be 
conducted  in  September  1996,  1997  and  1998  (September  is  the  month  of  peak 
transmission). 
Assessment of transmission.  Transmission  throughout the study area will  be  assessed  by 
cross-sectional,  outdoor  CDC  light  trap  catches.  The  genetic  composition  of  the  vector 
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population  will  be  compared  between villages of Group A and  B and  villages outside the 
study area. The duration of malaria transmission will  be assessed longitudinally from  June 
to December. The residual vector population and  its biting behaviour will  be determined by 
outdoor  CDC  light  trap  catches.  Antibodies  to  the  circumsporozoite  protein  (CS)  of 
Plasmodium  falciparum will  provide an  indication  of  intensity of transmission. 
Monitoring  coverage  and utilisation.  As-impregnation  and  installation  rates  are  recorded 
yearly at the time of re-impregnation.  Coverage will  be further assessed by visits to a 1  Oo/o 
random  sample of dwellings.  Utilisation will  be  assessed by pyrethrum  spray catches and 
by  surprise visits. 
Assessment  of insecticide  susceptibility.  Mosquito  susceptibility  to  permethrin  will  be 
assessed  once yearly,  by  the  standard WHO  method  on  impregnated  paper. 
Expected outcome 
The  proposed  study  will  maintain  the  intervention  in  both  groups  A  and  B  (yearly 
re-impregnation  of  curtains  and  replacement  of  damaged  curtains)  and  the  collection  of 
mortality  data  for  an  additional  three  years  (up  to  June  1999).  This  will  provide  the 
following  additional  data: 
Time  period  Treatment group A 
1996-97  Mortality during  third  year of  IIC 
1997-98  Mortality during  fourth  year of  IIC 
1998-99  Mortality during  fifth  year of  IIC 
Treatment Group B 
Mortality during  first year of  IIC 
Mortality during  second year of  IIC 
Mortality during third year of  IIC 
It  is  expected  that  the  opportunity  of  investing  on  impregnated  materials  for  controlling 
malaria  in  high  transmission  settings  will  be  evaluable  on  the  basis  of  the  results.  In 
addition,  the  relationship  between  transmission,  immunity and  disease will  be  clarified.  · 
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DEVELOPMENT OF A VACCINE  STRATEGY AGAINST HUMAN AND  BOVINE  SCHIS-
TOSOMIASIS 
Period: 
Co-ordinator: 
Objectives 
April  1,  1992 - March 31,  1995 
INSTITUT PASTEUR,  CENTRE D'IMMUNOLOGIE ET DE  BIOLOGIE 
PARASITAIRE, Lille,  France (A.  CAPRON) 
•  To  optimize the  formulation  of  a recombinant  vaccine  based  on  Schistosoma mansoni 
glutathione-S-transferase  (Sm28GST)  for  use  preferably  in  oral  immunization  against 
schistosomiasis. 
•  The  vaccine  will  be  used  in  Phase  Ia  human  trials  in  Europe. 
•  As  part  of  a  research  and  control  programme  in  Richard  Toll,  Senegal,  a  focus  of 
epidemic schistosomiasis mansoni, to study the immune status of the  population before 
and  after chemotherapy. 
•  In  phase  lb  clinical  trials,  non-infected  individuals  in  an  endemic  area  will  be  immu-
nized. 
•  Parallel  studies will  develop a vaccination  strategy for the  prevention and  control  of  S. 
bovis infection  in  cattle. 
Activities 
*  The  immunogenicity  of  synthetic  peptides  and  live  vectors  containing  molecular  con-
structs of Sm28GST will  be tested using appropriate adjuvants,  microencapsulation and 
oral  immunization.  This  work  will  be  supported  with  protein  crystallography  data  and 
3D-structural  analysis of  Sm28GST. 
*  Pre-phase  I clinical  studies  will  include  measurements  of  lgE  and  lgA antibodies  and 
T-cell  responses  to  Sm28GST as  well  as  to  S.  mansoni antigenic  extracts. 
*  Immune  and  non-immune  populations  will  be  identified  by  studies  of  reinfection  after 
chemotherapy. 
*  Phase  Ia  clinical  trials  on  European  volunteers,  and  Phase  lb  trials  on  non-infected 
individuals  in  an  endemic  country  will  be  planned.  In  both  trials  the  antibody  isotype 
titers  and  cytotoxic  capacity,  T-cell  and  interleukin  responses  to  Sm28GST will  all  be 
measured. 
*  Calves and goats will  be vaccinated with  recombinant  S.  bovis 28GST.  Measurement of 
vaccine  efficacy  will  be  done  by  determining  both  worm  and  egg  loads  following 
experimental  challenge  with  S.  bovis. 
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Expected outcome 
=>The production  of  a suitable  (mucosal)  vaccine  formulation  based  on  Sm28GST. 
=>  Phase  Ia  clinical  trials  of the  vaccine  and,  depending  on  success,  phase  lb  trials. 
=>  Detailed  plans for phase  II  and  Ill  clinical  trials. 
=>  Evaluation  of the  immune  responses  in  the  epidemic focus  in  Richard  Toll. 
=>  Detailed  information  on  the  efficacy of  S.  bovis 28GST as  a veterinary vaccine. 
Results 
Molecular characterization of protective antigens 
Several  significant advances  have  been  made: 
=>The  crystallization  of  Sm28GST  has  been  performed  and  a  3D  structure  based  on 
X-ray  diffusion  data and  molecular modeling  has  been  obtained. 
=>The  28GST  of  S.  haematobium  and  S.  bovis  have  been  successfully  cloned.  Of 
particular interest is  the fact that comparison  of the  peptide sequences of  S.  mansoni, 
S.  haematobium  and  S.  bovis  28GSTs  shows  interspecific  variability  in  the  major 
protective  epitope  115-131,  contrasting  with  a  relative  conservation  of  the  C-terminal 
190-211  epitope. 
=> The  chromosomal  gene of Sm28GST has  been  fully  sequenced.  The  promoter region 
shows  consensus  binding  sequences for  both  NF-Y and  AP1  transcription  factors. 
=>  Several  additional  genes  from  S.  mansoni have  been  identified  and  cloned  including 
glutathione peroxidase,  superoxide dismutase and  calreticulin. The latter is of particular 
interest  due  to  its  preferential  localization  in  reproductive  organs  (testes,  ovary  and 
vitelline  glands}. 
Effector mechanisms and vaccine optimization 
=>  Protective immunity can  be  induced by a single dose of rSm28GST in  rats and this can 
be  related  to  the  production  of  specific  lgE  and  lgA  antibodies  involved  in  the 
eosinophil-mediated  killing  of  schistosomula.  We  had  previously  shown  that  peptides 
corresponding to the N- and  C-terminal domains of the enzyme could  induce the same 
anti-fecundity effects after vaccination as the entire molecule.  Moreover lgA monoclonal 
antibodies  directed  against  the  C-terminal  domain  were  able  to  mediate  the  same 
effects  on  egg-laying  and  egg  viability. 
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=>  In  order  to  optimize  the  protective  response  induced  by  Sm28GST  or  its  peptides, 
different strategies have  been  employed.  We  have shown that lipopeptide constructs of 
the C-terminal peptide were much more effective in  inducing an anti-fecundity response. 
In  parallel  we  have  explored  the  ability·  of  the  filamentous  hemagglutinin  (FHA)  of 
Bordetella  pertussis to  induce  a strong  lgA response  after  mucosal  administration  by 
incorporating the  Sm28GST gene  in  frame  with  the  FHA structural  gene.  Recombinant 
B.  pertussis  express  the  fusion  protein  on  their  surface  and  induce  an  immune 
response  after  nasal  administration  that  protects  mice  partially  against  a  challenge 
infection.  Reductions in  worm  burden  and  fecundity have also been  obtained after oral 
administration  of  liposomes containing  the  entire  recombinant  Sm28GST. 
=> We  have  applied  the  28GST-based  vaccination  strategy  in  outbred  animal  infection 
models;  ruminants infected by S.  bovisand Erythrocebus patas monkeys infected by  S. 
haematobium.  A significant  reduction  in  female  worm  fecundity  is  consistently  induced 
by vaccination  in  these  models,  with  notably an  80o/o  reduction  in  overall  egg  output in 
the  faeces  and  urine  of  Patas  monkeys  cross-immunized  with  Sm28GST,  a reduction 
that was  sustained  over a 48  wk  period. 
Immune responses to Sm28GST in human populations 
=>This  part  of  the  work  was  carried  out  in  collaboration  with  A.E.  Butterworth  and 
colleagues in  Kenya and  more  recently in collaboration with  B.  Gryseels,  F.  Stelma and 
our Senegalese  colleagues  in  Richard  Toll. 
=>  lgA  antibodies  to  Sm28GST  have  been  shown  to  be  closely  associated  with  the 
age-dependent acquisition  of resistance to  infection.  Functional  analyses  revealed  that 
these  antibodies  inhibited  the  activity  of  the  enzyme  and  could  impart  schistosome 
fecundity  in  vitro.  Current  studies  in  Senegal,  although  preliminary  and  limited  to 
pretreatment cohorts,  show a relationship between the age-associated decrease in  egg 
output  and  the  lgA  response  specifically  directed  against  the  Sm28GST  C-terminal 
peptide. 
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EVALUATION  OF  DEFINED  ANTIGEN  VACCINES  AGAINST  SCHISTOSOMA  BOVIS 
AND  S.  JAPONICUM IN  BOVINES 
Period: 
Co-ordinator: 
Objectives 
November1, 1992-1April30, 1996 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, 
DEPT OF MEDICAL PARASITOLOGY, 
London, United Kingdom (M. TAYLOR) 
To  evaluate the  immunogenicity and  protective efficacy of existing and  newly defined  Schisto-
soma bovisand Schistosoma japonicum antigen vaccines in their natural bovine hosts, thereby 
contributing to  the  development of  a defined  antigen  vaccine  against schistosomiasis. 
Activities 
*  The  immunogenicity  and  protective  efficacy  of  glutathione  S-transferase  (GST),  keyhole 
limpet  haemocyanin  (KLH)  and  freeze-thaw  schistosomula  antigen  plus  BCG  will  be 
assessed  in  calves. 
*  S.  bovis paramyosin  will  be  cloned  and  evaluated  in  the  same  way. 
*  Native  and  recombinant  GST of  S.  japonicum and  KLH  will  be  tested  for  immunogenicity 
and  protective  efficacy  in  rodents  and  calves. 
*  The  contribution  of  serological  responses  to  the  immunity  to  S.  japonicum  stimulated  by 
irradiated  cryopreserved,  or  freeze-thaw  schistolomula,  will  be  investigated  by  passive 
transfer experiments  in  mice  and  calves. 
*  Antigens recognised by sera of immune bovines from China will  be  identified and  compared 
with  those  recognised  by  rodents  immunised  with  irradiated cercariae. 
*  S. japonicum eDNA libraries will be expressed and purified and  recombinant molecules used 
in  crystallographic  studies. 
*  Paramyosin and the Sm23 homologue from Chinese S.  japonicum will  be cloned and tested 
in  rodents  and  calves. 
*  S.  bovisand S.  japonicum GSTs will  be  expressed and purified and  recombinant molecules 
used  in  crystallographic studies. 
*  lgA  monoclonal  antibodies  to  S.  japonicum  GST  will  be  produced  and  their  effects  on 
fecundity  and  egg  viability  reported. 
Expected outcome 
The  production  of additional  defined antigen  vaccine  candidates. 
Results 
This work aimed to contribute to the development of defined antigen vaccines for schistosomiasis 
by  evaluating  the  immunogenicity  and  protective  efficacy  of  S.  bovis and  Chinese  strain  S. 
japonicum antigens produced  in  UK and  France in  their natural  ruminant hosts in Africa and  in 
China. The defined antigens selected for testing included: glutathione S. transferases; KLH which 
bears epitopes cross-reactive with schistosome antigenes; Sj23, the homologue of the protective 
S.  mansoni membrane antigen  Sm23 and  S.  japonicum paramyosin.  20 full  length clones of a 
28kDa isoenzyme of S. japonicum (Sj28GST) were produced and expressed ready for testing in 
livestock alongside  Sj26GST of  a  Philippine  strain  of  S.  japonicum expressed  by  the  pGBEX 
vector (we  showed that this  is  identical to  Sj26GST of our Chinese strain).  We  likewise cloned 
and  expressed a 3 FE fragment of Chinese S.  japonicum paramyosin and the large hydrophilic 
domain of the  Sj23 antigen of Chinese strain  S.  japonicum.  Further trials were carried out with 
biochemically-purified  native  GSTs  of  Chinese  S.  japonicum,  and  some  trials  included  KLH, 
obtained through commercial suppliers.  Protection experiments were also carried out using the 
Fff vaccine (Fff schistosomula of Chinese S. japonicum administered with BCG). In the S.  bovis 
trials, we used a recombinant version of the 28kDa GST isoenzyme (Sb28GST) together with an 
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S.  bovis  F!T  vaccine  (S.  bovis  F!T  schistosomula  +  BCG)  and  KLH.  Some  preliminary 
immunisation experiments using S. japonicum antigens were also carried out in  BALB/c mice to 
explore the usefulness of the mouse model in this type of vaccine development programme. 
The most important finding  was that  each  of  our panel  of  S.  japonicum recombinant  derived 
antigens  induced  significant  levels  of  protection  in  sheep.  Further  work  is  now  needed  to 
optimise vaccination  schedules,  and to  devise the  most effective vaccine delivery systems for 
safe and  effective  immunisation  of farm  animals,  and  ultimately,  humans. 
The S.  bovis trial in  cattle in  Sudan demonstrated that r-Sb28GST had some protective efficacy, 
though it was less effective than vaccination with unfractionated native SbGSTs which had been 
tested  previously,  perhaps  indicating  that other SbGST isoenzymes  are  also  required  for the 
induction of high-level  resistance  in  this model. The  S.  bovis F!T vaccine,  modelled on  the  S. 
japonicum F!T vaccine also showed some protective effects, but these were far less dramatic than 
we obtained in  the S.  japonicum work.  In  the cattle/S. bovis system, protection was manifested 
entirely as a reduction in worm fecundity, rather than a reduction in adult worm recovery. 
Protection was obtained in  BALB/c mice vaccinated with  rSj23,  but little evidence of protection 
was  obtained  using  native  or  recombinant  paramyosin  in  BALB/c  mice.  Thus  although  the 
mouse  model  may  well  be  of  value  for  investigating  the  immunogenicity  of  S.  japonicum 
candidate vaccine  molecules,  it  is  probably preferable to carry out the  protection  experiments 
in  the natural  ruminant  hosts. 
In an attempt to enhance vaccine-induced protection, co-administration of two different antigens 
was  attempted  for  both  S.  bovis in  cattle  (using  rSb28GST  and  KLH)  and  S.  japonicum  in 
sheep and  water buffalo  (using  native  SjGST and  KLH).  No evidence of significant additional 
protection  was  obtained  in  these co-administration  experiments. 
Finally,  screening  of  our  Chinese  S.  japonicum strain  libraries  with  immune  sera  led  to  the 
identification  and  characterisation  of two  novel  antigens  of vaccine  potential,  calreticulin  and 
calpain,  which  we  plan  to evaluate in  large animal  protection  experiments. 
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CELL  MEDIATED  IMMUNITY  TO  SCHISTOSOMES.  EVALUATION  OF  MECHANISMS 
OPERATING AGAINST LUNG  STAGE  PARASITES,  WHICH  MIGHT BE  EXPLOITED IN 
A VACCINE 
Period: 
Co-ordinator: 
Objectives 
December 1,  1992 - November 30,  1993 
UNIVERSITY OF YORK,  DEPT.  OF BIOLOGY 
York,  United Kingdom (R.  WILSON) 
To  evaluate  cell  mediated  immune  responses  to  lung  stage  parasites  of  Schistosoma 
mansoni in  mice  and  in  infected  humans. 
Activities 
*  Secreted .  and  soluble  antigens  derived  from  schistosomula,  cultured  in  vitro  for  eight 
days,  will  be  used  to  expand  T-cell  clones  and  lines  generated  from  lymph  node 
populations  recovered  from  mice  shortly  after  intradermal  vaccination  with  day  8 
attenuated  schistosomula. 
*  Of  the  phenotypic  and  functional  assays  to  be  employed,  proliferation  and  interferon 
gamma  production  by  clones  or  lines  when  co-cultured  with  live  lung-stage  schisto-
somula are  considered  most important.  Clones which  meet these criteria will  be  tested 
in  vivo  for  the  ability  to  mediate  delayed  type  hypersensitivity  responses  and  reduce 
maturation  of  parasite  infections  relative  to  irrelevant T-cell  clones. 
*  Following clinical and epidemiological investigations, including assessment of resistance 
to  reinfection  after  chemotherapy,  lymphocytes  will  be  collected  from  the  peripheral 
blood  of patients from  Bela  Fama and  the profile of their cytokine production  (IL2,  IL3, 
IL4,  IL5  and  Interferon  gamma)  in  response  to  the  same  larval  antigens  will  be 
described. 
Expected outcome 
=> The establishment of T-cell clones which  meet the criteria of proliferation and  interferon-
gamma  production,  and  the  measurement  of  human  cytokine  profiles  in  response  to 
lung  stage  antigens. 
=>  Development of  a longer-term  project. 
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GENETIC AND  IMMUNOLOGICAL FACTORS  IN  HUMAN  RESISTANCE  TO  SCHISTO-
SOMA MANSON/ 
Period: 
Co-ordinator: 
Objectives 
September 1,  1994 - August 31,  1997 
INSEAM U399, FACULTE DE MEDECINE, DEPT. IMMUNOLOGY AND 
GENETIC OF PARASITE DISEASES, Marseille, France (A. DESSEIN) 
•  To  determine  to  which  extent  genetic  factors  control  susceptibility  to  infection  and  to 
disease  in  subjects  living  in  an  endemic  area  (Brazil)  and  in  subjects  who  recently 
migrated from  a non-endemic area of  S.  mansoni (Kenya). 
+ To  identify and  characterize the  mode of action  of  susceptibility genes. 
•  To  evaluate two  schistosome  antigens as vaccine  candidates. 
+ To  develop a strong  group  of  immunology at the  Faculty of  Medicine  of  Uberaba. 
•  To  strength  the  expertise of the  group of  Salvador in  the  field  of schistosomiasis. 
Activities 
*  Epidemiological  studies  to  evaluate  the  weight  of  environment  and  behaviours  on 
infection  and  morbidity. 
*  Search  by  segregation  analysis  of  gene(s)  with  a  major  effect  on  infection  and 
morbidity. 
*  Mapping  of these  genes by  linkage analysis  using  the  microsatellite method. 
*  Analysis of the  anti-parasite  immune  response  of  susceptible and  resistant  subjects to 
uncover an  immunological  deficit in  genetically susceptible  individuals. 
*  Analysis of the lymphokine production pattern ofT-lymphocytes in  subjects with  various 
degree of fibrosis. 
*  Purification,  cloning  and  production  of  the  active  antigen  in  F28  fraction.  Mapping  of 
antigenic determinants of  Sm37. 
*  Evaluation of the cellular and antibody response of resistant and susceptible subjects to 
recombinant protein  and  to  peptides. 
Expected outcome 
~  The  demonstration  that  genetic  predisposition  to  infection  and  disease  accounts,  to  a 
large  extent,  for the  heterogeneous distribution  of clinical  phenotypes  in  endemic area 
of  Schistosoma  mansoni. 
~  The  demonstration  that  such  a genetic  predisposition  results  from  the  action  of  a few 
genes  (major genes)  controlling  infection  and  regulating  Symmer's fibrosis. 
~The identification  of  immune  mechanisms  that  play  a  critical  role  in  human  defences 
against  S.  mansoni. 
Progress  toward  the  vaccine  through  the  identtfication  of: 
~  The  protective  immune  mechanisms to  be  stimulated  by the  vaccine; 
~The immunological  deficit  that  must  be  "overcome"  by  the  vaccine  in  genetically 
susceptible  subjects; 
·~Vaccinating antigens. 
Strengthening of research capabilities of two brazilian laboratories 
This project is  based  on  a long standing collaboration  between  our groups;  it is  grounded 
on  observations made by  us  in  Brazil on  a major gene in  human  resistance to  S.  mansoni 
and  on  the  immunological  mechanisms that are  critical  to  human  resistance  to  infection. 
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A  similar  immunological  approach  has  been  taken  in  Kenya,  interactions  between  the 
partners will  allow the determination of whether the observations on  the genetic control  of 
resistance  can  be  extended  to  another  endemic  area.  This  project  has  a  major training 
component for young  scientists. 
Results 
=>  Evidence has been  obtained by segregation analysis for the existence of a major gene 
or a major locus  in  the control  of  infection  intensities. 
=> This major gene  (Sm  1)  has been  located  on  chromosome 5q31-33. 
=>Analyses  of  the  immune  response  of  homozygote  resistant  and  susceptible  subjects 
have demonstrated differences in  lymphokine production.  Resistance is associated with 
a Th0/2 type lymphokine production and susceptibility is associated with a Th0/1  type of 
lymphokine production  pattern. 
=> The  active  molecule  in  F-28  has  been  purified  and  cloned.  It  is  referred  to  as  Sm1 0. 
Antigenic determinants have  been  mapped on  Sm37. 
=>  Cellular and  antibody response to  these  antigens are  being  evaluated  in  resistant and 
susceptible subjects. 
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CELL  MEDIATED  IMMUNITY  TO  SCHISTOSOMES:  EVALUATION  OF  MECHANISMS 
OPERATING AGAINST LUNG  STAGE  PARASITES, WHICH  MIGHT BE  EXPLOITED IN 
A VACCINE 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1994 - September 30,  1997 
UNIVERSITY OF YORK,  DEPT.  OF BIOLOGY 
York,  United Kingdom  (R.  WILSON) 
•  To  identify  and  clone  the  antigens  mediating  lung  phase  immunity  to  Schistosoma 
mansoni in  mice  vaccinated  with  irradiated cercariae. 
•  To  use the  recombinant antigens for evaluation ofT cell  responses  in  mice exposed to 
the  irradiated vaccine,  and  for protection  experiments. 
•  To  examine  the  responses  of  peripheral  blood  lymphocytes from  human  patients  with 
different clinical  forms  of  schistosomiasis,  to  recombinant  lung  stage-antigens. 
•  To analyze selected lung stage antigens at the molecular level by mapping B and T cell 
epitopes  using  synthetic peptide constructs. 
Activities and Results 
Molecular Biology of Schistosome Antigens 
Experimental  work  performed  during  this  project  has  sought  to  use  several  different 
techniques  to  pinpoint  potential  vaccine  antigens.  This  has  involved  the  identification  of 
cDNAs encoding such  molecules, their sequence analysis,  and the subsequent production 
and  purification  of  recombinant  proteins  in  E.  coli.  A secondary aim  has  been  to  identify 
and  subsequently  characterize  genes  expressed  uniquely  by  lung-stage  schistosomula 
using  the  technique  of  RAP-PCR.  We  have  also  investigated  the  possibility of identifying 
cDNAs  encoding  putative transmembrane or secretory proteins from  expressed sequence 
tags  produced  as  part  of the  schistosome  genome  project. 
Serum  raised  in  rabbits  against  proteins  released  by  lung-stage  schistosomula  during  in 
vitro  culture  has  been  used  to  screen  both  lung-stage  and  adult  worm  DNA  libraries.  A 
novel  clone  coding  for  a  protein  of  Mr  16.4kDa  (A26)  has  been  identified,  sequenced, 
expressed in a pET vector,  and purified. A monospecific serum has been  produced against 
the  recombinant A26  protein  and  used  to  identify the  "native"  parasite  protein  by probing 
Western  blots  of  soluble  preparations  of  cercariae  (SCAP),  lung-stage  schistosomula 
(SLAP)  and  adult  worms  (SWAP).  Preliminary  results  indicate  that  a  protein  of  approxi-
mately  31 kDa  is  detected  in  all  three  preparations,  but  appears to  be  most  abundant  in 
cercariae.  The  same  screening  procedure  also  identified  three  previously  described 
vaccine  candidates,  paramyosin,  myosin  and  calpain,  the  last  of  which  we  are  pursuing 
further. 
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In  addition  to  the clones  identified  by screening  lung-stage  and  adult worm  DNA libraries 
with sera raised against lung-stage proteins, secretory proteins from  other life-cycle stages 
have  been  sought.  A schistosome  calcium-binding  protein  and  a  21.7kDa  antigen  have 
been  identified  from  a  cercaria  DNA  library,  plus  a  putative  cytochrome  C  and  four 
unknown  clones.  Screening  of  an  adult  worm  library  with  antibodies  directed  against 
released  proteins resulted  in the isolation of another four unknown clones,  plus  previously 
sequenced S.  mansoni HSP70, cathepsin and a known,  secretory protein,  LGG. A number 
of  the  unknown  clones  have  been  sequenced  more  extensively  and  subsequently  ex-
pressed  in  the  pQE  or  pET vectors.  As  well  as  being  vaccine  candidates,  such  proteins 
may  have  potential  use  as  markers  of  disease  progression  in  human  patients,  and  will 
enable  the  immunogenicity  of  proteins  released  at  different  life-cycle  stages  to  be 
compared  in  various  assays. 
The  contribution  of  the  Lille  Pasteur  Institute  group  to  the  project  has  involved  the 
subcloning and  expression of cDNAs encoding some of the proteins potentially involved in 
the  protective  immune  response  directed  against  lung  schistosomula  of  S.  mansoni, 
namely calpain,  the tegumental antigens Sm22.6 and  Sm21.7,  and a DNA encoding an  S. 
mansoni homologue  of  mammalian  epididymal  secretory  protein  I.  Attempts  to  express 
these  four  cDNAs  are  currently  underway  in  Lille  but  significant  difficulties  have  been 
experienced  with  all  of  the  clones.  A  variety  of  vectors  are  therefore  being  tried  to 
circumvent the  problems. 
In  a new departure,  the  lung stage library constructed  in  York  has been  transferred to our 
partners in  Belo  Horizonte for screening with  sera from  patients in  the acute phase of the 
disease and  five  clones  (HL-1  to  HL-5)  were  obtained. All  five  have been  sequenced  and 
expressed  in  either pET or pQE  vectors  and  are  now at the  purification  stage. 
Assessment of immunogenicity 
Now that we  have developed a panel  of recombinant proteins representative of molecules 
released  by  parasites  at  various  stages  throughout  the  life-cycle,  the  immunogenicity  of 
each  can  be  assessed.  Since parasite-specific Th1  cells play a pivotal  role  in  the  effector 
response  in  once-vaccinated  mice,  most attention  will  focus  on  assays  of T cell  prolifera-
tion  and cytokine production. The secretion of cytokines by cells  recovered from  the  lungs 
of mice 17 days post-vaccination will  be our main indicator of protein immunogenicity since 
it  is  this  sub-set  which  is  responsible  for challenge  parasite  elimination.  In  particular,  we 
shall  be  seeking  proteins  which  stimulate  high  levels  of  IFNy  production.  We  are  also 
developing an  in  vivo assay of antigen reactivity,  by injecting recombinant proteins into the 
pinnae  of  mice  previously  exposed  to  the  irradiated  vaccine  to  measure  delayed-type 
hypersensitivity responses. 
In collaboration with our Brasilian partners, we are currently testing the ability of peripheral 
blood mononuclear cells (PBMC) from  patients with different clinical forms of schistosomia-
sis  to  proliferate  in  vitro  in  response  to  each  recombinant  protein. 
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Four  recombinant  antigens  have  been  tested  so  far;  all  elicited  responses  above 
background but considerably lower than those to  SWAP and  SEA preparations (this is  not 
unusual  with  recombinants  and  represents  an  obstacle  to  their  evaluation  as  vaccine 
candidates by  direct probing of human  responses).  In  an  alternative screen,  we  are  using 
an  ELISA to determine total  lgG  responses to  each  recombinant of patients in the various 
clinical  categories  of  schistosomiasis,  as  an  indicator  of  preceding  T  helper  cell  re-
sponses. 
Human schistosomiasis in Brazil 
Field  surveys  of  schistosomiasis  in  the  vicinity  of  Belo  Horizonte  have  continued, 
concentrating  on  the  district  of  Sabara.  Stool  sampling  of  1413  residents  revealed  an 
overall  prevalence  of  27°/o,  with  a mean  egg  count  of  58  epg  (range  5 - 633).  Of  these 
infected  individuals,  only  12°/o  presented  egg  counts  above  500  epg  which  might  be 
considered  a heavy infection;  few  showed ·evidence  of  advanced  hepato-splenic disease. 
For this reason,  we  have continued  our studies of human  responses to  S.  mansoni in  an 
endemic area of Northern Minas Gerais state, centered on Corrego Bernardo,  using a field 
laboratory  in  the  city  of  Governador Valadares. 
Both  cellular and  humoral  responses  to  SLAP,  SWAP,  and  SEA have  been  evaluated.  In 
vitro stimulation of PBMC with SLAP leads to a significant proliferative response in patients 
with  the different clinical forms of the  schistosomiasis,  except in  hepatosplenic individuals. 
Neutralisation  of  cytokines  in  PBMC  cultures  reveals  that  the  proliferative  response  to 
SLAP  is  differentially  regulated  from  that  to  SEA  and  SWA,  with  no  effect  observed 
following the  addition of antibodies to  IL-4,  IL-5 and  IL-10.  On  the  other hand,  addition  of 
anti-IFNy antibodies to the  PBMC  cultures  readily decreased the proliferative  response to 
SLAP  as  it  did  for SWAP  and  SEA. 
Special  emphasis has been  given to the  development of  methods for the  intracytoplasmic 
staining for cytokines that would allow for their simultaneous identification together with the 
cell  type  secreting  them,  using  flow  cytometry.  Initial  intracytoplasmic  staining  data  was 
obtained for IL-2,  IL-4,  IL-5 and  IFNy in  PBMC.  Patients were divided into lgEhi  and  lgE
10 
groups on  the  basis of their serum  responses to  SWAP.  The  results  demonstrate that the 
lgEhi  group  had  a  significantly  higher  frequency  of  IL-4  and  IL-5  positive  cells  than  the 
lgE10  group. The frequency of  I  FNy positive cells was the  same in  both  groups but,  whilst 
in  the  lgEhi  group  the  ratio  for  IFNy/IL-4  was  13,  in  the  lgE
10group  it  was  35.  Taken 
together,  these  results  correlate  IL-4  directly and  IFNy inversely with  serum  lgE  levels.  It 
is  important to  note  that  in  this  study all  patients were  age-matched,  thus no  influence of 
age  can  be  attributed to  the  observed  results.  Furthermore,  all  individuals _were  from  the 
same  area and  to  date,  the  differences in  the two  groups of  patients cannot be  attributed 
to  different  levels of  water contact. 
We  have  also  demonstrated that exposed,  "normal  endemic"  individuals  have  a high  lgE 
antibody response which  is  elevated only to schistosomula tegumental antigens.  We  have 
previously demonstrated that  PBMC  from  "normal  endemic"  individuals secrete significant 
levels of  IFNy when  stimulated  in  vitro with  SWAP  or SEA. 
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The  data  obtained  with  the  intracytoplasmic  staining  for  cytokines  demonstrated  that 
infected  patients  with  low  levels  of  anti-SWAP  lgE  have  the  highest  frequency  of  INFg 
positive  cells.  We  have  postulated  that  the  effective  immune  response  to  a  S.  mansoni 
infection  is  multifactorial  and  that  it  is  site-dependent,  i.e.  different  compartments  may 
develop distinct effector responses  to the invading  parasite.  In  this context,  it is  possible 
that the  early attrition  may be  mediated  by  lgE  antibodies and  the  later,  as  the  parasite 
migrates  through  the  lungs,  the  immune  effector  mechanism  becomes  mainly  IFNy-
dependent.  The correlation  between  the  intracytoplasmic staining  of cytokines and  devel-
opment of  resistance to  infection,  or pathology  is  not yet adequate to  determine whether 
there  is  a cause/effect relationship  and  whether one can  distinguish between the roles  of 
Th1  and Th2  responses  in  these  situations. 
One of the  major criticisms of work on  human immune responses to  S.  mansoni infection 
has  been  that the  studies are  always  performed  using  PBMC,  which  may not  reflect the 
events in the lymphoid organs. To address this question we have compared the phenotype 
of cells  present  in  the  peripheral  blood  and  in  the  spleens of hepatosplenic patients.  We 
observed  an  increase  in  CD4*HLADR+,  CD5+CD19+,  CD8+HLADR+  and  NK cells  in  both 
compartments,  relative  to  that  in  normal  non-infected/non-exposed  controls  (accident 
victims).  These  results  demonstrate  that  analysis  of  the  peripheral  blood  reflects  the 
findings  in  a lymphoid organ,  such  as  the  spleen. 
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EVALUATION  OF  THE  REDIATION-ATTENUATED  SCHISTOSOME  VACCINE  IN  PRI-
MATES AS A MODEL FOR  HUMAN VACCINE  DEVELOPMENT 
Period: 
Co-ordinator: 
Objectives 
January 1, 1998- June 30, 2000 
UNIVERSITY OF YORK, DEPARTMENT OF BIOLOGY 
York,  United Kingdom (A. WILSON) 
•  To  investigate the  radiation-attenuated  (RA)  schistosome vaccine  in  chimpanzees  and 
simultaneously  examine  the  development of  the  granulomatous  responses  to  schisto-
some egg  disposition  in  the  liver of control  animals. 
•  To compare the immunological and pathological responses of human patients, exposed 
to  schistosome  infection  in  endemic areas of  Brazil,  with  those  of  the chimpanzees. 
•  To  explore  in  baboons aspects of the  RA vaccine,  crucial  to  its evaluation  as  a model 
for a human  recombinant vaccine. 
Activities 
A  core  vaccination  experiment  will  be  performed  involving  three  test  and  three  control 
chimpanzees. 
The  immune  responses  to  vaccination  and  challenge  will  be  compared  in  two  distinct 
physiological compartments,  the peripheral  blood  and  the  airways of the  lung.  Serum will 
also  be  obtained  for  determination  of  specific  antibody  responses.  Leucocytes  will  be 
recovered from blood for determination of antigen-driven proliferation and cytokine produc-
tion after 72-96h of in vitro culture. Lymphocytes in whole blood will be phenotyped by flow 
cytometric analysis. Airway leucocytes will  be  recovered  from  test and  control  animals by 
bronchoalveolar lavage over the  vaccination  period  to  determine  whether the  lungs  have 
been pre-armed with schistosome-reactive cells. The efficacy of vaccination after challenge 
with  normal cercariae will  be estimated from  faecal  egg counts.  Mature worm  burdens will 
also  be  estimated  by  the  measurement of parasite  gut-derived  circulating  antigens  (CAA 
and CCA) in serum and urine. The pathogenic mechanisms operating after the start of egg 
deposition  in  challenged  animals  will  also  be  intensively  monitored.  The  liver  will  be 
sampled at regular intervals by  needle biopsy.  A wedge surgical  biopsy will  be  taken  late 
in  the  study.  The  recovered  tissue  will  be  subjected  to  a  detailed  histopathological  and 
immunocytochemical analysis.  Observations will  be  made on  the gross pathology induced 
by  a schistosome  infection  by  estimating the  extent of hepatic fibrosis  using  non-invasive 
ultrasound scanning  of the  liver. 
Human  responses to schistosome infection will  be  evaluated  in  a cross-sectional  study of 
Brazilians patients during the acute and chronic phases of the disease. Characterization will 
use primarily peripheral blood leucocytes, but also cells from other compartments that may 
become available. Phenotypic analysis of lymphocytes will be performed for the same range 
of CD markers as in chimpanzees. The expanded T cell populations will also be phenotype 
to  pinpoint the characteristics of schistosome-reactive T cell  subsets.  Cytokine levels in  all 
PBL cultures will be evaluated by ELISA. Biopsy samples of livers and spleen, obtained from 
patients with chronic (hepatosplenic) disease, will be analysed by immunocytochemistry. 
Two experiments will  be undertaken in  baboons to define further certain parameters of the 
RA  vaccine.  The  question  of  whether  protection  is  long-lasting  will  be  addressed  in  an 
experiment  requiring  15  test  and  15  control  baboons.  The  test  animals  will  be  given  3 
vaccinations using the same pools of parasites. Protection will then be  measured by portal 
perfusion to determine adult worm burden at one, three and six months by challenging five 
test and  five  control  animals on  each  occasion. 
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A second experiment is designed to discover whether there is a ceiling to protection. Three 
groups of test animals will  receive five,  three of one vaccinations, respectively,  before they 
and  a single group of controls are  all  challenged with  the  same pool  of normal cercariae; 
protection  will  be  measured  six  weeks  after  challenge.  Assays  of  immune  reactivity, 
including  antigen-driven  proliferation,  secretion  of some  cytokine  proteins  (IL-2,  4,  5  and 
IFNy),  and  specific  lgG  titres,  will  be  performed.  Serum  samples  will  be  obtained  at 
perfusion,  to  determine circulating antigen  levels. 
Expected outcome 
Immunological  parameters will  be  monitored  in  primates from  the  start of experiments so 
that  the  effects  of  exposure  to  the  RA  vaccine  should  rapidly  become  apparent.  In  the 
case of chimpanzees, the most crucial sampling period will  be  after challenge with  normal 
cercariae when  the level of protection achieved will  be  determined by indirect methods.  In 
the case of the baboon experiments, a definitive estimate of protection will  be  obtained by 
counting the portal worm  burdens.  In  both situations, the level of protection will  be related 
to  the  range  of  immunological  parameters  measured.  Studies in  human  patients  in  Brazil 
will  take  place  in  parallel  with  the  primate  vaccination  experiments  and  attempts  will  be 
made  to  relate  these  to  the  experimental  findings  in  order to  evaluate  the  utility  of  the 
primates  as  models  for  human  schistosomiasis.  These  cross-comparisons  will  also  be 
important  in  the  studies on  liver pathogenesis in  the chimpanzee. 
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EFFICACY  OF  rSh28GST  AS  AN  ANTIFECUNDITV  VACCINE  AGAINST  SCHISTO-
SOMA  HAEMATOBIUM INFECTION  (II):  IMMUNE  MECHANISMS  IN  EXPERIMENTAL 
MODELS AND  IN  MAN 
Period: 
Co-ordinator: 
Objectives 
October 1,  1997 - September 30,  1999 
INSTITUT PASTEUR,  DEPT.  OF IMMUNOLOGY & 
PARASITOLOTY,  Lille,  France (A.  CAPRON I G.  RIVEAU) 
To  evaluate a well-founded  vaccine  strategy against the  trematode  parasite  Schistosoma 
haematobium by evaluating: 
•  the  immune  responses towards,  the 28  kDa glutathione  S-transferase  (Sh28GST)  and 
its  major epitopes,  in  infected  human  populations  in  three  endemic areas; 
•  the  present epidemiological  status and  transmission  process  in  each  endemic area; 
•  the feasibility of the  use  of new mucosal  delivery systems for the  recombinant subunit 
vaccine. 
In  addition,  the project will  promote the development of south-south collaborative research 
between the participating DC  partners,  in  terms of technological and staff exchanges. The 
bi-directional  programme  (North-south)  for  research  training  which  took place  in  1995 for 
the  cellular immunity analysis and epidemiological and  medical  studies,  will  be  continued. 
Activities 
*  Epidemiological survey of S.  haematobium infection in  Senegal, Niger and Madagascar. 
Study of the transmission  process of the  disease. 
*  Immune-epidemiology  of  S.  haematobium  infection  in  human  before  and  after  treat-
ment.  Humoral  and  cellular responses to  rSh28GST in  infected  human  populations,  in 
Senegal,  Niger,  and  Madagascar. 
*  Production of rSh28GST,  liposomes and nucleic vaccine vectors.  Humoral responses to 
mucosal  immunization  in  mice and  Patas  monkeys, 
*  Mouse  model  of  S.  haematobium infection  (parasite  life  cycle).  Humoral  and  cellular 
responses  in  infected mice,  mucosal vaccination  trials  in  mice. 
*  Monkey model of S.  haematobium infection. Humoral and cellular responses in  infected 
animals,  mucosal vaccination  trials. 
*  Training  of one  Senegalese technician  in  immunochemistry,  one  physician  scientist  in 
epidemiology from  Niger,  and  one  scientist in  Madagascar for cellular immunology will 
be  undertaken.  Training  of two  European  students  in  human  immunology,  one  for the 
studies  in  Madagascar (March  1998), the  other one  in  Senegal  (June  1998). 
The coordination of external services for toxicology analysis, and  Phase  I a clinical trial of 
rSh28GST  in  Europe will  be  engaged  by  Partner 1. 
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Expected outcome 
The epidemiology and immune-epidemiological studies on S. haematobium infected popula-
tions will give us an up to date view of the parasitic status and the specific immune status of 
the targeted populations allowing us to prepare the appropriate schedule for vaccine trials in 
infected populations (phase 2;  Sh28GST in Alum), which is planned in  1999. 
The studies on  the  proposed  new vaccine formulations for mucosal  immunisation  will  be 
the  last step of their evaluation. Their efficacy will  be confirmed,  and their capacity under 
field  conditions will  be  evaluated. 
The project will  ensure the training  of DC  partner technicians,  doctoral  and  post-doctoral 
students and technology transfers,  notably between the  DC  partners.  We place particular 
emphasis on the development of this collaboration in the context of the regional integration 
of research  efforts against infectious diseases. 
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DEVELOPMENT OF A VACCINE  FOR  SCHISTOSOMIASIS JAPONICA 
Period: 
Co-ordinator: 
Objectives 
October 1,  1997 - September 30, 2000 
LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE, 
DEPT. OF INFECTIOUS AND TROPICAL DISEASES, 
London,  United Kingdom (M.G. TAYLOR) 
To  develop a vaccine  for  schistosomias~s japonica. 
Activities 
We  will  evaluate  the  protective  efficacy  of  novel  formulations  of  several  recombinant  S. 
japonicum  antigens  in  their  natural  sheep  and  pig  hosts.  We  will  develop  improved 
methods of vaccine delivery by preparing and testing antigens delivered as  DNA vaccines 
or in  liposomes. Also,  with  a view to  planning  eventual  clinical  trials with  one  or more of 
these antigens, evidence of a protective role for antibody or cytokine responses to each of 
these antigens will  be  investigated using sera and whole-blood assays from "resistant" and 
"susceptible" S. japonicum patients in China. Antigens to be developed are those which we 
have already cloned,  expressed, and tested in  animal vaccination experiments: glutathione 
S-transferases,  paramyosin,  myosin,  a 23kDa integral  membrane protein,  and  Sj22.6. 
Expected outcome 
Cloning work for production  of recombinant paramyosin,  Sj23,  Sj22.6,  and  myosin  will  be 
completed  and  DNA vaccine  constructs  of  Sj23  and  Sj28GST  will  be  produced.  These 
preparations  will  be  scaled  up  and  tested  for  immunogenicity  and  protective 
efficacy/studies  of  immune  mechanisms  in  mice.  Liposome  formulations  of  paramyosin, 
Sj28GST,  Sj23,  myosin  and  Sj22.6  will  be  produced  and  tested  for  immunogenicity  and 
protective efficacy in  mice.  Promising formulations will be further tested in sheep and pigs, 
and  the antigenicity of the  recombinants  will  be  determined  in  humans. 
This work programme will establish the optimal formulations of our panel of recombinant S. 
japonicum antigens  for  subsequent  field  testing  in  livestock.  The  human  studies  should 
give indications as to which  if any of these antigens is  associated with  immune protection 
against  reinfection  in  man.  Ultimately this  work  may  lead  to  the  introduction  of  effective 
vaccines for  use  in  both  humans and  their domestic animals. 
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QUANTITATIVE DIAGNOSIS OF SCHISTOSOMA INFECTIONS BY MEASUREMENT OF 
CIRCULATING ANTIGENS  IN  SERUM  AND  URINE 
Period: 
Co-ordinator: 
Objectives 
March 1  , 1992 - February 28,  1995 
RIJKSUNIVERSITEIT LEIDEN,  DEPT. OF PARASITOLOGY 
Leiden, The Netherlands (A.M.  DEELDER) 
•  The  development  and  optimization  of  enzyme-linked  immunosorbent  assays  (ELISA) 
and  reagent  strips  for  the  quantitative  detection  of  circulating  anodic  (CAA)  and 
circulating  cathodic  (CCA)  antigens  and  other  adult  worm  antigens  (CA-2),  immune 
complexes,  and  for the  demonstration of several  antigens  in  one  assay. 
•  The evaluation of circulating antigen detection systems for use as sera-epidemiological 
tools  in  studies  of  the  chemotherapy,  immunology  and  morbidity  of  Schistosoma 
mansoni,  S.  haematobium,  S.  japonicum and  S.  intercalatum infection. 
Activities 
*  Monoclonal antibodies directed against schistosome circulating antigens will  be  used in 
ELISA assays. Once monoclonal antibodies are produced against circulating antigens of 
S.  japonicum,  an  ELISA assay will  be  established  and  optimized  for detection  of  this 
species. 
*  Appropriate,  alternative,  simple  procedures  for  pre-treating  urine  specimens  will  be 
investigated. 
*  The  daily fluctuations  of antigen  concentration  in  urine and  serum  will  be  investigated. 
*  Reagent strip  ("dipstick")  assays  will  be  employed  in  an  attempt to  develop  a simple, 
field  applicable assay. 
*  Following  training  and  technology  transfer,  sera-epidemiological  surveys  and  clinical 
field  trials will  be  conducted. 
Expected outcome 
==>  Improvement  in  the  sensitivity  and  specificity  of  the  circulating  anodic  (CAA)  and 
circulating cathodic (CCA) antigen detection ELISA assays for Schistosoma mansoni,  S. 
haematobium and  S.  japonicum. 
==>  Evaluation  of antigen  detection  assays as  sera-epidemiological tools. 
==>  The  development of a reagent strip  assay. 
==>  The  successful  transfer of  ELISA,  reagent  strip  and  immunochemical  expertise  to  the 
DC  partners. 
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FIELD APPLICABLE ANTIGEN ASSAYS  FOR  HUMAN SCHISTOSOMIASIS: A  MULTI-
CENTRE  DEVELOPMENT AND IMPLEMENTATION STUDY 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1997 - September 30, 2000 
UNIVERSITY OF LEIDEN, Dept. of Parasitology, 
Leiden, The Netherlands (A.M. DEELDER) 
+  field  assays for detection  of schistosome antigens  CAA and  CCA in  serum  and  urine 
will  be  developed  in  reagent  strip  and/or  filter  format  using  colloidal  gold-labelled 
monoclonal antibodies  (Mabs). 
+  assays  will  be  tested  in  pilot  field  trials  in  parallel  with  magnetic  bead  assays  for 
detection  of  CAA  and  CCA  in  serum  and  urine  of  patients  infected  with  the  major 
Schistosoma species (S.  mansoni,  S.  haematobium,  S.  japonicum). 
+ selected  assays  will  be  applied  in  sera-epidemiological  studies,  in  chemotherapy 
follow-up,  and  reinfection  studies  ~S.m.,  S.h.)  for  assessment  of  antigen  kinetics  (in 
relation  to egg output). 
+ new MAbs for detection  of circulating  antigens  will  be  developed for  S.  japonicum  in 
particular,  and tested and  applied  in  assays as described above. 
Activities 
Using McAbs already developed and optimized for ELISA's detecting parasite antigens in 
serum and/or urine, the format of a lateral flow diagnostic device (cf.  pregnancy test)  will 
be  evaluated and optimized. This format is  based on the reaction  of applied sample first 
passing and dissolving a dried labelled antibody,  and subsequently migrating to a zone of 
bound  capture  antibody.  This technology format  is now becoming commercially available 
and the necessary contacts have already been made. This approach will  result in  a very 
rapid assay (approx. 4 minutes) but probably with a sensitivity only high enough to identify 
moderate and  heavy infections. 
Starting at the end of the first year, the field-applicable assays developed in  Leiden will be 
evaluated by the three partners in the endemic areas in  study groups of about 50 infected 
and  50  uninfected  individuals.  For  these  studies,  the  rapid  ELISA  will  be  used  as  a 
reference assay.  It is anticipated that for each of the Schistosoma species this number of 
samples and  the available  reference  data will  allow selection  of the assay formats  most 
appropriate  for  addressing  specific  studies  in  larger  study  cohorts.  As  follow-up  of 
chemotherapy  will  be  essential  for  evaluating  sensitivity  of  assays  before  and  after 
chemotherapy,  such  studies  will  form  an  integral  part  of  the  work  on  each  of  the 
Schistosoma  species.  In  all  studies,  a  5o/o  sample  will  be  randomly  selected  for  quality 
control  of  the  assays,  initially  to  be  performed  in  Leiden,  and  at  a  later  stage  in  the 
laboratory of one of the African  DC  Partners (e.g.  in  Zimbabwe). 
The assays thus developed will  rapidly be transferred to DC partners for evaluation under 
field conditions. Technology will also be transferred to the Institute of Parasitic Diseases in 
Shanghai,  China,  to allow optimization with  the anti-S.j.  McAbs. 
180 Contract number IC18*CT970241 
The hydrophobic, chemically inert polypropylene fibre web material, which was developed by 
the  Dept.  of  Medical  Microbiology  and  Immunology  in  Goteborg  in  collaboration  with 
Molnlycke  AB,  Sweden,  as  sampling  material  for  blood  containing  CAA,  will  be  further 
investigated. It is anticipated that the fibre web sampling format could in a later phase of the 
project be included for quality control studies of samples which have been tested in the field. 
Sample pre-treatments, although currently already relatively simple, will be further adapted 
for field  use and  applicability to  larger sample  sizes. 
Expected outcome 
=> a field  applicable diagnostic assay for schistosomiasis 
=>  a field  applicable sample pre-treatment method 
=> a field  applicable sample collection  and  storage method  based  on  fibre  web 
=>anti Schistosoma japonicum McAb cell  lines applicable in  specific and sensitive assays 
Partners 
University of Leiden 
Department of Parasitology 
P.O.  Box 9605 
2300 RC Leiden 
The Netherlands 
University of Goteborg 
Dept. of Med. Microbial. & Immunology 
Guldhedsgatan 1  0 
413 46 Goteborg 
Sweden 
Institute of Parasitic Diseases 
Chinese Academy of Preventive Medicine 
207 Rui Jin Er Lu 
Shanghai200025 
China 
National Institute for Medical Research 
ISAMILO, P.O.  Box 1462 
Mwanza 
Tanzania 
Blair Research Institute 
Immunology and Schistosomiasis 
P.O.  Box CY573 
Causeway, Harare 
Zimbabwe 
Danish Bilharziasis Laboratory 
Jaegersborg Aile 1  D 
2920 Charlottenlund 
Denmark 
A.M. Deelder 
Tel:  +31n1/527.68.56 
Fax: +31n1/527.68.50 
E-mail: parasito@ rullf2.1eidenuniv.nl 
L.A.  Nilsson 
Tel:  +46/31/60.47.17 
Fax: +46/31/82.67.91 
E-mail: nilsla@ clavicula.mednet.gu.se 
Feng Zheng 
Tel: +86/21/64.37.63.08 
Fax: +86/21 /64.33.26.  70 
E-mail: zfeng @fudan.ac.cn 
R.M. Gabone 
Tel:  +255/51/307.70 
Fax: +255/51/318.64 
E-mail: nimr@tan2.healthnet.org 
P.O.  Ndhlovu 
Tel:  +263/4n9.27.47 
Fax: +263/4n9.24.80 
E-mail: blair@ healthnet.zw 
B. Jyding Vennervald 
Tel: +45/39.62.61.68 
Fax: +45/39.62.61.21 
E-mail: bjv@bilharziasis.dk 
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EPIDEMIOLOGY,  SEROLOGY AND  CHEMOTHERAPY  OF  SCHISTOSOMA  MANSON/ 
INFECTIONS  IN  A  RECENTLY  EXPOSED  COMMUNITY  NEAR  RICHARD  TOLL, 
SENEGAL 
Period: 
Co-ordinator: 
Objectives 
March 1  , 1992 - February 28,1996 
PRINCE LEOPOLD INSTITUTE OF TROPICAL MEDICINE 
Antwerp, Belgium (B. GRYSEELS) 
The  project initially had  four main,  inter-related objectives: 
+  To study patterns of infection and  reinfection with  Schistosoma mansoni and of humoral 
immune  responses  in  a  non-immune,  recently  exposed  community  near  Richard  Toll, 
Senegal,  and  to  test  hypotheses concerning the  role  of  acquired  immunity in  humans. 
+  To apply to this end,  assays for antigen detection in serum and urines besides classical 
epidemiological,  parasitological  and  immunological  (antibody patterns)  methods,  and  to 
evaluate  these  techniques  as  a  monitoring  tool  for  intervention  studies  and/or  as 
epidemiological  research  tool.  . 
+ To  provide  baseline  data  for  other  immune-epidemiological  and  intervention  studies, 
including  possible  vaccine  development;  and  to  contribute  to  the  epidemiological, 
serological  and  chemotherapeutic components  of these  other studies. 
+ To  develop  and  evaluate  optimal  chemotherapeutic  strategies  in  order to  prevent  the 
development  of severe  morbidity in  this  new  focus,  and  to  contribute  to  the  develop-
ment of durable,  integrated  control  measures. 
In  the  course  of the  project,  additional  objectives were  added  as  they became obviously 
important: 
+  To  study the  morbidity patterns  in  this  recently  but  heavily infected  population. 
+ To  investigate the  apparent and  unexpected failure  of praziquantel,  the  recommended 
drug for schistosomiasis,  to  cure  most infections. 
Activities 
*  Prevalence  and  intensity  of infection  were  measured  in  four  randomly  selected  popu-
lation samples of 400 individuals, at intervals of eight months,  in the village of Ndombo, 
Northern Senegal. Surveys consisted of repeated faecal egg counts, collection of serum 
and  urine,  standardised  medical  history and  clinical  examination. 
*  In  each cohort,  infected subjects were treated with  40  mg/kg praziquantel; acceptability 
and side-effects were monitored.  Parasitology,  serology and morbidity were follow-up at 
6 and  12  weeks,  and  at  12  and  24  months after treatment. 
*  Serological  samples were  screened for subclass  specific  antibody  responses  to  crude 
and  defined antigens with  immunogenic or immunodiagnostic potential. 
*  Circulating anodic and circulating cathodic antigens were measured in  urine and serum 
and  evaluated  against conventional  parasitological  results. 
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*  During the follow-up,  quantitative malacological studies and  water contact observations 
were  conducted  at  five  major  transmission  sites  in  Ndombo.  Reinfection  rates  were 
related  to  exposure to  infection  and  immunological  profiles. 
*  Alternative  drug  regimens  and  control  measures were  evaluated. 
Results 
lmmuno-epidemiological studies: infection and reinfection patterns 
The  cross-sectional  study of the four cohorts showed  extremely high  prevalences  (>90o/o) 
and  intensities  (25-40°/o  excreted  more  than  100  epg)  of  infection  in  this  community. 
Prevalences  rapidly  increased  in  children,  and  from  5 years  of age  the  whole  population 
was  infected.  The  age-dependent  intensity  curves  peaked  strongly  and  consistently  in 
children,  to  drop  in  adults,  although,  on  the  basis  of observations  in  other foci,  acquired 
immune  resistance  should  not have  yet developed  in  this focus. 
The  studies of antibody response  revealed  that lgE levels increased with  age,  while  lgG4 
peaked  in  the  age-group  10-19  years.  lgE  and  lgG4  levels  against  adult  worm  antigen 
(AWA)  and  soluble egg  antigen  (SEA)  increased between cohort 1 and cohort 4 in  almost 
all  age-groups.  In  all  cohorts  examined  a  strong  correlation  between  lgG4  and  pre-
treatment  egg  load  was  observed.  Further  analysis  and  comparison  with  chronically 
infected  populations  are  in  progress. 
Circulating antigen detection 
Circulating  antiger.  detection  (CAA  and  CCA)  in  urine  and  serum  besides  faecal  egg 
counts  was  used,  with  as  objectives:  (1)  to  apply  and  evaluate  the  circulating  antigen 
detection  assays  as  an  epidemiological  tool;  (2)  to  determine  the  relationship  between 
worm  burden  and  egg  output,  by comparing  antigens levels with  those  in  endemic areas; 
and  (3)  to  investigate  the  use  of  these  antigens  assays  for  the  assessment  of  cure 
following  chemotherapy. 
~  In  the  first  cohort,  the  use  of  antigen  detection  confirmed  the  extremely  high  preva-
lences  and  intensities  of  S.  mansoni infection  as  determined  by  stool  examination. 
Serum  CAA  provided  intriguing  epidemiological  information  on  worm  burdens,  while 
urine  CCA showed  promise  for  non-invasive diagnosis and  screening. 
~The comparison  of  the  Ndombo  situation  (recent  focus)  with  a  similarly  intense,  but 
chronic  focus  of  transmission  of  S.  mansoni in  Maniema,  Eastern  Zaire,  showed  that 
while  parasite  egg  counts  were  almost similar  in  the  two  populations,  serum  levels  of 
both  CAA  and  CCA  were  approximately  twice  as  high  in  the  chronically  exposed 
community. 
~  The  antigen  assays  confirmed  the  poor  efficacy  of  praziquantel.  No  significant  differ-
ences in cure rates between the two groups treated with two different dose regimens of 
praziquantel  (40  mg/kg  in  one  oral  dose,  and  30  mg/kg  in  2  oral  doses  at  6 
hour-interval)  were  observed. 
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Morbidity 
The  results  of  ultrasonographical  studies  confirmed  the  surprisingly  low  frequency  of 
hepatosplenic  pathology  and  the  high  intensities  of  infection.  There  was  no  correlation 
between  frequency  of  symptoms  and  egg  counts.  Preliminary  data  showed  that  early 
anti-schistosoma! treatment  reduced  early and  mild  hepatic morbidity despite the fact that 
it  does  not  prevent  reinfection.  The  study  further  allowed  the  optimisation  of  ultrasound 
methods  and  revealed  a  potential  new  application  of  ultrasound  for  assessing  intestinal 
schistosomiasis  pathology.  It also  raised  the  need  to  revise  the  current  grading systems. 
Efficacy of treatment with praziquantel 
The  studies  of  praziquantel  efficacy  repeatedly  and  convincingly  confirmed  early  field 
observations of low cure rates after praziquantel treatment in this focus,  even with the use 
of a higher dosage  (2  x 30  mg/kg).  Interestingly,  normal  (high)  cure  rates  were  obtained 
with  oxamniquine,  the  only  available  alternative  drug.  Further  collaborative  studies  are 
continuing  to  elucidate the  mechanism  of drug-resistance. 
Outcome 
=>  Increased work interactions,  exchanges,  training  and  capacity transfer and  strengthen-
ing.  Several  young  researchers  from  Senegal,  and  Europe,  have  been  and/or  are 
currently  training  at  Msc,  MD  and  PhD  levels  have  actively  joined  the  EC-
Schistosomiasis  network and  are  responsible  for of  new  research  and  control  projects 
in  Senegal. 
=>  New  insights  in  the  epidemiology of  schistosomiasis. 
=>Confirmation of epidemiological  use  of circulating  antigen  detection. 
=>  Development  of  ultrasound  protocols  for  intestinal  morbidity,  and  standardised,  com-
parative  assessment  of  intestinal  and  hepato-splenic  morbidity  in  different  areas  and 
types  of foci. 
=> A methodological  and  multidisciplinary approach  to  praziquantel-resistance  in  S.  man-
soni 
=>Scientific  bases  and  capacity  building  for  the  development  of  an  operational  control 
programme. 
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Partners 
Prince Leopold Institute of Tropical Medicine 
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IMMUNITY AND  MORBIDITY IN  HUMAN  SCHISTOSOMA MANSON/ 
Period: 
Co-ordinator: 
Objectives 
October 1,  1992 - September 30,  1995 
UNIVERSITY OF CAMBRIDGE, DEPT. OF PATHOLOGY 
Cambridge, United Kingdom 
(A.  BUTTERWORTH I D.  DUNNE) 
+ To  provide  a  framework  for  a  national  schistosomiasis  control  programme  based  on 
previous  research  on  the  impact of chemotherapy. 
+  To  analyze  potentially  protective  immune  responses,  in  particular  TH2  and  TH1 
responses  and  specific anti-schistosome  lgE  and  lgA antibodies. 
+  To  investigate  the  responses  to  candidate  vaccine  antigens,  particularly  the  Schisto-
soma mansoni glutathione-S-transferase (P28), and a 22kDa antigen recognised by lgE 
from  immune  individuals. 
+ To  screen  S.  mansoni l\GT11  eDNA  libraries  with  human  infection  serum  for  new 
potential vaccine  candidate antigens  recognised  by  lgE  antibodies. 
+  To  study  the  interactions  between  S.  mansoni  infection,  nutritional  status  and  other 
infections,  especially malaria,  in  the  development of morbidity. 
Activities 
*  Field  work  will  be  carried  out  near  Kambu,  Machakos  District  and  Kangundo,  Kenya, 
using  an  established  field  work  infrastructure  which  permits  detailed  and  systematic 
observations  on  parasitology,  malacology,  water contact,  cercariometry,  anthropometry 
and  pathology. 
*  Studies  of  potentially  protective  immune  responses  will  be  made  in  different  patient 
groups: 
- Study H will  be  done on  samples from  140 individuals (age 6-60 years)  obtained in 
1985-88. 
- Study  I  comprises  90  individuals  (age  10-40  years)  on  which  data  on  repeated 
chemotherapy and  reinfection  (1990-92)  are available.  Lymphocyte culture superna-
tants and serum samples from  these groups will  be  analyzed  in  relation to  levels of 
reinfection. 
*  Group I will be re-treated yearly between 1992 and  1995 (Study IR),  and bled 3 and  10 
months after treatment,  in  order to study a possible boosting effect of chemotherapy on 
immunological  responses.  A new cohort of schoolchildren  (age  8-9  years)  (Study  CR) 
will  be  treated annually and  bled 4 months later from  1992 onwards in  order to  assess 
longer term  effects  of  boosting. 
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*  Lymphocytes  from  studies  I  R  and  CR  will  be  cultured  in  order  to  study  the  role  of 
TH2-Iike  responses  in  protective  immunity.  Crude  antigen  preparations  and,  later, 
purified and  recombinant antigens will  be employed.  Cytokine profiles will  be examined. 
The  examination  of  lgE  and  lgA  responses  to  synthetic  peptides  and  recombinant 
antigens  will  include  glutathione-S-transferase,  paramyosin,  calpain  and  schistosomu-
lum  release  products. 
*  Attempts  will  be  made  to  produce  quantities  of  the  22kDa  antigen  for  use  in  ELISA 
assays. AGT11  libraries will  be screened with the existing human serum bank to identify 
other peptides  recognised  by  human  lgE.  Other  native  antigens  will  be  identified  and 
purified. 
*  The  relationship  of  nutritional  status  with  morbidity  will  be  addressed  by  measuring 
anthropometric  indices,  physical  performance,  school  attendance,  biochemical  indices 
and  ultrasound  morbidity  in  schoolchildren  by  comparing  the  effects  of  immediate 
versus  delayed  treatment.  After  schistosomiasis  chemotherapy,  a  group  receiving 
malaria  chemoprophylaxis  will  be  compared  with  a  placebo  group:  parasitological, 
clinical  and  immunological  profiles  will  be  followed  up  before  and  after  the  malaria 
transmission  season. 
Expected outcome 
::::}  Improved knowledge of the relative contributions of Th1  and TH2 cells, and lgE and lgA 
antibodies to  resistance  to  S.  mansoni. 
::::}  Evaluation  of  existing,  and  identification  of  new  candidate  vaccine  antigens. 
:=;  Evaluation  of  the  interaction  of  S.  mansoni related  morbidity  with  malaria,  nutritional 
status  and  other factors. 
Discussion and conclusions 
The  results  have  been  obtained  confirm  and  extend  the  observations  made  during 
previous phases of the STD  programme on  immune  responses  in  human  schistosomiasis 
mansoni.  In  particular,  they are compatible with  the  hypothesis that protective immunity is 
associated with Th2-regulated responses,  especially lgE production, while such  responses 
are  also  associated  with  a relative  lack of severe  morbidity. 
The antigens recognised by those lgE antibodies that are correlated with the expression of 
immunity  have  been  cloned  and  characterised,  and  appear  to  consist  of  a  group  of 
structurally  related  molecules,  in  particular  Sm22  and  Sm12  (a  fragment  of  another 
molecule,  Sm21.7). 
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These  molecules,  which  contain  potential  calcium  binding  domains,  are  present  in  the 
tegument  of  the  developing  schistosomulum  and  adult  worm,  as  well  as  the  gut  and 
certain  other structures such  as flame cells. 
However,  although  Sm22  is  released  into the supernatant of cultured  lung-stage schisto-
somula,  it  is  not expressed at the surface.  It has not yet been demonstrated conclusively 
that these molecules are targets, rather than simply markers, of protective immunity: if they 
are  indeed  targets,  it  is  not clear what  immune  effector mechanisms  might be  involved. 
One possibility is that, following release from the organism, they bind onto its surface, thus 
forming  a target for eosinophil-mediated ADCC  reactions:  another,  more simple  explana-
tion,  is that they elicit immediate hypersensitivity reactions in  the lung or liver that lead to 
reduced  parasite viability. 
In  contrast to protective  immunity,  the  expression  of severe  morbidity  is  associated  with 
the  production  of TNFa,  and  to  a  lesser extent  IFNy,  in  response  to  egg  antigens:  Th2 
responses  with  IL-5  production  are  associated  with  a  lack  of  morbidity.  Thus  it  would 
appear that,  in  contrast to  the  mouse  model  of  S.  mansoni infection,  Th2  responses  in 
humans  are  desirable,  in  that they are  associated  both  with  protection  and  with  lack of 
morbidity.  However,  the  factors  that  control  the  development  of  such  responses  remain 
uncertain,  and  one  important  area  for  future  study  is  the  question  of whether  the  slow 
development  of  protective  lgE  antibodies  in  older  children  and  adults  depends  on  the 
actual  duration  of  exposure  to  appropriate  schistosome  antigens,  or  more  simply  on 
age-related  physiological  changes.  Studies  to  address  this  problem  have  already  been 
initiated in  an  area of recent immigration.  Future studies will  also concentrate on the  role 
of genetic factors in  governing the developing of protective Th2 responses and pathogenic 
predominant Th2 response  in  the context of other infections. 
In the meantime, schistosomiasis remains a problem of public health importance in  Kenya, 
whose control through chemotherapy has continued. Our recent observations that children 
without severe clinical  manifestations of disease may still show improved physical  growth 
and enhanced examination performance following treatment of their schistosome infections 
indicates that even mild infections should be considered to be of importance in the context 
of the development of the school age child. 
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EPIDEMIOLOGY  AND  TRANSMISSION  DYNAMICS  OF  SCHISTOSOMA  INFECTIONS 
OF THE  S.  HAEMATOBIUM GROUP IN  MALl, SENEGAL AND ZAMBIA 
Period: 
Co-ordinator: 
Objectives 
January 1993 - June 1996 
FACULTEIT DIERENGENEESKUNDE, LABORATORIUM VOOR 
PARASITOLOGIE EN  PARASITAIRE ZIEKTEN, 
Merelbeke, Belgium (J. VERCRUYSSE) 
The central objective of the project is to define the ecological and genetic factors snail and 
parasite which determine the focal  levels of endemicity of Schistosoma infections of the  S. 
haematobium group  in  Mali,  Senegal  and  Zambia. 
Activities 
*  In  Mali,  levels  of  infection  and  re-infection  were  determined  from  5  selected  villages 
(high  and  low endemicity,  mixed  and  pure  infections;  200-300  individuals  each)  which 
were not covered by the Government control programme.  Parasitological and circulating 
Schistosoma antigen detection studies were determined before chemotherapy and at 6 
weeks,  1 year and  2 years  after treatment with  praziquantel. 
*  Water  contact  observations  were  made  in  the  sites  where  villagers  have  their  main 
water-contact  activities.  These  observations  were  carried  out  by  local  observers, 
working  from  six  in  the  morning  until  six  in  the  evening,  for  three  days  every  two 
months.  Malacological  studies  including  bi-monthly  snail  sampling,  identification  and 
snail  shedding  were  also completed. 
*  In  Senegal,  the prevalence and  intensity of  S.  haematobium and  S.  mansoni infections 
were determined in 5-14 year old children in  a series of villages in the Lower Valley and 
Middle  of  the  Senegal  River  Basin  (SRB).  Snail-parasite  inter-relationships  were 
investigated,  and  physical/chemical  characteristics  of  snail  habitats  and  transmission 
foci  were  analyzed. 
In Zambia,  schistosomes of the terminal spined egg-complex (S.  haematobium,  S.  mat-
theet)  and  their intermediate  hosts  were  identified  and  their interactions  in  cattle  and 
humans  were  studied.  In  addition,  the  potential  of  the  recombinant  S.  bovis-derived 
glutathione-S-transferase (GST) to protect cattle against S. mattheii infections was tested. 
*  Parasite  identifications  were  on  the  basis  of  egg  morphology,  enzyme  (isoelectric 
focusing electrophoresis) and  DNA (randomly amplified polymorphic DNA assay) analy-
sis.  Isolates of parasites were  used  for studying  snail  susceptibility. 
Results 
In  Mali,  a total  of  1262 individuals have  been  registered  from  the  5 villages:  Boro,  Kassa 
(Dogo  Country),  Rigande,  Siguivouce  (Office  du  Niger),  and  Massabla (Sikasso  Region). 
The  results  showed  that only  S.  haematobium and  S.  mansoni are  present  in  Mali. 
S.  haematobium was the  most prevalent species and  was  hyperendemic in  the  Office du 
Niger  region  (prevalences  of  77°/o  and  75°/o  in  the  villages  of  Rigande  and  Siguivouce, 
respectively:  with  more than 20°/o  of heavy infections:  i.e. >50eggs per 10 ml  urine),  hyper 
or hypo-endemic in  Dogon  Country (77°/o  and  27o/o  in  Boro and  Kassa,  respectively),  and 
non-endemic in  Sikasso  Regino  (>1o/o  in  Massabla).  Children  7 to  14 years old  were  the 
most  infected  age  group.  Apart  from  the  Office  du  Niger,  where  high  endemicity  was 
observed  with  more  than  55°/o  of  heavy  infections,  S.  manso_ni  infections  were  rare.  No 
evidence  for  current  infections  with  S.  intercalatum  was  found.  Treatment  with  a  single 
dose  of  praziquantel  significantly  reduced  for  up  to  two  years  the  prevalence  and  the 
intensity of the  disease  in  endemic areas. 
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No difference was observed between the results of parasitological and serological infection 
detection  methods  in  villages  with  high  level  of  endemicity,  whereas  in  those  with 
moderate  level  of  infection  the  serological  prevalence  was  significantly  higher  than  the 
parasitological  prevalence. 
The CAA test on  serum provided a more accurate assessment for both the  prevalence of 
schistosomiasis  and  the  impact  of  chemotherapy.  In  Office  du  Niger,  highest  prevalence 
was obtained  with  the urine-CCA assay,  and  this test was found to  be  the  most sensitive 
in diagnosing either a single S.  haematobium or S.  mansoni infection, or a mixed infection. 
Transmission studies showed that water contact activities were very varied  and  intense in 
Dogon  Country and  Office du  Niger,  contrary to Sikasso Region. The most frequent types 
of  water  contact  observed  were:  washing  of  clothes/utensils/vegetables,  swimming  and 
filling  of  wells.  Bulinus  forsalii,  B.  truncatus  and,  very  rarely,  Biomphalaria  pfeifferi were 
collected  from  various sites. 
In  Senegal,  7750  people  were  examined  from  the  9014  who  were  registered  from  180 
villages and 4 towns. S.  mansoni was found in the lower valley (Lower Delta - Senegal River, 
Lower Delta - Lampsar River, Upper Delta and Diere) but not in the Middle Valley. The mean 
prevalence ranged from 4.4% in the Lower Delta- Senegal River to 71.8°/o in the zone of Lac 
de Guiers, where prevalence and intensity of infections were higher on  the eastern side of 
the  lake  (81.3°/o  with  a mean  of eggs/g of 2088egg/g faeces)  compared with  the Western 
side (50.3°/o with a mean of eggs/g of 1,111 ).  S.  haematobium was recorded throughout the 
area of study,  ranging from a mean prevalence of 0.37°/o in the diere of the Lower Valley to 
41.5°/o in the Lower Delta - Lampsar River where the mean egg count was 313 eggs/1 0 ml 
urine. Adult schistosome worms were collected from infected sheep and cattle at Dakar and 
St Louis abattoir in  Senegal (n  = 313).  Examination of these worms by isoelectric focusing 
showed that all schistosomes from  Dakar were  S.  curassoni, and almost all worms from  St 
Louis were S. bovis. Rare cases of hybrids were observed in worms recovered from cattle at 
StLouis abattoir, which is good evidence of the occurrence of natural hybridization between 
S.  curassoni and  S.  bovis.  In  Senegal,  Biomphalaria  pfeifferi,  Bulinus  senegalensis,  B. 
globosus,  B.  umbilicatus,  B.  truncatus  and  B.  forskalii  were  collected.  Snail  infection 
experiments  suggested  the  existence  of  three  distinct  strains  of  S.  haematobium  in  the 
Senegal River Basin, each with a distinct intermediate host specificity: one B-globosus borne 
and one B-senegalensis borne in Senegal, and one B-truncatus borne in Mali. 
In  Zambia,  parasitological  surveys  were  conducted  in  school  children  in  Chisamba (rural) 
and  Lusaka  area  (urban).  Th~ prevalence  of  S.  haematobium  infection  was  56.7°/o  (n  = 
141)  in  Chisam be  and  21 °/o  (n = 235)  in  Lusaka.  No  S.  mansoni infection was  observed. 
The  presence  of polymorphic  shaped  eggs  in  urine  samples  suggested  possible  hybridi-
zation between  S.  haematobium and  S.  mattheei. Adult schistosome worms were collected 
from  cattle  at  slaughterhouses  in  Lusaka  (n  =  542).  Examination  of  these  worms  by 
isoelectric  focusing  electrophoresis  showed  that  S.  mattheei  was  the  most  prevalent 
species  (75°/o),  followed  by  S.  leiperi (12°/o)  and  S.  margrebowiei (2o/o).  Interestingly,  the 
remaining  11 o/o  of  worms  gave  two  distinct  heterozygote  patterns,  indicating  possible 
interactions  between  S.  haematobium and  S.  mattheei in  mixed  infections  revealing  the 
existence  of a mate  preference for each  of the  two  species. 
S.  haematobium  exhibited  a  greater  specific  mate  recognition  system  than  does  S. 
mattheei,  and  male  S.  haematobium  were  better  at  pairing  with  female  worms  than  S. 
mattheei  males.  Cross  infection  experiments  showed  the  viability  of the  hybrids  from  S. 
haematobium male  X  S.  mattheei female,  and  their ability to  develop  in  sheep.  Although 
the  experimental  protocol  was  designed  to  produce  both  reciprocal  crosses  between  the 
species  of  schistosomes,  the  reverse  cross,  i.e.  S.  mattheei  male  X  S  haematobium 
female  was  not  obtained.  This  cross  is  apparently  not  viable.  Interestingly,  snail  studies 
suggested  that  B.  africanus  is  not  present  in  Zambia,  and  that  only  B.  globosus  is 
commonly  involved  in  transmission  of  S.  haematobium and  S.  mattheei in  this country. 
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A  vaccination  study  showed  that  in  natural  infections  protection  against  S.  mattheei 
infection in cattle can  be induced by vaccination with the rSb28GST. The induced immunity 
affects  both  the  worm  viability  and  the  accumulation  of  eggs  in  the  host  tissues,  and 
significantly  reduces  the  excretion  of viable eggs. 
Conclusions 
The completion of epidemiological surveys of schistosomiasis showed that the prevalence 
and  incidence of both  urinary and  intestinal  schistosomiasis are  increasing  in  parts of the 
Senegal  River  Basin  at  an  alarmingly  rapid  rate.  The  distribution  and  the  levels  of 
endemicity  are  highly focal,  due  to  the  diversity  in  ecology,  the  local  water development 
projects,  the  behaviour and  the  activities  of  the  population.  The  principal  cause  for  this 
increase of schistosomiasis is the construction of the dams at Diama and Manantali on the 
Senegal River,  together with the creation of new irrigation schemes.  Because of the dams, 
sea  water  no  longer enters  the  river  beyond  Diama,  and  consequently  intermediate  host 
snails  are  able  to  multiply dramatically.  It  is  of  importance  that this  changing  situation  is 
carefully monitored over the forthcoming  years,  as  such  information  is  of relevance to the 
implementation  of  control  programmes. 
The  circulating  Schistosoma  antigen  detection  assays  were  found  to  be  useful  for 
determining  rates  of  infection  and  efficacy  of  chemotherapy.  Based  on  parasitological 
examination, it can be very difficult to distinguish re-infection from failure of cure,  especially 
in  areas  where  transmission  levels  are  high,  as  viable  eggs  may  still  be  found  in  the 
excreta  for  several  weeks  following  chemotherapy.  Since  it  takes  several  weeks  before 
CAA  and  CCA  can  be  detected  after  the  establishment  of  a  new  infection,  a  rapid 
decrease of antigen  levels following successful treatment would therefore make circulating 
antigen  determination  an  interesting  alternative.  Our  results  showed  that  serum  CAA 
detection was  at least as  effective as  urine examination for determining prevalences of  S. 
haematobium infection  in  a highly  endemic  village,  and  it  was  better than  parasitological 
examination  in  a moderately endemic village. 
In a mixed  S.  mansoni/S. haematobium area it was shown that before treatment and  each 
survey after treatment, the highest percentages of positives were found with CCA detection 
in  urine.  Sensitivity of a single urine CCA assay was found comparable with one stool and 
two urine examinations, but preliminary results suggested that sensitivity in mixed infection 
areas of low endemicity was low.  In a non-endemic area the assays were viewed as useful 
complementary  tools  in  the  detection  of  infections.  Although  further  improvement  of  the 
lower detection limit and simplification of the assay will  be needed to make it applicable for 
mass  screening,  it  is  useful  in  its  present  form  for  research  purposes  and  monitoring 
sentinel populations.  However,  due to the costs involved with the production of monoclonal 
antibodies, continuous material and financial support will be needed for their routine use in 
the  control  programme.  Interestingly,  the  study showed  that the  assay can  be  performed 
adequately  in  a regularly  equipped  public health  laboratory within  a developing  country. 
A reassuring finding of the effectiveness of chemotherapy was the  reduction  of prevalence 
and  intensity of infections, for at least two years.  Since the development of pathology (e.g. 
fibrosis)  is  related  to  high  intensity of infection,  it follows that reduction  of infection,  which 
was  remarkable  in  one  village  of  Dogon  Country,  Boro  and  the  two  villages  of  Office  du 
Niger  in  this  study,  will  prevent  progression  of  pathology.  For  control  of  the  disease,  the 
policy of the  NSCP was  applied,  i.e.  mass treatment when  the  prevalence of  infections is 
>40o/o  and/or the  prevalence of heavy infections >5°/o.  The  strategy proved to  be  efficient 
in  controlling the  prevalence and  intensities of  infections,  but  needs also to  be  evaluated 
on  the  longer  term,  not  only  with  regard  to  epidemiological  impact,  but  even  more  with 
reference  to  feasibility,  affordability and  sustainability within  the  existing  health  system. 
Training  activities were  an  important component of this  STD3  project. 
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MARKERS OF MORBIDITY IN  SCHISTOSOMA HAEMATOBIUM INFECTION 
Period: 
Co-ordinator: 
Objectives 
January 1,  1994 - December 31,  1996 
DANISH BILHARIASIS LABORATORY 
Charlottenlund, Denmark (B.J. VENNERVALD) 
+  To  evaluate and  further develop the ECP  (Eosinophil Cationic Protein) assay for use  in 
morbidity assessment  in  Schistosoma haematobium infection. 
+ To  develop  and  evaluate  assays  for  S.  haematobium  egg  antigens  in  urine  with 
particular  reference  to  protein  antigens  released  by  eggs  present  in  the  urine  and 
bladder  tissue  opposed  to  circulating  polysaccharide  antigens  excreted  through  the 
kidney. 
+ To  assess  the  effect  of  treatment  and  reinfection  on  urinary  tract  pathology  among 
school children  in two endemic areas using the non-invasive assays detecting ECP and 
S.  haematobium  egg  antigen  in  urine  compared  to  ultrasonography  findings  and 
conventional  diagnostic methods. 
+ To  train  Kenyan  and  Tanzanian  investigators: 
- in  laboratory techniques for ECP  and  schistosome antigen  detection; 
- on  ultrasonography including  assessment  of  intra- and  inter-observer variations  as 
means  of detecting  urinary tract pathology  in  S.  haematobium infection. 
+ To  transfer the  developed  non-invasive assays to  Kenya  and  Tanzania. 
Activities 
*  Further development and  adjustment of the  ECP  assay and  validation  of the assay for 
use  in  morbidity assessment of S.  haematobium infection. 
*  Development and  evaluation  of assays for  S.  haematobium egg  antigens  in  urine. 
*  Longitudinal  field  studies  in  Kenya  and  Tanzania  including  pretreatment and  short and 
long  term  follow-up  examinations  after  treatment  with  assessment  of  the  effect  of 
treatment and  reinfection  on  urinary tract pathology among  school  children. 
*  Training  and  technology transfer. 
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Expected outcome 
Availability of the  ECP  ELISA assay and  possibly an  ECP  reagent strip suitable for use  in 
S.  haematobium endemic areas and assessment of the perspectives of using ECP in urine 
as  a morbidity marker. 
Increased  information  about  the  extent  to  which  the  degree  of  eosinophiluria  in  S. 
haematobium-infected  children  reflects  inflammatory  activity  in  the  bladder  and  predicts 
development of pathological  lesions  in  the  urinary tract. 
Availability  of  a  S.  haematobium  egg  antigen  detection  assay  as  a  seroepidemiological 
research  tool  for research  groups  in  endemic areas. 
The  ECP  and  egg  antigen  assays  will  provide  new  non-invasive  tools  for  evaluation  of 
chemotherapy effect and  morbidity in  urinary schistosomiasis. 
The successful transfer of the  ECP  and  antigen  detection assays to  Kenya  and Tanzania. 
New  knowledge  concerning  the  time  interval  after  which  pathology  reappears  in  S. 
haematobium reinfection  after treatment. 
Additional  information  on  uropathy  changes  due  to  S.  haematobium in  on-going  control 
programmes. 
Results 
All  urine samples (approx.  3000 samples)  from  the  Kenyan  study have been  analyzed for 
ECP  and  the  samples  from  Tanzania  are  currently  being  processed.  Data  analysis  is  in 
progress and  results obtained so far show a good  correlation  between  levels of  ECP  and 
egg  counts both  pre- and  post-treatment. The diurnal variation  in  ECP levels is much  less 
pronounced  than  the  variation  in  egg  counts  or  hematuria.  These  is  a  considerable 
day-to-day variation  in the urinary levels of ECP but an  ECP level of more than  5 ng/ml  in 
urine  has  a higher diagnostic value  with  respect to  diagnosing  S.  haematobium infection 
compared with  a single egg  count.  ECP  in  urine has been  shown to  be  highly stable with 
less  than  1  0°/o  reduction  in  ECP  content  after  storage  at  25°C  for  24  hours  and  no 
reduction  after storage  at  4  oc  or below. 
A sensitive  and  specific  enzyme  linked  immunosorbent assay  for  detection  of  soluble  S. 
haematobium egg  antigens  in  urine  have  been  developed. 
Positive  correlations  between  antigen  levels  in  urine  (ng/ml)  and  egg  counts  (  eggs/1 0  ml 
urine)  have  been  demonstrated. 
Urine  samples  from  the  Kenyan  field  study  are  currently  being  tested  and  diurnal  and 
day-to-day variation  and  correlations with  morbidity will  be  assessed. 
The field  work  in  Kenyan  and  Tanzania  has  now  been  completed with  an  18  month  post 
treatment  follow  up  study  in  Kaloleni  district,  Kenya  and  a  2  year  follow  up  in  Mikumi, 
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Tanzania.  Out  of  the  initial  study  population  of  approximatively  500  children  in  each 
country,  296 children from  Kenya and 232 children from Tanzania w.ere  present throughout 
the  study for 6 or 7 examinations  respectively. 
The  data from  Tanzania  show a sharp  decline  in  urinary tract pathology within  the  first 6 
month post-treatment from  76o/o  of children having pathological lesions before treatment to 
only  11 o/o  pathological lesions at six month post treatment despite reinfection.  Furthermore 
these  data show that  urinary tract pathology  reappears  in  some  but  not all  children  who 
showed  pathology before treatment. 
Two  medical  doctors,  one  from  Kenya  and  one  from  Tanzania,  have  been  trained  in 
ultrasonography.  Two  Kenyan  technicians  and  2  Tanzanian  technicians  have  visited 
Tanzania  and  Kenya  respectively during the  field  surveys.  A Kenyan  scientist is  based  at 
the  Department  of  Parasitology,  University  of  Leiden,  working  on  a  PhD  project.  A 
workshop  on  "Morbidity assessment in  schistosomiasis" was  held  in  Mombasa November 
1995  with  the  participation  of  all  project  collaborators  for  presentation  of  preliminary 
results. 
The  ECP  assay is  currently being adapted  for field  use.  It will  be  transferred to Tanzania 
and  Kenya  in  due course. 
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THE  EPIDEMIOLOGY,  IMMUNOLOGY AND  MORBIDITY OF  SCHISTOSOMA  HAEMA-
TOBIUM INFECTIONS IN  DIVERSE COMMUNITIES IN  ZIMBABWE 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1994 - December 31 , 1997 
UNIVERSITY OF GLASGOW, 
DIVISION OF INFECTION AND IMMUNITY, 
Glasgow,  United Kingdom (G.  COOMBS) 
•  To examine patterns of infection and  reinfection with  S.  haematobium in  communities in 
Zimbabwe  in  relation  to  their (diverse)  transmission  dynamics. 
•  To  relate  levels  of  infection  and  reinfection  with  S.  haematobium  to  serological  and 
cellular  reactivities  to  parasite  antigens  and  to  observed  patterns  of  exposure  to 
infection. 
•  To allow the testing of hypotheses regarding the role of cellular responses and antibody 
responses  in  the development of human  resistance to  S.  haematobium infection. 
•  To  describe  S.  haematobium  related  morbidity  and  its  resolution  following  chemo-
therapy. 
•  To examine the effects of repeated chemotherapy on the development of pathology and 
resistance  to  infection. 
•  To  extend  and  improve  immunological  and  mathematical  modelling  expertise  at  The 
Blair Research  ~aboratories, Zimbabwe. 
Activities 
The  initial  phase  of  the  study  involved  parasitological  surveys  or  several  locations  in 
Zimbabwe to  identify areas of low and  high  prevalences of  S.  haematobium infection. The 
aim  was to  re-examine the  issue of the  inter-relationship between infection levels immune 
responses  and  age.  This  is  likely  to  be  a  complicated  relationship  since  infection  levels 
and  immune  responses  are  interdependent  and  both  may  be  related  to  exposure  to 
infection  and  possibly also  to  age.  Observations  of  a "peak  shift"  in  the  age  prevalence 
and intensity curves,  with children in  high transmission areas acquiring higher prevalences 
and  intensites  of  infection  at  a  younger  age  than  those  in  areas  of  lower  transmission 
raised  the  possibility  that  differences  might  also  exist  in  the  evolution  of  the  immune 
response  in  areas where infection patterns differed.  Investigation of such a situation could 
help  distinguish  between  past history of exposure to  infection  and  the  effects of age. 
Once  the  areas  of high  and  low prevalence were  identified  urine  samples were  collected 
for S.  haematobium egg counts prior to treatment with  praziquantel.  Serum samples were 
collected to allow measurements of antibody levels and peripheral blood mononuclear cells 
were  collected  for  measurement of  in  vitro cytokine  production  in  response  to  stimulation 
with  antigens and  mitogens.  Parasitological and serological measurements were  repeated 
at intervals after chemotherapy.  Ultrasound was  used to assess levels of pathology.  Some 
of  the  results  of this study are  described below. 
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In  a  separate  area  a  cohort  of  children  were  identified  for  an  investigation  of  repeated 
chemotherapy with  Praziquantel.  In this cohort parasitological and serological assessments 
are repeated at two-monthly intervals. Exposure to infection continues but adult worms are 
eliminated  or are  held  at  low  levels  by  the  repeated  chemotherapy. 
The  intention  is to examine the  evolution  of  serological  reactivity  in  a group encountering 
repeated  exposure to  larval  S.  haematobium in  the  relative  absence  of  exposure to  adult 
worms  and  egg  antigens.  This  study  is  ongoing.  Parasitological  and  serological  samples 
have  been  collected  but  the  serum  samples  have  yet  to  be  analysed  for  antibody 
responses  to  worm,  egg  and  larval  antigens. 
Pre-intervention Parasitology and Serology 
Antibody responses to  S.  haematobium worm  and  egg  antigens were  measured by ELISA 
in  133  people  from  the  low  infection  area of  Kaswa  and  of  147 people  from  Valhalla.  In 
keeping  with  the  pre-intervention  observations  prevalences  were  33.8o/o  and  62. 7°/o. 
Overall  infection  intensities  were  significantly  higher  in  the  high  infection  area  and  both 
prevalences  and  intensities  demonstrated  a "peak  shift"  with  the  prevalence  of  infection 
peaking at 8 years of age and  at a higher level than  in the  low infection area where peak 
infection  levels were  not  attained  until  21-25  years  of  age.  Those from  the  high  infection 
area  produced  significantly  more  lgE  and  lgG3  against  SEA  and  WWH.  They  also 
produced  significantly  lower .levels of  lgA against  SEA and  lgM  against  SEA and  WWH. 
Females  produced  significantly  more  lgG1,  lgG4  and  lgM  against  soluble  egg  antigens 
(SEA)  and  lgE  and  lgG1  against whole worm  homogenate  (WWH).  From  these data it is 
impossible  to  comment  on  whether  or  not  the  antibody  responses  which  have  been 
measured have a protective function.  Nevertheless the results illustrate marked differences 
between  the  two  areas  in  the  beahviour  of the  age-prevalence  and  age-intensity  curves 
with  evidence of a peak shift which would be consistent with the acquistion of an  acquired 
immunity to  infection.  Furthermore,  antibody  responses  differ between  the  areas  and  are 
slower to  develop  and  lower in  the  area of low  infection. 
Reinfection 
Antib  ody  responses  have  yet to  be  analysed  in  relation  to  reinfection  levels.  Reinfection 
post-chemotherapy  with  praziquantel  followed  the  expected  patterns,  given  the  pre-
selection  criteria  of  high  and  low  prevalence  of  infection.  After  chemotherapy  infection 
levels  in  both  areas fell  below  4°/o  but  by  8 months after treatment  infection  prevalences 
had  reached  50o/o  of  pre-treatment levels. 
Pathology 
Bladder abnormalities were  detected  in  only 0.6°/o  of people  pretreatment. After treatment 
no  bladder  wall  abnormalities  were  detected.  Similarly  right  kidney  abnormalities  were 
detected  in  5°/o  of  individuals pretreatment reducing  to  1.9°/o  after treatment. 
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Cytokine responses to infection 
Using the supernatants obtained from  the short field  trip to  an  S .ahaematobium endemic 
area The Gambia. Assays for IL-2,  IL-4,  IL-5,  IFN-y, TNFa and GM-CSF were established. 
Analysis of the data revealed that infected people irrespective of age had higher peripheral 
blood  eosinophil  counts  (p<0.0029)  and  produced  more  IFN-y on  stimulation  with  soluble 
egg  antigen  (SEA)  (p<0.0166)  and  whole  worm  homogenate  (p<0.02)  than  uninfected 
people. 
Uninfected people  had  a greater capacity to  produce  IL-4  (p-<0.0007)  and  produced  more 
IL-4  on  stimulation  with  SEA (p<0.0472).  No  significant differences  in  GM-CSF,  IL-2,  IL-5 
TNFa  or  cell  proliferation  were  found  between  children  and  adults,  or  infected  and 
uninfected groups. These  results  were  promising.  It appeared that the assays which  have 
been  established  in  the  laboratory are sufficiently accurate and  sensitive to  detect the  low 
levels of cytokine production  in  the supernatants from  antigen  stimulated  peripheral  blood 
cell  cultures.  Additional  work  has  been  done  on  the  comparison  of  the  ELISAs  with 
bioassays  and  we  are  now  confident  that  the  ELISAs  are  detecting  predominantly 
biologically active cytokine. These results are important for other reasons, they support the 
hypothesis that Th2-type responses may have a protective role  against schistosomiasis in 
humans,  one  of the  basic  hypothesis  being  tested  in  the  current  survey. 
The  cells  collected  from  the  surveys  in  Zimbabwe  from  August  to  October  1994  were 
defrosted and  used  in  stimulations and  cytokine assays.  Preliminary studies were done on 
peripheral  blood  cell  samples  from  individuals  who  failed  to  provide  all  the  necessary 
parasitological  samples for inclusion  in  the  study or provided  blood  samples which  would 
be  insufficient to  provide enough  cells for the  necessary stimulations.  Cytokine production 
could  not  be  detected  in  supernatants  from  these  antigen  stimulation  of  these  cells.  A 
whole  blood  stimulation  assay  was  then  tested  in  the  field  and  proved  to  be  more 
successful.  The  patterns of cytokine production  from  these cells are  now being  analysed. 
Water contact 
The  most striking observation  made during the  study of water contact activities is that the 
water contact  of  children,  under five  years  of  age  was  observed  frequently.  Follow-up  of 
this observation  revealed  high  levels of contact occur even  in  children  under two years of 
age.  This  contact  is  likely to  be  significant in  terms  of  the  immunology and  epidemiology 
of  S.  haematobium infection. 
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MODELLING FOR THE CONTROL OF SCHISTOSOMIASIS AND OTHER EXTENSIONS 
OF  CEC/STD  SCHISTOSOMIASIS RESEARCH  NETWORK ACTIVITIES 
Period: 
Co-ordinator: 
Objectives 
November 1,  1994- April 30,  1996 
RIJKSUNIVERSITEIT LEIDEN,  DEPT.  OF PARASITOLOGY 
Leiden, The Netherlands (B.  GRYSEELS) 
+  The  project  aimed  at  complementing  ongoing  research  activities  on  schistosomiasis 
within  the  EC/STD3  Network,  with  particular reference  to  the  following  subjects: 
+ To  develop,  assess  and  apply  epidemiological  simulation  models  for  the  planning, 
monitoring  and  evaluation  of  schistosomiasis  control  interventions,  with  particular 
reference  to  integration  in  basic  health  structures,  and  to  immune-epidemiology  and 
vaccinology. 
+ To  study  and  compare  by  ultrasound  the  dynamics  of  intestinal  and  hepatosplenic 
morbidity due to  Schistosoma mansoni infection  in  intense Sub-Saharan  foci. 
+  To  study  by  novel  DNA-based  technology  the  relation  between  HLA  (-D)  type  and 
susceptibility to  infection  and  disease. 
+  To  investigate factors contributing to  reduced  drug efficacy in  schistosomiasis  patients. 
+ To  further  extend  and  strengthen  collaboration  between  epidemiological  research 
groups in developing countries and Europe, and their interaction with  operational health 
programmes. 
Activities 
Modelling 
*  With  microsimulation and other techniques,  submodels were developed to describe and 
quantify  the  different  steps  in  the  epidemiology  and  control  of  schistosomiasis.  The 
submodels were integrated in  a comprehensive,  practically applicable simulation model. 
*  The first efforts were concentrated on  the interpretation of egg counts as a reflection of 
parasite  burdens.  This  has  led  to  important  new  insights,  and  the  development  of 
several  practical  tools  (pocket  charts)  which  allow  the  interpretation  of  survey  results 
much  more  accurately  than  was  possible  previously.  The  result  is  critical  for  the 
eventual  success of the simulation  efforts. 
*  A preliminary  computer simulation  model  (SCHISTOSIM)  has  been  developed  for the 
epidemiology  and  control  of  S.  mansoni  infection,  with  the  aim  of  evaluating  and 
predicting  the  effects  of  different  control  strategies.  By  simulating  a series  of surveys 
and  treatment,  short-term  effects  of  the  program  were  satisfactorily  explained  by  the 
model.  However,  long-term  predictions do  not yet fully  match  the  observed  data. 
*  A major outcome  of the  simulation  exercise  is  the  identification  of  many  gaps  in  our 
knowledge  of the  epidemiology and  control  of schistosomiasis. As  such,  the  modelling 
exercise  is  a  rich  source  for  clarifying  old  and  new  research  questions.  A  link  to 
qualitative public  health  models  (vertical  analysis)  has  been  established. 
Morbidity evaluation by ultrasound 
*  With  portable ultrasound technology,  morphometric evaluation of intestinal wall  enlarge-
ment  and  mesenteric  echogenicities  in  patients  with  Schistosoma  mansoni infections 
were  performed  in  intense foci  in  Senegal  and  Uganda. 
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*  In  these  foci,  hepatic  lesions  by  ultrasound  in  patients  with  (heavy)  S.  mansoni 
infections  were  defined  and  graded;  proposed  standard  systems  were  evaluated  and 
optimized. 
*  Sonomorphological  findings  were  compared  with  clinical,  anamnestic,  parasitological 
and serological parameters and evaluation of simple PHC-approaches to the diagnosis 
of severe pathology.  Parallel  studies on  this  issue were also performed  in  Tanzania. 
*  Morbidity findings  were  compared  between  a  recently  infected  focus  (Senegal)  and  a 
chronically  endemic  focus  (Uganda),  in  order  to  explore  the  evolution  of  chronic 
morbidity. 
*  Preliminary investigations of the  impact of praziquantel treatment on  morbidity in  these 
foci  were  performed. 
The  results  of  ultrasonographical  studies  confirmed  the  surprisingly  low  hepatosplenic 
pathology (despite the high  intensities of infection)  in  the  recently established focus  of S. 
mansoni in  Northern  Senegal,  already shown  by clinical  examination  in  previous studies. 
Preliminary data showed that early antischistosomal treatment not only lowers egg output, 
but also reduces early and  mild hepatic morbidity despite the fact that it does not prevent 
reinfection. 
The study allowed the optimisation of the ultrasound method and revealed a potential new 
application  of  ultrasound  for  assessing  the  intestinal  schistosomiasis  pathology.  It  also 
raised  the  need  to  revise  the  current  WHO  grading  systems.  Comparison  of  overall 
morbidity  patterns  in  five  different  countries  suggested  a  geographical  variation  of  S. 
mansoni induced  hepatic lesions in  Africa.  In  East Africa,  severe pathological  status was 
recorded  more frequently than  in  West Africa,  for comparable endemicity levels. 
HLA and susceptibility to infection and disease 
The  aim  of  this  component  was  to  use  novel  DNA-based  technology  to  compare  the 
structures  of  antigen-presenting  molecules  of  the  HLA-D  subgroup  in  schistosomiasis 
patients  grouped  according  to  differences  in  protection  from  intense  infection  and  in  the 
manifestation  of disease,  with  as aims: 
*  To  identify  individuals  or groups of  individuals  at risk for intense  infection  and  severe 
pathology. 
*  To  provide the basis for characterizing the T-lymphocytes involved and for approaching 
the  analysis  of  parasite  antigens  which  naturally  elicit  the  critical  T-lymphocyte  re-
sponses. This project component aimed mainly at exploring possibilities and setting up 
methodological  and collaborative  mechanisms. 
The  findings  from  the  HLA  studies  argue  in  favour  of  a  role  of  one  or  several  genes 
located  in  the  MHC  region  in  the  control  of  infection  with  S.  mansoni.  Additional  studies 
using  refined  phenotypes are  still  in  progress. 
The studies on  cellular immune responses showed that active infection with schistosomes 
is  associated  with  down-modulation  of  T  cell  proliferative  responses,  and  that  major 
differences  exist between  children  and  adults  in  lgG4 and  lgE  responses.  These  results 
clearly provide an  exciting perspective for extension to the particular S.  mansoni areas in 
Senegal and Uganda, and their relation with  morbidity and HLA-susceptibility studies. This 
will,  however,  require the establishment of adequate logistic conditions for cellular work in 
these  areas. 
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Praziquantel susceptibility 
The  studies  of  praziquantel  efficacy  repeatedly  and  convincingly  confirmed  early  field 
observations  of  low  cure  rates  of  praziquantel  treatment  in  the  S.  mansoni focus  in 
Northern  Senegal,  even  with  the  use  of  a higher dosage  of  drug  (2  x 30  mg/kg). 
Interestingly,  the  parasite  strain  was  fully  susceptible  to  oxamniquine,  which  could 
therefore  be  seen  as  an  alternative  drug.  This  problem  may  have  implications  for 
world-wide  control  of  schistosomiasis.  Further  collaborative  studies  are  continuing  to 
elucidate the  mechanism  of drug-resistance. 
Outcome 
These types of "gap-filling" projects have  proven to  be  highly productive in  the framework 
of  collaborative  network  research.  The  various  components  of  this  project  have  all 
generated  exciting  and  relevant  new  knowledge. 
=>  Basic  egg  count  models,  practical  applications and  preliminary comprehensive  simula-
tion  model. 
=>  Preliminary  data  on  HLA  vs.  infection  and  establishment  of  more  extensive  study 
protocol. 
=>  Development  of  ultrasound  protocols  for  intestinal  morbidity,  and  standardised,  com-
parative  assessment  of  intestinal  and  hepato-splenic  morbidity  in  different  areas  and 
types  of foci. 
=>  Confirmation  of  reduced  praziquantel  efficacy  in  the  Senegal  S.  mansoni focus. 
=>  Establishment  of  a  consensus  building  for  a  methodological  and  multidisciplinary 
approach  to  elucidate the  mechanisms of  praziquantel-resistance  in  S.  mansoni. 
=>  Increased  network interactions,  exchanges,  training  and  capacity transfer. 
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THE  DEVELOPMENT  OF  A  CONTROL  STRATEGY  FOR  SCHISTOSOMA  HAEMATO-
BIUM  IN  THE  SENEGAL RIVER  BASIN 
Period: 
Co-ordinator: 
Objectives 
October 1,  1996- September 30,  1999 
UNIVERSITY OF GENT,  DEPARTMENT OF PARASITOLOGY, 
Merelbeke, Belgium (J. VERCRUYSSE) 
+  To  carry  out  an  up  to  date  assessment  of  the  current  situation  on  prevalence  and 
morbidity  of  urinary  (and  intestinal)  schistosomiasis  in  the  Lower  Middle  and  Upper 
parts of the  Senegal  River  Basin  (SRB)  and  identify new  emerging  endemic foci. 
+ To  determine  the  factors  which  influence  seasonality  of  transmission  in  Senegal  and 
Mali.  This  information will  be  highly relevant  in  assessing the  best time for intervention 
procedures. 
+  To  determine  the  correlation  between  the  development  of  immunity  to  Schistosoma 
haematobium  infection  and  exposure  to  infection,  in  areas  with  different  types  of 
transmission  (short I long)  and  in  different types  of  foci  (old  I recent). 
+ To  determine  the  effects  of  agriculture  and  water  development  on  the  spread  of 
schistosomiasis  in  the  SRB. 
+ To  evaluate  reinfection  patterns  and  immunity  development  according  to  different 
timings of  treatment. 
Activities 
*  A survey will  be  carried  out  in  the  Upper part of the  SRB  (Bakel,  Manantali) to  assess 
the  current  situation  on  prevalence  and  morbidity  of  schistosomiasis  and  the  compat-
ibility of  Schistosoma haematobium with  the  local  intermediate hosts (transition  zone?). 
Suitable villages  in  Mali  will  be  selected  for the  further studies. 
*  Epidemiological,  morbidity  and  control  studies.  During  a  two  year  period  longitudinal 
immuno-epidemiological  studies will  be  carried  out  in  2-3 villages  in  the  department of 
Podor  (seasonal  transmission),  in  2-3  villages  in  the  department  of  Dagana  (long 
transmission  period)  and  in  2-3  villages  in  the  Upper Valley  around  Manantali  (perio-
dicity  of  transmission  still  to  be  determined).  Before  and  after  treatment,  the  current 
situation  will  be  assessed  by  blood,  faecal  and  urine  sampling  procedures,  clinical 
examination  and  echography.  Follow-up  will  be  done  in  relation  to  timing  of  initial 
treatment  (before the  rainy  season). 
Immunological studies.  Serum isotype analysis of specific human antibodies will  be carried 
out (with emphasis on the  lgA response to  rSh28GST)  and the functional properties of the 
antibodies  (capacity  to  inhibit  GST  enzymatic  activity)  will  be  assessed.  A comparative 
analysis  of  the  immune  responses  between  populations  living  in  old  or  new  foci,  the 
evolution  of  the  immunological  parameters  according  to  the  seasonal  or  perennial 
transmission  type,  and  the  influence  of  treatment  upon  the  acquisition  of  immunity  to 
subsequent exposure will  be  investigated  in  each  selected  cohort. 
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*  Transmission  studies.  Longitudinal  malacological  studies will  be  carried  out during two 
years  in  the  selected villages where the  transmission  sites will  be  identified.  Sampling 
will  be  conducted  at  monthly  intervals  in  Senegal  and  three-monthly  intervals  in  Mali. 
Further laboratory studies will  characterise fully the compatibility of the collected snails 
with  the parasite species (strains)  naturally transmitting  in  the SRB.  These procedures 
will  involve  SEM,  IEF  and  RAPD  techniques.  Physico-chemical  characteristics  will  be 
measured  over  time  from  a  number  of  transmission  foci  in  order  to  assess  the 
predictability  of  the  likely  outcome  of  potentially  newly  created  transmission  foci 
associated with  agricultural  development. 
Expected outcome 
It  is  expected that the  data generated from  these  studies  will  give  a clear lead  as to  the 
most effective  control  strategy for  schistosomiasis  in  the  Senegal  River Basin. 
These  studies  will  generate  important  information  for  future  vaccination  trials,  as  it  is 
possible  to  adapt  vaccine  formulation  (presentation,  type  of  vector)  to  the  different 
transmission  patterns  in  the field. 
It  is  anticipated  that the  south-south  axis will  be  strengthened  through  regional  coopera-
tion. 
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IMMUNO-EPIDEMIOLOGY,  CHEMOTHERAPY  AND  CONTROL  OF  SCHISTOSOMA 
MANSONI  IN  RECENTLY  ESTABLISHED  FOCI  IN  NORTHERN  SENEGAL 
Period: 
Co-ordinator: 
Objectives 
September 1  , 1996 - August 31 , 1999 
INSTITUTE OF TROPICAL MEDICINE, 
Antwerp,  Belgium (B.  GRYSEELS) 
•  To  continue  and  complete  ongoing  immuno-epidemiological  research  on  the  role  and 
development  of  age-related  acquired  resistance  to  (re-)infection  with  schistosoma 
mansoni in  recently established  foci  in  Northern  Senegal. 
•  To  investigate the  consistently observed  poor therapeutic  responses to  praziquantel  in 
this focus,  with particular respect to the  possibility of reduced parasite susceptibility and 
to  the  interference of  underdeveloped  immune  responses. 
•  To  further  investigate the  ecological  dynamics of  this  unstable epidemic situation,  with 
particular respect to  the  spread  and  vectorial  capacity of  the  intermediate  host. 
•  To  develop,  evaluate  and  implement  sustainable  intervention  strategies,  focussing  on 
passive  case  detection  and  safe  water  supply;  health  information  systems  within  the 
existing  health  services. 
•  To  follow-up  and  further  document  the  clinical  pathology,  community  morbidity  and 
public  health  impact  of  S.mansoni infection  in  this  epidemic  focus  in  its  transition  to 
endemicity. 
•  To further strengthen the research and  intervention capacity of the Senegalese team by 
providing  training  up  to  Msc/PhD  level  in  each  of  the  above  fields,  and  to  consolidate 
the  established  collaborative  and  network links. 
Activities 
*  In-depth  analysis  and  exploitation  of  data  and  samples  collected  in  the  previous 
STD3-project (immunology,  epidemiology,  diagnostics,  chemotherapy). 
*  Further,  well  oriented  studies  in  immuno-epidemiology,  chemotherapy,  morbidity,  in 
newly established  foci  in  the  area. 
*  Documentation  in  the  laboratory and  in  the  field  the  vectorial  capacity  of  the  interme-
diate  host,  and  the  possible  ecological  and  genetic determining factors. 
*  Breeding a number of isolates of the local  S.mansoni strain and to test in  vivo,  possibly 
in  vitro,  their  susceptibility  to  praziquantel  and  oxamniquine,  and  to  study  possible 
biochemical  and  genetic  markers  of  resistance. 
*  Clinical  and  community-based  studies  in  order  to  optimise  clinical  definition  and 
classification  of specific  intestinal  and  hepatoplenic disease and  morbidity. 
*  Translation  of  these  findings  in  optimal  decision  trees  for  case-management  and 
disease surveillance at  primary,  secondary and  tertiary  health  services. 
*  Masters- and  PhD-training to  Senegalese researchers and  health workers active  in  this 
project. 
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PATTERNS  OF  PRAZIQUANTEL  USAGE  AND  MONITORING  OF  POSSIBLE  RESIST-
ANCE  IN  AFRICA 
Period:  December 1  , 1997 - November 30,  2000 
Co-ordinator:  INSTITUTE OF CELL BIOLOGY,  Rome,  Italy (D.  CIOLI) 
Objectives 
To  establish  a network of scientists,  field  workers  and  health  administrators  dealing  with 
the treatment of schistosomiasis,  a parasitic disease affecting about 200 million  people in 
tropical and sub-tropical countries.  Since treatment is almost universally performed using a 
single drug,  praziquantel,  the  objective of this  Concerted Action  is to examine  in  a global 
perspective various  issues  related  to praziquantel  usage,  among  which: 
•  to  determine the  most cost-effective  ways  of  procuring,  distributing and  evaluating the 
drug; 
•  to  compare  various  local  experiences  regarding  drug  dosage  and  administration 
schedules; 
•  to  collect  information  on  major  side-effects  and  possibly  identify  any  associated  risk 
factors; 
•  to  compare  and  evaluate  all  available  data  on  the  suspected  appearance  of  drug 
resistance  in  the  human  population; 
•  to organise the collection of possible resistant isolates of the parasite, their propagation 
in  the  laboratory and  their testing  in  experimental  animal  models; 
•  to distribute biological samples to research  laboratories in  order to study the still largely 
unknown  mechanisms  of  praziquantel  action; 
•  to  identify a number of "reference  centres" for the  monitoring  of drug  resistance; 
•  to formulate  policies to assist national  health authorities to deal with  any occurrence of 
drug  resistance. 
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Activities 
The  initial  nucleus  of  six  European  and  nine  African  members  will  hold  three  general 
meetings, which will be extended to outside experts and additional participants, as deemed 
appropriate.  Guidelines  and  protocols  for  the  monitoring  of  resistance  will  be  developed 
and  field-tested,  suspected  resistant  isolates will  be  collected  and  distributed to  research 
laboratories.  One  or  more  reference  centres  will  be  established  in  Africa  and  basic 
equipment  and  training  will  be  supplied.  Information  on  drug  procurement,  costs,  sug-
gested  delivery  schedules  and  observed  side-effects  will  be  distributed  to  all  interested 
bodies  and  individuals. 
Expected outcome 
This  study will  collect a broad  range  of data on  praziquantel  usage  to  help field  workers 
and  health  administrators  in  the  planning  and  implementation  of  antischistosomal  chemo-
therapy.  The  controversial  issue  of  drug  resistance  will  be  tackled  by  organising  the 
collection  and  the  analysis  of  potentially  resistant  parasite  isolates.  The  use  of  such 
isolates for the  study of basic mechanisms of drug activity will  be  pursued.  Guidelines will 
be  developed  for  the  most  rational  use  of  praziquantel  and  for  alternative  strategies  in 
case  of  resistance. 
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MULTIDISCIPLINARY STUDIES OF  HUMAN  SCHISTOSOMIASIS MANSONI IN  KENYA 
AND  UGANDA:  NEW PERSPECTIVES  ON  IMMUNITY AND MORBIDITY 
Period: 
Co-ordinator: 
Objectives 
November 1,  1997 -April 30,  2001 
DANISH BILHARZIASIS LABORATORY 
Charlottenlund, Denmark (B. VENNERVALD) 
•  To  study the effect of age as such and duration of exposure on  resistance to reinfection 
with  Schistosoma mansoni. 
•  To  study  the  specific  lgE  responses  related  to  reinfection  with  emphasis  on  their 
regulation  at the cellular level  and  the  influence of host genetics on  the  lgE  response. 
•  To  study the immunological responses associated with  severe  schistosomiasis mansoni 
morbidity  with  emphasis  on  their  regulation  on  the  cellular  level  and  the  influence  of 
host genetics on  TNFa production. 
•  To  assess  morbidity  using  ultrasonography  and  alternative  markers  and  to  study  how 
exposure  to  other  infections  or  hepatic  insults  affect  the  severity  of  schistosome-
associated  morbidity. 
•  To  assess the effect of transmission  blockage on  morbidity regression. 
Activities 
In  Kenya  an  established structure for multidisciplinary field  and  laboratory studies  will  be 
maintained  and  sets  of  cohorts  are  already  available  for  detailed  study  and  longitudinal 
follow  up.  Further activities will  include: 
*  Comparison  of immune  responses  in  individuals of same age but with  different history 
of  exposure  including  serological  studies  and  assessment  of  lymphocyte  proliferation 
and  cytokine  production  in  response  to  worm  and  egg  antigens. 
*  Studies  on  immune  responses  associated  with  immunity  and  morbidity  and  any 
potential  linkage  with  polymorphic  microsatellite  markers  within  the  Th2  IL-4/5/9/13 
gene cluster on  chromosome  5. 
*  Case-control  studies with  detailed  examination  of  cytokines  associated  with  regulation 
of  Th1-type  responses,  the  ability  of  PBMC's  to  release  TNF  in  response  to  antigen 
stimulation  and  other factors  involved  with  the  expression  of  TNF. 
*  Focal mollusciding has been introduced iri Kambu  River and the regression of morbidity 
will  be  determined  in  this area where  transmission  has  been  blocked. 
Studies  in  Uganda will  include: 
*  Baseline  studies  with  systematic  collection  of  snails,  administration  of  questionnaires 
concerning  nature  and  time  of  different  water  contact  activities  by  age  and  sex 
supplemented  with  direct observations and  parasitological  examinations. 
*  A  treatment/reinfection  study  involving  500  individuals  randomly  selected  after  age 
stratification.  Reinfection will  be followed by stool samples at yearly intervals and blood 
samples  will  be  collected  for serological  studies. 
*  A case-control study involving individuals with or without severe morbidity (as judged by 
ultrasonography}  matched  for age,  sex and  intensity of infection.  Comparisons will  be 
made  with  respect  to  history  of  exposure,  alcohol  consumption,  nutritional  status, 
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presence of hepatitis B surface Ag  and anti-hepatitis CAbs. Blood and faecal  samples 
will be taken for measurement. of inflammatory and collagen markers.  DNA samples will 
be tested for TNFa polymorphisms. 
Bayesian statistical theory and Markov Chain Monte Carlo techniques will be applied using 
the  Gibbs sampler to  analyse the  large databases accumulated from  the  Kenyan  studies. 
Expected outcome 
The project will  widen and deepen the range of scientific skills and techniques of Kenyan 
scientists and facilitate the transfer of these same skills to scientists in  Uganda through a 
strong  South-South collaboration. 
In  addition,  results  from  this  project  will  lead  to  improved  and  refined  strategies  of  the 
development  of  anti-schistosome  vaccines  and  the  control  of  schistosome-associated 
morbidity. 
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A survey of Chagas cycles in  Uruguay by use of genetic 
markers with special emphasis on  reinfestation hazards of 
domestic structures by sylvatic cycles. 
Studies of the vaccine potential of recombinant invariant 
surface membrane proteins of the African trypanosomes. 
Biosystematics and adaptive trends in the genus rhodnius. 
Population genetics and control of Triatoma braziliensis in 
North East Brazil. 
Experimental study of the impact of population clonal 
structure on  relevant medical and biological properties of 
Trypanosoma cruzi. 
Risk of reinfestation from wild foci  of  Triatoma infestans in 
Bolivia, a country of the southern cone programme. 
Role of insect host defenses in trypanosome development in 
Chagas' disease vectors with emphasis on the activity of 
immune depression agents. 
Trypanocidal drugs: laboratory and field evaluation of novel 
controlled release systems. 
Characterization of a new therapeutic target on African 
trypanosomes: the glucose transporter and development of a 
vaccination strategy. 
Characterization of the immune response against 
Trypanosoma cruzi antigens (GP 50/55 and urinary antigen) 
involved in  immunopathology and their potential use in 
diagnostics. 
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A  SURVEY  OF  CHAGAS  CYCLES  IN  URUGUAY  BY  USE  OF  GENETIC  MARKERS 
WITH  SPECIAL  EMPHASIS  ON  REINFESTATION  HAZARDS  OF  DOMESTIC  STRUC-
TURES  BY  SYLVATIC  CYCLES 
Period: 
Co-ordinator: 
Objectives 
April  1,  1992 - March 31,  1995 
ORSTOM MONTPELLIER I,  LABORATOIRE DE GENETIQUE 
MOLECULAIRE DES PARASITES ET DES VECTEURS, 
Montpellier, France (J.P.  DUJARDIN) 
To  understand  why  northern  and  southern  areas  of  Uruguay  present  different  epidemio-
logically  features:  domiciliated,  more  infected  insects  (T.  infestans)  in  the  northern 
departments versus  peri-domiciliated,  less  infected  insects  in  the  southern  departments. 
Triatoma  infestans  (Hemiptera,  Reduviidae)  is  almost  exclusively  domestic  in  northern 
departments of Uruguay, such as Artigas, Cerro Largo,  Rivera and Tacuarembo, but mainly 
occupies  peridomestic  habitats  such  as  chicken  coops  in  the  southern  departments  of 
Soriano  or  Colonia.  These  areas  differ  in  median  temperature  and  humidity,  with  the 
northern  regions  tending  to  be  warmer  and  drier,  but  also  differ  in  socio-economic 
conditions such that rural  dwellings in  the northern departments are  usually constructed of 
wood  and/or  adobe  blocks,  whereas  brick  and  cement  houses  are  more  common  in 
Soriano.  This  parallels higher infection  rates  of  T.  infestans with  T.  cruzi (causative agent 
of  Chagas disease)  in  the  northern  departments. 
We  were  interested  to  examine  the  environmental  and  genetic  contributions  to  the 
observed  epidemiologic differences. 
To  understand the reinfestation mechanisms of treated areas by the original vector species 
(Triatoma  infestans),  or by  another one  (  T.  rubrovaria). 
Reinfesting  populations may  represent hidden  survivors  recovering  from  the  control  treat-
ment or they may be bugs immigrating from  untreated foci.  Operationally,  it is  important to 
distinguish between "survivors" (indicating control failure) and "immigrants" (indicating poor 
geographic coverage).  Moreover,  localized  domestic invasions occurring  in  Uruguay were 
due to  T.  rubrovaria,  a little-known species of Triatominae,  providing a certain imperative to 
identify bug populations that might present a future risk of domiciliation. 
This  research  programme  was  thus  naturally  inserted  in  the  activities  of  the  National 
Control  Programme  of  Chagas  Disease  in  Uruguay. 
Main results 
(1)  First objective 
Though  they were  not distinguishable  by  isoenzyme  electrophoresis,  northern  and  south-
ern  populations  of  T.  infestans  in  Uruguay  were  found  to  strongly  differ at  both  cytoge-
netical  and  morphometrical  characteristics.  These  results  were  related  to  the  two-ways 
entry  of  T.  infestans  in  Uruguay.  T.  infestans is  believed  to  have  originated  from  silvatic 
populations  in  central  Bolivia  and  to  have  been  dispersed  mainly  in  association  with 
human  migrations,  particularly during the  last century. 
218 Contract number TS3*CT91 0029 
Historical  reconstruction suggests that it entered northern Uruguay from southern Brazil at 
around  the  turn  of  this  century,  but  it  appears  to  have  entered  southern  Uruguay  from 
Argentina some 50 years earlier since "vinchucas" (the local term for domestic Triatominae 
in  Argentina  and  Uruguay)  are  mentioned  in  southern  Uruguay in  the  chronicles  of W.H. 
Hudson first published in  1865. Biogeographically, the northern and southern departments of 
Uruguay are separated by the  Rio  Negro,  which was bridged only a few decades ago,  so 
that  the  apparent  cytogenetical  and  metrical  differences  between  northern  and  southern 
populations  of  T.  infestans seems  to  accord  both  with  their different  origins  and  with  an 
ecological  barrier between  them.  In  both  cases,  we  can  infer development from  original 
founder populations, and assume that these would have differed slightly due to genetic drift 
which may or may not have been modified by adaptation to the different environments. 
(2)  Second objective 
The  various  data obtained  - cytogenetic,  morphometric and  isoenzymatic - converged  on 
the  idea that  reinfestant  specimens  arose  from  a  residual  population.  Indeed,  in  case  of 
exchange  of  individuals  between  departments,  between  sectionals  or between  segments 
(administrative units in  Uruguay), it was unlikely to find such an  amount of cytogenetic and 
morphometric differences between them.  Furthermore,  when  comparing  reinfestant speci-
mens with  the insects collected  before insecticide treatment,  it was  not possible to  detect 
s-ignificant  differences.  The  use of  blood  meal  identification brought further,  more defined, 
information  about  the  mechanisms  of  reinfestation  by  T.  infestans,  indicating  that  the 
residual  population  was  most  probably of peridomestic,  rather than  domestic,  origin. 
Bloodmeal identification in  T.  rubrovaria revealed that this species had no host preference, 
indicating that its trend to domesticity was probably not due to an  anthropophily,  but rather 
to habitat convenience.  Human blood was found  in  1  0°/o  of  T.  rubrovaria specimens, but in 
peridomiciliary  conditions  only,  indicating  that  in  limited  geographic  areas  this  silvatic 
species could  make  the  link between  the  domestic and  silvatic cycles of the  parasite. 
Partners 
ORSTOM, Montpellier I 
Labo de Genetique Moleculaire des Parasites 
et des Vecteurs 
Avenue Agropolis 911,  BP 5045 
34032 Montpellier 1 
France 
Universidad de Ia Republica 
lnstituto de Higiene 
Avenida Alfredo Navarro 3051 
11600 Montevideo 
Uruguay 
Universidad Autonoma de Madrid 
Dep. de Biologia 
Carretera de Colmenar Viejo 
28049 Madrid 
Spain 
J.P.  Dujardin 
Tel:  +33/1/48.03.77.77 
Fax:  +33/1 /48.03.08.29 
E-mail: jpdujard@ceibo.entelnet.bo 
L. Yarzabal 
Tel:  +598/247.12.88 
Fax:+598/280.15.97 
J.S. Rufas 
Tel:  +34/1/397.40.13 
Fax:  +34/1 /397.41 .23 
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STUDIES  OF THE  VACCINE  POTENTIAL OF  RECOMBINANT  INVARIANT  SURFACE 
MEMBRANE PROTEINS OF THE AFRICAN  TRYPANOSOMES 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1992 - September 30,  1995 
UNIVERSITE LIBRE DE BRUXELLES, LAB.  DE  PARASITOLOGIE 
MOLECULAIRE, Bruxelles, Belgique (E.  PAYS) 
The  proposal  concentrates  upon  five  specific experimental  objectives: 
•  The  cloning  and  sequencing of the  EDAG  4/GRESAG  4 genes from  T.  congolese and 
T.  vivax. 
•  The  expression  and  production  of  the  cloned  trypanosoma!  antigens  as  well  as  the 
production  of antibodies  against these  antigens. 
•  The  analysis  of  the  structure,  localisation  and  function  of  these  antigens  where  this 
information  will  either  aid  the  experimental  development  of  the  vaccine  or  help  to 
understand  how the  vaccine disrupts the  physiological  function  of its  target  receptor. 
•  Experimental  trials  of  the  pure  recombinant  antigens  and  defined  segments  of  these 
antigens as  immunogens and  the assessment of their potential for providing  protective 
immunity in  experimental  animals during  subsequent challenge  with  live  parasites. 
•  The  experimental  definition  of  the  optimum  immunisation  protocol  in  experimental 
animals. 
Activities 
Activities can  be considered chronologically as taking place within the first,  second or third 
year of the  project. 
Year 1 
*  Cloning  of the  ESAG  4 and  GRESAG  4 genes from  T.  congolense and  T.  vivax. 
*  Selection  of  appropriate gene fragments  and  tentative  identification  of the  extracellular 
domains including effector binding and potential glycosylation sites, the transmembrane 
spans and the cytoplasmic regions including active and phosphorylation consensus sites; 
*  Recombinant antigen  production  using  the  Baculovirus system; 
*  Structural  analysis,  i.e.  the  extent  of  glycosylation  of  the  different  antigens  will  be 
assessed; 
*  The functional domains of the EDAG 4 protein will be dissected by stable expression of 
unmodified  or mutated  versions of  ESAG  4 in  procyclic forms; 
*  Sera from  infected  animals  will  be  assayed  for circulating  antibodies and  antigens; 
*  Vaccine trials with the purified antigens will study the effect of systematic variation of the 
immunogen dose, route of administration, immunisation protocol and type of adjuvant. 
Year 2 
*  Subclones of fragments of ESAG  4 will  be  produced by either restriction  endonuclease 
digestion  or PCR  amplification; 
*  Studies of the  regulation  of chemosmotic potential  and  ion  fluxes; 
*  Second  wave  of  immunisation  trials. 
Year 3 
*  Completion  of work on  cloning  and  expression  of  T.  congolense/T.  vivax genes; 
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*  Final  functional  and  topological  studies; 
*  Third  wave  of  immunisation  trials. 
Expected outcome 
The following  goals should  be  achieved: 
=>  Genes  coding  for different  adenylate  cyclases  will  have  been  cloned,  sequenced  and 
compared for species of African trypanosomas and protein products made available for 
use as  antigens. 
=>  An  estimate  of species conservation/divergence will  be  available. 
=>Whether these  antigens circulate  in  the  bloodstream  of infected animals,  and the level 
of circulating  antibodies,  will  have  been  determined. 
Results 
=>  We  have  cloned  and  sequenced  an  ESAG  4-related  gene  from  T.  congolese.  The 
protein  encoded  by  this gene  has  been  produced  in  recombinant  E.  coli. 
=> We  have  cloned  ESAG  4,  CRESAG  4.1  as  well  as  mutated  versions  of  ESAG  4  in 
baculovirus  constructs,  and  used  these  recombinant  viruses  to  express  the  trypano-
some  genes  into  cells.  The  role  of  the  different  domains  of  these  proteins  is  under 
study. 
=>The localisation  of the  trypanosome  cyclases  and  their accessibility to  antibodies  has 
been  studied  in  detail.  The  cyclases  were  found  to  be  shielded  underneath  the  VSG 
coat. 
=>  Several  immunization  trials  have  been  performed  with  antigens  produced  either  in  E. 
coli or on  the surface of insect cells. Although a good immune response was obtained, 
no  significant protection  against challenge  infection  could  be  observed. 
=>  Given the lack of protection obtained with the pESAG 4-related antigens, vaccination of 
mice was attempted with total extracts from the flagellar pocket of the parasite,  instead 
of pure antigens. Two out of three experiments gave positive results. The sera from the 
protected  mice were  used  to  screen  a  Trypanosoma  brucei eDNA library expressed  in 
COS7 cells.  The clones selected  by this  approach  are  presently  under study. 
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BIOSYSTEMATICS AND ADAPTIVE TRENDS  IN  THE  GENUS RHODNIUS 
Period: 
Co-ordinator: 
Objectives 
February 1,  1993 -January 31,  1997 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, 
DEPARTMENT OF MEDICAL PARASITOLOGY 
London,  United Kingdom (C.J.  SCHOFIELD) 
This  project  addresses  a  problem  of  particular  relevance  to  Chagas  disease  control  in 
Mexico,  Central  America,  Venezuela,  Colombia,  Ecuador,  Bolivia,  Peru  and  Brazil,  where 
Rhodnius  species  are  important  vectors  of  Chagas  disease  but,  due  to  morphological 
similarities between key species, their relative importance and potential for control  remains 
unclear.  The  project addresses this  problem  by: 
+  Clarifying  the  taxonomic  status  of  members  of  the  genus  Rhodnius with  reference  to 
type  and  topotype  material; 
+  Defining the  geographic limits and  ecological characteristics,  including  relative vectorial 
capacity,  of the  main  vector species  within  the  genus; 
+  Assessing  the  evolutionary  trends  within  the  genus,  especially  in  relationship  to 
progressive adaptation  to  domestic and  peridomestic environments. 
Activities 
This  project  has  established  a network  of  collaborating  research  partners  based  in  eight 
Latin  American  countries  with  links to  research  institutions and  control  organisations  in  a 
further  five  countries.  The  network  provides  technical  support  and  coordination,  and 
assistance  with  field  and  laboratory  work,  although  most  of  the  research  partners  also 
have  additional  financial  support  from  national  sources.  All  the  partners  are  involved  in 
field  work,  either  as  a  research  activity  or  in  association  with  vector  control  services. 
Several  can  also  act  as  reference  centres  providing  technical  support  and  reference 
services  to  the  network  in  relation  to  specific  analytical  techniques  and/or  statistical 
analysis  of  results.  Through  the  network,  field  collections  of  different  Rhodnius species 
have  been  made  from  numerous  localities  in  Mexico,  Honduras,  Colombia,  Venezuela, 
Ecuador,  Bolivia and  Brazil.  Wherever possible,  material  has  been  collected from  original 
type  localities,  or  from  regions  with  similar  ecological  characteristics.  Other  species  of 
interest  as  actual  or  potential  vectors  of  Chagas  disease  have  also  been  collected  and 
processed  in  a  similar  way.  Material  is  first  identified  using  external  morphological 
characters,  and  then  processed  as  follows: 
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Head:  quantitative  morphometry;  antennae  and  mouthparts:  quantitative  analysis  of  sen-
silla  patterns;  salivary  glands:  gland  contents  isolated  for  analysis  of  protein  profiles; 
thorax:  alary  muscles  fixed  for  analysis  of  isoenzyme  patterns;  legs:  analysis  of  RAPD 
patterns;  wings:  analysis  of  cuticular  hydrocarbons  (some  also  mounted  for  studies  of 
fluctuating  asymmetry);  gonads:  fixed  for  chromosome  studies  and  karyotype  analysis; 
Genitalia:  mounted  for qualitative comparisons  of  cuticular structures. 
Results 
~  Field  studies:  natural  ecotypes  of 9  Rhodnius species  have  now  been  fully  character-
ised,  revealing  quite  specific  associations  with  certain  palm  species  in  several  cases. 
However,  Rhodnius prolixus in  Central  America  seems  to  be  entirely  domestic  and/or 
peridomestic while  Rhodnius domesticus in  southern  Brazil  seems associated  primarily 
with  certain  types  of  bromeliad  rather than  palm  trees. 
~  Laboratory  culture:  eight  of  the  13  recognised  species  of  Rhodnius  have  been 
established  in  laboratory  culture  for  reference  purposed  and  comparative  studies  of 
basic  population  parameters  (reproductive  rates,  fecundity,  survivorship,  etc.).  These 
include  all  species  currently considered  of  epidemiological  significance. 
~  Biosystematic  analysis:  all  species  of  Rhodnius  have  now  been  characterised  by 
external  genitalia,  revealing  one  new  species  (R.  sta/1)  previously  classified  as  R. 
pictipes.  Further  studies  are  underway to  analyze  morphological  variation  in  the  main 
vector  species.  A  system  of  quantitative  sensilla  analysis  has  been  developed,  and 
applied  to  several  populations  of  6 species,  providing  useful  taxonomic  information  on 
pair-groupings  and  on  sensory  relationships  in  relation  to  habitat  specificity.  Isoen-
zyme  analysis  and  head  morphometry has  been  carried  out on  various  populations of 
7  species,  including  all  those  of  greatest  epidemiological  significance.  The  results 
largely  confirm  the  pair-groupings  and  allow  construction  of  a preliminary  phonogram 
of  relationships  between  species.  Preliminary  work  has  been  carried  out  to  demon-
strate  the  feasibility  of  using  RAPD  analysis  for  studies  of  population  variability, 
showing  that  the  technique  can  be  applied  to  dry-mounted  Museum  specimens  over 
50  years  old  (this  opens  the  possibility  of  analyzing  specimens  from  regions  where 
they  no  longer occur).  Hydrocarbon  analysis  has  also  been  carried  out on  populations 
of  4 species,  showing  consistent specific differences  and  karyotype  analysis  has  been 
completed  for  8 species  of  Rhodnius and  2  species  of  the  closely  related  Psammo-
lestes. 
~  Within  the  prolixus  group  of  species,  which  include  those  of  greatest  epidemiological 
importance, the results show clear differences between  R.  prolixus,  R.  neglectus and  R. 
nasutus, but indicate little if any difference between  R.  prolixus and  R.  robustus. This is 
also  endorsed  by  results  of  interbreeding  studies  involving  14  populations  originating 
from  various  sites  in  Central America and  Brazil. 
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=> Training  activities:  through  the  network,  a number of  training  visits  have  been  carried 
out,  whereby  research  staff  either  receive  staff  from  other  institutions  for  specific 
training,  or  travel  to  other  institutions  to  advise  and  help  resolve  technical  problems. 
The  aim  of  these  visits  is  not  necessarily to  make  every  technique  available  in  each 
laboratory, but to ensure that each researcher is familiar with the aims and limitations of 
each  of  the  techniques  being  applied  (the  visits  also  help  with  the  difficult problem  of 
distributing  biological  material  between  laboratories).  In  addition,  a  total  of  6  post-
graduates have been  trained and  carried out MSc level  projects in  association with the 
network research. 
=>Support  for  vector  control  activities:  results  to  date  are  being  used  to  assist  in  the 
design  of  control  strategies  and  entomological  surveillance  directed  against  those 
species of greatest importance as vectors of Chagas disease. A network workshop was 
held  in  September  1995  in  Ecuador,  during  which  organizations  of  several  endemic 
countries  participated.  One  of  the  most  important  outcomes  is  the  indication  that  R. 
prolixus  in  Mexico  and  Central  America  seems  to  be  restricted  to  domestic  and 
peridomestic  habitats,  and  so  far  seems  to  show  low  levels  of  genetic  variability 
compared  to  populations  in  Venezuela  and  Colombia.  This  implies  that  R.  prolixus in 
Central America could  be  a feasible target for eradication,  which  would  greatly reduce 
the  risk of further transmission  of  Chagas disease  in  that region.  Elsewhere,  domestic 
populations  may  be  much  lower  than  anticipated,  which  would  also  favour  renewed 
emphasis on vector control to reduce Chagas disease transmission. A preliminary report 
and  recommendations  has  been  presented  to  the  control  authorities,  and  the  detailed 
report  (including  methodological  guidelines)  is  now being  finalised  for publication. 
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POPULATION  GENETICS  AND  CONTROL  OF  TRIATOMA  BRASILIENSIS IN  NORTH 
EAST BRAZIL 
Period: 
Co-ordinator: 
Objectives 
January 1,  1997 - December 31,  1998 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, 
London,  United Kingdom (C.J. SCHOFIELD) 
•  To  improve knowledge of the biology and population genetics of  Triatoma brasiliensis in 
support of  entomological  surveillance  and  control  activities against  Chagas  disease  in 
North East Brazil, including development of genetic and/or phenetic markers suitable for 
identifying  the  source  of  new  infestations. 
•  To  encourage  greater collaboration  between  research  scientists  and  Chagas  disease 
control  authorities throughout the  arid  Caatinga  of  North  East  Brazil. 
Activities 
*  Background field  work  in  selected  municipalities of  Ceara  and  Piaui 
*  Establishm  ent  of  laboratory  colonies  for  comparative  genetic  analysis  and  studies  of 
population  growth  rates  and  flight physiology 
*  Monitoring  of  reinfestation  rates  following  trial  control  interventions  using  modern 
pyrethroid  insecticides 
*  Analysis  of  reinfestant  populations to  determine  population  structure and  origin 
*  Technical workshop with control personnel from  8 north-eastern states (Aiagoas,  Bahia, 
Ceara,  Paraiba,  Pernambuco,  Piaui,  Sergipe,  Rio  Grande do  Norte)  to  discuss  results 
and  refine  operational  control  and  surveillance_ methods. 
*  Formal  presentation  of recommendations  to  Ministry of  Health. 
Expected outcome 
=>  improved  geographic database of  T.  brasiliensis distribution 
=>  establishment of  laboratory colonies  from  well  characterised  localities 
=>  basic  life-table data  under different laboratory conditions 
=>  discriminant analysis based  on  11-18 morphometric variables and  ratios,  and  on  up  to 
25  gene  loci  represented  by  isoenzymes 
=>  preliminary karyotype  analysis  and  RAPD  data 
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~  analysis  of  geographic  structuring  of  T.  brasiliensis  populations,  and  preliminary  esti-
mates of gene dispersal between  neighbouring populations 
~detailed characterisation  of field  trial  localities,  and  liaison  with  industries  interested to 
participate in  field  trials 
~  laboratory flight studies indicating  key factors  influencing flight  initiation 
~possible genetic markers for flight capacity 
~field studies  using  light traps to estimate potential flight  range 
~  morphometric and genetic characterisations suitable for analysis of reinfestations 
~  evaluation  of reinfestations following  control  trials,  and  reassessment of morphometric 
and  biochemical  profiles. 
(Note  that  during  the  course  of this  work we  also  expect  to  gather preliminary  data  on 
other  species  of  Triatominae  found  in  the  same  region  as  T.  brasiliensis,  which  might 
become of greater epidemiological  significance  in  the future.) 
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EXPERIMENTAL STUDY OF THE IMPACT OF POPULATION CLONAL STRUCTURE ON 
RELEVANT MEDICAL AND BIOLOGICAL PROPERTIES OF TRYPANOSOMA CRUZ/ 
Period: 
Co-ordinator: 
Objectives 
September 1,  1992 till August 31,  1995 
ORSTOM,  MONTPELLIER  1,  LABORATOIRE DE GENETIQUE DES 
PARASITES ET DES VECTEURS, Montpellier, France (M. TIBAYRENC) 
•  Extensive population genetic analyses have shown  that the  populations of  T.  cruzi,  the 
agent of Chagas disease,  are subdivided into natural clones,  stable in  space and time. 
The major clones refer to certain clones which  are much  more frequently sampled than 
others; it is suspected that their medical and epidemiological significance is considerable. 
•  The goal  of the  present study is to compare some relevant medical properties such  as 
virulence and  resistance to  drugs of the  major  T.  cruzi clones. 
Activities 
Studies will  involve a limited  sample  of  16  laboratory-cloned  stocks  representing  3 major 
clones,  selected  according  to  their  genetical  relationships,  ascertained  by  multilocus 
isoenzyme  electrophoresis.  Each  major  clone  in  the  present  sample  is  represented  by 
several stocks having extremely variable origins (host, place of isolation). Stocks pertaining 
to  these  3 clones  have  been  studied,  in  order to  consider possible  interactions  between 
two (or more) different clones. Such mixed infections seem to be common in  natural cycles 
in  both  triatomine bugs as  will  as  in  patients.  The  impact of clone  interactions in  a given 
host could  have  an  important impact on  Chagas'  pathogenesis.  To  follow the  behavior of 
such  mixed  infections,  we  used  the  PCR  KDNA  probes  specific  for  the  major  clones. 
Specific study areas will  include: 
Differentiation  in  axenic  culture  medium,  which  will  be  estimated  from  the  percentage  of 
trypomastigote  forms  at  given  times. 
Differentiation  of  epimastigote  forms  to  infective  metacyclic  trypomastigote  forrr::::  will  be 
monitored  every  day following  morphological  changes  in  a Thomas  chamber  in  order to 
obtain  at  least 20°/o  of  metacyclic trypomastigotes. 
Generation  of  tissue  culture  trypomastigotes;  study  of  in  vitro  infectivity;  experimental 
mouse  infections. 
Histopathological  studies  of  the  following  organs  in  mice:  heart,  brain,  liver,  spleen, 
ganglion,  skeletal  muscle  and  colon. 
*  Drug  sensitivity  studies  will  be  carried  out  on  both  in  vitro  and  in  vivo  models  using 
drugs  currently  applied  in  the  treatment  of  Chagas'  disease,  5-nitrofuran  and  2-
nitroimidazole. 
*  Statistical  analysis  of the  results  using  commercial  software. 
Expected outcome 
The  goal  project  was  to  define  the  medical  implications  of  the  considerable  genetic 
variability of  T.  cruzi. 
We  proposed  a  general  model  of  parasitic  protozoa  population  structure  that  strongly 
suggests  that  many  parasites  (e.g.  T.  brucei and  various  species  of  Leishmania),  have 
typical  clonal  population  structures,  like  T.  cruzt.  hence  the  approach  and  experimental 
design  proposed  could  be  the  basis for further studies  involving other parasites. 
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Results 
A set of 21  parasites stocks representing 4 major natural clones (clonal genotypes that are 
widespread  and  constitute  most part  of the  stocks  isolated  from  chagasic  patients)  have 
been  selected,  on  the basis of genetic characterization  involving  15 isozyme loci. 
Since the beginning of the project,  the following  goals have been  reached: 
*  Improved  genetic  characterization  of  the  21  stocks:  a  more  accurate  picture  of  the 
actual  genetic variability of our sample has been  provided by: 
*  increasing the  number of isozyme loci  from  15 to 23; 
*  using  random  primer amplification  of polymorphic  DNA or RAPD. 
During  biological  characterization  of  the  21  stocks  the  following  main  parameters  have 
been  screened: 
*  Virulence  in  Balb/C  mice. 
*  In  vitro  culture  kinetics  (pure  clones  and  mixtures  of  clones),  epimastigote/ 
trypomastigote transformation rate,  in  vitro drug sensitivity, transmissibility by the vector 
Triatoma  infestans (pure clones and  mixtures of clones). 
All  these  parameters  have  been  quantified.  A  highly  significant  correlation  was  found 
between  biological  variability and genetic diversity:  the stocks that are genetically closely 
related have a strong statistical tendency to have similar biological comportment, while the 
opposite is the case for the distantly related clones. The major clones tend to behave like 
distinct  taxa  for  these  biological  parameters.  The  stocks  attributed  to  the  clonal  group 
19/20 generally grow faster, transform more actively into trypomastigotes, are more virulent 
to  mice and less sensitive to  drugs. 
Complementary  analyses  from  anatomopathology  and  in  vivo  experiments  on  three 
different  mouse  strains  confirm  considerable  biological  diversity  among  T.  cruzi  stocks 
pertaining to  the different major clones. 
Conclusions 
Most  of the  work  outlined  at  the  start  of the  project  has  been  completed  together  with 
additional experiments on  T.  cruzi transmissibility by Triatoma  infestans and the biological 
behaviour of mixtures of clones. 
All  results fully confirmed the working  hypothesis of the  project,  that clonal  diversity of  T. 
cruzi has a major impact on this parasite's biological diversity including medically relevant 
parameters such as virulence,  resistance to drugs and transmissibility by triatomine bugs. 
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RISK OF  REINFESTATION  FROM  WILD FOCI  OF  TRIATOMA INFESTANS IN  BOLIVIA, 
A COUNTRY OF  THE  SOUTHERN  CONE  PROGRAMME 
Period: 
Co-ordinator: 
Objectives 
September 1,  1993 - August 31,  1995 
ORSTOM MONTPELLIER, LABORATOIRE DE GENETIQUE 
MOLECULAIRE DES  PARASITES ET DES VECTEURS, 
Montpellier, France (J.P.  DUJARDIN) 
•  To  evaluate  the  epidemiologicat  importance  of  wild  populations  of  Triatoma  infestans 
(Hemiptera,  Reduviidae).  This  species  is  the  principal  vector  of  Trypanosoma  cruzi, 
causative  agent  of  Chagas  disease,  throughout  the  seven  southernmost  countries  of 
Latin  America  (Argentina,  Bolivia,  Brazil,  Chile,  Paraguay,  Peru,  Uruguay).  In  these 
countries  it  has  become  the  primary  target  of  Chagas  disease  vector  control  pro-
grammes. 
•  To  determine the  invasive capacity of silvatic  T.  infestans:  do they  represent a risk for 
reinfestation? 
Activities 
Using  field  experiments  and  laboratory  studies,  we  studied  the  connections  between 
domestic and  wild  T.  infestans. 
Throughout most of its wide distribution,  T.  infestans seems to be exclusively domestic and 
peridomestic,  occupying  cracks  and  crevices  in  rural  dwellings  and  domestic  animal 
enclosures. True silvatic colonies are known only from the Cochabamba region of southern 
Bolivia,  where  the  insects  can  be  found  amongst  rockpiles  in  association  with  wild 
guinea-pigs.  The  original  silvatic  focus,  some  15  Km  south  of  Cochabamba  (Cercado 
province),  was  first  described  in  1946. 
A genetic interpretation of electrophoretic data has so far not revealed differences between 
the  silvatic  population  and  nearby  domestic  populations  so  that  the  degree  of  isolation 
between  them  is  unclear.  However,·  in  order to  apply  adequate  control  and  surveillance 
measures,  it is  important to  understand the  relationships between these ecotopes.  Control 
of  Chagas  disease vectors  relies  primarily  on  spraying  infested  dwellings  with  pyrethroid 
insecticides. After the  initial  intervention  however,  it is  important to continue entomological 
surveillance  so  that any  new infestations can  be  selectively retreated. 
Laboratory studies scored different population markers with  the idea that,  if not panmictic, 
the  ecotopes  under  study  should  show  some  genetic  differentiation.  Isoenzyme  electro-
phoresis  and  cytogenetic  studies  comparing  C-banding  polymorphism  failed  to  detect 
significant  differences  between  ecotopes,  whereas  random  amplified  polymorphic  DNA 
(RAPD)  evidenced  different  band  frequencies.  In  accordance  with  this  latter  genetic 
marker,  morphometric analysis  revealed  also  head  and  wing  differences.  The  post-ocular 
region  was  repeatedly  larger  in  silvatic  specimens,  either  nymphs,  males  or females,  in 
samples collected  at  various times  (1983,  1992,  1995 and  1996). 
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Field  experiments  explored  the  dispersive  behavior  of  wild  T.  infestans  in  Jamach'Uma 
(Cochabamba,  Bolivia).  This  locality  is  a  small  village  surrounded  by  silvatic  foci  of 
Triatoma  infestans.  The first experiment used "sentinel henhouses". Artificial,  adobe made 
henhouses  were  constructed  each  100  meters  from  Jamach'Uma  to  the  wild  focus. 
Though hens are very attractive animals for T.  infestans,  none were found colonizing these 
henhouses during a six months survey.  Hens were then replaced by rodents,  and monthly 
vigilance  was  continued  for  eight  months.  Again,  no  T.  infestans  were  found,  though 
another species (T.  sordida) invaded these artificial  structures. 
The second field experiment simulated a control programme in  Jamach'Uma. In  December 
1992,  infestation by a few nymphs of  T.  infestans was found  again which was sprayed in 
October 1993.  They were  compared  at seven  head  metrics with  36  fifth  instar domestic 
nymphs  coming  from  Jamach'Uma  before  treatment,  and  with  two  sets  of  nymphs 
originating  from  the  surrounding  silvatic  foci:  8  specimens  collected  in  1992  and  9 
specimens  collected  in  1995.  The  results  were  interpreted  in  terms  of  the  possible 
mechanisms of  reinfestation  whether there  was  a  residual  population  or reinvasion  from 
surrounding silvatic foci.  Metric comparisons strongly supported the hypothesis of infesta-
tion resulting from a residual population surviving the insecticide spraying. It is not possible 
to  definitively  rule  out the  idea that  some  of the  infestant  nymphs  are  of  silvatic  origin, 
mixed with a residual  population. Three arguments were consistent with the hypothesis of 
no regular migrants, or exceptional migrants, between Jamach'Uma and the wild focus: the 
delay  (ten  months)  between  insecticide  spraying  and  the  reinfestation,  the  stage  (fifth 
nymphs)  of the  infestant specimens and their metric characteristics. 
On the basis of these laboratory and field data, the silvatic focus of  T.  infestans in  Bolivia 
does not appear to represent a  serious obstacle to the application of the Southern  Cone 
Programme in  Bolivia. 
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ROLE  OF  INSECT  HOST  DEFENCES  IN  TRYPANOSOME  DEVELOPMENT  IN  CHA-
GAS' DISEASE VECTORS WITH EMPHASIS ON THE ACTIVITY OF IMMUNE DEPRES-
SION AGENTS 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1994 - December 31 , 1996 
UNIVERSITY COLLEGE OF SWANSEA, SCHOOL OF BIOLOGICAL 
SCIENCES, Swansea, United Kingdom (N.  RATCLIFFE) 
•  To  determine  the  presence  and  role  of  insect  vector  immune  defence  factors  in 
insect-parasite interactions. 
•  To  determine the  effect of parasites on  the vector immune defence reactions. 
Activities 
Year 1 
*  Lectin  staining. 
*  Hemolymph  and  crop lectins  purification initiated. 
*  Infectivity studies on  different parasite strains. 
Year 2 
*  Lectin  staining. 
*  Hemolymph  and  crop  lectins purification. 
*  Effect of immunosuppressive agent. 
*  Prophenoloxidase. 
*  Blocking  experiments commenced. 
Year 3 
*  Lectin  staining. 
*  Blocking  experiments. 
*  Test  pure  lectin  against parasites. 
Exchange  of scientists and  training. 
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Expected outcome 
:=::)To  learn  how  T.  cruzi and  T.  rangeli evade the normal insect defence mechanisms and 
colonize the  host. 
:=::)To  discover vector molecules  responsible for transformation  of the  parasites from  one 
stage to  another. 
:=::)  Eventually to show whether compounds which induce immune-depression in the vectors 
can  facilitate the control  of Chagas'  disease transmission. 
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TRYPANOCIDAL DRUGS:  LABORATORY AND  FIELD EVALUATION  OF  NOVEL CON-
TROLLED RELEASE SYSTEMS 
Period: 
Co-ordinator: 
Objectives 
January 1,  1994 - December 31,  1996 
INSTITUTE OF TROPICAL MEDICINE PRINCE LEOPOLD,  DEPT. 
ANIMAL HEALTH, Antwerpen, Belgium (S.  GEERTS) 
+ The  objective  of  this  research  programme  is  to  develop  novel  controlled  release 
systems  of  homidium  bromide,  isometamidium  and  diminazene  aceturate  in  order  to 
increase the  prophylaxis  period. 
+ Other features of the new formulations which will  be  examined in  detail:  minimal  risk of 
resistance development,  minimal  toxicity to  livestock,  minimal  residual  drug  concentra-
tions  in  the  carcasses  and  overall  cost of the  new devices. 
Activities 
*  Three  European  and  two  African  institutions  will  undertake  this  research  work  in  a 
coordinated  fashion. 
*  The development of the improved formulations will  primarily be the  responsibility of the 
University  of  Ghent  (polymer  division).  Different  biodegradable  (polymer)  controlled 
release  systems for subdermal  implantation will  be  developed. 
*  Pharmacokinetic  studies  using  radiolabeled  drugs  and  sensitive  analytical  techniques 
for the  detection  of circulating  drug  concentrations will  be  developed  by the  University 
of Glasgow. 
*  Laboratory testing of the  new formulations using  laboratory animals and  ruminants will 
be  carried  out  at  the  Institute  of  Tropical  Medicine,  Antwerp  and  at  Glasgow.  Both 
institutes  will  also  examine  the  possible  development  of  resistance.  Evaluation  under 
realistic field conditions and cost-benefit analyses of the use of these controlled release 
trypanocides  will  be  carried  out  under different  conditions  of management  and  tsetse 
challenge  in  2 African  countries  (Mali  and  Zambia). 
*  The  project will  offer opportunities for participating  scientists to  visit other institutes for 
training  and  for research  work. 
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Expected outcome 
It  is  expected to  collect scientific data about the  value  of  different sustained  or controlled 
release  devices,  based  on  currently  available  trypanocides,  for  the  chemoprophylaxis  of 
animal  trypanosomiasis:  composition  (type  of polymer,  drug  load,  etc.),  pharmacokinetics, 
protection  period  under laboratory and  field  conditions,  effect  on  resistance  development. 
These  data  should  allow  a  comparative  evaluation  of  these  novel  formulations  with  the 
trypanocidal  drugs,  which  are  currently available  on  the  market. 
Results 
Development of drug delivery devices and in vitro release studies 
Different  types  of  sustained  release  devices,  containing  mixtures  of  biodegradable  poly-
mers  and  isometamidium  (ISMM)  or  ethidium  were  synthesized.  The  effect  of  different 
parameters (solvent used for coating,  dexamethasone in  coating,  coating thickness,  buffer 
concentration  and  ionic  strength,  coating  polymers,  etc.)  on  the  in  vitro  release  of  the 
devices  was  studied.  The  studies  concerned  mainly  poly-(D,  L-lactide)  and  poly-
caprolactone-co-L-Iactide)  or poly-lactone-co-D,  L-lactide). 
Laboratory testing of the sustained release devices 
After  preliminary  trials  in  rabbits  challenged  with  Trypanosoma  congolense,  poly(D, 
L-lactide)  polymers were  selected  for further evaluation  in  cattle. 
Under controlled conditions (monthly challenge with tsetse flies infected with  T.  congolense 
clone IL 1180) it was shown that subcutaneous implantation of isometamidium-SAD (at 0.5 
mg/kg)  extended the  prophylactic period  by a factor 3.2  in  comparison  with  intramuscular 
(i.m.)  injection  of the  same  doses of the  drug.  Similarly the  protection  period  provided  by 
the  implantation  of an  ethidium-SAD  (at  1  mg/kg)  was 2.8 times longer than that obtained 
after  i. m.  injection  of the  drug  at  the  same  doses. 
Analysis  of  the  isometamidium  concentration  in  the  sera  of  the  treated  animals  (using 
ELISA)  showed  that  the  drug  remained  present  for  at  least  5  months  at  concentration 
between 0.4 and 0.8 hg/ml in the SAD-treated cattle, whereas in the i.m. treated group the 
isometamidium  concentration  dropped  already  below  the  detection  limit  (0.5  ng/ml)  85 
days post treatment. 
When  breakthrough  isolates derived from  treated rabbits or cattle were compared with the 
parent  stock or clone  of  T.  congolese,  no  evidence  could  be  found  that  drug  resistance 
was  developing faster  in  SAD-treated than  in  conventionally treated  animals. 
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Pharmacokinetic studies and trypanocidal drug ELISA's 
The  drug disposition  and  pharmacokinetic parameters of  homidium  bromide and  isometa-
midium  were  studied  in  different  groups  of  cattle,  infected  or  not  infected  with  T. 
congolese.  Furthermore,  various  modifications to  the  trypanocidal  drug  ELISA procedures 
were  investigated  in  order to  improve  their sensitivity and  specificity  using  field  samples. 
These  modified  ELISA's  were  then  used  to  analyze  the  isometamidium  and  ethidium 
concentrations  in  the  sera  of  the  cattle  involved  in  the  experiments  under controlled  and 
field  conditions.  The  detection  limit of  the  ISMM-ELISA was  approximately 0.5  ng/ml. 
Field trials using sustained release devices 
In  order  to  evaluate  the  efficacy  of  poly  (D,  L-lactide)-isometamidium-SAD  under  field 
conditions,  a trial was carried  out on  a ranch  in  Mali  where  a heavy tsetse challenge was 
present. Two  groups of about 40 cattle were treated with  isometamidium  (1  mg/kg),  either 
as  SAD  or  as  i.m.  injection,  and  compared  with  a  control  group.  Eight  months  after 
treatment  the  cumulative  percentage  of  trypanosome  infections  was  28,  59  and  77o/o, 
respectively  in  the  SAD-implanted,  the  i.m.  treated  and  the  control  groups.  Statistical 
analysis  proved  that  the  infection  risk  was  more  than  two  times  lower  in  the  SAD-
implanted  group than  in  the  conventionally treated  animals. 
A similar field trial was carried out in Zambia using poly (D,  L-lactide)-ethidium-SAD.  In this 
experiment  4  groups  of  about  20  cattle  were  involved.  They  received  respectively  the 
ethidium-SAD,  ethidium  i.m.,  ISMM  i.m.  or  no  treatment at  all  (control).  The  cattle,  which 
received the ethidium-SAD were longer protected (average of 107 days) than those,  which 
were  treated  with  the  same  dosis  of  ethidium  i.m.  (average:  75  days).  The  average 
protection period provided by  ISMM  i.m.  was  similar to that of the ethidium-SAD.  It has to 
be  mentioned,  however,  that - contrary to  the  trial  in  Mali  - resistant trypanosome  strains 
were  present  in  the  area,  where  the  experiment was  done. 
Other trials are currently being  conducted  in  Mali  and  Zambia in  order to  further evaluate 
the  efficacy of  ISMM  - and  ethidium-SAD  under field  conditions. 
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CHARACTERIZATION  OF A  NEW THERAPEUTIC  TARGET  ON  AFRICAN  TRVPANO-
SOMES:  THE  GLUCOSE TRANSPORTER AND  DEVELOPMENT OF A VACCINATION 
STRATEGY 
Period: 
Co-ordinator: 
Objectives 
December 1  , 1993 - November 30,  1996 
UNIVERSITE DE  BORDEAUX II,  URA CNRS 1637, LABO IMM. 
BIOL.  PARASITAIRE,  Bordeaux,  France {T.  BALTZ) 
The  African  Trypanosomas  escape  the  immune  defences  of  their  hosts  by  expressing 
variable antigens on  their surface.  This phenomenon  of antigenic variation  has  stimulated 
our research  on the non-variable proteins on the surface which may have functions vital to 
the  parasites  survival.  We  have  therefore  characterized  the  glucose  transporters  of 
different  Trypanosomas  with  the  aim  of  testing  their  capacity  to  vaccinate  and  also 
investigated  the  possibility of  developing  new trypanocidal  molecules  based  on  modifica-
tions  of hexose. 
Activities 
We  have  characterized  the  genes  encoding  the  glucose  transporters  of several  different 
species of Trypanosome:  T.  brucei and  T.  congolense which  express two distinct isoforms, 
one  expressed  at  all  stages  of parasitic  development  (THT2  and  TcoHT2)  and  the  other 
expressed uniquely on the trypomastigote stage (THT1  and TcoHT1 ),  T.  vivax (TvHT1) and 
T.  cruzi which  expresses a single  isoform  at all  stages of the  parasites development. 
Alignment of the sequences revealed strong similarities (60-80°/o). The areas of divergence 
were at the ends of N and C terminal regions as well as  in the first potentially extracellular 
loop  which  is  rich  in  cysteine.  Unlike  mammalian  glucose  transporters,  there  was  no 
systematic glycosylation. 
While  sequencing  the  gene  encoding  the  T.  brucei glucose  transporter  (50  Kb  Cosmid) 
several new genes were discovered including PI3K {Phosphatidyl inositol Kinase) a protein 
with  a structure comprising a repeated 43 amino acid,  proline-rich  motif with  a few copies 
to  about  fifty  copies  depending  on  the  isolate  and  the  species  and  which  constitutes  a 
potentially useful epidemiological marker.  "Run on" experiments have allowed us to identify 
a  promoter.  This  would  suggest  that  these  genes  are  under  the  control  of  a  promoter 
situated  upstream.  Studies of the  organization of this  region  of the genome reveal  strong 
similarities  among  the  species. 
The  study of THT gene  polymorphism  in  the  different strains  of the  brucei  group  and  in 
particular on  T.  gambiense has shown  that there  is great variation  in  the  number of gene 
copies  in  T.  brucei whereas  variation  in  T.  gambiense is  low,  this  finding  favors  a clonal 
origin. 
Direct functional studies on  the glucose transporters of  T.  brucei,  T.  vivax and  T.  cruzi and 
following  the  expression  of  their  genes  in  CHO  have  allowed  us  to  draw  the  following 
conclusions. 
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*  All  of  the  transporters  are  functional  and  are  capable  of  transporting  fructose  unlike 
human  glucose transporters and  in  particular Glut  1. 
*  High  affinity (THT2 =  68J.1M,  TcrHT1  =  84J.IM)  and  low affinity (ThT1  =  0.5  mM,  TvHT1 
= 0.58mM)  transporters can  be  identified. 
*  Studies  of  substrate  preferences  have  shown  several  important  differences  in  the 
transporters THT1  is  expressed  on  the  blood  stage  forms  of  T.  brucei and  recognizes 
only  derivatives  of  glucose  with  substitutions  at  position  C6.  This  property  has  been 
exploited  during  our collaboration  with  the  production  of fructose  with  substitutions  at 
position C6. This molecule (BrCH2 C(O)NH  Fructose) is trypanocidal in vitro but without 
effect  in  vivo.  Others strongly inhibit fructose transport but have  no  effect on  parasites 
in  culture. 
We  have  tried  to  express  the  native  THT1  protein  in  sufficient  quantities  for  vaccination 
experiments in  E.  coli and  Baqulovirus,  but without success. This may be  explained partly 
by  the  difficulties  in  expressing  any  membrane  protein.  We  have  prepared  a  polyclonal 
rabbit antiserum against a twenty amino acid synthetic peptide representing the extreme C 
and  N termini  and  against a fusion  protein  derived from  the  extracellular  region  which  is 
rich  in  cysteines.  Both  antisera  are  trypanocidal  when  cultured  in  the  presence  of 
complement but neither  p~events infection. 
Conclusion 
This  study  of  the  biochemistry  and  genetics  of  glucose  transporters  has  allowed  us  to 
demonstrate  the  possibility  of  developing  novel  trypanocidal  molecules  with  modified 
hexose  bases.  However,  it  has  not  been  possible  to  express  the  transporter  THT1  in 
sufficient quantities to  permit an  assessment of  its  capacity as  a vaccine. 
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CHARACTERIZATION OF THE IMMUNE RESPONSE AGAINST TRYPANOSOMA CRUZI 
ANTIGENS  {GP  50/55 AND  URINARY ANTIGEN)  INVOLVED IN  IMMUNOPATHOLOGY 
AND THEIR  POTENTIAL USE  IN  DIAGNOSTICS 
Period: 
Co-ordinator: 
Objectives 
June 1,  1993- May 31,  1996 
UNIVERSIDAD AUTONOMA DE MADRID, CENTRO DE BIOLOGIA 
MOLECULAR, Madrid, Spain (M.  FRESNO) 
•  To  improve  the  understanding  of  the  immune  responses  involved  in  protection  and 
pathology  in  Chagas'  disease  in  order to  help control  it. 
•  To  characterize  two  antigens  that  may  be  involved  in  pathology  and  also  may  be  good 
candidates for diagnostic. 
•  To  study the  cellular immune  response  against both  antigens. 
•  To  study the  potential  use  of  these  two antigens  as  diagnostic tools. 
Activities 
*  The  functional  and  biochemical  characterization  of  the  T.  cruzi antigen  GP  50/55  which 
shares an  epitope with  a lymphocyte activation antigen  and  induces crossreactive antibod-
ies  in  Chagasic patients which  suppress  lymphoid  activity. 
*  The  functional  and  biochemical  characterization  of a  T.  cruzi 80  kDa  urinary antigen  (UA). 
*  The  cloning  of the  genes  coding  for the  GP  50/55 and  the  UA proteins. 
*  To test the  reactivity of chagasic sera from  patients with different clinical status, with  purified 
natural  or recombinant  GP  50/55 and  the  UA proteins. 
*  To test the reactivity of chagasic sera from  patients with different clinical status, with  purified 
natural  or recombinant  GP  50/55  and  its  possible  relationship to  differential  diagnostic. 
*  To  study the cellular immune response to  T.  cruzi and the  role  in  vivo and  in  vitro of several 
cytokines.  A  special  interest  will  be  devoted  to  the  study  of  the  humoral  and  cellular 
response  against the  GP  50/55  protein  and  its  role  in  pathology. 
*  To develop simple and highly sensitive methods for detection of parasite circulating antigens 
in  urine to  improve Chagas'  disease diagnosis and  follow-up  of treated  patients. 
Results 
We  have  investigated  the  biochemical  and  functional  properties  of  T.  cruzi  GP50/55,  a 
glycosyl-phosphatidylinositol  (GPI)-anchored  membrane  antigen.  Some  of  the  properties  (e.g. 
molecular  mass,  susceptibility to  degradation)  were  reminiscent  of  those  displayed  by  the  T. 
cruzi lysosomal  cysteine  proteinase  (GP57/51 ).  A 50-52  kDa  proteinase  activity,  specifically 
inhibited by thiol protease inhibitors, was immunoprecipitated with monoclonal antibodies (mAb) 
to  GP50/55  (mAb  C1 0),  migrating  slightly  faster  than  the  enzyme  precipitated  by  mAbs  to 
GP57/51.  Moreover,  the  GP50/55  antigen  detected  by  mAb  C1 0 is  expressed  in  the  parasite 
membrane  whereas  the  GP57/51  is  not.  The  protein  GP50/55  has  been  purified  to  homoge-
neity.  We  have  found  that  the  cystein  protease  activity  copurifies  with  the  GP50/55  protein 
(defined by  reactivity with  our monoclonal antibodies).  However, the cysteine  protease may be 
in  fact  a protein  very tightly bound  to  GP50/55. 
This  has  led  to the  identification of a mucin-like protein complex of 30,40 and  50kDa (AgC1 0) 
as  the  one  recognized  by  mAb  C10.  The  aminoacid  composition  and  the  structure  of  sugar 
chains  have  been  elucidated.  The  epitope  recognized  by  Mab  C1 0 has  been  defined  as  well. 
This  purified protein  is  able to suppress the  immune  response  against  T.  cruzi and  selectively 
alters  the  production  of  tumor  necrosis  factor  (TNF)  but  not  interlukin  - 1  (IL-1)  by  macro-
phages.  These  strategies  may contribute  significantly to  the  survival  of the  parasite. 
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On  the  other  hand,  the  amino  acid  sequence  of  the  N-terminal  portion  of  an  80-kDa 
Trypanosoma  cruzi urinary  antigen  (UAg)  affinity  - purified  from  the  urine  of  infected  dogs 
showed  high  degree  of  homology  with  human  and  dog  transferrins.  Whereas  polycolonal 
antibodies  were  unable  to  discriminate  between  the  parasite  antigen  and  transferrin,  some 
MAbs  specifically and  selectively  recognized  an  80kDa  UAg  but  not  host transferrin,  and  also 
reacted  against a  T.  cruzi lysate. 
lmmunoprecipitation analysis showed that UAg specific antibodies bind to several trypanosome 
antigens including an 80 kDa polypeptide co-migrating with UAg. This UAg is a form of the host 
transferrin  taken  up  and  modified  by  the  parasite.  The  nature  of  this  modification  is  under 
investigation. 
In  agreement with  those  results  it was  not a surprise that we  were  unable to  isolate the eDNA . 
clone for a transferrin  related  UAg,  by  immunoscreening with  polyclonal  antibodies to transfer-
rin  and  by  PCR  with  degenerate  oligonucleotides  of  conserved  regions  of  transferrins. 
However,  we  succeeded to isolate a series of clones  expressing the  C-terminus portion  of the 
tubulin  protein  of  T.  cruzi. This finding was also supported by  immunoprecipitation experiments 
showing  that  the  anti-UAg  antibodies  referred  above  (used  for  screening  of  library)  were 
capable  of  recognizing  tubulin.  Simultaneously,  we  have  determined the  existence  of  a 50-55 
kDa  tubulin  as  a minor component of  the  purified  UAg  preparation,  therefore  secreted  in  the 
urine  of  infected dogs. 
This  recombinant  antigen  can  therefore  be  used  in  the  development  of  urine  tests  for 
diagnosis. 
We  have found that 1  OOo/o  of  all  human chronic chagasic sera  reacts with  this AgC1 0 complex 
which  underlines  the  importance  of  this  antigen  as  a  potential  candidate  for  diagnostics. 
Moreover, we have found that AgC1 0 induces cross-reactive antibodies that react with a 70kDa 
protein  of  lymphocytes.  By  screening  of  a  human  T-cell  eDNA  library  with  human  chagasic 
sera,  we  isolated  a  couple  of  eDNA  clones.  One  of  those  human  clones  (Cha  9.1 .2)  have 
homology with  the  repetitive  region  of the  T.  cruzi antigen SAPA,  thought to  be  involved in  the 
evasion  of  immune  response. 
This clone  is  recognized  by a large percent of chagasic sera having cardiomyopathy.  We  have 
mapped  to  this  site  the  reactivity  of  all  autoantibodies  in  the  chagasic  sera. 
Those  results  further  expand  our  previous  work,  indicating  that  sera  from  chagasic  patients 
recognize  antigens  present  in  human  T and  B lymphocytes.  Moreover,  the characterization  of 
autoantibodies  against  lymphocytes  may  lead  to  the  definition  of  a  prognostic  antigen  for 
predicting  the  outcome  of the  disease. 
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SYNTHETIC  PEPTIDE  ANTIGENS  AS  A  TOOL  FOR  SPECIES-SPECIFIC  SERODIAG-
NOSIS OF  LEISHMANIASIS WITH  FIELD APPLICATIONS IN  BRAZIL AND COLOMBIA 
Period: 
Co-ordinator: 
Objectives 
October 1,  1992 - September 30,  1995 
LIVERPOOL SCHOOL OF TROPICAL MEDICINE 
Liverpool,  United Kingdom  (M.  HOMMEL) 
The overall objective is to evaluate a series of synthetic peptides, derived from  Leishmania 
genes,  which  can  be  used,  under  field  conditions,  for  species-specific  serodiagnosis  of 
leishmaniasis.  The  original  rational  behind  the  proposed  study  was  the  finding  that  a 
synthetic  15 amino-acid peptide,  based  on  the sequence of a Leishmania donovani gene, 
could  be  used  in the laboratory for a specific serodiagnostic test of visceral  leishmaniasis. 
The  main  objectives of the  study are: 
•  To  field-test  the  existing  peptide  assay  in  selected  areas  of  Brazil  and  Colombia, 
endemic for visceral  leishmaniasis  in  order to  evaluate  its  predictive value. 
•  To  perform  similar  studies  in  areas  for  (muco-)cutaneous  leishmaniasis  and  Chagas' 
disease  in  order to  confirm  species-specificity. 
•  To  furth~r improve the  peptide-carrier construct. 
•  To  use the  same  rationale  and  technology to  be  applied to  the  Leishmania braziliensis 
complex. 
•  To  include  peptide-carrier constructs  in  assays  suitable for use  under field  conditions. 
•  To  set  up  a laboratory of  molecular biology at the  University of  Sucre. 
•  To collect isolates of Leishmania and patient blood and sera from  locations in  Colombia 
and  Brazil. 
Activities 
*  Improvement  of  the  methodology  for  the  preparation  of  peptide-carrier  constructs  by 
conjugation  of  peptides  to  the  human  serum  albumin  carrier  using  thi-oester  hetero-
bifunctional  reagents. 
*  Design  of  new  mixtures  of  peptide  sequences  ("mixotopes")  based  on  consensus  and 
variable  motifs  of  the  leishmania!  rK39  sequence,  an  antigen  which  has  proven 
diagnostic value. 
*  Testing the  potential  use of random  peptide phage  display libraries as  a means for the 
identification  of  immunodominant leishmania!  peptides. 
*  Investigation  of  the  scientific  basis  for  the  direct  agglutination  test  using  whole 
leishmania!  promastigotes. 
*  Collection  and  PCR  characterization  of  leishmania!  isolates from  Colombia. 
*  Development  of  an  antigen-capture  assay  for the  detection  of  leishmania!  antigens  in 
the  urine  of patients with  visceral  leishmaniasis. 
*  Collection  of  serum  from  patients  with  clinical  visceral  leishmaniasis,  cutaneous  and 
mucocutaneous  leishmaniasis,  Chagas'  disease,  asymptomatic  leishmania!  infections 
and  a variety of endemic controls  in  Brazil. 
246 Contract number:  ERBTS3.CT920052 
Results 
=>  Development  of  a  new,  ELISA-based,  serological  assay  for  the  diagnosis  of  visceral 
leishmaniasis  using  a  mixture  of  synthetic  peptides  linked  to  a  carrier  protein  (HSA). 
Publication  of the  description  of the  assay and  its  performance  in  scientific literature. 
=>  Characterization  of  new  foci  of  leishmaniasis  in  Brazil  and  in  colombia  (District  of 
Sucre). 
=>Completion  of  3  PhD  theses  on  leishmaniasis  (1  from  a  DC  student,  2  from  EU 
students);  2 other PhD  theses from  DC  students are still  in  the process of completion. 
=>  Setting  up  of  a  laboratory  for  the  study  of  leishmaniasis  and  the  use  of  molecular 
biology  methods  in  Sincelejo,  Sucre,  Colombia.  This  laboratory  has  been  given  the 
status  of  Regional  Leishmaniasis  Reference  Laboratory  by  the  Colombian  Health 
Authority. 
=>  Organization  in  Liverpool  of one  of the  Euroleish  Network meetings and  editing of the 
proceedings. 
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VISCERAL LEISHMANIASIS:  EPIDEMIOLOGY AND DISEASE CONTROL 
Period: 
Co-ordinator: 
Objectives 
September 1  , 1992 - August 31 , 1995 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE 
London, United Kingdom (M.A. MILES) 
The following  are the main  objectives: 
•  To  establish  research facilities at the  University of Teresina and a training  programme 
for local  staff. 
•  To  perform  a  thorough  comparison  of diagnostic serology and  diagnostic parasitology 
for  Brazilian  and  European  canine  and  human  visceral  leishmaniasis,  incorporating 
innovative diagnostic procedures. 
•  To  assess aminosidine (paromycin) for the treatment of canine visceral  leishmaniasis. 
•  To  identify asymptomatic dogs and people and to determine whether such carriers can 
act as a  reservoir of infection. 
•  To  recommend  and  implement  improved  strategies  for  disease  control  based  on 
research  findings from  the programme. 
Activities 
*  Comprehensive  epidemiological  data will  be  assembled  from  the  records  held  at the 
Ministry of Health and the  University at Teresina.  A thorough comparison  of the  latest 
appropriate  technologies  for  the  diagnosis  of  canine  VL  will  be  undertaken  with  a 
minimum sample size of 1  00 dogs assembled at the Centre for Zoonoses. 
*  A colony of Lutzomyia longipalpis will  be established at the University of Teresina; flies 
will  be  infected  by feeding  on  dogs with  heavy skin  infections of  L.  chagasi and  the 
infections  will  be  transmitted  to  an  experimental  group  of  animal  imported  from  a 
non-endemic area. 
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*  The  chemiluminescent  probe  will  be  tested  for  its  ability  to  detect  L.  donovani  in 
experimentally infected and wild-caught Lu.  longipalpis, and compared with detection by 
microscopy.  A prototype  diagnostic field  kit  will  be  assembled. 
*  Using  dogs  with  moderately  severe  VL  (without  severe  wasting)  the  efficacy  of 
aminosidine treatment,  using various regimes,  will  be  investigated. The infection will  be 
monitored  using  sequential  bone  marrow and  skin  biopsy techniques. 
*  Improved serological techniques will  indicate potential asymptomatic human carriers of 
VL and  detailed epidemiological  information  on  suburban visceral  leishmaniasis will  be 
available  as  a  result  of  this  study.  This  epidemiological  analysis  will  be  used  to 
recommend  improved  methods for disease control. 
Expected outcome 
The  following  outcomes are  expected from  this  project: 
=> A detailed epidemiological description of visceral leishmaniasis will become available as 
a result of this  project. 
=> The chemiluminescent DNA Probe will  be  evaluated  in  the field,  and  aminosidine trials 
will  have  been  conducted  in  dogs. 
=> Conclusions be drawn on the transmissibility of the disease from asymptomatic carriers. 
=>  Recommendations  will  be  made  on  the  best  diagnostic  procedures  that  are  currently 
available and  on  improved  strategies for disease control. 
Results 
=>  Data assembled include:  incidence of human VL (1981  - 1994); incidence of human VL 
by age and  by sex;  suburban distribution of human VL.;  suburban distribution of canine 
seropositivity;  records of suburban and periurban sandfly species;  suburban distribution 
of insectivide spraying. 
=>Clinical, parasitological and serological diagnostic methods have been compared with  a 
cohort of more than  200  naturally infected dogs,  and  an  L.  donovani-complex specific 
DNA  probe  assessed.  A  DNA-based  diagnostic  kit  was  described.  An  L.  donovani 
complex specific colorimetric  (visual)  PCR  assay was developed. 
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=>The L.  donovani-complex specific probe was shown to be an  effective tool for detecting 
L.  chagasi infections  in  wild  caught sandflies. 
=>  L.  chagasi was highly transmissible from dog to dog by Lutzomyia longipalpis, infectivity 
to  sandflies was  compared  with  clinical  status. 
=>A cohort  of  dogs  infected  experimentally  by  sandfly  bite  was  established,  and  parasi-
tological  positivity,  serological  conversion  and  transmissibility of  infection followed. 
=> A  trial  of  aminosidine  for  treatment  of  canine  VL  was  performed:  clinical  recovery, 
limited  cure,  and  some  adverse  effects were  obtained. 
=>A combination  of  serology  and  a  gamma  interferon  capture  assay  detected  putative 
asymptomatic  VL  among  families  with  index  clinical  cases.  Carrier  status  is  under 
investigation  (in  collaboration  with  Dr.  Carlos  Henrique  Costa).  Distribution  of  selected 
human  genotypic markers within  the  study cohort have  been  determined (Oxford,  UK). 
Results  on  the  diagnosis  and  transmissibility  of  canine  VL  question  the  efficacy  of 
serological  surveys  and  killing  of  dogs as  efficient means  of  VL control. 
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RECOMBINANT ANTIGENS  AS  SEROLOGICAL TOOLS  FOR  SPECIFIC  AND  SENSI-
TIVE TERGUMENTARY AND VISCERAL LEISHMANIASIS DIAGNOSIS 
Period: 
Co-ordinator: 
Objectives 
April  1,  1993 - March 31,  1996 
UNIVERSIDAD PERUANA CAYETANO HEREDIA 
Lima,  Peru  (Y.  MONTOYA) 
To  develop  rapid,  sensitive  and  highly  specific  tests  based  upon  recombinant  peptide 
antigens for the improved diagnosis of Visceral leishmaniasis (VL) and American tegumen-
tary leishmaniasis (ATL) 
Activities 
•  Sera from  patients co-infected with VL and HIV were followed up by Western blot using 
L.(L) infantum total proteins as antigens and by ELISA using rK-39 recombinant protein. 
+ Construction  and  screening  of  L.(L.)  infantum eDNA libraries  using  sera from  patients 
co-infected  with  VUH  IV. 
•  Selection and characterisation of the candidate recombinant antigens for L.(L.) infantum 
and  L. (V:)  peruviana. 
•  Assessment of the  diagnostic potential  of two  candidate  L.(V:)  peruviana recombinant 
clones. 
+  DNA  sequencing  of  the  two  selected  L.(V:)  peruviana  recombinant  antigens,  their 
derived synthetic peptides and  the  parasite extract as  diagnostic reagents for ATL and 
VL were  compared. 
•  Identification and  selection of highly specific and  sensitive  L.(V:)  peruviana epitopes by 
using  synthetic  peptides. 
Outcome 
~  The  development  of  an  improved  sero-diagnostic  test  in  terms  of  greater  specificity, 
sensitivity and  predictive value over conventional  tests  using  recombinant  antigens. 
~One  PhD,  one  MSc and  four Licentiate of Biology thesis from  Peruvian  students were 
finished  as  part of this  project.  Likewise,  one  PhD  thesis from  Spain  will  be  obtained. 
Results 
Research  in  the  last  three  years  identified  two  extremely  prom1s1ng  L.(V:)  peruviana 
recombinant  proteins  referred  as  "T26-U2  plus  T26-U4"  which  were  recognised  by 
individual  sera from  ATL  patients  with  successful  results.  The  combined  sensitivity=87o/o, 
combined specificity=87°/o and the combined total predictive value=87o/o obtained is a good 
alternative to  diagnosis. 
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The regional coverage was assessed with eleven Colombian sera and the sensitivity found 
was  92°/o  suggesting that "T26-U2 plus T26-U4" could be  used successfully in  other Latin 
American  countries. 
"T26-U2  plus  T26-U4"  recombinant  clones  were  DNA  sequenced  and  their  predicted 
aminoacid  structure  allowed  us  to  design  L.(\1.)  peruviana  synthetic  peptides  containing 
8-cell epitopes. The use of these synthetic peptides improved the specificity (92o/o)  and the 
sensitivity  was  comparable  with  the  obtained  with  ''T26-U2  plus  T26-U4"  recombinant 
protein.  Furthermore,  we  included  a  small  panel  of sera  of VL  patients  from  Spain  and 
these  sera  reacted  with  the  L.(L.)  infantum  total  proteins  by  Western  blots.  Variable 
patterns of antigenic bands were found  during comparison  among sera from  patients that 
were  apparently cured  and  those who  had  relapsed. 
Likewise,  L.(L.)  infantum eDNA libraries were prepared and  after screening with  a pool  of 
sera from  VL patients co-infected  with  HIV,  identified fifteen  L.  (L.)  infantum recombinant 
eDNA  clones.  Their  expression  products  were  assessed  with  individual  sera  of  VUHIV 
patients with  satisfactory results. 
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CLONAL VARIABILITY OF THE PARASITE AS A PREDICTIVE TOOL FOR DIFFERENT 
CLINICAL  MANIFESTATIONS  IN  TEGUMENTARY  LEISHMANIASIS  OF  PERU  AND 
BOLIVIA 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1992 - September 30,  1996 
INSTITUT VOOR TROPISCHE GENEESKUNDE "PRINS 
LEOPOLD", LAB. OF PROTOZOOLOGY 
Anvers, Belgium (D.  LE  RAY) 
Identification  of  molecular  marker(s)  that  correlate(s)  with  mucosal  compromise  of  New 
World  Tegumentary  Leishmaniasis.  Afterwards,  they  may  be  used  to  assess  its  or their 
predictive value. 
+  To follow-up approximately 1  00-150 patients in  Peru and Bolivia from whom isolates will 
be  obtained for subsequent molecular analysis. 
+ To  develop new DNA oligonucleotides or specific probes to improve DNA heterogeneity 
analysis from  the  population  genetics point of view. 
+ To  build  up  clustering  patterns  of  Leishmania  isolates  by the  use  of  phenotypic  and 
genotypic markers. 
Activities 
Field  work studies: 
*  Patients  selection:  patients  will  qualify for the  study  if  they have  active  cutaneous  or 
mucocutaneous lesion with demonstration of parasite without previous specific therapy, 
and  if they attest their willingness to participate  in  the study. 
*  Patients  follow  up:  after  conventional  treatment  with  antimonial  pentavalents  patients 
will  be followed up for any evidence of mucosal compromise. The patients however will 
become aware that they should visit the health post at the first sign of mucosal distress 
or cutaneous lesion  relapse. 
*  Parasite  isolation:  by  cultivation  of  biopsy  or  aspirate  samples  from  patients  with 
cutaneous  and/or mucosal  lesions  before  chemotherapy,  and  from  cutaneous,  treated 
patients who will  develop mucosal  compromise during follow-up. 
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Laboratory work to  include: 
*  Isoenzyme analysis 
*  Random  Primer Amplification  Method  (RAPD) 
*  Schizodeme  analysis 
*  Karyotype  analysis of  Leishmania  by  PFG 
Data  analysis: 
*  Polymorphism obtained through the methodologies described above will  be analyzed in 
terms  of  population  and  evolutionary genetics. 
Expected outcome 
*  To  obtain  clustering  patterns  after  characterization  of  Leishmania  isolates  that  can 
answer the  question whether genetic markers can  be correlated with  clinical categories 
of  the  disease. 
*  To  obtain  new  DNA oligonucleotides or probes specific for parasites causing tegumen-
tary  leishmaniasis.  As  PCR  will  be  tried  for  diagnosis  under field  work  conditions,  we 
expect to simplify this  methodology. 
Results 
Field  activities  have  framed  the  endemic  survey  area  in  Bolivia  (lvirgarzama  Health 
District,  Cochabamba  Dpt)  while  in  Peru  a field  laboratory was  erected  at the  Pilocopata 
Health  Post  (Madre  de  Dios,  Cuzco)  and  equipped  for  in  vitro cultivation,  PCR  tests  and 
PC  data  processing.  One  hundred  and  sixty  seven  Leishmania  parasites,  all  with  well 
documented  clinical  records,  were  collected:  seventy-nine  from  Bolivia  and  eighty-eight 
from  Peru.  More  isolates were  obtained  from  cutaneous  lesions than  from  mucosal  ones 
(128  vs  39  respectively).  Part  of them  (40)  has  been  subjected  to  molecular analysis. 
For  molecular  karyotype  studies  (Belgium),  several  DNA  probes,  each  recognizing  a 
different  chromosome,  were  tested  for  polymorphic  karyotype  patterns.  Six  new  probes 
were isolated from  a cosmid library of L.  braziliensis (courtesy of D.G.  Barker,  Cambridge, 
UK),  they are candidate probes for future studies on  karyotype polymorphism of sympatric 
isolates from  the  study areas. 
From  a  phenetic  analysis  of  4  sets  of  chromosomes  in  Leishmania  peruviana  and  L. 
braziliensis, concordance between geographical and genetic patterns was evidenced and a 
North-South  populational  gradient  was  identified  for  L.  peruviana  along  the  Peruvian 
Andes.  Northern  L.  peruviana  were  closer  to  L.  braziliensis.  Specific  chromosomal 
size-differences  were  suggestive  of  chromosome  rearrangement  and  their possible  asso-
ciation with specific clinical forms was  identified as compatible with the working hypothesis 
subtending the  global  project. 
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Nucleotide sequence of the chromosomal probe pLb-134p corresponded to the gp63 gene, 
whose  product  has  been  associated  with  Leishmania  virulence  by  other authors.  Quanti-
tative and qualitative variation of gp63 genes was evidenced among Leishmania species of 
the  L.  braziliensis  complex.  This  conclusion  was  established  after  RFLP  analysis.  The 
particular organization of gp63  genes  led  to the development of a PCR-based  characteri-
zation  method.  Primers  to  amplify  the  most  informative  region  of  the  gp63  genes  have 
been  obtained,  and  evaluation  is  in  progress. 
With  the  chromosomal  probe  pLb-22,  the  nature  and  organization  of ribosomal  genes  in 
discrete  clusters  along  corresponding  chromosome  were  identified.  Primers  for  DNA 
amplification  of  ribosomal  DNA  were  developed.  They  amplified  either  the  intergenic 
sequence  (IGS)  or the  internal transcribed  sequences  (ITS).  Both  presented  polymorphic 
traits  in  the  studied  isolates. 
In  an  outbreak  in  the  Eastern  Andean  valleys,  both  L.  braziliensis  (sylvatic  cutaneo-
mucosal  leishmaniasis) and  L.  peruviana (Andean  cutaneous leishmaniasis) were  isolated 
in  sympatry and,  putative  hyvrids were  found. 
The  Montpelier  group  (France)  proceeded  to  multi-locus  enzyme  analysis.  (MLEE,  16 
polymorphic  loci)  of  30  isolates  from  Peru,  Bolivia  and  Ecuador.  RAPD  (with  6 different 
primers)  was  evaluated  on  50  isolates  in  parallel  to  MLEE.  Beside  discrimination  of  L. 
peruviana from  L.  braziliensis,  L.  guyanensis and L.  lainsoni were detected in  Peru for the 
first time. Genetic tests showed that leishmania! Andean populations along the  North-South 
transect  through  Peru  displayed  a geographical  structure  as  well  as  a  strong  departure 
from  panmixia in  the  central  area,  suggestive  of  clonality.  There  was  a highly  significant 
correlation  between  MLEE  and  RAPD  genetic  distances  and  - in  most  instances  but  for 
some  specific  locations  - both  MLEE  and  RAPD  did  corroborate  karyotype  data. 
Preliminary  results  showed  a  strong  linkage  disequilibrium  of  RAPD  data  in  natural 
populations.  Contradiction  with  karyotype  data was  observed  and  deserves further atten-
tion.  Clonality appears to  be  the  principal  reproduction  mode  in  Leishmania,  but  pseudo-
sexual  phenomena  might  be  present. 
Respective  prevalences  of  different  genetics  markers  in  parasites  isolated  from  mucosal 
and  cutaneous  patients  support  our  initial  hypothesis  that  there  is  a  genetic  basis  for 
virulence. 
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VISCERAL LEISHMANIASIS IN  THE  SUDAN:  AN  EPIDEMIOLOGICAL AND  ENTOMO-
LOGICAL STUDY 
Period: 
Co-ordinator: 
Objectives 
Epidemiology 
January 1,  1994 - December 31,  1996 
UNIVERSITY OF AMSTERDAM, ACADEMIC MEDICAL CENTRE, 
Amsterdam, The Netherlands (P.  KAGER) 
•  To  study the  epidemiology  in  an  endemic  area  of  VL in  eastern  Sudan,  including  the 
prevalence  of  clinical  and  subclinical  cases  and  complications  as  Post-Kala-Azar 
Dermal  Leishmaniasis. 
•  To  evaluate  the  performance  of  the  Direct Agglutination  Test  under field  conditions  in 
the  Sudan. 
•  To  evaluate  the  performance  of  new molecular biological  tools  in  the  diagnosis  of  VL 
and  during  follow-up. 
Entomology 
•  To determine the population dynamics of the vector and thus the time of the year when 
the  transmission  of  VL  takes  place.  To  describe  the  circadian  cycle  of  the  vector  to 
show the time of maximum  risk. 
•  To  investigate the  main  resting  sites of the sandfly vector. 
•  To  study the  host  preferences  of  the  vector to  indicate  putative  animal  reservoirs  of 
infection. 
Activities 
The  Sudan  has  by  far  the  most  important  leishmaniasis  problem  in  Africa.  A  major 
epidemic  is  taking  place  in  south  Sudan,  since  1988,  causing  thousands of deaths.  The 
clinical  course of infection and  epidemiology of Sudanese VL are  imperfectly known.  This 
proposal  addresses the following  questions: 
Epidemiology 
Sere-epidemiological surveys will be carried out during which the prevalence of clinical and 
subclinical cases and  Post-Kala-Azar Dermal  leishmaniasis will  be  assessed.  Some of the 
individuals have been previously exposed to  L.  major. The value of the Direct Agglutination 
Test  will  be  evaluated  under  field  conditions.  In  addition,  new  molecular  biological 
techniques  such  as  PCR  and  in  situ  hybridization  will  be  tested  in  diagnosis,  after 
treatment  as  test  of  cure  and  as  predictors  of  possible  relapse.  This  will  be  done  on 
aspirates of  lymph  node,  bone  marrow and  spleen  and  on  peripheral  blood. 
Entomology 
Population  dynamics of the  vector as  well  as  main  resting  sites  will  be  determined.  Host 
preferences of the  vector to  indicate putative animal  reservoirs will  be  studied. 
Several  components  of training  and  transfer of  technology  are  included  in  the  proposal. 
The  results  may  lead  to  the  design  of a control  programme. 
Results so far 
Epidemiology 
Yearly 2 surveys of the total  population  of 2 villages,  Urn  Salala and  Mushra Koka,  were 
done.  The  OAT  proved  a  useful  and  reliable  tool,  the  freeze  antigen  proved  to  be  an 
advantage. 
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This test does not differentiate  between  active or past infection  however and can  not be 
used as ''test of cure".  Within  a certain  epidemiological and clinical context, the DAT may 
replace  invasive  diagnostic  procedures.  Lymph  node  aspiration  is  a  reliable  diagnostic 
procedure for VL with  few complications. 
PCR  on  lymph  node  material  proved  very  valuable,  in  peripheral  blood  the  PCR  was 
positive in  about 79o/o  of VL patients.  In  PKDL patients PCR was a useful method both on 
materials from  the skin and from  lymph  nodes.  Whether PCR  (in  relation to LST reaction 
and  DAT,  or not)  can  be  helpful  in  prediction  relapse,  development  of  PKDL or cure  is 
bering analyzed.  Laboratory work and analyses are  ongoing. 
Entomology 
Field  studies  were  done  in  and  around  villages  and  in  adjacent  Dinder  National  Park 
where visceral leishmaniasis occurs in  the game wardens.  Very few sandflies were caught 
in  the village,  1  00 times more in  the forest in  the park.  P.  orienta/is,  a proved vector,  was 
caught in termite hills. A colony of P.  orientalis was established, but unfortunately lost when 
the team  was working  in  the field. 
Preliminary  studies  of  host  preference  of  P.  orienta/is  did  not  indicate  a  preference  of 
Arvicanthis niloticus,  a  common  rodent  that  could  possibly  be  a  reservoir  animal  (in  the 
park a zoonotic situation is suggested, in and around the villages man to man transmission 
is  likely). 
The  biology of  P.  orienta/is  in  this  area of Sudan  appears  to  differ from  the  situation  in 
Upper Nile  Province,  where  intensive  studies of this sandfly were  performed  some thirty 
years ago. 
Work and analysis are ongoing. 
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MOLECULAR  TECHNIQUES  FOR  VECTOR  AND  PARASITE  IDENTIFICATION  AP-
PLIED TO  A  PILOT VECTOR  CONTROL STUDY OF LEISHMANIASIS 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1994 - December 31 , 1996 
UNIVERSITY OF KEELE,  DEPARTMENT OF BIOLOGICAL 
SCIENCES, Staffordshire, United Kingdom (R.D.C.  MAINGON) 
Leishmaniasis,  a rural  and  periurban  disease of high  morbidity and  prevalence  in  tropical 
areas and  in  the  Mediterranean,  is  transmitted by a variety of sandfly species.  Generally, 
due to outdoor transmission,  vector control  is  of limited value in  diminishing the  incidence 
of  leishmaniasis  except  in  those  instances  where  transmission  is  predominantly  inside 
houses. 
The  overall  goal  is  to  use  previously established  molecular techniques to  investigate the 
potential  preventive  value  of  permethrin-impregnated  curtains  from  reducing  manbiting 
rates  in  a pilot control study in  a selected highly endemic focus of cutaneous  leishmania-
sis.  The present study is  a pre-requisite for further intervention vector control trials aimed 
at  reducing  the  incidence of the disease  in  areas of domestic transmission. 
Specific objectives 
•  To  determine the vectorial capacity of anthropophilic sandfly species in  two ecologically 
different regions  (Lara and  Miranda states). 
•  To  gather epidemiological information in  the Guayamure/Rio Claro of Lara and Miranda 
state  using  molecular techniques combined  with  classical  field  methods. 
•  To  evaluate the efficacy of permethrin-impregnated curtains against endophilic phlebot-
omine sandflies with  respect to a reduction of biting rates in  a highly endemic pilot area 
in  Lara  state  and  Miranda states. 
Activities 
Extensive field work indicated a high  level of endophilic transmission of cutaneous disease 
in  El  lngenio,  Miranda State and  to  a lesser extent  in  Guayamure and  Rio  Claro villages 
in  Lara State, Venezuela.  El  lngenio village consists of 54 houses with a population of 254 
inhabitants of predominant agricultural  occupation. 
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This  and  other features  such  as  high  prevalence  of  cutaneous  cases,  long  term  surveil-
lance  of  these  villages  made  them  suitable  to  investigate  the  efficacy  of  insecticide-
impregnated  curtains  in  reducing  intra-domiciliary sandfly number and  their biting  rates. 
This  project  is  in  its  third  year.  During  the  first  year  of  the  project  the  entomological 
analysis  of  the  densities  and  sandfly  species  inside  vs  outside  house  in  El  lngenio 
provided the base line data for selecting the study and control houses for a pre-pilot vector 
control trial. This aimed to gain an  insight into the relative value of all variables involved in 
an  effective  trial.  This  preliminary  trial  took  place  at  the  end  of  the  first  year  between 
November  1994  and  April  1995.  Deltamethrin  at  a dose  of  15  mg/m
2  was  used  to  soak 
curtains  (6mm  mesh  size). 
During  the  second  year of  the  project,  a number of  issues  related  to  the  El-lngenio trial 
have  been  examined  to  identify specifically the  cause(s)  for the  apparent  lack  of  vector 
control: 
*  Sandfly trapping  methods  used  for monitoring the  trial. 
*  Variables affecting sandfly susceptibility to  a number of insecticides such as  insecticide 
source  and  concentration  and  curtain  fabrics  and  curtain  mesh  size. 
*  Changes  in  the  local  sandfly population  density and/or sandfly behavior. 
*  Changes  in  the  community  behavior particularly of those  people  living  in  the  selected 
houses. 
Results 
Progress towards the  specific objectives of the  original  proposal  is  summarized  below: 
=>The  vectorial  capacity  of  anthropophilic  sandflies  in  El  lngenio  and  Altragracia  de 
Orituco (Northcentral Venezuela)  has  been  partially elucidated.  Since dissection to find 
out natural infection rates is currently being carried out,  it will be important to implement 
the  PCR  technique  with  pooled  sandflies  (of  a  given  species,  i.e.  ovallesi  with  Le. 
braziliensis specific  primers,  MpL 1 and  MP3H). 
=>Epidemiological  information  in  the  Rio  Claro  and  Guayamure  foci  of  Lara  and  in 
Altragracia  de  Orituco  (Guarico  State)  and  El  lngenio  (Miranda  State)  has  used 
classical  and  molecular  techniques  except  in  the  Northern  region.  Implementation  of 
human  DNA detection  by  PCR  in  sandfly bloodmeals would  enhance  the  sensitivity of 
ELISA detection. 
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For  evaluating  the  efficacy  of permethrin-impregnated  materials  against endophillic  sand-
flies  a  second  three-way  trial  is  required  comparing  both  vector  control  methods: 
insecticide-impregnated curtains with  insecticide wall  spraying inside houses in  El-lngenio. 
Due to weather pattern changes there has been very reduced number of sandflies in  both 
places  throughout  1995.  The  three-way  trial  is  scheduled  to  take  place  as  soon  as  the 
sandfly density increases. 
An  intensive course in  molecular entomology organized by Dr.  Maingon in  Maracay during 
April  22  - May  6 funded  by  WHO-PAHO  was  very  well  received  by  the  Latin  American 
students  on  the  Maracay  based  M  Ses  on  Medical  Entomology.  Agricultural  Pests  and 
Public  Health.  The  course  consisted  of  1  0 lectures  of  2h  each  followed  by  practicals  5h 
each.  Topics  comprised  DNA  probes,  species-specific  PCR,  RAPD-PCR,  insecticide 
resistance  mechanisms,  immunity  in  insects,  the  molecular  biology  of  parasite-insect 
interactions.  A  manual  in  Spanish  of  Protocols  in  Molecular  Entomology  was  produced .. 
Also  in  Spanish,  a  practical  manual  on  sampling  and  mounting  sandflies  has  been 
produced for field workers by  Drs.  M.  Maroli and  Feliciangeli. Two  PhD  studentships (one 
British  and  one  Venezuelan)  are  sponsored  by  this  project. 
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COMPARATIVE  EVALUATION  OF  CLASSICAL AND  MOLECULAR  TOOLS  FOR  THE 
DIAGNOSIS AND  FOR  ECO-EPIDEMIOLOGICAL INVESTIGATIONS  OF  LEISHMANIA-
SIS 
Period:  October 1, 1993- September 30,  1996 
Co-ordinator:  INSTITUT PASTEUR DE TUNIS 
Tunis Belvedere, Tunisia (R.  BEN-ISMAEL) 
Objectives 
•  To  develop  a  DNA  probe  specific  for  Leishmania  infantum;  to  measure  its  general 
efficiency for diagnosis of human  and canine leishmaniasis (in  particular during disease 
development in the dog),  using the dot blot technique; to evaluate the results with those 
obtained  by  non-molecular,  classical  methods. 
•  o  evaluate  the  comparative  sensitivities  and  specificities  of  kDNA  probes  for  the 
identification  of  L.  infantum. 
•  To  measure  cytokine  production  by  PBMC  in  response  to  parasite  antigen  to  under-
stand  the TH1  versus TH2  balance  in  clinical  groups as  a function  of age. 
•  To  measure  the  intrinsic  validity  and  extrinsic  validity  parameters  for  DNA  probes 
specific  for  Leishmania  major,  as  used  in  the  dot  blot  technique  for  the  diagnosis  of 
zoonotic  cutaneous  leishmaniasis  in  man;  and,  to  compare  the  results  with  the 
estimates  of  these  parameters  for  classical  techniques  (direct  examination,  culture, 
inoculation  of  animals,  serology) 
•  To evaluate squash blotting,  ELISA and classical dissection techniques for the detection 
of  Leishmania  in  the  phlebotomine  vector,  for  the  pairs  Phlebotomus  papatasi/ 
Leishmania major,  P.  perniciosus/  Leishmania infantum and P.  perfiliewi/L.  infantum. 
Activities 
Phlebotomine  sandflies  necessary  for  the  various  molecular  tasks  were  successfully 
collected  from  different regions  of Tunisia. 
For the  evaluation of the  sensitivity and  specificity of probes for dot-blotted promastigotes 
of  L.  infantum  3E9/Haelll-12  and  388/Haelll-2,  the  two  mini-circle  kinetoplast  (k)  DNA 
probes  were  tested  using  49  promastigote  preparations,  including  7  different  species  of 
Leishmania  and  Sauroleishmania  tarentolae originating  from  several  Old  World  countries. 
Promastigotes  were  cultured  in  RPMI  medium  with  foetal  calf  serum.  Serial  dilutions  of 
1  0
6
,  1  0
5
,  1  0
4  and  1  0
3  promastigotes  were  applied  to  replicate  nylon  DNA  transfer 
membranes  using  a vacuum  blot apparatus. 
For  the  evaluation  of  the  diagnostic  potential  of  probes  specific  for  L.  infantum  infecting 
man  and  dog  and  comparison  with  classical  techniques  samples  were  collected  from  32 
human  cases  and  152 dogs. 
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In a basic health care centre in the Sidi Bouzid focus,  54 patients were selected as having 
ZCL  on  a clinical  basis  (epidemiological  context,  clinical  presentation  and  site  of  lesion, 
duration  of  lesion  for  more  than  3  weeks,  inefficacy  of  antibiotics).  The  patient  sample 
constituted 25  males  (43°/o)  and  29 females  (57°/o)  varying  in  age from  2 to  81  years old. 
The  number  of  lesions  per  patient  varied  from  1 to  11  (average  =  3).  30  patients  had 
already started  a course  of Glucantime treatment. 
Samples  were  taken  from  each  lesion  for 
*  A direct dermal smear on  a microscope slide was colored by the  May-Gunwald-Giemsa 
technique  and  read  with  an  optic  microscope at x1 000  magnification  (54  patients). 
*  A  culture  was  made  in  NNN  medium  with  Penicillin  G  (800  U/ml  rabbit  blood  and 
Streptomycin  (500mg/ml  rabbit blood)  (49  patients). 
*  3 to 6 drops of dermal fluid (ca.  5ml each) were spotted on to a Genescreen Plus nylon 
DNA  transfer  membrane;  after the  normal  denaturation  and  neutralization  processes, 
each membrane was treated with proteinase K (1 00 mg/ml in  0.1 M Tris-HCI  pH 7.5) for 
1 hour at  37°C  (54  patients). 
*  Dermal  fluid  was  inoculated  in  to  the  hind  footpads  of a Balb/c  mouse. 
*  A blood  sample was  taken  for  ELISA and  IFAT tests. 
Results 
In  general,  serological  tests  were  the  most  sensitive  (73°/o  for  IFAT,  94.6°/o
0/o  for  ELISA), 
followed  by  the  Balb/c  inoculation  (48.2°/o). 
=>  Balb/c  mice  (MI):  the  lesions appeared from  4 to  9 weeks  (max 67  days). 
=>  NNN  cultures  (C):  12  were  positive within  the  first week and  3 in  the  second  week of 
subcloning.  Only  one  of  the  samples  giving  a positive  culture  was  negative  in  Balb/c 
mice. 
=>  Direct  smear  (DS):  of .the  26  samples  positive  in  Balb/c  mice  only  12  (46.15°/o)  were 
also positive by direct smear,  but 4 smears were positive when  the  Balb/c results were 
negative. 
=>  ELISA: soluble antigens were prepared by the classical technique from a Tunisian strain 
of  L.  major  (MPSA!TN/86/RON44;  zymodeme  MON-25/LON-1)  and  uses  at  1/500 
dilution;  sera were  diluted  at  1/1 00;  positive and  negative controls were  used  on  each 
ELISA plate;  spectrophotometry  reading  was  at  420  nm. 
=>  IFAT:  the  same  strain  of  L.  major was  used;  sera  were  diluted  1/50  in  PBS,  and  the 
fixed  antibodies were  revealed  with  anti-human  antiglobulins labeled  with  fluorescein. 
=>  Dot  blots:  samples  from  54  patients  were  hybridized  with  the  85  bp  universal  probe 
(SU),  the  450  bp  Taql  probe  (Taql)  and  the  250  bp  Avail  probe  (Avail)  (see  section 
8.2.2 of  first technical  report).  Autoradiographic  exposure was  set at one  week for the 
first  two  probes  and  two  weeks  for  the  third  probe.  The  presence  of  Leishmania 
parasites in the samples was confirmed by at least one direct test. The variable number 
of dot-blot samples (3-6) made for each lesion was shown to be adequate, even though 
the  intensity  of  the  autoradiographic  signal  varied  both  within  and  among  lesion 
samples. 
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However,  only  some  of  the  patients'  lesions  had  demonstrable  parasites,  and  so  the 
evaluation of the various indirect techniques can  be  better estimated after selection of the 
positive  patient  sample.  This  "gold  standard"  was  the  positivity  demonstrated  by  at  least 
one  of the three classical techniques that allow visualization of the parasite,  namely direct 
smear,  culture  and  Balb/c  inoculation.  The  gold-standard  sample  is  constituted  by  30 
patients among the total  of 54.  For this sample the  dot blot sensitivity was  46. 7o/o  (14/30) 
or  40.0o/o  (12/30)  depending  on  the  probe.  The  24  patients  not showing  any parasites  in 
their  lesions,  when  assessed  by  the  three  gold-standard  tests,  constituted  the  negative 
control sample that permitted calculation of the specificity of each of the indirect tests. The 
specificity was  100o/o  for all  techniques  except for  ELISA and  IFAT. 
Probe  3E9/Haelll-12  (=  3E9)  can  be  considered  as  an  excellent  tool  for  the  specific 
identification  of  L.  infantum in  Tunisia  (and  in  the  Mediterranean  Basin  in  the  absence  of 
L.  donovant)  when  1  0
5  or  fewer  promastigotes  are  used:  then,  both  the  specificity  and 
predictive value of the positive result were  1  00°/o.  As  with  most diagnostic tools,  there is a 
trade-off  between  specificity  and  sensitivity,  with  a  loading  of  1  05  promastigotes  being 
optimal. 
Probe 388/Haelll-2 (=388) was assessed to  be  less efficient than 3E9,  its sensitivity being 
one  order less  and  the  predictive value  of a negative  result  never reaching  1  00%. 
Achievements 
Measurement of the  intrinsic validity parameters for DNA probes  specific for  L.  major,  as 
used  in  the  dot  blot  technique  for the  diagnosis  of ZCL  in  ·man,  and  comparison  of  the 
results with the estimates of these parameters for classical techniques (direct examination, 
culture,  inoculation  of animals,  serology). 
Using the  KDNA probes previously isolated,  the dot-blot DNA test was  shown  to  be  100% 
specific,  as  were  the  three  direct visualization  tests  (direct smear,  Balb/c  mouse  inocula-
tion,  NNN  culture).  The  serological  tests  (IFAT,  ELISA)  showed  significantly lower specifi-
city  but  higher  sensitivity.  Inoculation  of  Balb/c  mice  proved  to  be  the  test  with  highest 
"global  efficiency".  The  dot blot test  is,  therefore,  a useful  addition  to  the  battery of  tests 
now available for diagnosis of ZCL due to  L.  major,  performing as well  as all  tests except 
inoculation  of  Balb/c  mice  and,  unlike the  serological  tests  used,  having  1  OOo/o  predictive 
value  of a positive  result. 
Confirmation  was  obtained  of  the  diagnostic value  of a ribosomal  IGS  DNA probe for the 
identification  in  different  regions  of  Tunisia  of  P.  papatasi,  the  only  known  vector  of  L. 
major in  north  Africa.  Development  was  started  of  DNA  probes  specific  for  the  most 
abundant and  widespread Tunisian vectors of  L.  infantum:  restriction  mapping,  subcloning 
and  sequencing  permitted  the  identification  of  DNA  fragments  and  internal  repeat  se-
quences that showed  marked  specificity for  P.  perniciosus and  P.  perfiliewi. 
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ANALYSIS OF PHOSPHOFRUCTOKINASE AND PYRUVATE KINASE OF LEISHMANIA, 
POTENTIAL TARGETS  FOR  NEW DRUGS 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1994 - December 31 , 1997 
ICP,  RESEARCH UNIT FOR TROPICAL DISEASES 
Brussels, Belgium (P.  MICHELS) 
To  contribute  to  the  development  of  new  drugs  against  leishmaniasis,  by  a  rational 
approach. Enzymes playing a key role in the metabolism of the parasite will be selected as 
targets  for  new  drugs.  The  target  enzymes  of the  parasite  will  be  studied  in  very  great 
detail, to search for structural  and  kinetic differences with  the enzymes of the mammalian 
host.  Selective  inhibitors  will  be  designed  that  exploit  these  differences.  Such  inhibitors 
might be  used  as  lead  compounds for drug  development. 
Activities 
Glycolytic enzymes were  chosen  as  targets for drugs to  be  designed,  because glycolysis 
plays an  essential  role  in  the  energy and  carbohydrate metabolism  of Leishmania.  Phos-
phofructokinase (PFK) and pyruvate kinase (PYK),  key enzymes of the glycolytic pathway, 
are  promising  candidates  for  selective  inhibition,  because  the  parasite's  enzymes  have 
some unique structural and regulatory properties. The genes will  be  characterized. Subse-
quently, the proteins will  be overexpressed in  E.  coli,  purified and used for detailed kinetic 
studies.  The  primary  structure  of  Leishmania  PFK  and  PYK  will  be  modelled  into  a 
three-dimensional  structure,  using  the  available crystal  structure  of homologous  proteins. 
Detailed  information  about  enzyme-ligand  interaction  will  be  obtained  by  combining  the 
results of the kinetic analysis, binding assays and molecular modelling. From this information 
hypotheses will  be constructed as to how unique (sub)domains in  the  Leishmania proteins 
could be involved in specific kinetic features. The hypotheses will be tested by site-directed 
mutagenesis and subsequent analysis of the  mutated proteins. Those domains conferring 
unique  kinetic  features  to  the  proteins  will  be  used  for designing  selective  inhibitors that 
could be used as lead compounds for the development of chemotherapeutic agents. 
In  parallel  with  the  above  described  studies,  the  bacterially-overproduced  PFK  and  PYK 
will  be  used  in  crystallization  trials.  If good  crystals can  be  obtained,  they will  provide  us 
with  the  most accurate information about the three-dimensional  structure of the  enzymes. 
Results 
Phosphofructokinase 
The  initial  analysis  of  PFK  was  performed  using  the  enzyme  of  Trypanosoma  brucei,  an 
organism  closely  related  to  Leishmania,  because  the  trypanosome  enzyme  was  already 
available in purified form before the start of the project. Amino-acid sequences of some peptide 
fragments from the purified PFK were determined and used to select degenerate oligonucle-
otides, for amplification of a PFK gene segment by PCR. Subsequently, this amplified segment 
was  used  to  identify  clones  containing  PFK  genes  in  genomic  libraries  of  T.  brucei,  L. 
mexicana, L.  donovani and  L.  major. Sequence determination of the Leishmania gene is in 
progress, whereas the Trypanosome PFK gene characterization has been completed. 
The  Trypanosome  PFK  appears  to  be  very  different  from  the  human  enzyme  (20o/o 
amino-acid  identity),  reinforcing  the notion that his  enzyme  is  a promising target for drug 
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design. Very striking is the observation that this AlP-dependent PFK of the Trypanosoma-
tidae is  more related to the PPi-dependent PFKs of anaerobic protests and bacteria (up to 
40o/o  identity) than to  any other AlP-dependent enzyme.  The enzyme has now also been 
purified from  L.  mexicana promastigotes,  and  will  be  used for kinetic analysis. 
Pyruvate kinase 
The PYK gene of L. mexicana has been cloned and characterized. The encoded polypeptide 
has about 50°/o amino-acid sequence identity with its mammalian homologue. The Leishma-
nia enzyme has been over-expressed in  Escherichia coli and purified from the bacteria. The 
enzyme has also been purified from  L.  mexicana promastigotes. The bacterially expressed 
enzyme appeared to differ from the natural protein in two respects: the value of some kinetic 
parameters was significantly different and the  isoelectric point of the two proteins have a 
value of 5.90 and 5. 75,  respectively. These differences are attributed to phosphorylation of 
the promastigote  PYK.  Such phosphorylation could play an  important physiological  role  in 
the activity regulating of the enzyme. This is currently under investigation. 
Considerable efforts  have  been  made to  crystallize the  Leishmania PYK expressed  in  E. 
coli.  Crystals have been  obtained,  but their size and quality remain  to be  improved before 
the  enzyme's  structure  could  be  solved.  Currently,  mutants  are  being  prepared  in  an 
attempt to produce a more  rigid  enzyme to  aid  its crystallization. 
Based on the amino-acid sequence of both the  L.  mexicana PYK and the related  T.  brucei 
enzyme,  models have been  made of their three-dimensional structure,  using the available 
X-ray  coordinates  of two  mammalian  muscle  PYKs.  In  these  models,  a  pocket  could  be 
identified  possibly  containing  the  binding  site  of  fructose  2,  6-bisphosphate,  a  potent 
allosteric effector,  specific for the trypanosome. This site  is a potential target for selective 
drugs  and  is  being  studied  further  by  site-directed  mutagenesis.  Indeed,  some  mutants 
have been obtained in which the affinity for fructose bisphosphates, and their effect on the 
activity of the  enzyme was affected. Additional  mutants are being  made to  obtain  further 
information  about  the  hypothetical  effector  site  and  to  determine  which  residues  are 
essential  for the observed  allosteric effects. 
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DISSECTION OF THE MECHANISMS LEADING TO THE SELECTIVE TRIGGERING OF 
PROTECTIVE  AND  NON  PROTECTIVE  MURINE  T-CELL  RESPONSES  FOLLOWING 
INFECTION WITH LEISHMANIA: RELEVANCE FOR THE INDUCTION AND DETECTION 
OF HUMAN  PROTECTIVE  IMMUNITY 
Period: 
Co-ordinator: 
Objectives 
January 1,  1995 - December 31,  1997 
INSTITUT PASTEUR, UNITE D'IMMUNOPHYSIOLOGIE 
CELLULAIRE, Paris,  France (G.  MILON) 
To  define  the  early  priming  conditions  that  may  commit  naive/virgin  T-cell  populations 
within  lymphoid  organs  draining  Leishmania-loaded  sites  to  produce  a  given  set  of 
cytokines  upon  subsequent reactivation  in  the  non  lymphoid  parasite-loaded tissues such 
as the dermis. The terms of priming conditions refer to different cellular components:  mast 
cells,  mononuclear  phagocytes,  dendritic  leucocytes  (mast  cells,  NK  leucocytes,  neu-
trophils,  eosinophils,  either  infected  or  loaded  with  parasite  extracts  as  sources  of/or 
exposed  to  priming  cytokines  such  as  IL4,  IL 12,  IFNy;  IN Fa  later  named  "polarizing 
cytokines". 
To  specify the  relative  contribution  of the  different  cells  (a)  able  to  process  and  present 
parasite-derived  peptides  to  naive  T-cells,  i.e.  dissect  the  roles  of  infected  mononuclear 
phagocytes  versus  dendritic leucocytes,  and  (b)  able  to  release  a given  set of  polarizing 
cytokines. If a peculiar combination of cytokines and antigen-presenting cells is recognized 
as critical,  a logical consequence is to ask whether such  priming conditions will  be  rapidly 
set in  motion in  vivo,  in  both the skin site of infection and draining lymph nodes depending 
upon the genetically dependent ability of mice to control  (resistance) or not (susceptibility) 
the parasitic/pathogenic processes initiated by Leishmania spp.  (L.  major,  L.  brazillensis, L. 
panamensis). 
To  define more relevant correlates of a protective versus non  protective immune response 
within a very well studied polymorphic human  population exposed to Leishmania brazilien-
sis,  L.  panamensis while  extending  the  training  of  scientists  in  the  domain  of  endemic 
human  leishmaniasis/asymptomatic parasitic processes. 
Activities 
To  pursue  in  vitro studies  using  naive/virgin  and  experienced  mouse or human T-cells to 
specify the priming/reactivation conditions that determine whether T cells will  produce IL4, 
IL 10,  IL 13  or  interferon  y  (IFNy)  upon  subsequent  rechallenge,  namely  cytokines  which 
deactivate mononuclear phagocytes rendering them permissive to  Leishmania spp.  growth 
(IL4,  IL 10,  IL 13)  or  which  activate  mononuclear  phagocytes  rendering  them  no  more 
permissive to  Leishmania spp.  growth  (IFNy). 
270 Contract number ERBTS3*CT940319 
To  pursue  in  vivo  studies  in  conditions  allowing  access  to  both  the  Leishmania-loaded 
dermis and draining lymph nodes: (ears of mice are optimal sites to inject Leishmania spp. 
and from  which to recover all the cells presently thought to be directly or indirectly critical 
for T  cell  priming,  polarization  and  for T  cell  reactivation  namely  in  addition  to  dendritic 
leucocytes,  mononuclear  phagocytic  leucocytes  and  Natural  Killer  cells,  mast  cells, 
neutrophils,  eosinophils,  keratinocytes). 
Expected outcome 
A better understanding of the T-cell priming and reactivation conditions set in motion within 
clinically/epidemiologically defined susceptible and resistant human populations exposed to 
Leishmania spp.  The Brazilian and Colombian teams have studied for several years areas 
where humans are continuously exposed to Leishmania. These areas are unique places to 
study the  influence ofT-cell responses on  outcome of the parasitic process toward either 
and  asymptomatic process or a disease of variable severity. 
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DEVELOPMENT AND  IMMUNOLOGICAL EVALUATION  OF A VACCINE  FOR  CANINE 
VISCERAL LEISHMANIASIS 
Period: 
Co-ordinator: 
Objectives 
January 1, 1996- December 31,  1998 
ROYAL TROPICAL INSTITUTE, DEPT OF BIOMEDICAL RESEARCH 
Amsterdam, The Netherlands (L.  OSKAM) 
•  Purif  ication  of  a  defined  parasite  antigen,  dp72,  for  use  in  laboratory  vaccine  trials 
against canine leishmaniasis. 
•  Development  of  molecular  biological  methods,  specifically  reverse  transcriptase  -
polymerase chain reaction (RT-PCR), to measure cytokine responses,  lnterleukin (IL) 4, 
-10,  Tumor  necrosis  factor-a  (TN F-a)  and  lnterferon-y  (INF-y),  in  vaccinated  dogs 
following  infection. 
•  Examination of Th1  and Th2 responses to vaccine antigens in  the experimental  model 
for canine leishmaniasis. 
•  Identification of a suitable site in Western Turkey where a vaccine field can be carried out. 
Activities 
*  Rever  se  transcriptase  polymerase  chain  reactions  (RP-PCR)  for  the  detection  in 
canine  peripheral  blood  mononuclear  cells  (PMBC)  of  lymphokines  known  to  be 
important in  protective and  exacerbating  responses to  Leishmania  infections.  This will 
include the measurement of  11-4,  IL-10, TNF-a and IFN-y.  PMBC will  be developed by 
standard  Ficoii-Hypaque technique  using  whole  dog blood  and  mANA isolated  by the 
guanidinium/silica method. 
*  The  antigen  dp72  from  L.  d.  infantum  will  be  produced  for  use  in  vaccination  and 
immunological  studies  in  dogs.  Enough  protein  to  vaccinate  about  25  dogs  (approxi-
mately  900  J..tg)  will  be  purified.  The  protein  dp72  will  be  purified  from  a  crude 
membrane fraction of L.d.  infantum (LV9)  by affinity chromatography with a monoclonal 
antibody (mAb)  D13 against the antigen. 
*  Protection  studies  in  an  experimental  model for canine visceral  leishmaniasis. 
*  In  parallel,  dogs  with  clinical  VL  will  be  identified  in  the  field  by  positive  serological 
diagnosis  and  tissue  biopsies  or cultures.  Th 1  and Th2  T-cell  lymphokine  expression 
will  be  examined  by  RT-PCR  following  antigen-specific  and  mitogen  stimulation  of 
PMBL  taken  from  these  dogs.  This  will  be  compared  with  the  vaccinated  dogs  as 
described above. 
*  Field  sites will  be  identified for vaccines trials. The prevalence of canine leishmaniasis 
will  be  examined  longitudinally in  all  the  potential  field  test sites,  as described above, 
during  the  period  preceding  the  vaccine  trial.  In  addition,  a  survey  of  the  human 
population in  these areas will be carried out and includes a medical check-up, the DAT 
and leismanin skin test. This will be used to evaluate the immune status of the dog and 
human populations at the field  trial  site. 
Results 
Attempts  to  develop  an  IL-4  RT-PCR  based  on  sequence  information  from  other  IL-4s 
have  not been  successful.  We have postponed  I  L  -4  detection for the assessment of T  H2 
response,  and  continued  with  IL-10  RT-PCR  for  monitoring  T  H2  response.  We  have 
developed a competitive RT-PCR using in  vitro internal control (IC)  mANA which  is added 
to the sample in  order to be able to  quantify the  amount of RNA present in  the  sample. 
Peripheral  blood  mononuclear cells  (PBMC)  from  several  dogs  were  tested  in  this  way: 
one dog was parasitological positive for VL,  two dogs were asymptomatic but serologically 
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positive and  one dog was  parasitologically and  clinically negative at time of sampling but 
became symptomatic over time. 
PBMCs were incubated either in the absence of antigen or in the presence of Leishmania 
LV9  antigen or ConA. Ten-fold serial dilutions of IC-RNA were added to the  RNA isolates. 
In  general, pPBMCs which  have been stimulated with either LV9  antigen or Con1  showed 
a  rise  in  the  production  of  IFN-y;  no  significant differences could  be  observed  for  IM-10 
and TNF-a mANA levels. 
Dogs  were  vaccinated  with  Leishmania  antigen  dp72  plus  BCG  as  an  adjuvant.  As 
negative controls they used dogs vaccinated with  BCG  or saline or nothing at all.  PBMCs 
from  these  dogs  were  isolated  at  five  different  time  points  before,  during  and  after 
vaccination. These samples were stimulated with nothing (negative control), ConA (positive 
control)  or different amounts of antigen. 
Preliminary experiments indicate that,  in  a qualitative RT-PCR  using  J3-actin,  IL-10, TNF-a 
and  IFN-y primers, the only significant difference that could be  observed was an  increase 
in  IFN-y levels  upon  stimulation  with  ConA.  Further quantitation  revealed  a  100- to  400-
fold  increase  in  I  FN-y levels.  However,  J3-actin  levels were  also  increased  up  to  1  00-fold 
after stimulation  wit  ConA. 
We  are  presently testing  more  samples and  working  on  the  interpretation  of the  data. 
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CHARACTERISATION  OF  PHOSPHOFRUCTOKINASE  AND  PYRUVATE  KINASE  OF 
LEISHMANIA. POTENTIAL TARGETS  FOR  NEW DRUGS. 
Period: 
Co-ordinator: 
Objectives 
November 1,  1996 - August 31,  1998 
INTERNATIONAL INSTITUTE OF CELLULAR AND MOLECULAR 
PATHOLOGY (ICP) 
Brussels, Belgium (P.  MICHELS) 
+ To  study the  structure and  kinetics  of phosphofructokinase  (PFK)  and  pyruvate  kinase 
(PYK)  of Leishmania,  key enzymes in the metabolism of the parasite, and to determine 
differences with  the corresponding  mammalian  enzymes. 
•  To  design  and  synthesize  selective  inhibitors  of  the  Leishmania  enzymes,  based  on 
their differences with  the  mammallian  enzymes. 
Activities 
*  Cloning and  sequence determination  of the  Leishmania PFK and  PYK genes. 
*  Overexpression  of  the  Leishmania  enzymes  in  bacteria  (Escherichia  coli)  or  yeast 
(Hansenula polymorpha). 
*  Purification  of the  recombinant  enzymes. 
*  Kinetic  analysis of the  purified  enzymes. 
*  Structure  modelling  of  the  Leishmania  enzymes,  using  the  X-ray  coordinates  of  the 
crystal  structures of homologous enzymes. 
*  Structure-function  analysis  of  residues  potentially  important  for  inhibitor  design  by 
site-directed  mutagenesis. 
*  Crystallization  trials of recombinant  Leishmania PFK and  PYK. 
*  Synthesis of potentially selective  inhibitors of Leishmania PFK  and  PYK. 
Expected outcome 
=>The primary structure of  Leishmania PFK and  PYK  will  become available. 
=>The enzymes will  be  overexpressed  in  a heterologous system  and  purified. 
=>  Kine~ic parameters of the  enzymes will  be  established. 
=>  Preliminary information  on  the  structure of the  enzymes will  become available. 
=>Compounds with  (some)  inhibitory activity on  the  Leishmania enzymes will  be  synthe-
sized. 
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ANTILEISHMANIAL  AND  ANTITRYPANOSOMAL  ACTIVITIES  OF  ALKYL-LYSOPHO-
SPHOLIPIDS 
Period: 
Co-ordinator: 
Objectives 
1 October 1996 - 30 September 1999 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, 
London,  United Kingdom (S.L. CROFT) 
•  To  determine  the  mechanisms  of  action  of  alkyllysophospholipids  (ALPs)  against 
Leishmania and  Trypanosoma  cruzi,  including  effects on  the  host immune  response 
•  To  identify novel  biochemical  and  molecular targets  in  Leishmania and  Trypanosoma 
•  To  establish ALP  resistant clones and  identify mechanisms of resistance 
•  To  define  interspecies and  interstrain variation  in  sensitivity to ALPs 
•  To  define  a  structure-activity  relationship  of  the  antileishmanial  and  antitrypanosomal 
activities of ALPs as they represent a new selective model for further antiprotozoal drug 
development 
•  To  define  rational  drug  combinations to  be  used  in  treatment. 
Activities 
*  The  activities  of ALPs,  alone  and  in  combination  with  other drugs,  will  be  determined 
against both exacellular and intracellular forms of different strains/species of Leishmania 
and  Trypanosoma by microscopical  and  biochemical  techniques. 
*  The  effects  of  ALPs  on  membrane  pathways,  in  particular  sterol,  lipid  and  glycosyl-
phosphatidylinositol  (GPI)  anchor biosynthesis,  will  be  studied. 
*  Effects on  parasite differentiation and signal transduction  will  be  examined  in  particular 
in  relation  to  roles  of  protein  kinases,  phospholipases,  calcium  levels  and  adenylate 
cyclase. 
*  The  uptake  and  distribution  of ALPs  by  parasites and  host cells  will  be  measured  by 
isotopic and  chromatographic  methods. 
*  lmmunomodulating properties of ALPs will  be  studied in  relation to killing of intracellular 
stages of  Leishmania and  Trypanosoma  cruzi in  macrophages. 
*  Resistant clones of Leishmania and  Trypanosoma cruzi will  be  established through the 
stepwise  exposure of extracellular parasites to  increasing concentrations of ALPs. 
Expected Outcome 
~  An  understanding of the mechanisms of activity of a novel group of antiprotozoal drugs 
and  the  identification  of novel  drug  targets 
~  Data on  drug activities and  drug combinations useful for clinical studies on  leishmania-
sis  and  trypanosomiasis 
~  PhD  students  will  be  trained  in  laboratories  in  Europe  and  South  America  and 
international  links cemented. 
~  Results  will  be  published  in  international  journals,  presented  at  international  meetings 
and  be the central  focus  of an  EC  meeting to  which  representatives of pharmaceutical 
companies will  be  invited. 
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Partners 
London School of Hygiene and Tropical 
Medicine 
Department of Infectious and Tropical 
Diseases 
Keppel Street 
London WC1 E 7HT 
United Kingdom 
lnstituto Venezolano de Investigaciones 
Cientificas 
Apartado 21827 
Carrertera Panamericana Km  11 
Altos de Pipe 
Caracas 1  020A 
Venezuela 
lnstituto de Biotecnologia 
Grupo Bioquimica y Parasitologia Molecular 
Campus Fuentenueva s/n 
18071  Granada 
Spain 
lnstituto Oswaldo Cruz 
Departamento de Ultra-estrutura e Biologia 
Celular 
CP 926 
Av.  Brasil, 4365 
Manguinhos 
Rio de Janeiro 21045-900 
Brasil 
Escola Paulista de Sao Paulo 
Universidade Federal de Sao Paulo 
Department of Microbiology, Immunology and 
Parasitology 
Rua Botucatu 862, 8 andar 
04023-062 Sao Paulo 
Brazil 
S.L.Croft 
Tel:  +44/171 /927.2345 
Fax: +44/171 /636.8739 
E-mail: s.croft@lshtm.ac.uk 
J.A.Urbina 
Tel:  +58/2/501.1479 
Fax: +58/2/501.1093 
E-mail: jaurbina@cbb.ivic.ve 
A. Osuna Carrillo 
Tel:  +34-58-24.32.63 
Fax: +34-58-24.31.74 
E-mail: aosuna@ goliat.ugr.es 
S.  Lisboa de Castro 
Tel:  +55/21/598.4330 
Fax: +55/21 /590.3545 
E-mail: solange@ gene.dbbm.  fiocruz.br 
M.L.Cardosa de Almeida 
Tel:  +55/11/572.4711 
Fax: +55/11/571.5877 
E-mail: mlcalmeida.dmip@epm.br 
277 Contract number ERBIC18CT960123 
CLINICAL  VARIABILITY  OF  AMERICAN  TEGUMENTARY  LEISHMANIASIS  IN  PERU 
AND  BOLIVIA:  RELATIONSHIP  WITH  POLYMORPHISM  OF  THE  PARASITE  WITHIN 
THE LEISHMANIA BRAZILIENSIS COMPLEX OF SPECIES {SYN. SUBGENUS VIANNIA)  .. 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1996 - September 30,  1998 
PRINCE LEOPOLD INSTITUTE OF TROPICAL MEDICINE, 
PARASITOLOGY DEPARTMENT, Antwerpen, Belgium 
(JEAN CLAUDE DUJARDIN,  DOMINIQUE LE  RAY) 
To  identify  parasite  characters  linked  with  variability  in  clinical  response  to  infection  with 
parasites  of  the  Leishmania braziliensis complex  in  Peru  and  Bolivia: 
•  To collect and analyse comparable clinical and epidemiological data from three endemic 
areas  in  the  Amazon  basin  of  Peru  and  Bolivia  in  order  to  discriminate  factors 
underlying  clinical  variability  in  infection  and  disease. 
•  To  strengthen  the  argument that there  is  apparently a consistent  association  between 
parasite  genetic variation,  virulence and  clinical  variability. 
•  To  initiate  experimental  studies  on  biological  parameters  that  might  be  involved  in 
Leishmania  virulence,  by  using  isolates  with  well  defined  genotypes  obtained  from 
representative  clinical  categories. 
Activities 
*  To  collect  comparable  epidemiological  and  ecological  data  in  the  two  previous  STD3 
(LEISHBOLPE  3)  study  areas  (Pilcopata,  Amazonian  foothills,  Peru;  lsiboro  Secure, 
Amazonian  lowlands,  Bolivia)  in  reference  to  the  methodology  already  developed  for 
Huanuco  Valley  (Peru). 
*  To  quantify  clinical  variability  of  both  cutaneous  and  mucosal  stages  of  infection  and 
disease  by  data  collection  with  the  same  standardised  gradings  in  the  3 study  areas 
(Pilcopata,  lsiboro Secure,  Huanuco). 
*  To  undertake  epidemiometric  statistical  analysis  of field  data for  discriminating  factors 
underlying  clinical  variability  in  infection  and  disease. 
*  To  collect  both  biopsy  samples  and  parasite  isolates  from  lesions  of  patients  docu-
mented  above,  for activities described  below. 
*  To  pursue  genomic  and  genetic  characterization  of  parasites  according  to  clinical 
grading. 
*  To  qualify  the  predictive  value  of  candidate  genetic  markers  associated  with  specific 
clinical  and  phenotypic patterns  by: 
•  Analysis  of the  genetic structure of parasite  populations  under study. 
•  Characterization  of  identified  marker  chromosomes  and  corresponding  nucleotide 
sequences. 
Validating  the  operational  value  of corresponding probes and  primers on  the  collection 
of  biopsy samples  (cryobanked)  if time  and  tools  permit. 
*  Complete  molecular  characterization  of  isolates  collected  by  the  previous  project 
LEISHBOLPE 3 until  isolates considered  herein  (LEISHBOLPE  4)  become  available. 
*  Developing  biological  in  vitro and  in  vivo characterization  of a limited  set of parasites, 
preferably cloned,  representative of the genetic and clinical categories identified above. 
*  Assessing  Leishmania  survival  inside  the  macrophage  as  a  measurement  of  parasite 
virulence. 
*  To  process  the  data  for  global  analysis  of  correlations  between  genetic  and  clinical 
variability. 
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Expected outcome 
~Comparable  epidemiological, ecological and clinical data in the three study sites of Peru 
and  Bolivia (Andean valleys, Amazonian foothills,  Amazonian  lowlands). 
~  Collection  of  parasites  from  isolates  and  in  biopsies,  characterized  genomically  and 
genetically according to clinical  grading. 
~  In  vivo  and  in  vitro models for biological  characterization of parasite virulence. 
~  Discrimination of factors  underlying clinical  variability  in  infection  and  disease. 
~  Documenting  whether  there  is  a  correlation  between  parasite  genetic  variability  and 
clinical variability.  If there is. a correlation, validation of (i)  corresponding  risk factors for 
patient's care,  and of (ii)  corresponding probes and primers for parasite identification in 
field  biopsies.  · 
~  Genetic structure of parasite populations  in  the  three  study sites. 
Partners 
Prince Leopold Institute of Tropical Medicine 
Laboratory of Protozoology 
Parasitology Department 
Nationalestraat 155 
B - 2000 Antwerpen 
Universidad Peruana Cayetano Heredia 
Dept. of Biochemistry 
IMT AVH,  UPCH 
AP 4314 PE- Lima 100 
Centre d'Etudes sur le Polymorphisme des 
Micro-organismes 
UMR CNRS/ORSTOM 9926 
911  Avenue Agropolis 
Bp 5045 
F - 34032 Montpellier cedex 1 
Universidad Peruana Cayetano Heredia 
Public Health Centre 
Facultad de Medicina 
Apdo 4314 
PE- Lima 100 
Universidad Mayor de San Simon 
CUMETROP/IIBISMED 
Casilla 3119 
BO - Cochabamba 
London School of Hygiene and Tropical 
Medicine 
Vector Biology and Epidemiology Unit 
Dept.  of Medical Parasitology 
Keppel street 
UK - London WC1  7HT 
Jean Claude. Dujardin 
Dominique Le Ray 
Tel:  +32-3-247.63.55 
Fax: +32-3-247.63.62 
E-mail: jcdujard@ proto.itg.be 
dleray@ proto.itg.be 
Jorge Arevalo 
Tel:  +51-14-81.51.77 
Fax: +51-12-64.05.35 
E-mail: zimic@ upch.edu.pe 
Michel Tibayrenc 
Tel:  +33-467-41.62.07 
Fax: +33-467-41.62.99 
E-mail: michel.tibayrenc@cepm.mpl.orstom.fr 
Alejandro Llanos-Cuentas 
Tel:  +51-14-82.05.95 
Fax: +51-14-82.  77.39 
E-mail: allano@ upch.edu.pe 
Hernan Bermudez 
Tel:  +59-1-422.15.45 
Fax: +59-1-425.15.43 
E-mail: cumetrop@ pino.cbb.entelnet.bo 
Clive Davies 
Tel:  +44-171-927.23.50 
Fax: +44-171-636.87.39 
E-mail: clive.davies@lshtm.ac.uk 
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HOST-PARASITE  RELATIONSHIP  IN  CANINE  VISCERAL  LEISHMANIASIS  (L. 
INFANTUM/L.  CHAGASI):  DEVELOPMENT AND  VALIDATION  OF THE  DOG  MODEL 
Period: 
Co-ordinator: 
Objectives 
January 1,  1998 - December 31, 2000 
INSTITUTO DE SALUD CARLOS Ill, Centro Nacional 
de Microbiologfa, Majadahonda, Spain (J. ALVAR) 
•  To  define  the  kinetics  and  characteristics  of  infection,  immune  response  and  clinical 
evolution  of  Leishmania  infantum  infection  in  the  dog,  the  main  reservoir  of  visceral 
leishmaniasis. 
•  To describe the natural history of canine leishmaniasis in  inbred dogs, with emphasis on 
the  prepatent period 
•  To  develop reagents  that  may have  prognostic value. 
•  To develop a model useful for future immunoprophylactic and therapeutic studies and to 
establish  a  reproducible  infection  protocol  that  results  in  consistent  parasitological, 
immunological  and  clinical  patterns. 
•  To compare and validate the experimental model with natural infection in endemic areas 
(New and  Old  World).  Validate the  experimental  model  by comparing  clinical,  immuno-
logical and  parasitological data of asymptomatic dogs (defined by parasite burden,  and 
biochemical  analysis)  from  endemic areas  in  Colombia and  Spain. 
Activities 
The  natural  history  of  canine  leishmaniasis  in  inbred  dogs  will  be  investigated  with 
emphasis on  the  prepatent period  by: 
*  Clinical  analysis including analytical  biochemistry and  blood  cell  count. 
*  Measurement  of systemic  and  cutaneous  cell-mediated  responses  by  studying  immu-
nocytochemical characterization of the first and second signals of lymphocyte activation. 
Cytokines  will  be  measured  and  the  specific  response  to  defined  antigens  will  be 
studied  and  T-cell  subsets established. 
*  Investigation  of the  immunostimulatory and  effector roles  of dendritic cells  in  a canine 
model  of visceral  leishmaniasis. 
*  Measurement of antibody isotype  responses  in  particular  lgM,  lgG  and  lgE 
*  Parasite  burden  and  parasite  distribution  will  be  established  by  direct  microscopy,  by 
culture  in  NNN  and  by  PCR. 
*  Infectivity for sandflies (epidemiological risk)  will  be assessed at different time points by 
Xenodiagnosis  with  Phlebotomus  perniciosus  or  Lutzomyia  longipalpis  and  asympto-
matic and  symptomatic dogs from  endemic areas  (Spain  and  Colombia). 
Reagents that may have prognostic value including PCR primers for IL-4,  IL-10,  IL-12, and 
TGF-J3  will  be developed together with a quantitative PCR of genomic DNA for determining 
parasite  burden. 
Additional  work will  attempt to  develop a model  useful for future  immunoprophylactic and 
therapeutic  studies  with  the  aim  of  establishing  a  reproducible  infection  protocol  that 
results  in  consistent parasitological,  immunological and clinical patterns.  The experimental 
280 Contract number IC18*CT970213 
model  will  be  validated  with  natural  infection  in  endemic areas  (New  and  Old  World)  by 
comparing clinical,  immunological and  parasitological data of asymptomatic dogs (defined 
by parasite burden, and biochemical analysis) from endemic areas in  Colombia and Spain. 
Expected outcome 
=>A better understanding  of the  infection  on  the  basis  of correlating  the  immunobiology, 
clinical  and  epidemiological  features. 
=>  Practical  recommendations will  result from  this project in  terms of risk for humans and 
control  measures  through  a  better  understanding  of  the  natural  history  of  canine 
leishmaniasis. 
=>  Moreover,  the  response  to  defined antigens  will  establish  the  immunological  basis for 
further projects  related  to vaccine development or for drug/immunological synergy. 
=>  Finally,  several  reagents  are  expected  to  be  obtained  for both  diagnosis and  cytokine 
detection,  that will  be  of value for the  scientific community. 
Partners 
Institute de Salud Carlos Ill 
Centro Nacional de Microbiologla 
Crta. Majadahonda-Pozuelo km.  2 
28220 Majadahonda (Madrid) 
Spain 
CIDEIM 
Avenida 1  N No.3-03 
P.O.  Box 5390 
Cali 
Colombia 
University of Cambridge 
Department of Pathology 
Tennis Court Road 
Cambridge CB2 1  QP 
United Kingdom 
Consejo Superior de Investigaciones 
Cientlficas 
Centro de Investigaciones Biol6gicas 
Velazquez,  144 
28006 Madrid 
Spain 
Universidad Central 
Institute de Biomedicina 
San Nicolas a Providencia 
Apartado 4043 
Caracas 1010A 
Venezuela 
J. Alvar 
Tel:  +34/1/509.70.78 
Fax: +34/1/509.79.66 
E-mail: jalvar@ isciii.es 
B. Travi 
Tel:  +57/2/668.21.64 
Fax:  +57  /2/667.29.89 
E-mail: cideim@cali.cetcol.net.co 
D.C. Barker 
Tel:+44/1223/33.37  .37 
Fax:+44/1223/33.37  .37 
E-mail: dcb12@ mole.bio.cam.ac.uk 
L.  Rivas 
Tel:  +34/1/561.18.00 
Fax:  +34/1/562.75.18 
E-mail: ciblr@fresno.csic.es 
F. Tapia 
Tel:  +58/2/83.82.77 
Fax.  +58/2/86.12.58 
E-mail: ftapia@telcel.net.ve 
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NEW TRYPANOCIDAL COMPOUNDS BASED ON  INHIBITORS OF GLYCOLYSIS AND 
THE SPECIFIC IMPORT OF THESE INHIBITORS INTO THE PARASITE 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1997 - September 30, 2000 . 
UNIVERSITE PAUL SABATIER, Groupe de Chimie Organique 
Biologique, Toulouse,  France (J.  PERlE) 
+  to develop novel compounds active against human trypanosomiases and leishmaniasis; 
•  to take advantage of an essential metabolism in these trypanosomatidae that glycolysis 
represents; 
+ to  design  irreversible  and  quasi-irreversible  inhibitors  of glycolytic  enzymes  based  on 
differences between parasites and mammalian enzymes and to import them into the cell 
either via passive diffusion or via the glucose THT1  transporter. 
Activities 
The  first  set  of  irreversible  GAPDH  inhibitors  will  be  extended  to  structures  directed 
towards Arg 231  and the compounds will  be transformed into the corresponding prodrugs. 
Cocrystallisation experiments of these compounds with the enzyme GAPDH from  Trypano-
soma  brucei  will  be  made  for  the  design  of  improved  structures  after  corresponding 
modelling. 
A  parallel  work  will  be  made  on  the  T.brucei  aldolase  enzyme,  starting  from  active 
structures already identified.  In both cases the residue responsible for the formation of the 
covalent bond will  be  identified  using  mutants for the  most likely locations. 
All the compounds will be assayed for their transport by the glucose transporter THT1  and 
also  on  Trypanosome cytosolic esterases which  are expected to transform  prodrugs  into 
drugs within the cell.  Compounds of natural origin will  be also studied within the program. 
Expected outcome 
The study will develop compounds capable of specifically blocking glycolysis and therefore 
limiting the survival of trypanosomas. The work will  lead to an improved knowledge of the 
glycolytic enzymes and transport systems in  trypanosomas and  leishmania. 
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Partners 
Universite Paul Sabatier 
Groupe de Chimie Organique Biologique 
118 Route de Narbonne 
Bat.  IIR 1 
31062 Toulouse Cedex 4 France 
International Institute of Cellular 
and Molecular Pathology 
Research Unit for Tropical Diseases 
Avenue Hippocrate 74 
1200 Brussels 
Belgium 
Universite Victor Segalen Bordeaux 2 
146, rue  Leo Saignat 
33076 Bordeaux 
France 
Universite Yaounde I 
Faculte des Sciences 
Departement de Chimie Organique 
BP 812 
Yaounde 
Cameroon 
Fundacao Oswaldo Cruz 
Institute de Tecnologfa em  Farmacos 
Rua Sizenando Nabuco 100, Manguinhos 
21041-250 Rio de Janeiro 
Brazil 
Universidad de Los Andes 
Unidad de Bioqufmica de Parasites 
Centro de lngenerfa Genetica 
CIGEN - Facultad de Ciencias - ULA 
La Mechicera 
5101  Merida 
Venezuela 
J. Perie 
Tel:  +33/5/61.55.64.86 
Fax: +33/5/61.25.17.33 
E-mail: perie@cict.fr 
F.  Opperdoes 
Tel:  +32/2/764.74.39 
Fax: +32/2n62.68.53 
E-mail: opperd@trop.ucl.ac.be 
T.  Baltz 
Tel:  +33/5/57.57.16.44 
Fax:  +33/5/57.57.1 0.15 
E  -mai  I:  baltz@ hippocrate.  u-bordeaux2.  fr 
B.  Nyasse 
Tel:  +237/22.35.01 
Fax: +237/23.53.88 
E-mail: bnyasse@ uycdc.uninet.cm 
B. Gilbert 
Tel:  +55/21/290.07.96 
Fax: +55/21/270.39.12 
E-mail: gilbert@far.fiocruz.br 
M.  Dubourdieu 
Tel:  +58/74.44.24.50 
Fax: +58/7  4.44.24.50 
E-mail: dubourdi @ciens.ula.ve 
283 Contract number IC18*CT960028 
A  NETWORK  APPROACH  TO  RESEARCH  ON  LEISHMANIASIS  IN  CENTRAL 
AMERICA WITH  EMPHASIS ON  DRUG  SENSITIVITY IN  THE  FIELD 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1996 - January 31 , 1998 
KEELE UNIVERSITY,  DEPT. OF BIOLOGICAL SCIENCES, 
Staffordshire, United Kingdom (R. WARD I R.  MAINGON) 
•  To  obtain  information  on  the  nature  and  mechanisms  of  drug  sensitivity  in  the  field 
using  a controlled  prospective population-based  study. 
•  To  improve  diagnosis  and  parasite/vector identification  in  Central  America  using  tradi-
tional  and  new molecular methods. 
•  To  improve  human  resources  with  expertise  on  leishmaniasis  using  a  network  ap-
proach. 
Activities 
The  project  focuses  upon  an  examination  of  drug  sensitivity  to  glucantime  by  the 
Leishmania  species  circulating  in  Guatemala  and  other  American  countries.  Genetic 
analysis of glycoprotein genes in  Granada,  Spain  is  complemented  by work at  Keele,  UK 
using  broader  molecular  approaches  such  as  differential  display.  In  Nicaragua  and 
Panama  PCR  methods will  be applied to examine for post treatment parasite persistence. 
Studies  in  Honduras  and  El  Salvador  are  focused  upon  isolation  of  new  strains  of  L. 
chagasi from typical and atypical clinical cases along with  preliminary studies on  transmis-
sion  dynamics  in  the  San  Juan  Bautista and  Choluteca areas. 
Results so far 
During  the  first  year of the  project  a modified  work  plan  was  drawn  up  as  a result  of  a 
preliminary  meeting  in  Guatemala  in  January  1997.  Specific  gene  expression  patterns  in 
Leishmania  are  being  studied.  Using  the  mANA  differential  display  technique  putative 
species  specific transcripts  of  L.  mexicana and  braziliensis have  been  obtained.  Further-
more transcripts specific to  a glucantime  resistant cloned  L.  tropica have  been  produced. 
Several  members  of  th  group  have  participated  in  training  exchanges  with  partner 
laboratories  and  have  participated  at  the  First  World  Congress  on  leishmaniasis  held  in 
Istanbul  during  May  1997. 
A single  batch  of  5500  glucantime  ampoules  were  obtained  from  France  and  are  being 
used  in  Guatemala  in  the  patient  cohort  study.  Leishmania  isolates  from  patients  in  El 
Salvador  have  been  characterised  in  Honduras  and  the  strains  passed  to  the  UK 
laboratory and  Nicaragua.  In  Panama studies are  revealing the wide diversity of treatment 
regimes  which  make  evaluation  of drug  sensitivity a difficult  parameter to  monitor.  Blood 
samples and aspirates of lesions from the Penonome endemic area have been carried out 
and  results  are  expected  in  the  near future. 
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A  member  of  the  Panamanian  group  has  received  training  in  PCR  techniques  in  the 
Nicaraguan  laboratory.  The  Nicaraguan  group  have  also  recorded  the  occurrence  of 
atypical  visceral  leishmaniasis similar to those cases  recorded  from  Honduras and  Costa 
Rica.  The predominant vector in  this  area was  Lutzomyia longipalpis. 
Partners 
Keele University 
Department of Biological Sciences 
Staffordshire ST5 5BG 
United Kingdom 
Universidad del Valle 
Centro de Investigaciones en  Enfermedades 
Tropicales 
Apartado Postal 82 
01013 Guatemala City Guatemala 
Complejo Nacional de Salud 
Dra Concepcion Palacio 
P.O.  Box 2900 
Managua 
Nicaragua 
Universidad Santa Marfa 
La Antigua 
Av Ricardo J Alfaro 
Apdo 6-1696 Estafeta el  Dorado 
Panama 
Panama 
Ministerio de Salud 
Unidad de Laboratories 
9A Av Norte 120 
San Salvador 
El  Salvador 
Ministerio de Salud 
Laboratorio Central 
Alonso Suazo 
Tegucigalpa 
Honduras 
Institute de Parasitologfa y Biomedicina 
(CSIC) 
cNentanilla 11 
18001  Granada 
Spain 
R.  Ward I R.  Maingon 
Tel:  +44/1782/58.34.17 
Fax: +44/1782/58.35.16 
E-mail: bia40@ keele.ac.uk (R. Ward) 
bia25@ keele.ac.uk (R.  Maingon) 
B. Arana 
Tel:  +502/364.03.36 ext. 334 
Fax: +502/364.03.54 
E-mail: BAAZ@Ciddpd3.em.cdc.gov 
A.  Belli 
Tel:  +505/289.77.23 
Fax:  +505/289.77.23 
E-mail: abelli@ibw.com.ni 
P.  Carreira 
Tel:  +507/236.13.11 
Fax: +507  /236.14.72 
E-mail: pfrance@Canaa.usma.pa 
J.Soundy 
Tel:  +503/71.15.23 
Fax: +503/73.03.55 
C. Ponce 
Tel:  +504/32.58.40 
Fax: +504/32.89.42 
E-mail: carponce@datum.hn 
F.  Gamarro 
Tel:  34/58/20.38.02 
Fax:  +34/58/20.33.23 
E-mail: gamarro@ipb.csic.es 
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PRODUCTION AND CHARACTERISATION OF SYNTHETIC INHIBITORS OF PARASITE 
OF  PROTEASES  AS  DRUG  CANDIDATES  FOR  THE  PREDOMINANT  PROTOZOAL 
DISEASES OF SOUTH AMERICA AND  OTHER  DEVELOPING  REGIONS 
Period: 
Co-ordinator: 
Objectives 
October 1,  1997 - September 30,  2001 
CARLSBERG LABORATORY,  DEPT.  OF CHEMISTRY, 
Valby,  Denmark (M.  MELDAL) 
To  develop  specific  inhibitors  of  parasitic  cysteine  proteases  as  drug  candidates  for the 
treatment of the  predominant protozoal diseases (in  particular Leishmaniasis and  Chagas 
disease)  of  South  America  and  other  developing  countries.  This  goal  will  be  attained 
through  the  implementation  of  molecular  biology,  enzymology  and  state  of  the  art 
combinatorial  chemical  library techniques. 
Activities 
Solid  phase  chemical  synthetic  methodology  will  be  developed  simultaneously  with 
molecular  and  recombinant  technology  which  will  generate  large  quantities  of  cysteine 
proteases for screening. An  iterative process of screening and optimization will  lead to the 
target  drug  candidates.  The  measurable  objectives  are  outlined  as  follows  in  quasi-
chronological  order. 
*  The development of resins  suitable  for both  synthesis of  non-peptide inhibitor libraries 
as  well  as  solid  fluorescent-quenched  enzymatic assays. 
*  The  isolation  of recombinant and  native  Leishmania cysteine  proteases  (CPs)  in  large 
amounts. 
*  The  determination  of  substrate  specificity  of  recombinant  cruzipain  and  important 
Leishmania CPs  using  substrate  libraries and  MS  detection. 
*  The  development of several  methods  (nanoprobe  MAS-NMR of single beads,  MS-MS, 
and  ladder  synthesis/MS)  for  the  fast  and  efficient  analysis  of  resin-bound  peptide 
substrates  and  non-peptide  inhibitors. 
*  The  development  of  solid  phase  synthetic  methodologies  for  the  rapid  generation  of 
potent and  selective CP  inhibitors. 
*  The  construction  of  a  novel  syntheziser for  manual  organic  library  synthesis  with  the 
capacity  to  provide  inert  reaction  conditions,  for  temperature  control  and  for  refluxing 
conditions. 
*  The screening of substrate and  inhibitor libraries with  T.  cruzi and  Leishmania CPs and 
the  detection  of potent  inhibitors. 
*  The  synthesis of inhibitors  in  larger quantities and  an  analysis of their activity towards 
pure  CPs.  The  selectivity  of  the  inhibitors  will  be  assessed  by  comparison  with 
mammalian  cathepsins  B and  L. 
*  The  testing  of  inhibitors for antiparasite activity in  vitro and  in  vivo. 
*  The  application  of  gene  knockout  and  over-expression  of  CPs  in  L.  mexicana  and 
subsequent transfer of that methodology to other Leishmania species in order to identify 
and  characterize  key  CPs  and  to  produce  recombinant  enzymes  for  use  in  drug 
development. 
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Another  important  aspect  of  this  project  is  the  transfer  of  knowledge  and  techniques 
required for synthesis and  enzymatic assays of chemical libraries and methods of reverse 
gene technology to partners in  developing countries. The transfer will partly be established 
by  training  visits  in  the  EU-based  laboratories.  In  addition,  a  multidisciplinary  research 
network in  LA-EEC will  be  established to foster the development of the field of drug leads 
and  design  using  an  interdisciplinary  approach  involving  state-of-the-art  molecular  and 
biochemical techniques and  combinatorial  chemistry. 
Expected outcome 
Since the chemotherapeutic treatment of parasitic diseases is  not satisfactory because of 
drug  toxicity  and  the  development  of  drug  resistant  parasites,  the  development  of 
alternative drugs is  of grave import.  By the end  of this project,  we  will  have developed a 
new class of antiparasitic drugs. Simultaneously, we will have deepened the understanding 
of  the  mechanism  and  specificity  of  CPs  and  the  mode  of  action  of  various  parasites. 
Moreover,  we  will  have  established  a  multidisciplinary,  international  research  network  to 
foster innovations in  the  drug  discovery approach. 
Partners 
Carlsberg Laboratory 
Department of Chemistry 
Gamle Carlsberg Vej  10 
2500 Valby 
Denmark 
University of Glasgow 
Institute of Biomedical and Life Sciences 
Joseph Black Building 
Glasgow G12 8QQ 
United Kingdom 
Escola Paulista de Medicina 
Department of Biophysics 
Rua Tres de Maio 
Sao Paolo 
Brazil 
lnstituto de Biofisica Carlos Chargas Filho 
Laboratory of Immunology 
Cidade Universitaria 21944-900 
Rio de Janeiro Brazil 
Universidade Peruana Cayetano Heredia 
Division of Biochemistry 
Av.  Honorio Del Gado 430,  URB. 
lngeneria 
San Martin De Porras,  Lima 
Peru 
M. Meldal 
Tel:  +45/33.27  .53.01 
Fax: +45/33.27.47.08 
E-mail: mpm@crc.dk 
G. Coombs 
Tel:  +44/141/330.47.77 
Fax: +44/141/330.80.16 
E-mail: gbza60@udcf.gla.ac.uk 
L.Juliano 
Tel:  +55/11 /575.96.17 
Fax: +55/11/575.90.40 
E-mail: juliano.biof@ epm.br 
J. Scharfstein 
Tel:  +55/21/280.20.10 
Fax: +55/21/280.81.93 
E-mail: sharf@ibccf.biof.ufrj.br 
J. Arevalo 
Tel:  +51/1/48.20595 
Fax: +51/1/48.15177 
E-mail: labc@upch.edu.pe 
287 Contract number IC18*CT970252 
MOLECULAR GENETICS, CELLULAR IMMUNOLOGY AND PEPTIDE-CHEMISTRY FOR 
THE  DEVELOPMENT OF CONTROL TOOLS AGAINST LEISHMANIOSIS 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1997 - September 30,  2000 
INSTITUT PASTEUR, UNITE DE GENETIQUE MYCOBACTERIENNE 
Paris,  France (B. GICQUEL) 
There  are three  main  objectives: 
•  The  study  of  the  biological  function  and  role  in  the  Leishmania  infectivity  of  two 
molecules encoded by developmentally regulated  Leishmania genes,  namely a putative 
nuclear growth  related  factor (LNP18)  and  an  immunodominant membrane  protein. 
•  The  dissection  of the  cellular  immune  responses  conferring  resistance  to  Leishmania 
spp.  driven  pathogenic processes. 
•  Development of  new reliable  diagnostic products for early detection  of leishmaniosis. 
This project aims at identifying parasite factors  essential  for  Leishmania infectivity and  at 
dissecting  cellular  immune  responses  conferring  resistance  to  Leishmania  spp.-driven 
pathogenic  processes.  Such  advances  should  pave the  way for the  development of  new 
strategies  and  the  rational  design  of  future  immunoprophylactic  and  immunotherapeutic 
measures  to  control  leishmaniosis.  Leishmaniosis  constitutes  not  only  a  major  public 
health  problem  of socio-economic  importance  but  is  also  a veterinary problem  in  various 
parts of the world and especially in  Mediterranean countries. Thus,  there is a need for the 
development  of  new  effective  tools  for  their  control.  Recent  advances  in  the  field  of 
molecular genetics,  cellular immunological tools that the  European  partners have  recently 
developed for characterizing  and  studying  parasite and  host factors  promoting  or circum-
venting  the  development  of  the  disease.  The  rational  approach  that  will  be  pursued  is 
based  on  the  use  of  all  these  tools  focusing  on  two  Leishmania  molecules,  a  putative 
nuclear  growth  related  factor  (LNP18)  and  a  8-cell  immunodominant  antigen  (P32)  that 
induces also T cell  responses encoded by two novel genes recently identified by partners 
n°2  and  n°4 respectively,  for the  elucidation of (a)  their functions  in  pathogenesis  (b)  the 
nature  of  molecular  and  cellular  effectors/regulators  on  which  they  act  as  sites  of 
Leishmania delivery or spread (c) their impact on the selective activation and differentiation 
of the CD4+ and CDS+ T-cell subsets to drive a protective Th1-cell response and  (d)  their 
potential  use  as  reagents  for  diagnosis.  The  immunogenic  potential  of  the  different 
Leishmania  molecule  formulations  will  be  studied  in  the  murine  model  and  the  recently 
established  by  partners  n°3  and  n°5,  canine  models.  Such  understanding  will  allow the 
design  of  rational  approaches to  combat leishmaniosis. 
Activities 
In  particular,  we  propose to: 
*  Develop  Leishmania mutants by sequential targeted gene  replacement or site directed 
mutagenesis. 
*  Determine the  phenotype conferred  by LNP18  and  P32  mutations. 
*  Evaluate the  role  of  LNP18 and  P32  in  parasite  infectivity. 
The  study will: 
*  Investigate  the  host-protective  capability  of defined  Leishmania antigens.  New  protec-
tive antigens and two B immunodominant molecules  LNP18 and  P32  will  be  identified, 
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cloned,  sequenced  and  characterized,  using  recombinant  molecules  as  well  as  syn-
thetic peptides  modelled from  their respective  amino-acid sequences. 
*  Determine  ways  and  parameters  of directing  the  immune  system  towards a Th1  type 
response,  by  examining  both  CDS+  and  CD4+  lymphocyte  responses,  using  vectors 
such  as  live  recombinant  BCG  expressing  Leishmania antigens  e.g.  LNP18  and  P32, 
and  synthetic  microspheres carrying  these  antigens. 
*  Conduct protection  studies  in  canine  experimental  models. 
More specifically,  we  will  evaluate the  diagnostic potential  of: 
*  recombinant  LNP18 and  P32 
*  synthetic peptides modelled from  P32 and LNP18 amino acid sequences, as targets for 
ELISA.  Data  on  P32  and  on  a  LNP18  20-peptide  make  these  molecules  promising 
reagents for serodiagnosis. 
Expected outcome 
Following  completion  of the  project,  the  results  obtained  will  be  sufficiently  robust  for the 
industrial  environment and will  provide new strategies and  tools to  help the  leishmaniosis 
control  such  as:  Leishmania  mutants  and  live  recombinant  BCG  expressing  Leishmania 
antigens,  as  possible vaccine candidates,  host-protective parasitic synthetic peptides and 
recombinant  molecules as  well  as  particulate antigens,  and  reliable  diagnostic tools. 
Partners 
lnstitut Pasteur 
Unite de Genetique Mycobacterienne 
25 rue du  Dr.  Roux 
75724 Paris Cedex 15 
France 
lnstitut Pasteur Hellenique 
Dept.  Biochimie 
127 av.  Vassilissis Sofias 
Athenes 11521 
Grace 
Universidade de Lisboa 
Facultade de Farmacia 
Av.  das For<;as Armadas 
1600 Lisboa 
Portugal 
lnstitut Pasteur de Tunis 
Laboratoire d'lmmunologie 
13 place Pasteur 
B.P.  74 
1002 Tunis-BelvedereTunisie 
lnstitut Agronomique et Veterinaire Hassan  II 
Parasitologie et Maladies Parasitaires 
B.P.  6,  202 Rabat-lnstitut 
Rabat 
Maroc 
B.  Gicquel 
Tel:  +33-1-45.68.88.28 
Fax: +33-1-45.68.88.43 
E-mail: bgicquel@ pasteur.fr 
K.  Soteriadou 
Tel:  +30-1-64.30.044 
Fax: +30-1-64.23.498 
E-mail: ksoter@ leon.nrcps.ariadne-t-gr 
J. Moniz Pereira 
Tel:  +351-1-793.30.64 
Fax: +351-1-793.42.12 
E-mail: Zemoniz@oscar.pt 
K.  Dellagi 
Tel:  +216-1-789.608 
Fax: +216-1-791.833 
A.  Dakkak 
Tel:  +212-7-776.432 
Fax:  +212-7-776.432 
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INVESTIGATIONS  ON  POLYMORPHIC  GENOMIC  MARKERS  IN  RELATION  TO  AP-
PLIED  FIELD  RESEARCH  ON  THE  BIOLOGY OF  LEISHMANIA PARASITES IN  VARI-
OUS  ECO-EPIDEMIOLOGICAL SETTINGS IN  THE  MEDITERRANEAN  BASIN 
Period: 
Co-ordinator: 
Objectives 
November 1  , 1997 - October 31 , 2000 
INSTITUT PASTEUR DE TUNIS, LABORATOIRE 
D'EPIDEMIOLOGIE ET D'ECOLOGIE PARASITAIRE 
Tunis Belvedere, Tunisie (1.  GUIZANI) 
To  provide genomic tools to  measure the extent of DNA polymorphisms among  natural  L. 
infantum  parasite  populations  and  to  approach  underlying  molecular  mechanisms  to 
parasite populations diversity; intra-chromosomal recombination; chromosomal assortment, 
gene  rearrangement and  chromosomal  size variability.  These  DNA tools will  be  applied  in 
at  least  three  eco-epidemiological  settings  in  the  Mediterranean  area:  France,  Lebanon 
and  Tunisia.  In  particular,  molecular  tools  will  be  used  to  complement  field  studies  in 
Lebanon  which  aim  at better defining  the  epidemiology of leishmaniases in  this  country. 
Activities 
*  DNA markers for polymorphisms will  be  identified  using  different approaches:  chromo-
somal size variability,  variations in  copy numbers,  RFLP and sequence analysis.  Newly 
identified  markers  will  be  submitted  to  extensive  molecular analysis which  will  include 
mapping  and  sequences. 
*  Repeated coding sequences (gp63,  PSA2,  rONA,  miniexons) will be targeted to look for 
RFLPs  and  to  study  variations  in  copy  numbers  in  relation  to  chromosomal  size 
variability. 
*  PCR  tests  will  be  developed  based  on  the  gp63  gene  family,  minisatellites  and 
microsatellites. A thorough screening for microsatellites on  chromosome V will  be  made 
using  a  sequencing  approach.  Evaluation  of  these  PCR  tests  will  be  performed  on 
promastigote  populations  that  will  be  the  subject  of  this  study  and  on  the  biological 
material  that will  be  collected  from  patients and  dogs  in  Tunisia and  Lebanon. 
*  The study of the  mechanisms underlying the  genetic diversity in  natural  populations of 
parasites  will  be  done  on  parasite  populations  collected  in  close  sympatric.  lntrachro-
mosomic  recombination  will  be  studied  on  chromosome  V.  The  chromosomal  assort-
ment will  be  studied  by  using  unique  markers  to  defined  chromosomes  (RFLP  and/or 
PCR  tools). 
*  Correlations  between  chromosomal  size  variability  and  variations  in  copy  number  of 
target  genes  will  be  investigated.  These  results  will  also  be  correlated  to  clinical 
outcome  of  the  parasite  infection:  cutaneous  leishmaniasis  (CL)  vs.  visceral  leishma-
niasis  (VL).  To  avoid  biases  which  could  be  encountered  while  working  on  closely 
related  parasite  populations,  this  study will  be  conducted  on  groups  of  parasites from 
sympatric  VL  and  CL cases,  isolated  in  different geographical  areas. 
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Expected outcome 
A better  understanding  of  the  epidemiology of  leishmaniasEs  in  Lebanon  is  expected  at 
the  end  of this  study.  This will  provide a better identification  of the causal  agents.  Earlier 
preliminary  studies  have  pointed  to  the  possible  occurrence  of  the  L.  donovani complex 
parasites  in  this  country.  It  will  be  particularly  interesting  to  understand  why  CL  is 
predominantly  recorded  in  this  area.  PCR  tools  for  studying  parasite  polymorphisms 
constitute an  innovative approach which will provide new insights in  the field situation and 
on  the  molecular epidemiology  of leishmaniases  caused  by  parasites  of the  L.  donovani 
complex. The study will provide well characterized DNA tools. Such tools will allow a better 
understanding of the parasite genetics and thus will  help in  defining parasite determinants 
involved  in  the  biology of the  Leishmania parasites. 
Partners 
lnstitut Pasteur de Tunis 
Lab. d'Epidem. et d'Ecologie Parasitaire 
13 place Pasteur, BP 7  4 
1  002 Tunis Belvedere 
Tunisia 
Centre Nat. de 1a  Recherche Scientifique 
Delegation Languedoc Roussillon 
Lab. de Biologie Moleculaire et GenOme des 
Protozaires 
CNRS EP613 
163 rue Auguste Broussonet 
34090 Montpellier 
France 
Prins Leopold lnstituut voor Tropische 
Geneeskunde 
Dept. of Parasitology 
Lab. of Protozoology 
Nationalestraat 155 
2000 Antwerpen 
Belgium 
American University of Beirut 
Human Morphology, Faculty of Medicine 
Tissue culture/Immunology laboratory 
Bliss street- Ras Beirut 
P.O.  Box 11-0236 
Beirut 
Lebanon 
I. Guizani 
Tel:  +216-1-792.429 
Fax: +216-1-791.833 
C. Blaineau & M. Pages 
Tel:  +33-4-67  .63.55.13 
Fax: +33-4-67.63.00.49 
J-C Dujardin & D.  Le Ray 
Tel:  +32-3-247.63.55 
Fax: +32-3-247.63.62 
E-mail: jcdujard@ proto.itg.be 
Nuha Nuwayri-Salti 
Tel:  +961-1-35.00.00 ext4781 
Fax: +961-1-34.53.25 
E-mail: racha@ layla.aub.ac.lbt 
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Areas of interest: 
5.  Filariases 
Lymphatic Filariasis 
TS3*CT910031 
TS3*CT920141 
IC18CT950014 
IC18CT950026 
IC18CT970245 
IC18CT970257 
Onchocerciasis 
TS3*CT910037 
TS3*CT920056 
TS3*CT920058 
TS3*CT920096 
TS3*CT930235 
Dynamics of lymphatic filarial infection at the cellular and 
molecular level. 
Studies on the development of protective immunity in 
lymphatic filariasis caused by Brugia malayi in an age-
graded population. 
Immunology of lymphatic filariasis T-cell responsiveness and 
protective antigens. 
Vaccination against filarial infections/use of Loa loa a murine 
model for identification of protective mechanisms and 
antigens. 
Immunology of lymphatic filariasis. 
Brancroftian filariasis: the interrelationship between 
transmission, infection, host response and clinical 
manifestations in endemic communities before and after 
intervention. 
Characterization and utilization of two new filarial models for 
investigation of immunity, chemotherapy and pathology. 
Can cattle protect man from onchocerciasis?: reduction of 
similium vectorial capacity and crossreacting immunity as 
factors of zooprophylaxis. 
Immune responses in onchocerciasis: studies with molecular 
probes in patients and an animal model. 
Protein components of chemoreceptor organelles and of the 
cuticle of nematodes: identification and cloning of the genes, 
production as recombinant proteins and analysis of the 
immune response elicited. 
Genetic variation in  Onchocerca volvulus from Cameroon, 
Tanzania and Sierra Leone. 
Page: 
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293 TS3*CT940271 
IC18CT950017 
Chemotherapy 
TS3*CT920057 
TS3*CT920082 
294 
Anti-oxidant enzymes in filarial nematodes: their role in 
defense and persistence. 
Isolation, characterisation and immunological evaluation of 
recombinant vaccines for filarial parasites. 
lvermectin - facilitated immunity in onchocerciasis. 
Exploitation of targets for chemotherapy in  polyamine 
metabolism of filarial worms. 
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DYNAMICS OF LYMPHATIC FILARIAL INFECTION AT THE CELLULAR AND MOLECU-
LAR  LEVEL 
Period: 
Co-ordinator: 
Objectives 
April  1,  1992 - March 31,  1995 
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE, 
DEPT.  OF BIOLOGY,  London,  United Kingdom  (R.  MAIZELS) 
•  To  study  the  dynamics  of  the  host-filarial  interaction  over  time  in  individuals  and 
populations  using  established  indicators  of  infection,  T  cell  activation  and  antibody 
production. 
•  To  study the  role  of T cells  in  immunity and  pathogenesis  in  human  filariasis: 
(a)  as  a function  of immune status and  clinical  category of individual  patients 
(b) in terms of lymphocyte regulation and activation by cytokines and antigen presenting 
cells. 
•  Training of scientists from,  and strengthening of research capability at,  the University of 
Indonesia  and  consolidation  of  the  long-standing  collaborations  between  institutes  in 
Indonesia,  the  Netherlands and  the  UK. 
Summaries of achievements 
In the period covered by this project, it has been possible to carry out a unique longitudinal 
study of subjects  resident  in  an  area  endemic for lymphatic filariasis  in  Central  Sulawesi, 
in  Indonesia.  The  immunological changes  as  measured  by  antibody isotypes and  cellular 
reactivities  have  been  documented  in  individuals who  were  categorized  as  asymptomatic 
amicrofilaraemics  and  asymptomatic  microfilaraemics.  It  has  become  clear  that  both 
humoral  and  cellular  immune  responses  are  strongly  modulated  by  filarial  parasites  and 
that the  changes  in  parasite density can  affect the  immune  parameters such  as prolifera-
tion  and  cytokine  production.  The  studies  point  toward  a  role  for  IFN-y  and  IL-5  in 
immunity towards filarial  parasites. 
Activities 
*  Contact  of  Indonesian  team  with  the  authorities  of  The  Centre  for  Disease  Control  in 
Sulawesi  to  initiate the field  study.  Preliminary visits to  the  study area  (two  villages  in 
the  area  of  Langa  Leso  in  the  Palu  Valley  in  Central  Sulawesi)  to  organize  health 
education  programme  which  would  inform  the  villagers  not  only  about the  project and 
its  aims  but  also  about filariasis  in  general.  Recruitment  of  the  members for the  local 
team  in  charge  of the  project.  One  member of  staff from  Jakarta was  housed  for  two 
years  in  the  area for continuous  monitoring  of the  study. 
*  Screening  of the  inhabitants of two  villages  by  questionnaires,  by  night blood  filtration 
and  by  clinical  assessment.  A detailed  map  of  the  village  was  constructed  and  each 
member of the  house was  registered  alongside its parasitological  and  clinical  status (if 
the  inhabitants  had  taken  part in  the  survey). 
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*  Individuals  giving  informed  consent  and  selected  for  participation  in  the  project  were 
asked to  donate blood  at 3-4 month  intervals.  Individuals younger than  16 were  asked 
to  give  blood  only  at  the  start and  one  year later at the  end  of  the  study period.  Any 
person  who developed symptoms  related to filarial  infection was  treated with  DEC  and 
the  excluded  from  the  study. 
*  The  presence  of  microfilariae  was  determined  in  1 ml  night  blood  at  time  points  over 
one  year.  Also,  20mls  of  blood  was  drawn  for  immunological  studies.  The  blood  was 
transported  to  Jakarta for fractionation  into  plasma  and  mononuclear cells. 
*  Isolated cells were cultured for antigen and  mitogen stimulated cytokine production and 
the  rest  of the  cells were  cryopreserved for use at a later time.  The  plasma was  used 
to  perform  tests  in  Jakarta  (anti-L3  surface  antibody  detection,  immunoblots)  and  in 
Edinburgh/Imperial  College  (antibody  isotype  ELISA  and  immunoblots).  Cells  and 
culture  supernatants  were  used  for  detecting  proliferation  and  cytokine  production  as 
well  as  generation  of T cell  lines. 
*  Parasite  antigens  were  cloned  and  used  for antibody  isotype  reactivity by  ELISA.  The 
analysis  of  lgG4  reactivity  in  particular  to  parasite  antigens  was  also  determined  by 
immunoblots and  I  FAT. 
*  Culture supernatants were tested for the presence of IL-4,  IL-5,  IL-10,  IL-13 and  IFN-y. 
Cryopreserved  cells  were  used  to  generate  T-cells  for  TCR-VJ3  gene  analysis  at  the 
molecular level. 
Results 
Immunological Profiles of Individual Infected with  Filarial Parasites 
It  has  become  clear  that  individuals  infected  with  Brugia  malayi  show  elevated  lgG4 
against filarial  antigens  in  the  face  of  relatively  low specific  lgE.  If worms  are  cleared  by 
DEC  treatment,  lgG4 levels decline within  a period  of  12  months whereas  anti-filarial  lgE 
responses  remain  largely unchanged. 
Thus,  the  presence of filarial  parasites is a major stimulus for the extremely high  levels of 
lgG4.  At  the  cellular  level,  infected  individuals  show  a  defect  in  T-cell  proliferative 
responses  to  filarial  antigens.  In  terms  of  cytokines,  IFNy  production  in  responses  to 
parasite  antigen  appears  to  be  low  in  Mf  carriers  whereas  cells  respond  to  antigen  by 
releasing  IL-4,  IL-5,  IL-1 0  as  well  as  IL-13.  In  one  study  it  was  possible  to  look  at 
proliferation  as  well  as  IFNy  and  IL-4  production  before  and  after  chemotherapy.  After 
treatment both  T-cell  proliferation  and  IFNy production  increased,  whereas  IL-4  remained 
unchanged.  These  studies  indicate that exposure  to  parasites  leads to  T-cell  proliferative 
unresponsiveness  as  well  as  suppressed  I  FNy  production. 
By  comparing  Mf-positive  individuals  with  Mf-negative  ones,  it  is  possible  to  determine 
which  responses  are  altered  by  high  parasite densities.  We  have  confirmed that  IFN-y is 
suppressed  in  Mf-positive  persons,  but  we  also  noted  that  IL-5  production  can  be 
significantly lower in  infected  individuals whereas  IL-4 production  was  the  same  when  all 
age  groups were  considered  together. 
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These results have lead us to the conclusion that not only TH1  but also selective TH2 type 
responses  can  be  suppressed  by  the  presence  of  filarial  parasites.  This  has  important 
implications  for  the  design  of  prophylactic  measures  as  appropriate  cytokines  must  be 
stimulated for successful  parasite elimination. 
Changes in Anti-Filarial Immune Responses as a Function of Age 
As  the  length  of exposure to  parasites or age can  be  an  important factor in  determining 
the level of immunity to a parasitic infection, we have examined the changes in the specific 
antibody levels as well  as cytokines  in  an  age  stratified manner.  During the initial  survey 
we  collected  400  serum  samples  and  have  consequently  performed  ELISAs  for  the 
determination of anti-filarial antibody isotypes. The study has shown that anti-filarial  lgG4 
increases with age and reaches a plateau in  early adulthood. The pattern of other isotypes 
is less clearly associated with  age. The increases in  lgG4  may indicate the acquisition of 
increasing parasites by an  individual. The results could also be  interpreted as a measure 
of increasing exposure to incoming L3,  but the decline of lgG4 after chemotherapy means 
that  the  presence  of  worms  contributes  to  the  elevated  lgG4.  In  a  subset  of  the  study 
subjects  it  was  possible  to  analyze  IL-4,  IL-5  and  IFNy  as  a  function  of  age.  When 
considered together,  IL-5 was the only cytokine that seemed to decrease as  a function  of 
age.  However, when  segregated into Mf+ and  Mf-,  there was a profound effect of age on 
the cytokine release profiles.  IFN-y increases with age in  asymptomatic amicrofilaraemics, 
whereas  IL-4  increases with  age  in  Mf positive  individuals.  These  results  might  indicate 
that I  FN-y could play a role in  immunity to incoming larvae when a person remains free of 
parasites, whereas IL-4 might be important in  immunity to incoming larvae when a person 
is  infected with  adult worms. 
Fluctuation in parasite densities and immunological parameters 
It  has  been  possible  for  the  first  time  in  lymphatic  filariasis  to  monitor  longitudinally 
parasitological  changes  and  the  accompanying  immunological  responses.  Study  partici-
pants were screened 3 times throughout one year (at 4 monthly intervals) for the presence 
of Mf in  1 ml  night blood. The levels of Mf fluctuated considerably, starting at relatively high 
levels in April, to significantly lower levels in July, with a subsequent increase in  November. 
The reason for the observed fluctuation  is not clear.  Such fluctuations have been  reported 
before and are thought to accompany climatic changes. As the adult worms live more than 
5 years and  the time before an  L3  becomes and adult worm  is  more than  3 months,  the 
fluctuation  in  Mf density is  most likely a result of change in  the reproductive activity of the 
female worms.  It is possible that when the number of biting mosquitoes is low,  it would be 
more advantageous for the parasite not to produce many microfilariae. July marks the end 
of the dry season  in  the  area when  numbers of mosquitoes is  low and  indeed this  might 
be the reason for low levels of Mf seen in the study population. Although at the present we 
are  unable  to  clarify  the  Mf  fluctuation,  it  is  evident  from  our study  that  immunological 
parameters  can  also  alter.  The  antibody  levels  remained  fairly  constant  throughout  the 
study  period.  However,  T-cell  responses  fluctuated  considerably.  T-cell  proliferation  was 
low  in  April,  became  significantly  higher in  July and  decreased  again  in  November.  This 
indicates that an  increase in  reproductive activity of the female worms might be associated 
with a more profound suppression of the T-cell proliferactive responses to filarial antigens. 
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lgG4 antibodies in Brugian filariasis 
A comprehensive qualitative and quantitative analysis of lgG4 antibodies in filarial infection 
has  been  possible through  this  project.  Thus,  it was  shown  that parasite-specific  lgG4 is 
preferentially directed against low molecular-weight antigens relative to other isotypes, and 
5  individual  target  proteins  were  identified.  Some  of these  correspond  directly to  known 
recombinant  antigens,  and  others were  new. 
Over the  course  of  the  longitudinal  study,  we  have  measured  levels  of  each  isotype  of 
anti-filarial  antibody  as  well  as  microfilaraemic  status.  We  now  have  data  indicating  that 
high  lgG4  levels  (measured  against  total  BmA)  in  amicrofilaraemic  patients  are  not 
necessarily  prognostic  of  a  future  conversion  to  Mf-positivity,  and  conversely  that  some 
low-lgG4  Mf-negative  cases  do  convert  to  Mf-positive  within  a  few  months.  This  finding 
indicates  that  serodiagnosis  cannot  rely  on  total  lgG4  levels,  but  will  require  more 
restricted  antigenic specificity afforded  by recombinant antigens. 
We  have  also  completed  a  study  on  the  isotype  of  antibodies  binding  directly  to  the 
surface of the  infective  larva (L3)  stage,  presumed to  be  the  target of protective  immune 
responses.  Most  interestingly,  little  of  this  antibody  is  of the  lgG4  isotype,  although  that 
subclass  predominates  among  antibodies  reactive  to  whole  worm  (larval  and  adult) 
antigens. This strengthens the case that the L3 surface contains exclusive specificities, not 
present  in  later stages,  which  may be  good  candidates for vaccine development. 
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STUDIES  ON  THE  DEVELOPMENT  OF  PROTECTIVE  IMMUNITY  IN  LYMPHATIC 
FILARIASIS CAUSED  BY  BRUGIA MALAY/IN AN  AGE-GRADED  POPULATION 
Period: 
Co-ordinator: 
Objectives 
January 1,  1995 - May 31,  1996 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE 
London,  United Kingdom  (D.  DENHAM) 
To  analyze  immune  responses towards filarial  antigens  in  a well  characterized  population 
resident  in  areas endemic for lymphatic filariasis.  Parasitological,  clinical  and  immunologi-
cal  markers of  infection,  when  correlated  with  age,  can  yield  important  information  about 
the  dynamics  of the  host  parasite  interaction.  Comparison  of  infected  versus  uninfected 
as  well  as  children  versus  adults  should  identify  immune  pathways  that  operate  to 
decrease  susceptibility to  infection  in  either the  uninfected  individuals  or  in  subjects  who 
resist  incoming  L3,  despite  harboring  adult  worms.  Both  antibody  isotype  profiles  and 
cytokine  levels  released  in  response  to  parasite antigens  (in  vivo as  well  as  in  vitro)  can 
indicate the extent to  which  TH 1 and  TH2  cell  subsets are  reactive  in  lymphatic filariasis. 
The  exact  contribution  of  these  two  subsets  to  immunity  or  pathogenesis  of  filarial 
infections  has  yet  to  be  delineated.  As  the  fine  specificity  of  immune  recognition  is 
determined  by  MHC,  the  HLA  typing  of  the  study  population  will  be  necessary  for  our 
complete  understanding  of  immune  reactivity  in  filarial  infected  subjects.  As  far  as  our 
understanding  of  immunity  to  filarial  parasites  is  concerned,  our  objectives  can  be 
summarized  as  follows: 
•  Extensive  epidemiological  surveys  to  gather  precise  demographic  information  and  to 
assess  parasitologic and  clinical  status of the  study subjects. 
•  HLA typing  of  the  study population  to  correlate  infection  status and  disease  with  HLA. 
•  Antibody isotype analysis in the study population with  particular emphasis on  lgG4 and 
lgE,  isotypes that are  elaborated  in  helminth  infections and  seem  to  play an  important 
role  in  resistance  or susceptibility to  schistosome  infections. 
•  Cytokine profiles in  serum  of the  study population  in  order to  correlate their levels with 
infection  status. 
•  Cytokine  production  by  PBMC  in  response  to  parasite  antigen  to  understand  the  TH1 
versus TH2  balance  in  clinical  groups as  a function  of  age. 
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Activities (so far) 
The coordination of the project is now from the University of Leiden and a new developing 
country  partner  Hasanuddin  University  in  Indonesia  has  been  included.  Dr.  Medeiros 
started  her training to  become  a pathologist and  therefore  some  of the  Portuguese tasks 
were  performed  in  Leiden  on  their behalf. 
*  A second  field  trip  to  Sulawesi  was  undertaken  in  July  1995.  Two  of  the  members  of 
staff from  Leiden  University and  3 staff members from  Hasanuddin  University were  in 
charge  of  the  field  activities.  A  continuation  of  the  screening  of  villages  involved 
completion  of  questionnaires,  night  blood  filtration  (1Om I)  for detection  of  microfilariae 
and complete clinical examination. The study has examined in total 248 individuals with 
an  age  range  of 7 to  80  (see  results  for  study  population  description). 
*  HLA analysis of  the  study population  was  carried  out by  oligotyping. 
*  Measurements of  anti-filarial  lgG4 and  lgE. 
*  Total  lgG4 and  lgE levels were determined and  related to the specific antibody levels in 
order to  understand  how these  two  isotypes are  regulated  as  a function  of age  at the 
polyclonal  as  well  as  antigen  specific level. 
*  Anti-filarial  lgG1,  2 and  3 levels were measured and  expressed as  a function of clinical 
status  and  age. 
*  Serum  levels of  IL-4,  IL-6,  IL-8,  IL-10 and  IFNy were  measured.  In  addition,  the  levels 
of LPS-binding protein,  ICAM, E-selectin and TNF receptors I and  II  were determined to 
assess  the  extent  of  granulocyte  activation  as  well  as  stimulation  of  inflammatory 
cytokines  in  filarial  infections. 
*  For the  assessment of age  graded T cell  responses,  it  proved  to  be  more  feasible  to 
carry  out  the  study  in  Central  Sulawesi  where  an  ongoing  CEC-supported  project 
(CT1-CT1-0928  and  TS3*CT920031)  enabled  the  use  of facilities  that  are  needed  for 
cell work.  In the meantime, the laboratory at Hasanuddin has established an operational 
laboratory with  flow hood  and  centrifuges that would  enable future  cell  work.  IL-4,  IL-5 
and  IFNy  production  by  PBMC  was  measured  in  response  to  filarial  antigens  and 
analyzed  as  a function  of  aye. 
*  A proportion  of  the  infected  individuals  participated  in  DEC  chemotherapy.  The  treat-
ment  was  administered  for  1  0  days  and  repeated  3  times  at  2  week  intervals.  The 
antibody levels were  followed  and  a study is  now  set  up,  for the  first time  in  filariasis, 
to  address the  issue  of  reinfection. 
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Achievements so far 
The  study area is the north of Mamuju  in  South  Sulawesi. The  study population consisted 
of  248  individuals  with  a mean  age  of 25.7  (range  7-80).  Mean  length  of  residence  was 
14.9 years (range 1-80). 26o/o were mf+,  75°/o  lgG4E and 64o/o  lgE+. GMmf count was 241. 
A subset of these individuals have been typed for HLA class I and  II.  So far the data have 
been  analyzed to search for correlates between  HLA and elephantiasis.  No significant and 
reproducible  correlations could  be  found.  The  use  of anti-filarial  lgG4 for determining  the 
degree  of  endemicity  of  Brugian filariasis  indicates  that  this  test  can  indeed  be  a useful 
and  more  sensitive substitute for the  night blood  sampling.  The  levels  of anti-filarial  lgG4 
have  been  analyzed  as  a  function  of  gender  to  show  that  males  and  females  show 
consistent differences  in  infection  pattern. 
Filarial  infections increase as  a function  of age  in  both  males and  females.  Males appear 
always  to  be  infected  to  a  greater  extent  than  females  (irrespective  of  age  or  clinical 
status).  The  level  of anti-filarial  lgE  in  the  study population  indicates that microfilaraemics 
show  depressed  levels  of  lgE  when  compared  with  mf  negative  subjects.  The  data  are 
now  being  analyzed  as  a  function  of  age  and  gender.  Although  the  analysis  is  not  yet 
complete,  it  appears  that  anti-filarial  lgE  is  high  in  young  subjects  exposed  to  filarial 
infections and decreases with  increasing age.  However,  individuals aged 50 or older show 
increases in  levels of lgE directed to filarial  parasite antigens. Although  all  the  ELISAs for 
anti-filarial  lgG1,  2 and  3 have  been  performed,  the  data  have  yet to  be  analyzed. 
The  levels of inflammatory cytokines as  well  as  acute phase  reaction  proteins  have  been 
analyzed  in  a  subset  of  the  study  subjects.  It  was  found  that  there  was  a  significantly 
higher  levels  of  IL-6  in  individuals  with  elephantiasis  than  in  microfilaremics  or amicro-
filaremic  individuals.  No  differences were  seen  in  any of the  other parameters  mentioned 
above. The response of PBMC to filarial antigen  in terms of IL-4,  IL-5 and  IFNy production 
was  also  analyzed  in  order to  assess  how age  and  clinical  status influences the  balance 
between  these  cytokines.  It  is  clear  that  the  presence  of  mf  suppresses  both  IL-5  and 
IFN-gamma leaving  IL-4 unabated. Age  was  shown  to have a significant effect on  profiles 
of cytokines released  by different clinical  categories.  However,  we were unable to observe 
any correlates with  concomitant  immunity. 
Finally,  the  lgG4  ELISA is  now operational  in  Ujung  Pandang  and  the  research  team  will 
be  able to  carry out their own  surveys  for control  programmes. 
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An  additional  field  trip  is  planned  for  sampling  of  blood  from  young  children  (<1 0 
years). 
The  blood  will  be  collected  onto  filter  paper.  The  levels  of  lgG4  in  particular  will  be 
assessed.  If possible,  the levels of  lgE will  also be  determined. The individuals who have 
participated  in  DEC  chemotherapy  will  be  followed  for  re-infection  as  well  as  antibody 
reactivity.  Once the  re-infection  data is  available,  the immunological  reactivities  measured 
will  be  analyzed within  a framework of immunity to filariasis taking  into account age,  sex 
and  clinical  status. 
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IMMUNOLOGY OF  LYMPHATIC  FILARIASIS  T  CELL RESPONSIVENESS  AND  PRO-
TECTIVE ANTIGENS 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1996 - December 31 , 1998 
UNIVERSITY OF EDINBURGH 
Edinburgh, United Kingdom (R.  MAIZELS) 
+ To  identify protective antigens  in  lymphatic Filariasis suitable for vaccine  use. 
+ To  measure human  antibody and T cell  responses to these antigens. 
+ To  clone and  express major T cell  immunogens as recombinants. 
+ To  express selected  recombinant filarial  antigens for vaccine tests  in  animals. 
+ To  enhance expertise and  research  resources of endemic count scientists. 
Activities 
*  Identification of subjects exposed to  Filariasis transmission but show evident immunity. 
*  Measurement of antibody responses to a  range  of recombinant antigens. 
*  Identification and  cloning  of filarial  antigens which  most strongly stimulate T cells. 
*  Analysis of different geographic strains of Brugia malayi. 
*  Expression  of filarial  T cell  for vaccine testing  in  rodent  models. 
Expected outcome 
==>  Identification  of  a  panel  of  immune  individuals  whose  serological  and  lymphocyte 
reactivities will  define key in  immunity. 
==>  Identification  of the  major T cell  antigens  in  lymphatic Filariasis,  and their cloning  and 
expression  in  a variety of vectors. 
==>  Evaluation  of  potential  vaccine  antigens  against  lymphatic  Filariasis  in  rodent  model 
systems. 
304 Contract number IC18CT950014 
Partners 
University of Edinburgh 
ICAPB, Ashworth Labs 
West Mains Road 
Edinburgh EH9 3JT 
United Kingdom 
University of Leiden 
Department of Parasitology 
62 Postbus 9605 
Wassenaarseweg 
Leiden 2300 RC 
The Netherlands 
Imperial College 
Department of Biochemistry 
Exhibition Road 
London SW7 2AZ 
United Kingdom 
University of Indonesia 
Department of Parasitology 
P.O.  Box 1358 
Salemba Raya 6 
Jakarta 1  0430 
Atmadja 
Indonesia 
Shanghai Second Medical University 
Shanghai Institute of Immunology 
280 South Chongqing Road 
2916 Shanghai 
R.M. Maizels 
Tel:  44-131-6505.511 
Fax: 44-131-6505.450 
E-mail: R.Maizels@ed.ac.uk 
M. Yazdanbakhsh 
Tel:  31-71-276.863 
Fax: 31-71-276.850 
E-mail: MARIA@ rullf2.LeidenUniv.nl 
M.E. Selkirk 
Tel:  44-171-5945.412 
Fax: 44-171-5945.207 
E-mail: M.Selkirk@ ic.ac.uk 
A.  Kurniawan-Atmadja 
Tel:  62-21-3102.135 
Fax: 62-21-3924.607 
B.Ma 
Tel:  86-213.28 ext 6590 
Fax: 86-21.320 
305 Contract number ERBIC18CT950026 
VACCINATION  AGAINST  FILARIAL  INFECTIONS/USE  OF  LOA  LOA  A  MURINE 
MODEL FOR  IDENTIFICATION  OF  PROTECTIVE  MECHANISMS AND ANTIGENS 
Period: 
Co-ordinator: 
Objectives 
January 1,  1996 - June 30,  1997 
MUSEUM NATIONAL D'HISTOIRE NATURELLE 
Paris,  France (ODILE BAIN) 
*  To determine the mechanisms of protection induced by irradiated infective larvae of Loa 
loa  in  monkey and  of  Litomosoides sigmodontis in  laboratory mice. 
*  To  identify the  mechanisms of natural  protection against microfilariae of  L.  sigmodontis 
in  laboratory mice  and  cotton  rats. 
*  To  identify  and  clone  antigens  associated  with  protection,  for  incorporation,  into  live 
single dose  oral  recombinant vaccines. 
Activities 
*  Spleen  T-cell  and  antibody  responses  will  be  measured  in  L.  simodontis vaccinated 
mice and controls,  in  the  presence of antigens derived from  microfilariae,  L3  and adult 
worms.  Knock-out mice and  cytokine depletion with  specific monoclonal  antibodies will 
be  used.  The  pattern  of  antigen  recognition  will  be  investigated  by  Western  blot  and 
radio-i mmuno-precipitation. 
*  A similar investigation  will  be  performed  with  Loa loa mandrills. 
*  Survival and migration of Loa loa L3 in vaccinated and control mice, and the associated 
pathology will  be  studied. 
*  The  pattern  of  microfilaraemia  and  the  immune  response  of  mice  and  cotton  rats 
infected with  normal  L.  sigmodontis L3  will  be  investigated,  as  in  1.  Modulatory effects 
of cytokines  will  also be  investigated. 
*  mANA from  L.  sigmodontis and  Loa loa infective larvae will be isolated for production of 
eDNA libraries. eDNA clones identified in the primary screens will  be sub-cloned in  high 
expression vectors for production  of the  corresponding  recombinant  antigens. 
*  Screening  reagents  (rabbit  antisera)  from  L.  loa  and  L.  sigmodontis  stages  (adult 
worms,  microfilariae,  infective  larvae,  fourth  stage  larvae)  will  be  prepared.  Antisera 
raised against fractionated native and  recombinant antigens will  be  used to localise the 
molecules  in  the  parasites. 
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Expected outcome 
1)  Determination of the  relative  role  of Th1  versus Th2  responses  in  the development of 
protective immunity following immunisation of mice with  irradiated infective larvae of  L. 
sigmodontis. 
2)  Comparison  with  the  Loa  loa  specific  immune  responses  in  mandrills  following  a 
similar procedure of immunisation with  irradiated larvae. 
3)  Comparison  with  natural  protection against microfilariae of  L.  sigmodontis in  mice and 
cotton  rats. 
4)  Identification and  production  of at least some antigens associated with  protection. 
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IMMUNOLOGY OF LYMPHATIC  FILARIASIS 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1998 - December 31 , 1999 
UNIVERSITY OF EDINBURGH, 
lnst. of Cell, Animal and Population Biology, 
Edinburgh, United Kingdom (R.  MAIZELS) 
+  To  establish the relationship between immune response to filarial parasite antigens and 
the  length of exposure to  transmission. 
+ To  identify  major antigens  from  the  infective  L3  stage  of  Brugia malayi,  as  defined  by 
reactivity with  human  immune sera and  T cells. 
+  To  identify the major antigens from  the  microfilarial (Mf)  stage,  and to test for antigenic 
variants of these  antigens. 
Activities 
The  immunology of exposure to and  infection with  lymphatic filarial  parasites,  with  respect 
toT cell subsets and stage-specific antigens, will be assessed. The first aspect will be the 
relationship  between  exposure  to filarial  transmission  and  the  evolution  of  immunomodu-
lated  responses,  evident  in  a  strongly TH2  biased,  TH1  down-regulated  profile.  Patients 
subject to lifelong transmission of filariasis will be compared with  immigrants into the same 
area whose exposure is limited to  only 4 or 8 years. The progression  of the T cell  subset 
bias,  and  the development of antigen-specific unresponsiveness seen  in  filariasis,  will  be 
monitored. An  important question  is whether this subset bias relates primarily to the adult 
stage,  or whether other stages are  similarly involved. 
Secondly,  prominent  antigens  from  L3  and  Mf  stages  will  be  isolated  and  cloned  for 
functional  analyses.  The  importance  of  such  antigens  in  mediating  protection  against 
disease can  be directly assessed using sera and T cells from  the study populations; their 
biological  role  in  the  host-parasite  relationship  may  also  be  deduced  from  database 
sequence  similarities  and  the  opportunity  to  discover  new  antigens  from  immature 
parasites through  the  new  Filarial  Genome  Project. 
A number of other biological questions which  underpin filarial disease and  its cure will also 
be addressed.  Preliminary evidence for antigenic polymorphism  in  the  Mf sheath antigens 
will  be  pursued,  using  different  isolates  and  species  of  filarial  parasite.  The  interaction 
between  the  anti-filarial drug,  DEC,  and  Mf antigens will  be  studied. The  role  of non-CD4 
T cells,  which  may prejudice the immune response towards the TH2  pathway from  a very 
early stage,  will  be  examined. 
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Expected outcome 
~  An  understanding of stage-specific immune responses  in  pathology and  immunity. 
~  Molecular data on  sequence and  polymorphism of Mf sheath antigens. 
~  Sequence and  profile of immune  recognition  of L3  antigens. 
Partners 
University of Edinburgh 
Institute of Cell, Animal & Population Biology 
King's Buildings 
West Mains Road 
Edinburgh EH9 3JT 
United Kingdom 
University of Leiden 
Department of Parasitology 
Wassenaarseweg 62 
Postbus 9605 
Leiden 2300 RC 
The Netherlands 
Hasanuddin University 
Parasitology Department 
Faculty of Medicine 
Jl Peri ntis Kemerdekaan Km.  1  0 
Ujung Pandang, Sulawesi Selatan 
Indonesia 
Regional Medical Research Centre 
Indian Council for Medical Research 
Chandasekharpur 
Bhubaneswar 751  016 
India 
R.M. Maizels 
Tel:  +44/131/650.55.11 
Fax: +44/131/650.54.50 
E-mail: r.maizels@ed.ac.uk 
M. Yazdanbakhsh 
Tel:  +31n1/527.68.63 
Fax: +31/71/527.68.50 
E-mail: MARIA@rullf2.LeidenUniv.nl 
G.K. Abadi 
Tel: +621411/31.65.38 
Fax: +62/411/31.45.13 
B. Ravindran 
Tel:  +91/674/44.03.91 
Fax: +91 /67  4/40.70.00 
E-mail: icmr@ iopb.ernet.in 
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BRANCROFTIAN  FILARIASIS:  THE  INTERRELATIONSHIP  BETWEEN  TRANSMIS-
SION, INFECTION, HOST RESPONSE AND CLINICAL MANIFESTATIONS IN  ENDEMIC 
COMMUNITIES  BEFORE AND AFTER  INTERVENTION 
Period: 
Co-ordinator: 
Objectives 
September 1, 1997 - August 31, 2000 
THE DANISH BILHARZIASIS LABORATORY, 
Charlottenlund, Denmark (P.E.  SIMONSEN) 
•  To  assess and analyse the  effect of different levels of transmission  on  the age  profiles 
of infection, disease and host immune response in  bancroftian filariasis,  and to analyse 
the  interrelationship between  these. 
•  To  assess  and  analyse  the  heterogeneity  of  infection,  disease  and  host  response 
patterns  within  endemic  communities,  especially  the  relationships  between  infection 
status of children and that of their parents and the effect of exposure at household level 
on  between-host variability  in  infection  and  disease levels. 
•  To  assess  and  analyse  the  effect  of  control  measures  on  transmission,  infection, 
disease and  host immune responses  in  communities with  different levels of endemicity, 
and  to  analyse the  cost-effectiveness of these  measures. 
Activities 
The field  part of the project will  be  carried  out  in  Tanga  Region  of Tanzania and  in  Kwale 
District of Kenya,  where the  partner members  have  intensive experience from  studies on 
the  epidemiology,  transmission,  chemotherapy  and  immunology  of  bancroftian  filariasis. 
Basically, the project will comprise of a series of cross sectional parasitological, clinical and 
immunological  investigations  accompanied  by  intensive  longitudinal  entomological  and 
clinical  surveillance  at  village  and  household  level  in  selected  high  and  low  prevalence 
communities.  Mass chemotherapy with  DEC will be introduced after the first baseline year, 
while  the  same type of investigations continue. 
Data  from  individually  designed  sub-studies  will  first  be  analysed  and  documented 
separately.  However, the design of the project provides a unique opportunity for evaluating 
the forms of the functional relationships occurring between exposure, infection and disease 
dynamics,  and  host  immune  responses,  both  at  community  and  individual  level.  These 
relationships will be studied via a combination of mathematical models and more advanced 
statistically-based analyses. 
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Expected outcome 
The  project  will  address  some  important  unanswered  questions  related  to  bancroftian 
filariasis  epidemiology and  control,  in  particular the  following: 
=>What is the role of transmission intensity in shaping the age profile patterns of infection, 
disease  and  host  immune  responses  seen  in  endemic  areas,  and  what  roles  do 
transmission  intensity  and  various  host  immune  responses  play  in  resistance  mecha-
nisms and  pathological  processes? 
=> What  is  the  role  of  individual  exposure  intensity  in  determining  the  heterogeneity  of 
infection,  disease  and  host  response  patterns  seen  within  the  endemic  communities? 
And  what  role  do  parents  infection  status  play  for  the  infection  status  and  immune 
responses  seen  in  their children? 
=>What effect do parasite intervention measures have on  transmission,  infection,  disease 
and  host  immune  responses  in  communities  with  different  levels  of  endemicity,  and 
especially  at  what  level  of  microfilaraemia  in  the  human  population  will  transmission 
cease? And  how  will  cost-effectiveness of  intervention  measures differ in  communities 
with  high  and  low endemicity? 
Partners 
The Danish Bilharziasis Laboratory 
Jaegersborg Aile 1 D 
2920 Charlottenlund 
Denmark 
The Wellcome Trust Centre for Epidemiology 
of Infectious Diseases 
South Parks Road 
Oxford OX1  3PS 
United Kingdom 
The Division of Vector Borne Diseases 
Ministy of Health 
P.O.  Box 20750 
Nairobi 
Kenya 
The National Institute for Medical Research 
P.O.  Box 9653 
Dar es Salaam 
Tanzania 
P.E. Simonsen 
Tel:  +45/31.62.61.68 
Fax:  +45/31.62.31.21 
E-mail: pes@bilharziasis.dk 
D.A.P. Bundy 
Tel:  +44/1865/28.12.46 
Fax:  +44/1865/28.12.45 
E-mail: don.bundy@ zoo.ox.ac.uk 
J.H. Ouma 
Tel:  +254/2/72.43.02 
Fax:  +254/2/72.56.24 
W.L.  Kilama 
Tel:  +255/51.30.770 
Fax: +255/51.31.864 
E-mail: nimr@costech.gn.apc.org 
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CHARACTERIZATION  AND  UTILIZATION  OF  TWO  NEW  FILARIAL  MODELS  FOR 
INVESTIGATION  OF IMMUNITY,  CHEMOTHERAPY AND  PATHOLOGY 
Period: 
Co-ordinator: 
Objectives 
March  1,  1992 - February 28,  1995 
MUSEUM NAT.  D'HISTOIRE NATURELLE/CNRS-URA 114, LABO DE 
BIOLOGIE PARASITAIRE, PROSTISTOLOGIE, Paris,  France (0. BAIN) 
The  objective  of  this  proposal  is  to  utilize  two  new  models  for  filariasis:  Litomosoides 
sigmodontis in  the white mouse and  Monanema martini dermal microfilaria in  a species of 
murine,  in  order to: 
+  investigate  the  immunological  and  genetic  mechanisms  involved  in  the  pathology  of 
filariasis  and  of the  both  natural  and  acquired  resistance to  infection. 
•  evaluate the action  of antifilarial drugs,  for example  lvermectin and  macrofilaricides,  on 
both  the  parasite and  the  host. 
Activities 
The  French  partner  (Paris)  has  the  two  models  available  and  is  specialized  in  parasite 
biology,  morphology  and  pathological  anatomy.  This  laboratory  has  contributed  in  the 
following  ways: 
*  Definition  of the  parasitological  findings for the  two  models. 
*  Vaccination with  irradiated L3s,  recombinant antigens from  experimental filaria and their 
homologues. 
*  The  effect  of  macrofilaricides  on  the  parasites  and  the  host,  including  pathology  and 
immunology. 
*  Pathological  investigations using  ophthalmology and  pathological  anatomy. 
The  UK  partner  (Cambridge)  possesses  great  experience  in  the  characterization  of 
parasite  antigens and  immune  responses.  The  work plan  was  as  follows: 
*  The  analysis  of  the  humoral  and  cellular  response  stimulated  by  L.  sigmodontis  in 
different  strains  of  mice,  for  example  in  Balb/c  and  Balb/k  (susceptible)  or  810 
(resistant). 
*  The  production  of  recombinant  antigens  of  0.  volvulus  from  different  life  cycles  for 
vaccination  experiments. 
*  The  analysis  of  the  immune  response  following  attempts  at vaccination. 
*  The  estimation  of  the  role  of T cells  (Th1  and  Th2)  and  the  production  of  cytokines. 
Some  of this  work will  be  carried  out using  the  rodent  Lenmiscomys striatus. 
The  German  partner  (TObingen)  will  study  the  mode  of  action  of  lvermectin  in  the  two 
animal  models.  Different protocols  will  be  used  and  the  immune  response  and  pathology 
analyzed  in  each  case. 
The Nigerian partner (Enugu) will  analyze problems of drug distribution in the host and the 
parasite  as  well  as  the  problem  of  drug  resistance,  including  the  pharmacokinetics, 
detoxicification  mechanisms  and  enzymology. 
Expected outcome 
It  is  expected  that this  investigation  will  lead  to  progress  in  understanding: 
=>The mechanisms  of  resistance  following  vaccination. 
=> The  mechanism  of action  of the  drugs  used  and  the  role  of the  immune  response. 
=>The mechanisms important for the development of ocular and dermal pathology, as well 
as  consequences for the  choice  of the  appropriate  drug  regime. 
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Results 
=>  Resistance,  or tolerance,  in  the  natural  hosts:  reduction  of the  ratio filariae  recovered: 
infective  larvae  inoculated  was  obtained  by  multi-inoculation  of  homologous  L3,  and 
inoculation of heterologous L3  (Acanthocheilonema  vite/M.  martint).  Three other proce-
dures were started: inoculation of offspring from infected and uninfected parents; long term 
administration of cytokines to infected rodents with an osmotic pump; antifilaricidal drugs. 
=>Biology and  immunology  in  the  L.  sigmondontis-mouse  system:  ten  strains  of  inbred 
mice  were  sub-cutaneously inoculated  with  L.  sigmodontis L3.  The  Balb/c  is  the  most 
susceptible  (1 00°/o  mice with  adult filaria,  47°/o  with  blood  microfilariae 2 months p.  1.). 
The  BIOD2  is  almost  totally  resistant.  The  proportion  of  larvae  which  develop  was 
similar in  the two strains during the first month  p.i.,  but since the tenth  day the filarial 
growth was  reduced  in  the  BIOD2. 
=>  Molecular cloning,  description and  properties of five  0. volvulus recombinant antigens: 
Ov 1.9 (16000Mr),  Ov 2.5 (50,000Mr),  Ov 3.11  (42,000Mr),  Ov HSP and  Ov GST. 
=>Vaccination trials in  L.  sigmodontis-mouse model:  83°/o  of reduction of the recovery rate 
was  obtained  with  an  irradiated  L3  procedure.  Use  of a Triton  insoluble fraction  of  L. 
sigmodontis resulted in  a facilitating effect. Among the recombinant antigens tested, Ov 
3.11  showed a slight sterilizing effect.  Experiments of poly-vaccination using Salmonella 
typhimurium with  Ov GST or HSp  were  started. 
=>  Pathology: Onchocerca-like ocular lesions induced by Monanema martini were confirmed 
by an ophthalmological study of 49 Lemniscomys striatus and 26 Arvicanthis niloticus, the 
chorio-retinal atrophy and the punctate keratitis are respectively predominant is these two 
murine hosts, which also represent two biological systems: high microfiladermia and adult 
worm with  long life in  the first murine species,  low microfiladermia and adult worm with 
short life in  the second.  Histology showed that the chorioretinal atrophy corresponds to 
the  destruction  of  the  pigmentary  epithelium  and  sensorial  retina,  which  evokes  a 
degenerative process originating from choroidal vascularization. 
=>  Drug  treatments and  side  effects  in  M.  martini-L.  striatus:  among  the  14 drugs tested, 
one  of  the  four  benzimidazoles  used,  UMF  289,  appeared  very  efficient  (micro-and 
macrofilaricidal)  and  with  less  acute  side-effects  as  shown  by  the  histopathological 
analysis.  M.  martini microfilariae,  which  are  resistant to ivermectin  in  vitro and  in  vivo, 
were  also  resistant to  moxydectin. 
Partners 
Museum Nat. d'Histoire Naturelle 
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Cambridge University 
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CAN  CATTLE  PROTECT  MAN  FROM  ONCHOCERCIASIS?:  REDUCTION  OF 
SIMULIUM  VECTORIAL  CAPACITY AND  CROSSREACTING  IMMUNITY AS  FACTORS 
OF ZOOPROPHVLAXIS 
Period: 
Co-ordinator: 
Objectives 
April  1,  1992 - March 31,  1996 
UNIVERSITAT HOHENHEIM, DEPARTMENT OF PARASITOLOGY, 
Stuttgart, Germany (A.  RENZ) 
Despite  an  extremely  high  Simulium  damnosum  s.l.  biting  rate  on  man  (up  to  150.000 
bites per year at the  riverbank)  and  intensive  Onchocerca transmission potentials (60.000 
L3  0. ochengi and  2.000  L3  0. volvulus per man  and  year),  human  onchocerciasis was 
found  to  be  rare  in  a  cattle-farming  highland  area  of  Cameroon.  The  concept  of 
zooprophylaxis was  studied  with  a view to: 
+  Assessing the  reduction  of the vectorial capacity of Simulium populations as a result of 
blood  meals on  non-human  hosts. 
+  Establishing  the  degree  of  cross-transmission  of  invasive  L3s  of  various  strains  and 
species  of  Onchocerca parasites between  humans and  animals,  particularly cattle. 
•  Determining  whether  antigenic  cross-reactivity  exists  between  0.  volvulus  and  0. 
ochengi and  whether exposure to  0. ochengi affords a degree of protection against 0. 
volvulus in  man. 
•  Utilizing  the  0.  ochengi cattle  model  as  a  system  for  testing  potential  vaccines  for 
human  onchocerciasis. 
Strategies for local  onchocerciasis control  can  be  developed integrating live stock produc-
tion and socio-economic development in  rural  areas. The proof of concomitant homologous 
and  cross-reacting  heterologous  immunity  in  human  and  bovine  onchocerciasis  would 
support the  development of a vaccine  against human  onchocerciasis. 
Activities 
Activities  have  been  broadly  divided  into  two  categories  - studies  of  the  epidemiology 
(Germany,  Cameroon  and  Nigeria)  and  the  immunology  (Glasgow).  The  epidemiological 
topics addressed included:  (i)  the  life cycles of Simulium-transmitted animal filariae,  using 
microfilaria isolated from  fresh  hides injected  intrathoracically into  neonate  Simulium flies; 
(ii)  whether L3  invade unsuitable hosts,  by assessing the readiness of the various species 
of  filariae  to  leave  their  vector  during  a  blood  meal;  (iii)  the  prevalence  of  human  and 
animal  onchocerciasis  in  selected  villages  in  Cameroon  and  Nigeria;  (iv)  Simulium biting 
rates  and  Onchocerca transmission potentials on  man  and cattle;  (v)  investigations on  the 
biology  and  epizootiology  of  bovine  onchocerciasis,  0.  ochengi in  particular;  (vi)  cross-
immunization  experiments  in  cattle,  using  0.  volvulus larvae  as  a  live  vaccine  against a 
challenge  infection  by  0. ochengi L3. 
Immunological  topics  covered:  (i)  Onchocerca-antigen  recognition  by  human  and  bovine 
sera;  (ii)  comparison of surface and excretory-secretory (E-S) antigens of  0. volvulus and 
0. ochengi using biochemical preparative techniques followed by SDS-PAGE and  isoelec-
tric  focusing;  (iii)antigenic  analysis  of  radiolabelled  molecules  for  antigenicity  and  cross-
reactivity and  (iv)  investigation  of  lymphocyte  responses. 
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Expected outcome 
The  results  of  this  study will  enable: 
=> The  national  health  authorities in  Cameroon  and  Nigeria to  formulate control  strategies 
and  to  assist  local  public  health  authorities  in  the  control  of  onchocerciasis  - these 
results  could  have  a direct impact on  rural  development planning. 
=>  An  evaluation  to  be  made  of  the  epidemiology  and  intensity  of  disease  transmission 
before the mass-distribution of ivermectin, which is expected to strengthen the effects of 
zooprophylaxis by  reducing  the  proportion  of  0. volvulus larvae  in  the  man-biting files. 
=> An  assessment  to  be  made  of  the  importance  of  cross-reactive  immunity  and  the 
possibility of  vaccine  development. 
Results 
Quantitative aspects of the transmission dynamics of Onchocerca volvulus,  0. ochengi and 
0. ramachandrini have  been  studied  in  savanna  and  rain-forest  areas  of  Cameroon  and 
Northern  Nigeria.  The  proportion  of  non-0.  volvulus  infective  larvae  (L3)  in  man-biting 
Simulium damnosum s.l.  flies  in  the  Sudan  savanna  (prior to  the  now  starting  ivermectin 
campaigns) varied from 20-60°/o and consisted mainly of 0. ochengi during the dry season, 
when  nomadic cattle gather along the perennial  rivers,  with  an  increasing proportion  of  0. 
ramachandrini (former  Type  D  sensu  stricto,  adult  worms  in  warthogs)  during  the  rainy 
season.  In  the Adamaoua  highland,  where  cattle  outnumber the  human  population  by  a 
factor of 5 to  20,  over  90o/o  of all  infective  larvae  were  0. ochengi,  but  warthogs  and  0. 
ramachandrini are  absent.  0. volvulus L3  leave  their vector flies  during  a blood  meal  on 
cattle  in  similar proportions as  do  0. ochengi L3  (ca  60 to  80°/o  of  L3}.  The same  escape 
seems to occur if L3 of 0. ochengi are transmitted on  man by boo-anthropophilic flies. This 
is a prerequisite for a naturally occurring crossreactive immunization. 
The  homology  of  0.  volvulus  and  0.  ochengi  gravid  female  worm  antigen  and  their 
recognition  by  sera  of  human  onchocerciasis  patients  from  villages  exposed  to  various 
amounts  of  0.  Ochengi co-transmission  was  studied  by  one- and  two  dimensional  gel 
electrophoresis.  There  was  a high  degree  of  homology  in  the  protein  composition  of the 
two  filarial  species  and  a  marked  crossreactivity  in  the  humoral  recognition  of  antigens. 
Patients  groups  from  the  savanna  (with  high  microfilarial  density  in  the  skin)  recognized 
low molecular weight antigens of both filarial  species more strongly than  patients from  the 
highland (which  had few microfilaria or were skin-negative). However,  antibodies from  sera 
of  highland  patients  bound  to  0.  ochengi  rather  than  to  0.  volvulus  antigens.  These 
patients also  showed  a pronounced  lgG3-reactivity to  0. ochengi antigens  indicating that 
lgG3  might  be  important  in  acquired  immunity to  onchocerciasis. 
Excretory/secretory (E-S)  and  surface antigens are  likely to represent potential targets for 
protective  immune  responses.  Infective  larvae  of  0.  volvulus  and  0.  ochengi  have 
therefore  been  subjected  to  a variety of  intrinsic (biosynthetic)  and  extrinsic  radiolabelling 
procedures  in  order to  assist E-S.  antigen  analysis by two dimensional electrophoresis.  In 
spite  of  much  effort,  only  the  extrinsic  procedures  (iodination)  resulted  in  a  degree  of 
radiolabelling applicable to analysis and only with  E-S Iodinated 0. volvulus L3  E-S appear 
to contain  four major products with  molecular weights of  180,  140, 55 and  51  kD  and  0. 
ochengi L3  appear to  contain  at  least three  of  these. 
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Highly sensitive and specific ELISAs have been developed for the measurement of bovine 
lgM,  lgG1  and  lgG2  antibodies  to  parasite  molecules.  These  assays  demonstrate  that 
infection  is  generally  quickly  associated  with  elevated  lgM  and  lgG 1  levels  to  parasite 
antigen.  lgG2  levels  appear  to  be  much  less  affected.  Conversely,  we  have  obtained 
some  preliminary  evidence  that  lgG2  levels  may  rise  following  our  successful  ''vaccina-
tion"  of  cattle  against  0.  ochengi  with  living  0.  volvulus  infective  larvae.  As  the 
vaccination  result  is  of potential  importance,  we  are currently investigating this  interesting 
possibility  further  using  both  ELISA  and  Western  Blotting  to  target  individual  antigens 
being  recognized. 
A  sandwich  ELISA  for  detection  of  phosphorylcholine-containing  circulating  antigen  has 
been  applied to cattle from  Cameroon  infected with  0. ochengi.  Preliminary observations 
suggest that it can  successfully detect infection and hence it may be of some value in the 
cases  where the  presence of infection  is  uncertain. 
An  heterologous cross-immunization experiment was carried out with the aim of immuniz-
ing  calves  with  live  infective  larvae  of  0.  volvulus  against  a  challenge  infection  by  0. 
ochengi  L3.  In  the  1  0  naive,  non-vaccinated  calves,  26  worms  (22  female  and  4  male 
worms)  had  developed to the  adult stage  and  were  found  in  22  palpable  nodules (26  of 
254 L3 larvae injected = 1  Oo/o  development rate).  In the vaccinated group (1 0 animals, 545 
to 800 live 0. volvulus L3 s.c.  per calf),  only 2 nodules containing 2 females but no males 
were  recovered  (2  of 254  0. ochengi L3  injected  =  1.5o/o).  This  experiment showed that 
the  human  parasite  afforded  some  degree  of  protection  against  a  challenge  infection  in 
cattle,  much  in  the same way as the bovine parasite protects the  human  population.  It is 
the  first  successful  vaccination  in  a  nodule-forming  Onchocerca-species  using  a  live 
vaccine  in  its  natural  host. 
In  conclusion,  our results strongly corroborate the  hypothesis of cross-protection between 
the  bovine  and  human  parasite  and  confirmed  that  0.  volvulus  is  indeed  unable  to 
establish  patent  infection  in  the  bovine  host.  The  now-starting  mass-distribution  of 
ivermectin  in  Africa  is  likely to  enhance  these  effects  of  cross-immunization  by  reducing 
the  proportion  of  infective  L3  of  0.  volvulus  in  the  anthropozoophilic  Simulium  vector 
flies.  A  mathematical  model  is  presently  being  developed  to  describe  the  quantitative 
effects  of  zooprophylaxis  and  cross-transmission  on  the  epidemiology  or  human  on-
chocerciasis. 
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IMMUNE RESPONSES IN  ONCHOCERCIASIS: STUDIES WITH MOLECULAR PROBES 
IN  PATIENTS AND AN  ANIMAL MODEL 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1992 - September 30,  1995 
UNIVERSITY OF SALFORD, DEPARTMENT OF BIOLOGICAL 
SCIENCES, Salford, United Kingdom (J.E.  BRADLEY) 
The  major objective  of this  project were  to  produce  recombinant  proteins of  the  parasitic 
nematode  Onchocerca  volvulus for  the  development  of  specific  serodiagnostic  tests  and 
candidate  vaccines.  A  parallel  approach  involved  the  use  of  the  rodent  filarial  model 
system  A.  vitae  in  the  Jird  and  the  production  of  recombinant  proteins from  this  parasite 
with  the  objective of performing  protection  experiments. 
Results 
A)  Isolation  and  characterisation  of  recombinant  proteins. 
Many recombinant antigens have been  isolated and expressed as part of this project.  Most 
have  been  previously  reported.  Recent work has  focused  on  the  cloning,  expression  and 
purification  of  the  full  length  molecule  corresponding  to  a  previously  described  20kDa 
molecule Ov 20. This has  now been  achieved using the  pET 15 expression system  and  it 
is  now  possible  to  express  this  molecule  at  a level  of  1  OOmg/L.  This  has  allowed  us  to 
perform a number of experiments to determine the  structure and function of this molecule. 
It  has  been  determined  using  a  fluorescence  binding  assay  that  Ov20  binds  retinoids 
strongly with  a dissociation constant of 0.0851JM.  It also binds other fatty acids but  not as 
strongly  as  retinol  (dissociation  constant  0.971JM).  This  is  in  contrast  to  a  recently 
described  fatty  acid  binding  protein;  the  polyprotein  allergen  from  Ascaris.  The  structure 
was  shown  to  be  60°/o  alpha  helix  by  circular  dichroism  and  using  structure  prediction 
programmes  it  was  also  predicted  to  be  predominantly alpha  helical  and  formed  a coiled 
coil  which  is  highly  unusual  for  such  proteins.  Thus,  it  appears  that  Ov20  represents  a 
novel  retinoid  binding  protein  with  a structure  quite  unlike  any  so  far  described. 
Retinoid binding proteins have been  isolated by protein purification from  0. volvulus in  the 
past and  based  on  size (19kD)  may be  identical to  Ov20.  This molecule was  shown to  be 
able  to  bind  ivermectin.  As  Ov20  represents  such  an  unusual  molecule  it  may  be  an 
important target for chemotherapy. 
B)  Serodiagnosis and  seroepidemiology 
Collection  of  well  characterised  patient  sera  from  the  hyperendemic  area  of  the  Lekie 
region  of Cameroon  has been described in  earlier reports. As  has the  utilisation of various 
recombinant antigens for serodiagnosis.  The serodiagnostic part of the  project has  largely 
been  completed.  The  use  of  a cocktail  of  three  recombinant  antigens  (Ov1 0,  Ov11  and 
Ov29)  to  detect  antibody  in  patients  sera  work  with  a  high  degree  of  specificity  and 
sensitivity.  The  addition  of  a fourth  antigen  to  the  cocktail  (Ov33)  was  shown  to  further 
improve  the  sensitivity. 
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Epidemiological studies using sera from Cameroon in attempts to associate disease status 
with  antigen  recognition  have,  in  general,  proved  fruitless.  All  the  recombinant  antigens, 
isolated  as  part  of  this  project,  have  been  tested  at  the  isotype  level  with  sera  from 
ophthalmologically characterised onchocerciasis individuals but no correlations were found. 
Analysis of sera from these individuals by immunoblotting against adult worm antigens has 
indicated  that  certain  antigens  were  recognised  more  frequently  by  these  individuals  in 
comparison  to  asymptomatic patients. 
A further aim  of the  study was to  evaluate the  effect of host genetics on  the  outcome of 
infection.  HLA  studies  have  so  far  revealed  no  correlation  with  any  disease  state  or 
response to  any individual antigen.  Expression of novel  DPB alleles,  however,  was found 
in  some  individuals from  this  region. 
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PROTEIN COMPONENTS OF CHEMORECEPTOR ORGANELLES AND OF THE CUTICLE 
OF NEMATODES: IDENTIFICATION AND CLONING OF THE GENES, PRODUCTION AS 
RECOMBINANT PROTEINS AND ANALYSIS OF THE IMMUNE RESPONSE ELICITED 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1993 - December 31 , 1995 
CENTRO INTERUNIV. RICERC.  PAESE  IN VIA Dl  SVILLUPO 
Napoli, Italy (P.  BAZZICALUPO) 
•  Increase  our knowledge  and  understanding,  at the  cellular and  molecular level,  of the 
ontogenesis,  structure  and  physiology of chemoreception  and  of  the  cuticle  of  nema-
todes. 
•  Clone and study parasite molecules, components of the chemoreception system and of 
the cuticle,  as  potential  target for drug  and/or vaccine  development. 
•  Study the  immune  response  toward  molecularly defined  antigens  of nematodes. 
•  Perform  pilot  epidemiological  studies  to  identify,  in  the  Northern  region  of  Morocco, 
special  communities  or situations  were  nematode  infections  are  more  frequent  and/or 
severe. 
•  Train scientists from  European and developing countries in the field of biotechnology as 
applied to  the  control  of nematode  infections. 
Activities and results 
Chemoreception 
We  have completely characterized a chemoreception  mutant identifying a new gene dyf-1 
and  have  shown  that  it  affects  the  structure  of  the  amphids,  the  main  chemosensory 
organs  of  nematodes. 
Avoidance mutants 
We  have designed  a completely new test for the  chemical  avoidance  response.  The test 
is  relatively  easy  to  perform,  fast  and  unambiguous  and  has  enabled  us  to  screen  over 
150 different chemicals for the ability to trigger the avoidance reflex in  C.  elegans. Among 
the newly identified repellents are cupper ions,  quinine and other antimalarial drugs.  Using 
the  assay  described  above,  we  have  isolated  13  new  mutants  unable  to  avoid  quinine. 
Some of these mutant are particularly interesting in  that they apparently have normal cilia 
and  amphidial channels. Two of these mutants do not complement and define a new gene 
qui-1  which  we  have  mapped  genetically  on  chromosome  IV  near  the  gene  tra-2.  The 
mutants fail  to  avoid  quinine  but  are  still  able to  avoid  other repellents,  including  cupper 
ions and garlic extracts. This finding,  together with the apparent normal architecture of the 
cilia,  suggests that the two mutations are likely to affect the  receptors directly and  not the 
general  functioning  of chemosensory neurons. 
Cuticle 
We  have  identified  and  cloned  three  homologues of  cut-1  in  Ascaris lumbricoides and  at 
least two in  Brugia pahangi. Southern blots with conserved regions have shown that genes 
homologous to  cut-1  are  conserved  in  all  other nematode  species tried. 
Together with  several  cut-1  like  genes which  have  been  discovered  in  C.  elegans by the 
genome  sequencing  project  they  represent  a  new  gene  family  with  an  important  role  in 
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making  up  the  protective layers of nematodes.  One Ascaris gene has been  studied  more 
completely and the whole genomic and  eDNA sequences determined. The homology with 
C.  elegans cut-1  is  higher than  85o/o  as the  amino  acid  level  and  like  in  C.  elegans the 
protein  begins with  a signal  peptide. 
Recombinant Ascaris CUT-1  has been  obtained from  E.  coli expression vectors and  used 
to  raise specific antisera in  rabbits.  lmmuno-electron-microscopy has been used to localize 
CUT-1  and CUT-2 epitopes in  nematode cuticles.  Determination of the genomic sequences 
and  identification  of eDNA clones from  Brugia pahangy are  in  progress  in  Glasgow. 
Using recombinant CUT-2  produced in  E.  coli we  have studied CUT-2 cross-linking in vitro 
and demonstrated the importance of hydrophobic interactions in this process, which occurs 
during cuticle  assembly  in  vivo,  and  involves the formation  of dityrosine bridges between 
different CUT-2  molecules. 
Immune  response  to  gp  30  and  filarial  antigens 
We  performed  a series  of  experiments to  establish  the  cellular and  immune  response  of 
mice to native gp30 and to a synthetic gp30 peptide which corresponds to aT cell epitope. 
A variety of  immunization  protocols were  used: 
~mice immunized and  boosted  with  L3  of  Brugia pahangi; 
~  mice immunized sub.-cutaneously with  1  00  micrograms of the synthetic gp30 peptide or 
with  100 micrograms of  native  Brugia antigen; 
~  mice  infected with  adult  B.  pahangi by transplantation  into the  peritoneal  cavity; 
~  mice  immunized  by footpad  injection  with  the  peptide and  or the  adjuvant alone. 
Sera  and  lymphocytes  from  these  animals  were  then  analyzed  for  presence  of  specific 
antibodies, for proliferation for cytokine production.  In  general,  peptide immunized animals 
had  no detectable antibody response to Brugia antigen, while animals immunized with the 
native  antigen  or with  worms  did.  Similarly,  lymphocytes  from  native  antigen  immunized 
animals  proliferated  in  response  to  Brugia  antigen  but  not  to  peptide  while  cells  from 
peptide immunized animals did not proliferate in  response to native antigen but there was 
a modest stimulation with  peptide.  Finally no differences were observed  in  the expression 
of  any  cytokine  mRNA  from  lymph  nodes  of  peptide  immunized  animals  compared  to 
adjuvant only controls. 
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GENETIC  VARIATION  IN  ONCHOCERCA  VOLVULUS FROM  CAMEROON,  TANZANIA 
AND SIERRA LEONE 
Period: 
Co-ordinator: 
Objectives 
January 1,  1994 - June 30,  1996 
KONINKLIJK INSTITUUT VOOR DE TROPEN, DEPT OF BIOMEDICAL 
RESEARCH Amsterdam, The Netherlands (L.  OSKAM) 
+  To  investigate the genetic diversity within  0.  volvulus using  molecular markers. 
+ To  assess the  role  of strain  variation  in  the epidemiology of onchocerciasis. 
Activities 
*  We collected 0. volvulus samples from foci from different biotopes within different endemicities 
and with different parasitological, clinical, and ophthalmological manifestations. 
*  We  investigated  the  genetic  variation  within  0.  volvulus  from  Cameroon,  Tanzania  and 
Sierra  Leone  using  molecular biological  techniques  such  as  microsatellite  PCR,  Southern 
blotting and  hybridization and  nucleotide sequencing. 
Results 
Epidemiology 
In  Cameroon  0.  volvulus  samples  were  collected  in  five  villages  located  in  three  different 
biotopes, namely savannah, forest and savannah-forest mosaic. In  all villages prevalence rates 
were well above 50°/o.  There appeared to be no difference in  blindness rates between the three 
biotopes. 
In  Tanzania samples were collected  in  eight villages located  in  four foci:  3 savannah foci  and 
one  altitude forest focus.  In  three  out  of four foci  we  found  a  high  percentage  of the people 
(9-18°/o)  presenting  with  onchocerciasis  related  blindness.  To  our  knowledge  this  is  the  first 
description of the  extent of blinding onchocerciasis  in  East Africa. 
Random amplified polymorphic DNA analysis (RAPD) 
We tried to develop a RAPD PCR for the detection of genetic differences between  0. volvulus 
isolates.  We  found  that  this  technique  is  not  suitable  for  the  analysis  of  0.  volvulus  DNA 
because of the presence of traces of human DNA present in  the nodule tissue which clings to 
the worms during isolation. This lead to extremely polymorphic patterns. Moreover, the patterns . 
were  highly dependent on  the amount of input DNA. 
Nucleotide sequence analysis 
From  a selection of samples two  different parts of the  genome were cloned  and sequenced. 
1.  Internal  Transcribed  Spacer  (ITS)  This  area  comprises  the  intergenic  region  between  the 
18S and  5.8S  rRNA genes.  It  is  known  that this  is  an  area with  a  high  degree of sequence 
variation. We found that in  0. volvulus the sequence of the ITS was highly conserved between 
different isolates. 
2.  150 base  pair  repeat The  150 bp  repeat of 0.  volvulus  is  present  at approximately 4500 
copies  per  haploid  genome.  This  makes  this  repeat  an  ideal  target  for  PCR.  Nucleotide 
sequence  has  shown  that  there  is  sequence  variation  within  the  150  bp  repeat.  From  the 
sequence analysis we  performed we  concluded that there are differences,  but that these are 
not systematic differences,  making it  impossible to  develop specific probes or primers. 
PCR and Southern hybridization using 0. volvulus and "non-blinding" strain specific probes 
Based on the nucleotide sequence of the 150 bp  repeat, two oligonucleotide probes have been 
identified in the past: OVS-2 being specific for 0. volvulus and OVF for "non-blinding" 0. volvulus. 
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We found that probe OVS-2 did  not react with  19/99 (19°/o)  of the PCR amplified DNA isolates 
of  0.  volvulus.  All  these  isolates  were  from  outside  the  Onchocerciasis  Control  Programme 
(OCP)  area for which  the  probes were originally designed. 
We found that none of the samples from Tanzania reacted with probe OVF. This corroborates the 
finding  described  in  "epidemiology"  that  blinding  onchocerciasis  is  common  in  Tanzania.  In 
Cameroon the situation was less clear. All 4 isolates from the Savannah forest mosaic that were 
tested reacted with  probe OVF despite the fact that two were isolated from blind people.  In the 
forest area, 90°/o of the samples reacted with probe OVF. 
We conclude that, at least outside the OCP area, one has to be cautious with the interpretation 
of  results  obtained with  probes  OVS-2  and  OVF. 
Microsatellite PCR 
Microsatellites  are  short  (2-5bp)  tandemly  repeated  sequences  that  have  been  shown  to  be 
useful  as  polymorphic  markers  for populations  and  individuals.  We  screened  an  0.  volvulus 
genomic library for the presence of microsatellite sequences and identified one locus consisting 
of a (CA) 30 repeated sequence containing one insertion and 5 point mutations. Based on  this 
sequence,  primers  were  chosen  and  a  PCR  amplification  reaction  was  developed  and 
optimized. 
With this PCR we were able to identify 7 different alleles at this locus, namely A,  B,  B', C1, C2, 
C3  and  D.  When  comparing  isolates  from  Sierra  Leone,  Cameroon  and  Tanzania,  we  found 
that  the  isolates  from  Sierra  Leone  showed  almost  exclusively  the  A  allele,  the  Cameroon 
isolates showed A,  Band B'  and the isolates from Tanzania showed all  seven alleles, thereby 
being  the  most heterogenous population. 
We conclude that microsatellite PCR is a suitable technique for the detection of genetic variation 
between 0. volvulus isolates. However, it is at the moment impossible to correlate the presence 
of certain alleles with clinical findings.  In  order to make this possible, we will have to develop a 
set of microsatellite PCRs at different heterogenous loci. 
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ANTI-OXIDANT ENZYMES IN  FILARIAL NEMATODES: THEIR ROLE IN  DEFENCE AND 
PERSISTENCE 
Period: 
Co-ordinator: 
Objectives 
July 1,  1993 - June 30, 1996 
BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE, 
Hamburg, Germany (K.  HENKLE) 
•  To  characterize  the  anti-oxidant  enzymes,  glutathione  peroxidase  and  superoxide 
dismutase,  in  0.  volvulus  and  B.  malayi,  and  to  define  the  stage-specificity  of 
expression and secretion  of these enzymes in  vivo  and  in  vitro. 
•  To  assess the role of anti-oxidant enzymes in  different stages of filariae in  the defence 
against  mediators  of cytotoxicity  and  to  biochemically  define  the  damage  caused  by 
oxidants. 
•  To train scientists from Banaras Hindu University in techniques of molecular biology and 
biochemistry,  and  to  integrate  and  co-ordinate  the  efforts  of independent  laboratories 
working in  closely related  subject areas. 
•  To  assay the  immune  response  to  anti-oxidant  enzymes  in  human  filariasis  patients, 
and in  particular the effect of antibodies which  neutralize parasite enzyme activity. 
Results and activities 
*  The glutathione peroxidase has been extensively characterized  in  B.  malayi,  including 
its structure, activities,· localization, stage-specificity and secretion. A functional counter-
part  in  0.  volvulus  has  not  been  identified,  although  an  enzyme  with  overlapping 
function and a very similar localization profile, the glutathione S-transferase I,  has been 
characterized. 
*  Two distinct CuZn SODs have been characterized  in  0. volvulus and  B.  pahangi. The 
structure, function,  localization, stage-specificity and secretion of these two enzymes in 
both  parasitic nematodes has been examined. 
*  The characterization of the "extracellular'' form  of the CuZn  SODs in  both  0. volvulus 
and  B.  malayi provides evidence that this  enzyme is  involved  in  the defense  against 
host superoxide anion radicals since it was found to be secreted in  in  vitro and in  vivo 
studies. 
*  To  assess the role of anti-oxidant enzymes in  different stages of filariae in the defence 
against oxidative stress and to biochemically define the damage caused by oxidants, in 
vitro studies were performed with  B.  malayi. The sensitivity of microfilariae and adult B. 
malayi to hydrogen  peroxide (H20 2)  was assessed and  both  stages were found to be 
surprisingly  resistant  to  peroxide  stress.  Microfilariae  showed  an  impaired  viability  at 
concentrations  at which  adult worms were  unaffected,  correlating  with  the  concentra-
tions of the antioxidant enzymes in  these two stages. 
324 Contract number ERBTS3*CT940271 
*  The  rate  of  H20 2  consumption  by  parasites  was  determined,  and  showed  that  adult 
worms  metabolised  it  at  a  rate  24  X faster than  microfilariae. Assessment  of  enzyme 
activities  in  parasite  extracts demonstrated that  H20 2  metabolism  was  affected  princi-
pally  by  catalase  activity,  which  was  elevated  in  adult worms  relative  to  microfilariae. 
Cytochrome  c  peroxidase  activity  was  also  detected,  and  was  roughly  equivalent  in 
both  stages.  Glutathione  peroxidase  and  NADH/NADPH-dependent  consumption  of 
H20 2  were  absent,  and  the  rate  of  non-enzymatic  reduction  of  H20 2  coupled  to 
glutathione oxidation  did  not contribute significantly to  metabolism.  Glutathione  reduct-
ase  activity and  total  glutathione content were  equivalent in  adults and  microfilariae. 
*  It  was  determined  that  B.  malayi is  much  more  resistant  to  H20 2  than  other  filarial 
species  examined  to  date,  and  can  effectively  metabolize  levels  in  excess  of  those 
potentially generated  by  activated  leucocytes. 
*  Dr.  Henkle-Duhrsen  has  visited  Dr.  Selkirk  in  London  and  Dr.  Rathaur  in  Varanasi  to 
.  discuss  results  and  coordinate ·future  experiments.  Dr.  Selkirk  will  visit  Dr.  Henkle-
Duhrsen and  Dr.  Rathaur late in  1996 to analyze,  integrate and summarize results from 
each  partner. 
*  The human  immune responses of Indian patients infected with  W.  bancrofti have been 
examined  with  the  recombinant  glutathione  peroxidase  and  superoxide  disumutase 
enzymes.  Studies to detect antibody reagents which neutralize enzymatic activity are in 
progress. 
*  Dr.  Suman  Misra from  Varanasi  spent 7 weeks  in  1995 at the  Bernhard Nocht Institute 
in  Hamburg for training in  molecular biology methods,  as well  as  in  the production and 
purification of recombinant proteins.  Dr.  Sushma Rathaur spent 6 months in  1996 at the 
Bernhard  Nocht Institute in  Hamburg to learn  advanced  molecular biology methods. 
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ISOLATION, CHARACTERISATION AND IMMUNOLOGICAL EVALUATION OF RECOM-
BINANT VACCINES  FOR  FILARIAL PARASITES 
Period:  January 1,  1996 - December 31,  1998 
Co-ordinator:  SALFORD UNIVERSITY 
Salford, United Kingdom (J.BRADLEY) 
Objectives 
•  Development  of  candidate  vaccines  against  parasitic  filarial  infections,  in  particular 
Onchocerca  volvulus. 
•  To  identify,  isolate and  express antigens that are  specific to  the  larval  stages  of these 
parasites. 
•  To  analyse  of  the  immune  responses  of  humans  exposed  to  0.  volvulus  and  animals 
infected  with  Acanthoche lonema  viteae to  these  antigens. 
•  To  assess the  protective capacity of these  antigens  in  a rodent filarial  model  system. 
Activities 
*  Production  of  quantities  of  L3  and  L4  larval  stages  of  the  parasites  Onchocerca 
volvulus and  Acanthocheilonema viteae. 
*  Identification and characterisation of antigens that are specific to the larval stages of the 
parasite  by  protein  analysis and  differential  display  PCR. 
*  Cloning  and  Expression  of  stage  specific  antigens  from  eDNA  libraries  of  each  larval 
stage. 
*  Characterisation  of  the  cellular  and  humoral  responses  to  the  larval  antigens  of 
putatively immune  humans  exposed  to  onchocerciasis transmisson. 
*  Evaluation  of  the  protective  capacity  of  the  recombinant  larval  antigens  in  a  rodent 
filarial  model  system. 
Expected outcome 
=:::}  The  identification  of  novel  candidate vaccine  antigens for onchocerciasis. 
=:::}The  identification  of  the  type  of  immune  responses  that  are  protectiveagainst  filarial 
infections  in  humans and  animal  models. 
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IVERMECTIN - FACILITATED  IMMUNITY IN  ONCHOCERCIASIS 
Period: 
Co-ordinator: 
Objectives 
December 1, 1992 - November 30,  1995 
UNIVERSITY OF TUBINGEN, INSTITUT FOR TROPENMEDIZIN, 
Tubingen, Germany (P.T.  SOBOSLAY) 
•  To  activate  parasite-specific  cellular  responses  of  onchocerciasis  patients  before  and 
after single  and  repeated  doses of ivermectin. 
•  To  characterize  antibody  responses  of  onchocerciasis  patients  before  and  after  iver-
mectin  treatment  in  terms of  isotypes and  antigen  specificity. 
•  To  characterize and  localize immunodominant Onchocerca volvulus antigens potentially 
involved  in  protection  or pathology. 
•  To examine a possible immune-dependent regulation of the reproduction of Onchocerca 
volvulus. 
Activities and results 
In  West  Africa,  control  of  onchocerciasis  relies  on  both  vector  eradication  and  mass 
treatment  campaigns  with  ivermectin,  the  drug  of  choice  for  onchocerciasis  treatment. 
Humans chronically infected with  0. volvulus demonstrate not only a prominent production 
of  all  subclasses  of  parasite-specific  immunoglobulins  but  also  a  depressed  cellular 
reactivity  in  vitro and  deficient production  of cytokines  in  response  to  0. volvulus-specific 
antigenic  stimulation.  A  longitudinal  investigation  was  conducted  into  the  cell-mediated 
immune  responses of onchocerciasis patients after a single-dose treatment with  ivermec-
tin.  The  in  vitro cellular reactivity to  Onchocerca  volvulus  - derived  antigens  (OvAg)  was 
reduced  in  untreated patients as compared to controls,  and the cellular reactivity to OvAg 
and  bacterial antigens improved up to 14 months post treatment. These results suggested 
a  distinctly  improved .cellular  immunity  in  human  onchocerciasis  that  was  facilitated  by 
single  ivermectin therapy.  In  continuation,  the  parasite-specific antibody response,  cellular 
reactivity and  cytokine production profile was examined  in  onchocerciasis patients repeat-
edly treated  with  ivermectin  for several  years.  Cellular  reactivity to  OvAg  increased  after 
several  rounds of ivermectin dosing, and furthermore,  proliferative responses were greater 
in  treated  microfilaria-free  patients than  in  microfilaria-positive  onchocerciasis  patients.  In 
amicrofilaridermic patients such  reactivity approached the  magnitude observed in  endemic 
control  individuals.  Peripheral  blood  cells  from  subclinical  amicrofilaridermic  patients  or 
exposed endemic controls produced significantly more IL-2 and IFN-y in  response to OvAg 
than  cells  from  patently  infected,  mf-positive  humans.  Titers  of  parasite  specific  lgG 
subclasses  continuously  declined  with  repeated  treatments,  and  Onchocerca  volvulus 
antigen  recognition  by  circulating  antibody  isotypes  gradually  weakened.  These  results 
suggest  that  onchocerciasis-associated  immunosuppression  is  reversible  following 
ivermectin-induced permanent clearance of microfilariae from the skin;  and that a vigorous 
parasite-specific  Th1-type  reactivity  in  amicrofilaridermic  individuals  may  contribute  to 
controlling  Onchocerca  volvulus infection. 
In  order to  identify those  parasite  antigens which  may account for the  differential  cellular 
responsiveness with distinct states of Onchocerca volvulus infection total adult worm-derived 
OvAg were fractionated into antigen fractions of continuously decreasing molecular weight. 
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While  PBMC  from  onchocerciasis  patients  did  not  respond  to  any  of the  OvAg  fractions, 
reactivity  of  PBMC  from  exposed  endemic  controls  was  depressed  to  only  high 
molecular  weight  antigens  of  Mr  200-30  kDa.  However,  antigens  of  Mr<30kDa  induced 
vigorous  responsiveness  in  mf-negative  individuals,  with  highest  proliferative  responses 
being  observed  in  response  to  OvAg  of  Mr  15-11  kDa.  Furthermore,  these  low 
molecular  weight  antigen  fractions  induced  substantial  production  of  IL-2  and  IFN-y  in 
PBMC  from  endemic  controls,  but  not  in  those  from  onchocerciasis  patients.  In  contrast, 
PBMC  from  patients  clearly  produced  more  IL-10  than  did  cells  from  endemic  controls. 
These  results  suggest  that  vigorous  Th1  type  cellular  responsiveness  encountered  in 
endemic  controls  is  restricted  to  low  molecular weight  antigens  of  Onchocerca  volvulus, 
such  reactivity  is  not  present  in  mf-positive  individuals.  These  traits  of  cellular  immunity 
may  contribute  to  the  differential  outcome  of  Onchocerca  volvulus  infection,  the  mani-
festation  of clinical  disease,  and  may  also  regulate  the  build  up  of  acquired  immunity  in 
humans. 
In  onchocerciasis  microfilariae  play  the  key  role  for the  transmission  of  the  parasite  and 
the  development  of  pathology,  and  since  microfilariae  released  from  the  adult  worms 
accumulate  and  survive  in  the  host  for  considerable  time,  the  parasites'  reproductive 
biology  and  population  dynamics  are  of  prime  consideration  for  the  control  of  filariases. 
The analysis of the  reproductive capacity of adult 0. volvulus has  revealed that reproduc-
tion  occurs in  asynchronous cycles,  and  only a portion of the  intra-uterine microfilariae will 
leave the female worm.  The mechanisms that regulate microfilarial production and  release 
seem  to  be  multifactorial;  partially  or  even  predominantly  regulated  by  factors  and 
mechanisms  intrinsic  to  the  host;  e.g.  the  current  state  of  immunity.  In  patients  without 
microfilariae  in  skin  biopsies  (after  ivermectin  treatment,  or  humans  with  postpatent 
infection)  the  reproduction  of  the  parasite  continues  with  regular  embryonic  and  micro-
filarial  development;  there  was  however,  a spectacular and  unusual  accumulation  of  vital 
microfilariae  in  the  uteri,  microfilariae  did  not  leave  the  uteri,  degenerated  and  were 
subsequently resorted.  Reduced transmission of the parasite and  ivermectin treatment will 
interfere with  the  delicately balanced  host-parasite equilibrium and  with  parasite  reproduc-
tion.  lvermectin-facilitated  immunity,  as  a  consequence  of  repeated  therapy,  may  be  of 
significant relevance to the control of onchocerciasis,  immunological alterations in  the  host 
which  alter the  worm  population  and  its  reproductive  capacity  may  synergistically help to 
prevent the  clinical  manifestations  of  onchocerciasis. 
Conclusions 
The severity of chronic disease produced  by the  parasitic nematode  Onchocerca  volvulus 
varies  widely,  ranging  from  asymptomatic  infection  to  cutaneous  involvement  and,  most 
severely,  to  ophthalmologic  pathology  which  may  finally  cause  blindness.  At  present, 
onchocerciasis control  relies  on  vector eradication and  on  mass treatment campaigns with 
ivermectin.  Cellular  immunity of  onchocerciasis  patients  underwent  substantial  alterations 
following  repeated  ivermectin  treatment  indicating  that  cellular  hyporesponsiveness  in 
chronically  infected  patients  is  reversible  following  permanent  clearance  of  microfilariae 
from  the  skin.  Control  strategies which  are  aimed  at  reducing  aggregation  of  0. volvulus 
may facilitate the expression and persistence of parasite-specific Th 1-type immunity, which 
may  suffice  to  reduce  the  serious  morbidity of  0. volvulus infection. 
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Onchocerciasis  is  the  fourth  common  cause  of  blindness  and  inflammatory eye  disease. 
An  autoimmune cause for ocular onchocerciasis has been  suggested  since the  identifica-
tion  of  a  recombinant  antigen  (Ov39)  that  shows  immunologic  cross-reactivity  with  a 
human ocular tissue component. The structural similarities between host self-antigens and 
Onchocerca  volvulus  may  thus  be  involved  in  expression  of  autoimmune  reactivity  and 
development of autoimmune  disease.  The  tissue  distribution  of  Ov39  correlates  with  the 
sites  of  pathology  in  onchocerciasis  and  antibody  reactivity  could  be  detected  in  all 
persons  with  onchocerciasis  and  pathology  of  the  posterior  segment  of  the  eye.  By 
immunohistological  methods  epitopes  cross-reactive  between  parasite  Ov39  and  human 
ocular hr44 were  localized to the optic nerve,  neural  retina,  retinal  pigment epithelium,  as 
well  as  the  epithelial  layers of the  ciliary  body and  iris.  These  observations  propose that 
immunological  cross-reactivity  contributes  to  the  immunopathogenesis  in  onchocerciasis, 
and  it is  suggested that intraocular presentation  of this cross-reactive  parasite antigen by 
microfilariae  is  essential  for the  development of disease. 
For prevention of onchocercal ocular disease repeated annual treatment with  ivermectin is 
recommended.  Repeated  treatment  for  several  years  effectively  reduced  ocular  micro-
filariae  and  achieved  a  considerable  regression  of  early  ocular  lesions  of  the  anterior 
segment of the  eye,  however,  observations also indicated that the  most beneficial  effects 
were  only  achieved,  if  therapy  was  conducted  regularly.  From  these  observations  we 
conclude,  that  for  the  long-term  ivermectin-supported  control  of  onchocerciasis,  imple-
mented  through  primary  health  care  activities,  the  compliance  of  endemic  populations  is 
urgently required. 
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EXPLOITATION  OF  TARGETS  FOR  CHEMOTHERAPY  IN  POLYAMINE  METABOLISM 
OF  FILARIAL WORMS 
Period: 
Co-ordinator: 
Objectives 
February 1,  1993 - October 31,  1996 
BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE, DEPT OF 
BIOCHEMICAL PARASITOLOGY, Hamburg, Germany (R.D. WALTER) 
The  project  has  the  following  objectives: 
•  The development of urgently needed, safe and potent drugs against onchocerciasis and 
lymphatic filariasis. 
•  The  assessment of filaricidal  efficacy and  selectivity of potential  biochemical  targets  in 
the  polyamine  metabolism  of filarial  worms. 
•  The  strengthening of research  capacity in  tropical  diseases both within the  EC  and the 
developing  countries,  here  the  consolidation  of  a  standing  co-operation  started  under 
STD-2  with  the  University of  Benin-City in  Nigeria. 
Activities 
The  activities  which  form  part  of  this  project  are  the  assessment  and  exploitation  of 
peculiarities  in  the  polyamine  metabolism  of  filarial  worms  with  a  view  to  rational  drug 
development.  The  research  project will  address  the  following  questions: 
*  How do filarial  worms  regulate  their polyamine  synthesis  and  content? 
*  Can  the  parasite  evade  toxic  levels of polyamines? 
*  Is  the  polyamine  oxidase  a candidate  target for chemotherapy? 
Results 
1  .  Biosynthesis 
Activity  of  ornithine  decarboxylase  (ODC),  the  initial  step  in  the  polyamine  synthesis 
pathway,  could  not  be  detected  in  various  parasitic  nematodes  and  it  has  been 
suggested  that  filarial  worms  do  not  synthesize  putrescine.  To  obtain  a  better  insight 
into  the  polyamine  synthesis  of  nematodes  and  in  order  to  establish  a  model  for 
studying  polyamine  metabolism  in  culture  at  the  biochemical  and  molecular  level,  the 
free-living nematode Panagrellus redivivus was established as an  experimental system, 
which  has similarities in  overall structure and development to  parasitic nematodes. The 
ornithine  decarboxylase  gene  from  P.  redivivus was  isolated,  expressed  in  a bacterial 
system  and  both  the  gene  and  the  recombinant  enzyme  were  characterized  at  the 
molecular  level.  Further  attempts  to  identify  the  ODC  gene  in  0.  volvulus,  Brugia 
pahangi and  Ascaris suum by  use  of  PCR  analysis  as  well  as  screening  of  genomic 
and  eDNA libraries of these parasitic nematodes with the  OCD eDNA from  P.  redivivus 
as  probe were  not successful. These  results suggest that filarial worms do  not depend 
on  their own  biosynthesis of  purtrescine. 
S-Adenosylmethionine  decarboxylase  (SAMDC),  another  rate  limiting  step  in  the  bio-
synthesis of polyamines was proposed as potential drug target. The filaricidal efficacy of 
this  target  was  assessed  by  treatment  of  maintained  worms  with  specific  enzyme 
inhibitors,  which  led  to  depletion of the  polyamine content and  to  death  of the  worms. 
To  assess  the  selectivity  of  the  target,  the  0.  volvulus  SAMDC  gene  was  isolated, 
expressed in  E.  coli and the  recombinant enzyme was analysed on the molecular level. 
The  amino  acid  sequence  of  the  filarial  SAMDC  shows  only  a  moderate  degree  of 
similarity  with  the  mammalian  SAMDC,  indicating  structural  differences  which  are  a 
necessary prerequesite for the  synthesis  of  specific  inhibitors. 
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2.  Polyamine sequestration  and  N-acetylation 
The occurrence and nature of polyamines covalently bound to proteins were investigated 
in  parasitic  and  free  living  nematodes.  Acid  hydrolysis  of  various  fractions  of  the 
homogenate  of  0. volvulus,  A.  suum and  P.  redivivus,  followed  by  RP-HPLC  analysis 
clearly confirmed the occurrence of conjugated spermidine and spermine in  the soluble 
and pellet fractions of reproductive tissues,  muscles and cuticle. This result is of special 
interest,  because  the  reversible  conjugation  of  spermidine  and  spermine  could  be  a 
process  by  which  the  nematodes  regulate  and  control  the  concentration  of  "free" 
polyamines. This could be  a mechanism for them to avoid lethal  levels of spermine,  by 
sequestering  the  excessive  polyamines.  The  absence  of  polyamine  N-acetylation,  a 
process  which  has  been  reported  from  0.  volvulus and  A.  suum,  whereas  activity  of 
diamine  N-acetyltransferase  was  measured  and  discovered  to  be  involved  in  the 
excretion process of putrescine. In trematodes, a single enzyme has been shown to fulfill 
the combined function of diamine, polyamine and arylalkylamine acetylation. Investigation 
of  the  former  nematodes  revealed  the  occurrence  of  distinct  N-acetyltransferases  for 
diamines and arylalkylamines. Based on the absence of polyamine N-acetylation in filarial 
worms and allied nematodes, it is concluded that the degradation of excess spermine and 
spermidine proceeds via the interconversion pathway to putrescine,  which  is  acetylated 
by the diamine N-acetyltransferase prior to excretion. 
3.  Polyamine  oxidase and  the  polyamine  interconversion  pathway 
In  parasitic  nematodes,  the  polyamine  oxidase  has  been  shown  to  be  the  rate-limiting 
step  in  the  interconversion  pathway.  The  nematode  enzyme  differs  with  respect  to 
substrate  and  inhibitor  specificities  from  the  mammalian  counterpart.  The  parasite 
specific  inhibitor  MDL  72145  was  considered  as  a  suitable  chemical  lead  for  the 
chemotherapy  of  filarial  parasites,  but  the  chemotherapeutic  strategy  of  spermine 
accumulation  to  lethal  concentrations  failed,  since  not  spermine,  but  the  reaction 
products of the polyamine oxidase,  reactive and toxic aldehydes and  H20 2  were shown 
to  be  responsible  for the  lethal  effect  of  elevated  spermine  levels.  lmmunolocalization 
studies  with  antiserum  against  the  polyamine  oxidase  revealed  an  abundance  of  the 
enzyme  in  the  hypodermis  and  possibly  in  the  cuticle  of  0.  volvulus,  a  result  which 
together  with  the  demonstration  of  polyamine  oxidase  in  the  spent  medium  of  main-
tained  0.  volvulus,  point  to  an  outstanding  function  of  the  polyamine  oxidase  at  the 
interface of  parasite  and  host. 
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IDENTIFICATION  OF  CANDIDATE  PROTECTIVE  MOLECULES  OF  E.  GRANULOSUS 
AND  DEVELOPMENT OF COMBINED  SALMONELLA VACCINES 
Period: 
Co-ordinator: 
Objectives 
May 1992 - October 1995 
UNIVERSIDAD DE  LA REPUBLICA, FAC.  QUIMICA DE 
IMMUNOLOGIA, Montevideo, Uruguay (A.  NIETO CADENAZZI) 
Long  term  aim  is  development of effective  vaccines  for  hydatidosis and  immediate  aims 
are: 
•  The identification of vaccine candidate E.  granulosus antigens (Ags) through analysis of 
immune evasion  mechanisms as well  as  isolation  of recombinant clones encoding the 
relevant  Ags  from  eDNA  libraries.  Ags  to  be  investigated  will  include  glutathione-S-
transferase (GST) and myosins.  lmmunogenicity and protection will  be tested in  animal 
models. 
•  The  analysis  of the  structure of  E.  granulosus glycans and  their influence,  as  well  as 
that  of the  idiotype  network,  on  the  balance  between  susceptibility  and  protection  to 
infection. 
•  The expression of recombinant antigens in  live  Salmonella vaccines to obtain  maximal 
expression  of the  recombinant  antigens  in  an  integrated  and  maximally  immunogenic 
form. 
Activities 
The  Uruguayan  partner (Montevideo)  will: 
*  purify the  E.  granulosus metalloproteases; 
*  purify anti-complement molecules obtained from  E.  granulosus; 
*  identify  putative  protective  antigens  from  protoscolex  (PSC)  surface  antigens  used  to 
protect mice; 
*  assay the immunogenicity of those antigens; those exhibiting protective capacity will be 
cloned  in  the  laboratory of the  UK partner (Newcastle); 
*  identify  and  characterise  immunogenic  parasite  glycans  and  analyze  their  role  in 
immune evasion  as  well  as  that of anti-idiotypes; 
*  analyze  the  influence  of  E.  granulosus  on  Th1/Th2  balance  and  susceptibility  to 
infection. 
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The  UK  partner (Newcastle)  will  be  responsible  for: 
*  the  optimisation  of  expression  of  recombinant  antigens  in  aro  and  htrA  Salmonella 
vaccines.  The  antigens  will  be  expressed  both  as  the  whole  protein  and  as  immuno-
genic peptide fused  to  LT-8; 
*  the  testing  of  the  construct  in  the  mouse  model  for  developing  humoral  and  cell-
mediated  immunity. 
The  French  partner (Paris) will  participate in  collaboration with  Prof.  Ehrlich's laboratory in 
the  search  of  genes coding  for  proteins essential  for parasite  survival. 
Expected outcome 
E.  granulosus  protease  clones  will  become  available  for  use  as  immunogens  and  for 
sequence  analysis.  Complement  activating  glycans will  be  functionally  characterised  and 
the  in  vivo  role  of  complement  in  susceptibility  to  infection  will  be  tested.  Candidate 
protective  molecules  and  specific  antibodies  (Abs)  will  be  prepared.  Putative  protective 
molecules  will  be  cloned  in  Salmonella  and  tested  as  immunogens.  Optimisation  of 
expression of recombinant antigens in  Salmonella vaccines will  lead to the development of 
a  putative  Sa/monel/a-hydrated  vaccine,  using  the  recombinant  hydatid  antigens  which 
become  available. 
Results 
Uruguayan partner 
E.  granulosus metalloproteases (EgMP) cleaving human  lgG3 and  lgG1  were purified. Abs 
recognizing  the  75kDa  EgMP  band,  were  found  in  sera from  infected  mice  and  humans 
but not dogs.  Rabbit anti-EgMP was  used to screen  a eDNA library. A clone was purified, 
but no sequence homology was found with any known protease. Complement activation at 
different  steps  of  the  cascade  by  different  parasitic  preparations  was  assayed  Cyst  fluid 
(CF)  produced  the  maximum  TCC  levels.  CF  derived  N-linked  oligosaccharide  which 
produce  TCC  by  fluid  phase  complement  activation  were  identified.  In  addition,  in  vivo 
complement depletion  was  shown  to  decrease susceptibility to  infection  in  mice.  At  least 
four  glucoproteins  from  the  protoscolex  (PSC)  surface  have  been  identified  which  are 
recognised by sera from protected mice and included in  ISCOMs which were immunogenic 
intranassally.  Parasite GST and  a candidate protective  E.  granulosus clones,  one  homolo-
gous  to  tropomyosin  (EgDf5)  and  the  other  to  fatty  acid  binding  proteins  (EgDf1)  were 
isolated  in  Prof.  Ehrlich's laboratory in  collaboration  with  Prof.  Nieto's laboratory.  The  role 
of  CD4+  and  CDS+  T-cells  in  immunity as  well  as  the  IL  profiles they  produce  during  in 
vitro  proliferation  were  also  analyzed  in  the  mouse  in  collaboration  with  Dr.  Anders  Orn 
(Karolinska  Institute,  Stockholm).  A MAb  (E492)  was  prepared  recognizing  Gala1-4Gal  in 
PSC  and  used  to  isolate  a  fraction,  containing  complement-activating,  mitogenic,  and 
immunodominant  T-independent  glycan  Ags.  Surface  PSC  glycans  obtained  by  EndoF 
treatment,  were  mitogenic  in  vitro  and  produced  hypergammaglobulinemia  in  vivo.  They 
were  immunodominant  in  mouse,  eliciting  low  avidity  Abs  and  an  unexpected  lgM  titer 
increase after booster.  Cyst membranes (CM)  glycans were also characterized and  found 
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to contain  both  N-linked and  Q-linked oligosaccharides which  are  immunogenic in  infected 
hosts.  A MAb  (285)  recognizing  the  immunodominant  Gal-gicNAc-Man  motif  in  N-linked 
oligosaccharides from  CM was prepared.  Four major N-linked oligosaccharides were found 
containing  GlcNAc,  Man,  Fuc,  Gal  and  NeuAc.  Their structures were  further analyzed  by 
FAB-MS  in  collaboration  with  Prof.  Anne  Dell  (Imperial  College,  London).  The  role  in 
immune  regulation  of  anti-idiotypes  mimicking  CF Ags  was  analyzed. 
UK partner 
A student from  Prof.  Nieto's laboratory completed  his  PhD  degree in  Cambridge perform-
ing  this  research.  Methods  for  the  expression  of  recombinant  antigens  in  Salmonella 
vaccines  as  fusion  proteins  to  fragment  C  of  tetanus  toxin  (TetC)  were  optimised. 
Preimmunisation  with  tetanus  toxoid  did  not  suppress  the  response  to  guest  antigens 
presented  as  such  fusions  to  Tete.  He  expressed  glycoprotein  D of  herpes simplex virus 
in  that  system  and  obtained  protection  of  mice  from  challenge  with  virus.  As  fatty  acid 
binding  proteins  conferred  protection  from  fascioliasis  and  schistosomiasis,  EgDf1  was 
considered candidate for protection  in  E.  granulosus.  EgDf1  was cloned and  expressed in 
Salmonella  and  an  htrA  vaccine  expressing  it  was  orally  administered  to  be  used  for 
expression  of  EgDf1  as  above  and  its  protective  potential  in  dogs  will  be  tested  in 
Uruguay. 
French partner 
Prof.  Scazzocchio  has  participated  in  collaboration  with  Prof.  Ehrlich's  laboratory  as 
described  above. 
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Universidad de Ia Republica (Uruguay) 
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Uruguay 
Universite de Paris Sud 
Centre Universitaire d'Orsay 
lnst. Genetique et Microbiologique 
Batiment 409 
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France 
University of Newcastle 
Dept. of Microbiology 
The Medical School 
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Fax: +598/2/4  7.43.20 
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Tel:  +33/16/941.63.56 
Fax: +33/16/941 .  78.08 
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C.E. Hormaeche 
Tel:  +44/191/222.77.04 
Fax: +44/191/222.77.36 
E-mail: c.e.hormaeche@ ncl.ac.uk 
339 Contract number:  ERBTS3*CT91 0039 
MOLECULAR APPROACH TO  ECHINOCOCCUS  DEVELOPMENT 
Period: 
Co-ordinator: 
Objectives 
July 1,  1992 - September 30,  1995 
UNIVERSIDAD DE LA REPUBLICA,  FACULTAD  DE CIENCIAS, 
Montevideo, Uruguay (R.  EHRLICH) 
The  main  objectives of the  project were  the  understanding  of the  molecular bases  of: 
+ growth  and  development processes that take  place  during the  E.  granulosus life cycle 
and 
+ the  mechanisms involved in  the adaptation to  its specific hosts. The  leading concept of 
the  proposal  was  that  the  knowledge  of  the  regulatory  processes  controlling  E. 
granulosus development,  growth  and  host  adaptation  could  made  important  contribu-
tions  to  hydatid  disease control. 
Furthermore, a complementary objective was proposed: it was focused on the optimisation 
of  the  expression  of  specific  parasitic  antigens  in  bacterial  vectors,  in  particular  in 
Salmonellae,  attempting to  contribute to the  production  of anti-parasitic  live vaccines. 
Activities 
The  study  of  E.  granulosus growth  and  development have  been  undertaken  focusing  on 
the  following  aspects: 
*  Search  for transcription  factors  able  to  be  involved  in  the  regulation  of developmental 
events  during the  parasite  life-cycle; 
*  Characterization of developmentally regulated genes in order to establish initial molecu-
lar  markers to  decipher regulatory mechanisms; 
*  Analysis  of the  parasitic-host adaptive  processes through  the  study of the  heat shock 
response; 
*  Study of cytoskeletal  protein  genes; 
*  Cloning  and  expression  of  antigen  encoding  genes; 
*  Analysis  of the  parasite's genome organization; 
*  As  a complementary objective, the  improvement of the expression of parasitic genes in 
attenuated  Salmonella have  been  also  undertaken. 
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Expected outcome 
Major contributions expected from  this  project included: 
=>  Contribution  to  deciphering  the  basis  for  the  specific  host-parasite  adaptation  and 
characterising  key  genetic switches during  parasite  development; 
=> The  improvement of the  expression  of  Platyhelminth  genes  in  Salmonella; 
=> Training  of  Latin  American  scientist in  molecular approaches to  parasitic diseases. 
Results 
In  a  first  step  we  have  completed  a  great  deal  of  descriptive  work,  mainly  involving 
isolation, cloning and sequencing of several genes. During a second period, the main effort 
has  been  centred  on  expression  studies  (characterization  of  promoters,  mapping  of 
transcription  start  sites,  improvement  of  different approaches  to  study complex formation 
between  promoters  and  specific  transcription  factors,  spatial  and  temporal  analyses  of 
gene  expression). 
Concerning molecular studies of development, growth and adaptation of  E.  granulosus, the 
following  work has  been  carried  out by  our groups: 
=>  Characterization of transcription factors possibly involved in  regulation of developmental 
events  during  the  parasite  life  cycle:  five  homcobox- containing  genes  have  been 
described:  Eghbx1-5.  The  expression  of  two  of  these  genes  has  been  detected  in 
protoscoteces (Eghbx1-2);  in  particular Ebhbx1-3 appeared to be  expressed specifically 
in  cells  associated to  calcareous corpuscles; 
=>  Isolation of two  protoscolex differentiation markers:  EgDf1 , a gene coding for a protein 
related to the fatty acid binding proteins family (FABPs) and  EgDf5,  coding for a protein 
related  to  tropom-yosins.  The  EgDf1  protein  could  be  involved  in  the  binding  and 
transport of lipids from  host origin,  a function  of crucial  importance for an  organism like 
E.  granulosus,  unable to synthesize  de novo most of its own  lipids.  Proteins related  to 
the  FABI's family were  also described  in  Schistosoma mansoni and  Fasciola  hepatica; 
it  was  reported  that  both  proteins  are  able  to  induce  significant  protection  against 
experimental  infection  in  animal  models.  The  Egdf5  gene  appeared  to  be  expressed 
specifically in  cells  of the  protoscolex suckers; 
=>With the  aim  of studying the  mechanisms of parasitic adaptation to  the  specific  hosts, 
the  heat shock response and  its time course in  E.  granulosus has been  characterized. 
Several  stress  proteins  were  identified  by  20-electrophoresis  and  a  genomic  clone 
containing  the  complete  coding  region  of  a  Hsp70  protein,  including  the  5  regulatory 
domain  was  characterized; 
=>  Several  genes  coding  for  proteins  involved  in  cytoskeleton  organization  were  charac-
terized;  three different actins, the troposyosin-like protein mentioned above, and a gene 
coding for a putative actin-filament-fragmenting  protein. 
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=>Two  genes  coding  for  enzymes  have  been  characterized  a cytocolic  malate  dehydro-
genase  gene  and  a gene  coding  for a thioredoxin-like  protein. 
=> A gene  coding  for  calcium-binding  protein  (EgCaBP)  was  isolated  and  its  expression 
has  been  focalized  at the  level  of calcareous  corpuscles. 
=>  Six putative RNA polymerase  II  transcription regulatory domains have been  identified in 
Porto  Alegre  and  Montevideo  labs;  they  include  the  proximal  promoter  domains  of 
EgDf1,  Eghbx, 1, two actions, malate dehydrogenase and a hsp70 gene.  Several targets 
for  general  and  specific  transcription  factors  were  identified  and  some  conserved 
sequences,  that  could  constitute  the  binding  site  for  specific  protoscolex  transcription 
factors,  were  detected. 
=>  In  relation  with  E.  granulosus  genome  organization,  a  middle  repetitive  sequence 
organized  like  a  mobile  element  has  been  reported  and  the  structure  of  a functional 
rONA gene  and  its  regulatory  domain  have  been  recently  established. 
Finally,  with  respect  to  the  complementary  objective  of  the  proposal,  the  UK  team 
developed a system  which  allows expression  of  recombinant antigens  in  live  Salmonellae 
as  either  full  length  proteins  or  multiple  tandem  copies  of  immunogenic  epitopes  as  C 
terminal  fusions  to  the  immunogenic fragment C of totanus toxin,  under the control  of the 
anaerobically  inducible  nirB  promoter.  Using  this  system,  a  trivalent  experimental  S. 
typhimurium vaccine has been  constructed,  which  protects mise from  typhoid,  tetanus and 
schistosomiasis  following  a  single  oral  dose  of  the  vaccine.  The  EgDf1  gene  from  E. 
granulosus  has  been  expressed  using  the  system  described  above.  Preliminary  results 
indicate that the  construct  is  immunogenic  in  mice. 
An  important number of publications have been  produced,  from  which  several correspond 
to  joint articles.  The  number of young  Latin American  scientist trainee within  the  frame  of 
the project was  equally important:  5 PhD  have been  completed either in  the  L.A.  or in the 
European  laboratories  and  also  in  "sandwich"  programmes  including  work  carried  out  in 
both  sides;  finally  9M.  Sc.  degrees  were  completed  in  the  L.A.  laboratories.  The 
collaboration  between  all  the  partners  has  proved  very  fruitful  not  only  in  promoting 
North-South  and  South-South  transfer  of  expertise,  but  also  in  building  up  research 
capability  in  both  DC  labs.  A multidisciplinary  collaboration  was  established  through  the 
interaction  with  another  project  centred  on  immunobiological  aspects  of  hydatidosis 
(TS3*CT91 0038).  The  Latin American  partners were  also involved  in  the  recent launching 
of  a  Network  for  Research  and  Training  in  Parasitic  Diseases  at  the  Southern  Cone  of 
Latin America.  Finally,  a FAO Collaborating Centre on  Epidemiology,  Diagnosis and Control 
of  Echinococcosis/llydatidosis  has  been  created  in  Montevideo,  including  the  partners  of 
projects TS3*CT91 0038  and  0039. 
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HUMAN CYSTIC AND ALVEOLAR ECHINOCOCCOSIS IN  NORTHWEST CHINA: COM-
MUNITY SCREENING,  CASE  FOLLOW-UP AND TRANSMISSION  STUDIES 
Period:  January 1,  1994 - December 31,  1996 
Co-ordinator:  UNIVERSITY OF SALFORD, United Kingdom  (P.  CRAIG) 
Objectives 
+  Screen  populations  at  risk  and  measure  exposure  and  disease  in  two  selected  rural 
communities  in  China  where  either  cystic  or  alveolar  echinococcosis  is  predomi-
nantly  endemic,  using  a  combination  of  immunoserology  and  portable  ultrasound 
scanning. 
+  Undertake immunoserological and  ultrasound follow-up on  hydatid patients and asymp-
tomatics. 
+ Quantify  transmission  potential  of  dog  definitive  hosts  in  the  study  communities  and 
elucidate the  major life-cycle of  E.  multilocularis in  south  Gansu. 
Activities 
Human echinococcosis (hydatid disease) is a major problem  in  northwest China especially 
in  Xinjiang and  Gansu  Provinces.  Both  Echinococcus granulosus and  E.  multilocularis are 
endemic  in  ~hese  provinces  and  responsible  for  some  of  the  world's  highest  human 
prevalence  rates.  One community was  investigated,  in  each  province,  where transmission 
of  either cystic  (Tacheng,  Xinjiang)  or alveolar  echinococcosis  (Zhang,  Gansu)  predomi-
nates.  Between  1500-2000  people  in  each  community  were  screened  using  combined 
ultrasound  scanning  and  serology.  Image  positive  and/or  seroreactors  (against  cyst 
antigens)  were  followed  up  serologically  (primarily  including  lgG1  and  lgG4  antibodies) 
before treatment (medico-surgico) during treatment and up to  12 months post-treatment. A 
natural  history  of  human  alveolar  echinococcosis  has  begun  to  be  described  based  on 
ultrasound  and  serological  data.  Risk  factors  were  identified  using  a  questionnaire.  The 
role  of the  domestic  dog  in  transmission  of cystic  echinococcosis  was  assessed  through 
immunodiagnostic tests (coproantigens)  in  conjunction with  parasitological  prevalence and 
rate  of re-infection  studies (after praziquantel treatment).  For each  community the  primary 
transmission  cycle(s)  and  resultant  risk  of  human  exposure  and  infection,  were  investi-
gated.  Human  and  animal  data  (parasitologic and  immunologic)  were  analyzed  to  enable 
construction  of  transmission  pattern(s),  including  rodent  parasitological  and  ecological 
studies for  E.  multilocularis. 
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The  long  term  aims  include  recommendation  of  appropriate  hydatid  disease  screening, 
surveillance  and  treatment  follow-up  strategies  for  Chinese  rural  communities,  and  to 
consider  optimal  approaches  for  monitoring  regional  control  programme  or  disease 
transmission  within  defined  regions. 
Results 
This joint research  project has already achieved most of the original expected outcomes. 
The  most  important  to  quantify  the  human  infection  and  disease  rates  of  alveolar 
echinococcosis  (AE)  in  south  Gansu  and  cystic  echinococcosis  (CE)  in  north  west 
Xinjiang; also to establish optimal community based screening and the successful process 
of training  Chinese scientists in  UK and  France. 
In south Gansu province (Zhang County) people from 16 villages were screened for AE by 
hepatic  ultrasound.  In  addition  3  more  villages  screened  prior  to  1994,  and  8  villages 
(screened  in  1996)  from  the  Zhang  - Min  County  border  were  included.  Thus  - 2000 
people from 27 villages in the region are included in the Gansu study. The total human AE 
prevalence rate  was 5°/o  with a mean village prevalence rate  of 4.5o/o  and a range of 0% 
to  15.8°/o.  These AE rates were extraordinarily high compared to other important endemic 
areas such  as Alaska,  Siberia and  Western  Europe. 
Two  major  observations  derived  from  the  study.  The  resultant  large  numbers  of  AE 
patients  (>  1  00)  presenting with  early or advanced  lesions provided  a  unique  data set to 
consider the evolution  of AE  disease.  Disease  probably progresses from  small  hemangi-
oma  - like  lesions  through  to  hyperechoic  lesions  and  advanced  disease  with  large 
hyperechoic  areas  with  central  cavitation.  The  study  also  indicated  through  specific 
antibody assays  that  natural  resistance  to  AE  probably occurs  which  exhibits  as  puncti-
form,  linear  or circular  calcifications.  Interestingly  a  predominant  proportion  of  early AE 
cases were lgG1  rather than  lgG4 antibody positive, while advanced cases exhibited both 
lgG1  and  lgG4  sero  reactivity.  Full  immunoserologic  profiles  will  be  obtained  from  the 
patient  panel. 
The other important observation  in  Gansu  was that of the significant correlation  between 
human  AE  village  prevalence  rates  and  the  village  landscape  profile.  Land-use  indices 
showed  that  villages  close  to  areas  with  high  ratio  of  scrub  or  rough  pasture  had 
significantly higher human AE rates,  while villages surrounded by larger areas of ploughed 
field exhibited much lower disease rates. The densities of Microtus oeconomus, a potential 
rodent  intermediate  host  of  E.  multilocularis,  were  significantly  correlated  with  the  latter 
village  landscape profiles. 
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The  distemper  induced  dog  population  crash  in  the  region  between  1991  and  1994 
prevented  a study of  E.  multilocularis in  that  host. 
However,  our hypothesis is that human AE  infection  rates  reflect transmission  1  0-15 years 
in  the  past,  when  the  dog  population  density  was  higher.  Furthermore,  known  cyclical 
changes  in  Microtus  spp.  which  coincide  with  increased  canid  populations  (dogs  and 
foxes)  lead  to  local  increases  in  transmission  within  both  wild  (fox-rodent)  and  semi-
domestic  (dog-rodent)  cycles.  Over  time  (decades)  gradual  deforestation  in  the  upland 
areas  probably  initiates  increased  cyclicity  of  M.  oeconomus,  which  in  close  association 
with  marginal  villages  increases  local  transmission  of  E.  multilocularis.  Eventually  with 
increased  area under plough  microtine densities will  decrease together with  predicted AE 
rates. 
Parallel  collaborative  studies  in  Tacheng  prefecture,  Northwest  Xinjiang  revealed  a  very 
different pattern  of  echinococcosis  amongst  community  of  predominant  mongolian  pasto-
ralists  residing  close  to  the  Kazakhstan  border,  where  cystic  echinococcosis  is  the 
dominant endemic  parasitic  disease.  Screening  of  1823  persons  by  ultrasound,  serology 
and  questionnaire  revealed  a CE  rate  (due  to  E.  granulosus)  of 3.9°/o  (71/1823). 
36°/o  of the  population owned a dog,  which  increased to  1  OOo/o  of the families who  moved 
to  the  summer mountain  pasture  at  Kokehada.  Preliminary analysis  showed  that  77°/o  of 
CE  cases  were  seropositive  against  antigen  B  and  28.5°/o  of  persons  who  exhibited 
isolated  calcifications.  Antibody  lgG  sub-class  analysis  is  currently  being  undertaken. 
Domestic  dog  population  in  both  winter  and  summer  pastures  is  being  screened  by  the 
Echinococcus  coproantigen  ELISA  test  developed  by  the  research  team.  In  contrast  to 
south Gansu, the pastoral area of Kokehada was dominated by the ground squirrel Cite/Ius 
erythrogenys whose  status  in  transmission  of  E.  multilocularis requires  confirmation.  Also 
no advanced AE cases were detected during the screening but 2 putative cases with small 
hepatic  lesions were  identified for follow-up. 
The  resultant cooperation that has developed between Salford University and  University of 
Franche-Comte  (with  the  associated  partner  - University  of  Bourgogne)  has  been  very 
successful.  This  new  European  based  cooperation  has  also  resulted  in  development  of 
collaborative  research  on  the  transmission  of  E.  multilocularis in  Eastern  France.  Further-
more,  prior to  this  STD3 project the  French  research  team  (unlike  the  UK  group)  had  no 
collaborative  projects  in  China.  Now  as  a  result  a  separate  Franco-sino  ecology  project 
has developed with  Xinjiang and  Lanzhou  Medical  Colleges. Also,  within  China,  the  move 
toward  inter  institute  and  inter-provincial  cooperation  on  echinococcosis  has  been  set  in 
motion. 
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A northwest provinces research  meeting  (Xinjiang,  Gansu,  Qinghai,  Ningxia and  Sichuan) 
on  echinococcosis  was  very  successfully  organized  in  Lanzhou  through  the  UK  and 
France  initiatives.  As  well  as  direct  research  cooperation  and  collaboration,  training  of 6 
Chinese scientists (for periods 3m-12m)  in  areas of immunodiagnosis, ecology and clinical 
aspects  has  been  successfully  undertaken  so  far.  Therefore  the  basis  for  not  only 
continued  research  collaboration but also importantly self-sustained research  programmes 
with  Lanzyhou  and  Xinjiang  Medical  Colleges are  now firmly placed. 
Expected outcomes that were achieved wholly or in  part 
=>Quantification  of the  human  infection  and  disease  rates  of  alveolar and  cystic  echino-
coccosis  in  selected  communities. 
=>  Establishment of appropriate community based  patient follow-up  procedures. 
=>  Identification  of  the  probable  main  transmission  cycles  and  risk  factors  for  human 
echinococcosis  in  Gansu  and  Xinjiang. 
=>  Establishment of optimal  community based  ~creening strategies. 
=> Training  of  Chinese  scientists  especially  in  immunodiagnosis  and  animal  host 
parasitology/ecology,  data  handling  skills. 
=>Cooperation between  UK and  French  Institutes and  between  Europe  and  China. 
=>  Recommendation  at  provincial,  regional  and  national  level  for  research  and  control  of 
cystic and  alveolar echinococcosis. 
Partners 
University of Salford 
The Crescent 
Salford, M5 4WT 
United Kingdom 
University of Franche-Comte 
Faculte de Medecine 
Besangon 
France 
Xinjiang Medical College 
Urumqi (Xinjiang Province) 
China 
Lanzhou Medical College 
Lanzhou (Gansu Province) 
China 
P.  Craig 
Tel:  +44/161/745.50.00 
Fax:  +44/161/745.59.99 
E-mail: p.s.craig@ biosci.salford.ac.uk 
D. Vuitton 
Tel:  +33/81/66.55.05 
Fax:  +33/81/66.50.25 
W. Yang 
Tel:  +86/991/44.33.98 
Fax:  +86/991/44.14.91 
D. Shi 
Tel:  +86/931/24.311 
Fax:  +86/931.412.723 
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CONTROL OF  TAENIA  SOLIUM CYSTICERCOSIS THROUGH  SPECIFIC  DIAGNOSIS, 
SYSTEMATIC EPIDEMIOLOGY AND DEVELOPMENT OF A  RECOMBINANT VACCINE 
Period: 
Co-ordinator: 
August 1,  1993 till July 31,  1996 
UNIVERSITY OF EDINBURGH, CENTRE FOR TROPICAL 
VETERINARY MEDICINE, Edinburgh, Scotland (L.J.S. HARRISON) 
General and long term objectives: 
Taenia  solium cysticercosis is responsible for serious public health problems, in  addition to 
creating financial losses to pig producers in countries where the parasite is endemic. While 
control  of the  parasite  can  be  achieved  to  some  extent through  improvements  in  public 
health,  sanitation  and  pig  management/husbandry practices,  the  development of  reliable 
and  sensitive  diagnostic  procedures  would  greatly  assist  control  through  facilitating  the 
execution  of  reliable  epidemiological  surveys.  Such  surveys  not only  form  the  basis  for 
pinpointing  and  evaluating  control  measures,  but  are  also  essential  for  the  design  of 
environmentally appropriate control  strategies,  including the introduction of a  recombinant 
vaccine.  The  proposal  therefore  aims  1)  to  improve  diagnosis  of  human  and  porcine 
cysticercosis 2)  to conduct epidemiological surveys as a prelude to  selecting  appropriate 
study areas  for assessing  control  via  drug  treatment and  3)  select  potentially  protective 
antigens, for use in  the design of a recombinant vaccine in  a second phase of this project 
proposal.  Of particular importance will  be the detection of neurocysticercosis in  man. 
Specific objectives to be achieved by this proposal: 
•  To  transfer  established  diagnostic  procedures  from  Europe  to  Mexico,  via  a  training 
programme. 
•  To  conduct epidemiological surveys for porcine and human cysticercosis:  the former in 
order to identify areas for control (e.g.  by drugs such as praziquantel) and the latter as 
a guide to appropriate medical treatment. 
•  To clone, sequence and express metacestode excretory/secretory proteins of diagnostic 
potential. 
Activities 
*  To  transfer established procedures from  Europe to Mexico via a training programme. A 
Mexican  student  will  be  trained  in  the  use  of  a  monoclonal  antibody  based  antigen 
detection ELISA assay developed in  UK.  The assay will  then  be transported to Mexico 
where  it will  be  standardised  for use  in  the  detection  of  human  and  porcine  cysticer-
cosis  followed  by  epidemiological  studies.  A  follow  up  visit  by  a  member  of  the 
European component is then to be carried out to Mexico once the student has returned 
to the laboratory. 
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*  Existing  DNA  probes  for  the  differentiation  of  T.  solium  and  T.  saginata  will  be 
sequenced  and  developed  into  a PCR  diagnostic test for use  in  the  field. 
*  To  conduct  epidemiological  studies  for  porcine  and  human  T.  solium  infection.  The 
immediate  objectives  of  this  study  are  to  carry  out  a  survey  in  pigs  reared  under 
different  management  systems,  comparing  the  results  obtained  with  the  ELISA assay 
with  the  presently  used  meat  inspection  procedures and  detailed tongue  examinations 
in  pigs.  At  the  same  time  studies  will  be  conducted  to  determine the  efficiency of the 
assay and  to  determine sere-prevalence  in  hospital  patients. 
*  To  clone,  sequence  and  express  potentially protective  oncospheral  genes.  Due  to  the 
known extensive cross reactions between  T.  solium and  T.  saginata, and to the hazards 
of working with  T.  solium oncospheres,  the  identified potentially protective oncospheral 
antigens  will  be  cloned  from  (A-Zap  (Stratagene))  eDNA  libraries  of  T.  saginata 
oncospheres. 
*  To clone sequence and express excretory/secretory proteins of diagnostic potential. The 
first  activity,  which  was  already achieved,  was  to  identified  the  protein  antigens which 
were to  be  cloned;  the second to  prepare or collect suitable serum  samples for use  in 
the primary and secondary screening of the eDNA library; the third activity is to prepare 
a eDNA  library from  T.  saginata metacestodes.  Finally,  any  identified  clones  from  this 
library and  the  library  prepared  from  T.  saginata oncospheres  will  be  recloned  into  a 
suitable vector for more efficient expression. Clones first identified using the  T.  saginata 
system  will  be  subject to  secondary screening  in  order to  identify that sub-set  is  also 
reactive  with  T.  solium. 
Results 
Training 
The  newly  prepared  HP1 0  monoclonal  antibody  reagents  were  titrated  and  standardise 
prior to  shipment.  The  Mexican  student  trained  in  the  conduct  of  the  ELISA  assay  and 
lyophilised  reagents  were  transported  back  to  Mexico,  lyophilised  for  use  in  the  screen-
ing  work.  DNA  probes  were  grown  up  and  sent  to  Spain  for  sequencing  and  further 
analysis. 
Epidemiological studies for porcine and human T.  solium infection 
A  collect~on of  sera  from  pigs  and  human  either  T.  solium infected  or non-infected  were 
collected  in  order  to  evaluate  the  sensitivity  and  specificity  of  the  diagnostic  ELISA 
assay. 
A group  of  293  sera from  non-infected  (49)  and  experimentally  infected  pigs  (244)  were 
obtained  (from  pigs  experimentally  infected  and  maintained  in  the  Veterinary  School  in 
UNAM). 
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Pigs  lightly or  heavily infected  were  bled  at  different times  during  the  infection  and,  after 
the number of cysticerci were determined in a representative sample of each  pig  (to obtain 
sera from  rustically  bred  pigs),  we  examined  different slaughter houses  near Mexico  city, 
and  identified  one  in  Zacatepec,  Morelos,  which  introduces  a  considerable  amount  of 
rustically  bred  pigs  from  the  states  of  Puebla  and  Morelos  (Mexico).  This  is  of a special 
interest considering that this  is  the  population  exposed to  the  higher risk  to  the  infection. 
With the support of the authorities of this abattoir, we collected 200 ml of sera for each pig 
and  also their tongues. 
Tongues  were  maintained  in  formol  saline  and  the  parasite  number determined  by  slicing 
the  tongue  to  count  all  the  cysts  present.  Cysticerci  collected  were  conserved  for 
confirmation  by  an  immunopathologist.  In  addition,  a  panel  of  32  sera  from  a slaughter 
house  in  which  only  pigs  from  technified  farms  were  included  were  used  to  test 
serological  assays,  sera from  rustically bred  pigs from  Tianguizolco,  Guerrero. A panel  of 
43  sera  from  Tianquizolco  were  collected.  These  43  pigs  were  randomly  selected  and 
completely  necropsied  to  determine  the  presence  of  cysticerci  or  other  disease.  A 
collection  of  112  CSF  were  obtained  from  the  Institution  Nacional  de  Neurologia  y 
Neurocirugia,  Mexico,  D.F.  For  each  patient  the  diagnosis  was  confirmed  based  on  the 
clinical  examination,  nuclear  magnetic  resonance  and  tomography.  The  pathology  and 
type of  infection was  also recorded.  Finally we  prepared  a collection  of  human  sera from 
a neurological  institution  (lnstituto  Nacional  de  Neurologia y Neurocirugia,  D.F.).  For this, 
we  collected  392  sera  from  patients  that  consulted  the  institution  for  the  first  time.  For 
each  the sex,  age,  clinical  diagnosis, AIDS,  NMR,  TC,  and  other pathology and  infections 
were  recorded. 
All  the  results obtained  in  the  evaluation  of the  assays based  on  the  detection of antigen 
HP10  and  antibodies  against  vesicular  fluid  antigens  indicate  that  both  assays  are 
appropriate to cysticercosis diagnosis in  pigs maintained in technified conditions.  However, 
both  assays showed  a lower specificity and  sensitivity for the detection of cysticercosis  in 
rustically  bred  pigs  and  infected  humans. 
Several  clones  have  been  identified  and  sequenced  from  the  T.  saginata  oncospheral 
library  including  the  gene  encoding  the  principal  18kDa  secreted  antigen  of  activated 
oncospheres of  T.  saginata. The sequence and  immunogenicity of  T.  saginata ferritin  has 
been  established.  Various  expression  systems  have  been  examined  with  a  view  to 
selecting  the  most  promising  for the  larger scale  expression  of  T.  saginata proteins.  The 
selected  systems  are  now  functional  in  the  IAH  Pirbright  laboratory,  where  preliminary 
experiments  have  been  initiated. 
For the  cloning,  sequencing  and  expressing  of excretory/secretory  proteins  of  diagnostic 
potential,  groups  of  calves  were  infected  with  T.  saginata  metacestodes  in  order  to 
produce 4 week old  metacestodes.  These  were  extracted  and  used  in  the  preparation  of 
a "AZ.AP  (Strategene) eDNA libraries on three separate occasions. Libraries are constructed 
according  to  routine  procedures.  Metacestodes of this  age  have  been  shown  to  produce 
diagnostically important excretory proteins.  The  intention  is  to  use  these  protein  antigens 
as  the  trapping  layer  in  ELISA  assays  designed  to  detect  anti-parasite  antibody  in  the 
serum  of  infected  cattle. 
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The initial extraction and preparation of the RNA was conducted at CTVM while the eDNA 
preparation and titration of the resultant libraries was conducted at IAH  Pribright. Once the 
libraries were prepared they were  screened with  sera  in  Madrid. 
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FIELD  EVALUATION  AND  FURTHER  CHARACTERIZATION  OF  AN  INVASIVE-
SPECIFIC  MONOCLONAL ANTIBODY AGAINST ENTAMOEBA HISTOLYTICA 
Period: 
Co-ordinator: 
Objectives 
January 1,  1994- December 31,  1996 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, 
DEPT.  OF MEDICAL PARASITOLOGY, London, United Kingdom 
(D. WARHURST) 
Application and  development of techniques for distinction of  Entamoeba histolytica and  E. 
dispar,  with  a view to clarifying  the  epidemiology of  amoebiasis  in  different areas  of  the 
world,  and focussing  the treatment effort.  Training  and  transfer of technology,  to  enhance 
research  potential  of scientists from  countries with  endemic diseases. 
Activities 
Training  visits,  collaborations and  joint publications. 
Results 
A colorimetric PCR  technique (Solution  Hybridisation  Enzyme  Linked Assay (SHELA)  has 
been  developed  for  differentiation  of  faeces  containing  E.  histolytica  and  E.  dispar.  A 
comparison  of  the  zymodeme  of  culture  of  Bangladesh  isolates  with  SHELA results  on 
culture  in  Bangladesh  was  agreement  in  detection  of  E.  histolytica  in  23/23  cases  (13 
zymodeme  2,  and  10 zymodeme  14).  However,  three  cultures  identified  as  zymodeme  1 
were tested and 2 reacted  in  the SHELA as  E.  histolytica and  the other one as  E.  dispar. 
It  is  clear  more  testing  of  non-pathogenic  material  from  Bangladesh  is  needed  to 
determine whether this degree of non-agreement is significant, since it has not been seen 
in  material from  other areas.  It is encouraging to  note that zymodeme 14 reacts as well  in 
PCR-SHELA as  zymodeme  2. 
The  parallel  examination  of  the  original  faecal  specimens  using  the  Entamoeba  and  E. 
histolytica-specific ELISA technique of  Petri  and  colleagues gives some contradiction  with 
zymodeme  and  with  the  PCR-SHELA.  The  common  occurrence  of  apparently  mixed 
infections is notable. However, given that the original faeces is being examined and culture 
is inevitably selective,  this is  not so  much of a problem as the rather low sensitivity of the 
immunological technique for detection of  E.  histolytica itself.  To  investigate this further 40 
more faecal specimens from  Bangladesh are being tested in the UK laboratory and will  be 
compared  with  the  results  of culture and  of the  Petri  ELISA. 
Improvements to the  protocol  and  kit  for the  PCR-SHELA have  been  developed.  Using a 
modified  system  named  Demi-Nested  PCR-SHELA.  This  has  been  successful  for  both 
amoebiasis  and  malaria  context.  The  advantage  of  the  technique  is  that  the  labelled 
internal probe, which  normally needs to be added to the PCR product after the reaction,  is 
incorporated in  the sealed tube,  and acts as a primer of a PCR  nest,  and as the detector 
for the  1st and  2nd  products of the  PCR. 
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All that needs to be done at the end of the single PER run  is to dilute the product in buffer 
and  apply  it  to  the  microtiter  plates  for  the  avidin  capture  and  digoxigenin  enzymatic 
detection  procedure.  This substantially reduces the time taken for the technique. 
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IMMUNOLOGICAL CORRELATES OF RESISTANCE AND SUSCEPTIBILITY TO  INFEC-
TIONS WITH  GASTRO-INTESTINAL NEMATODES IN  NORTH  EAST BRAZIL 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1994 - December 31 , 1996 
UNIVERSITY OF NOTTINGHAM, DEPT.  OF LIFE SCIENCES, 
Nottingham, United Kingdom (D. WAKELIN) 
The overall objective of the proposal is to make a detailed study of the immune responses 
to infection with gastro-intestinal nematodes and to identify causal correlates of resistance 
and  susceptibility to  these  important parasites.  The  specific objectives are: 
+  Determine the  prevalence and  intensity of gastro-intestinal  nematode  infections across 
an  appropriate  age  range  in  populations  living  in  communities  where  these  parasites 
are  endemic. 
+  Follow the  patterns of reacquisition  in  these  populations after effective chemotherapy. 
+  Identify and characterize individuals showing resistance or susceptibility to  infection and 
re-infection. 
+ Analyze  the  antibody,  cellular responses to  each  infection,  correlate these with  param-
eters  of  resistance  and  susceptibility,  and  identify  target  antigens  of  the  parasites 
concerned. 
Activities 
Infections  with  the  major  gastro-intestinal  nematodes  of  man  are  endemic  in  the  Recife 
area  of  N.E.  Brazil,  a  pilot  study  showing  high  prevalence  in  poor  urban  and  rural 
communities,  and  the  excellent  laboratory  facilities  at  CPq  AM,  Recife  offer  a  unique 
opportunity to  examine the parasitology and  immunology of these infections. Collaboration 
with  the  laboratories  in  Nottingham  and  Marseille  provides  an  unrivalled  combination  of 
expertise  in  the  immunoparasitology  of  helminth,  specifically  intestinal  nematode,  infec-
tions.  The  proposal  is  to  carry  out  a  detailed  study  of  immune  (serological,  cellular and 
cytokine)  responses  in  individuals of known  infection/reinfection status.  The  data obtained 
will make it possible to correlate resistance or susceptibility to infection with the capacity to 
mount  particular  responses,  and  throw  light  on  those  mechanisms  which  regulate  the 
development  and  expression  of  host  protective  immunity.  In  this  context  definition  of  T 
helper subset  responses,  and  of target parasite antigens are  seen  as  key  priorities. 
Expected outcome 
The project has  provided the first detailed survey of intestinal nematode infections in  N.E. 
Brazil.  Extensive clinical  data on  the  surveyed communities  have  been  collected  and  are 
being analyzed. The populations have been extensively surveyed, blood and stool samples 
have  been  taken  on  several  occasions.  It  is  clear that  the  parasites  Ascaris,  Hookworm 
and  Trichuris have  high  prevalence,  particularly in  children. 
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Worm  burdens:  particularly  in  the  case  of  Ascaris,  can  reach  very  high  levels  and  are 
therefore likely to cause a number of clinical problems. The populations have been treated 
with  anthelmintic  and  the  patterns  of  reinfection  followed.  Lymphocytes  and  sera  from 
individuals  shown  at  each  survey  to  be  repeatedly  heavily  of  lightly  infected  are  being 
analyzed for antibody and cytokine responses in  order to look for immunological correlates 
of  resistance  and  susceptibility.  The  data collected  have already contributed to  increased 
public health  awareness of the  importance of intestinal  nematode  infections  in  the  Recife 
area.  The  research  capabilities of the  Brazilian  partner have  been  considerably strength-
ened.  Surveys carried out in  poor urban and rural  areas in  the Recife area showed a high 
prevalence  of gastrointestinal  (GI)  nematode  infections. 
In the urban area Ascaris lumbricoides and  Trichuris trichiura were the commonest species 
(57  and  62°/o),  whereas  in  the  rural  area  hookworm  (Necator)  was  commonest  (79°/o). 
Infections  were  present  in  all  age  groups,  but  were  most  prevalent and  most  intense  in 
children below 16 years. Only Ascaris infections occurred at very high  intensity, faecal  egg 
counts  of  more  than  20,000  eggs  per  gram  being  recorded.  The  study  groups  have  all 
received chemotherapy, and this proved largely successful in  eliminating infection, but with 
time  since  treatment  levels  of  infection  are  again  rising.  Sera  taken  before  the  first 
chemotherapy have to  date been  analysed  for total  and  parasite  specific  lgE  responses, 
as this isotype is considered to give the greatest degree of parasite specificity.  High levels 
of  total  and  parasite  specific  lgE  have  been  recorded  in  individual  infected  with  Ascaris 
and  with  Trichuris.  Although  the  first  result  was  unexpected,  high  anti-Trichuris  lgE 
responses were not. Assays for lgG isotypes are now in  progress,  and it is hoped soon to 
have data on  cytokine responses from  individuals who have consistently shown either high 
or low worm  burdens. All  of these data will then  be  analysed for association with  level of, 
and  predisposition to,  infection. 
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INTEGRATED  MULTIDISCIPLINARY  STUDY  OF  HUMAN  FASCIOLIASIS  IN  THE  BO-
LIVIAN  NORTHERN ALTIPLANO 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1994 - September 31 , 1997 
UNIVERSIDAD DE VALENCIA,  DEPT.  PARASITOLOGIA, 
FAC.  FARMACIA, Valencia,  Spain (S.  MAS COMA) 
Characterization  of  human  fascioliasis  in  the  Bolivian  Northern  Altiplano  (in  humans 
endemic  with  very  high  prevalences,  very  high  altitude)  in  preparation  for  control  meas-
ures.  Important  related  objectives  are  interaction  and  transfer  of  technology  between 
European  partners  and  the  INLASA  Institute  of  the  Bolivian  Health  Ministry,  as  well  as 
transfer  of  personnel  from  the  Bolivian  Health  Ministry,  to  the  European  Community 
laboratories and  vice  versa. 
Activities 
Research  includes field  and  laboratory work for: 
*  Biological  characterization  of  parasite  and  snail  vectors. 
*  Assessment  of  the  present situation  of  human  fascioliasis  and  vector geography. 
*  Development of a new immunodiagnostic assay for the  detection of human  and  animal 
fascioliasis. 
*  Application  of  the  new  immunodiagnostic  assay  in  the  Bolivian  Altiplano  endemic 
area. 
Moreover  in  the  first  two  years,  several  Bolivian  professionals  have  participated  in 
laboratory  research  activities of the  project  in  European  centres. 
Results 
Concerning  the  first  two  objectives  the  main  results  obtained  in  the  first  two  years 
are: 
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~The  endemic zone appears to be  isolated between the Lake Titicaca and  La Paz (about 
250.000  people  living  in  the  zone:  more  than  2  million  people  in  the  neighbourhood; 
boundaries  marked  by  geographic,  climatic  and  soil-water  chemical  characteristics; 
large livestock population at risk),  and the transmission foci  are stable (maintained both 
during the  year and  along  pluriannual  periods)  and  patchily distributed. 
~  The parasite has developed several strategies to adapt to the altitude conditions which 
favour transmission  (very long  cercaria!  shedding  period,  assuring a more  prolongated 
infection  of  the  environment with  free-living  metacercariae;  very high  cercaria!  produc-
tion,  very  great  survival  capacity  of  the  intramolluscan  larval  stages,  production  of 
floating metacercariae. Therefore drinking fresh-water may serve as an additional mode 
of infection, very large  infection capacity of metacercariae and  adults,  normal  develop-
ment in the  pig and very high transmission rates of pig  isolates at molluscan level, high 
prevalence  in  cattle  and  sheep,  also  numerous  additional  potential  domestic  and  wild 
definitive hosts are  present) 
~The transmitting  snails  have  proved  to  belong  to  only  one  species,  the  European 
species  Lymnaea truncatula imported  by  European  colonizers,  appears to  have  devel-
oped  several  strategies  to  adapt  to  the  altitude  conditions  which  favour  transmission 
(markedly  precocious  sexual  activity;  high  reproduction  capacity,  very  rapid  develop-
ment  chronology,  long  survival  capacity,  large  adaptation  capacity  to  extreme  condi-
tions,  postparasitation  viability  linked  to  permanent  water  collections  permitting  trans-
mission during the whole year,  enzymatically identical populations with total  absence of 
polymorphism). 
~Man  has  proved to be  a very effective and  viable definitive host (human  isolates show 
very  high  transmission  rates  at  molluscan  level),  with  very  high  prevalences  (up  to 
90.0°/o  by serology and  66. 7°/o  by coprology in  the total  population and  up to 38.2o/o  by 
coprology  among  school  children),  very  high  individual  infection  levels  (amounts  of 
more  than  1000  eggs/g  faeces  are  numerous  in  children;  even  up  to  5064  eggs/g  in 
extreme cases),  and  with  up to  12  different protozoan  species and  5 helminth  species 
concomitantly  infecting  fasciliasis-infected  children,  including  well  know  pathogens,  as 
Entamoeba histolytica,  Cryptosporidium sp.,  Giardia intestinalis, Ascaris lunbricoides or 
Trichuris  trichiura. 
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=::::)  Andean  inhabitants show several customs  related to  transmission  (eating of aquatic or 
semiaquatic  vegetables  by  adults,  swallowing  or chewing  of  aquatic  plant  stems  and 
roots  by  children,  defaecating  in  the  external  environment,  tradition  of  each  family 
sustaining  its  own  livestock,  including  cattle,  sheep,  pigs  and  horses  or  donkeys,  a 
custom  of  great social  settledness  among Aymara  Indians,  life  in  dispersed communi-
ties). 
Concerning the  last two  objectives  main  results  obtained  in  the  first two years  are: 
=::::)Two  cysteine  proteinases  secreted  by  adult  Fasciola  hepatica  (from  bile  ducts  of 
infected. bovine  livers)  were  isolated,  characterized  and  prepared  by  immunologically 
screening;  they were  designated  cathepsin  L  1 (27  kDa)  and  cathepsin  L2  (29.5  kDa). 
=::::)  lmmunoblotting  experiments  demonstrated  that  prepared  antisera  specifically  detect 
cathepsin  L.  Proteinases  in  extracts of adult  F.  hepatica. 
=::::)  Adult  fluke  eDNA library was  prepared  and  cDNAs  encoding the  two  cysteine  protein-
ases cathepsin  L  1 and  cathepsin  L2  isolated. 
=::::)When  working with  sera samples obtained from  96  native Aymara living  in  the  Bolivian 
locality  of  Calasaya,  cathepsin  L  1 (Cathepsin  L  1)  proved  to  be  more  reliable  for  the 
detection of infected  individuals than  liver fluke  extracts and  was as  good as  or better 
than  ES  product,  the  predominant  antibody  isotypes  elicited  by  liver  fluke-infected 
humans  are  lgG1  and  lgG4. 
=::::)  By  exploiting  this  fact  an  ELISA was  developed  which  detects  anti-lgG4  reactions  to 
cathepsin  L  1,  this  assay shows a 99o/o  reliability  in  detecting  infected  humans. 
=::::)  F.  hepatica  cathepsin  L  1  has  been  successfully  expressed  and  has  functional  and 
physicochemical  properties  in  common  with  the  native  proteinase  produced  by  adult 
liver flukes;  immunoblotting  experiments  showed  that the  yeast-expressed  molecule  is 
also  reactive  with  antibodies  prepared  against the  native  enzyme. 
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PARTNERSHIP BETWEEN EUROPE AND DEVELOPING COUNTRIES 
IN  HEALTH RESEARCH 1 
The  European  Commission  has  been  supporting  joint  research  activities  relevant 
to  development,  including  health  related  research,  since  1983,  and  has  recently 
issued  the  second  call  for  scientific  proposals  within  the  programme  of  Interna-
tional  Cooperation  with  Developing  Countries  (INCO-DC)  which  has  become  a 
broader programme than  its predecessor.  Health  research  remains  a priority area, 
together with  research  on  agriculture and the sustainable use of natural resources. 
The  Commission's  International  Scientific  Cooperation  Programme  is  an  integral 
part  of  the  European  Union's  Fourth  Framework  Programme  on  Research.  It 
serves  Europe's research  policy but it does even  more.  It  is  also an  instrument to 
support  other  European  policies,  such  as  development  cooperation,  external 
relations  or economic cooperation  with  third  countries. 
A guiding  principle  of  the  European  Union  is  a desire  to  contribute  to  worldwide 
sustainable  development.  A desire  which  stems  from  a sense  of  co-responsibility 
for  the  problems  faced  by  third  countries.  This  responsibility  must  be  shared  by 
every citizen  but a special  role,  undervalued  in  the  past,  must be  reserved  for the 
scientists who  have  chosen  to  address  problems  of  developing countries. 
The  most  important  commodity  for  sustainable  development  is  knowledge  and 
knowledge  will  be  the  number  one  production  factor  in  the  21st  century.  Its 
importance will  far outweigh that of capital  and  labour in  the  present century,  and 
if  one  wishes  to  safeguard  the  future  and  to  increase  knowledge,  more  needs  to 
be  invested  in  research  now.  Research  is  increasingly  perceived  as  a  basis  for 
welfare within the EU.  Research must therefore be just as important for the welfare 
of  third  countries.  This  assumption  has  received  too  little  attention.  Knowledge  is 
an  invaluable  commodity  and  to  acquire  knowledge  one  has  to  help  develop  a 
culture  of questioning. 
Responsibility and Mandates 
The  development  of  a  culture  of  science  and  research  is  the  responsibility  of 
everyone.  Scientists  within  the  individual  member  states  of  the  European  Union 
are already involved at personal,  institutional, regional,  or national level  in  a variety 
of  programmes  with  a  variety  of  goals  related  to  Health  in  tropical  areas  or 
developing countries. A wealth of research activities are,  or can also be,  performed 
or developed  on  a bilateral  basis  by  each  of the  European  Member States.  The 
Commission  strongly encourages  all  these  efforts. 
1  Reprinted  with  permission  from:  Tropical Medicine and International Health  1996 5 553-557. 
363 Moreover, the Commission has a mandate to  keep informed of any such  initiatives 
and  whenever possible to  be  in  synergy with them,  but the  Commission's strength 
lies in  its ability to harness expertise at a supra-national level within  Europe,  in the 
context  of  its  relations  with  third  countries.  Adding  a  European  dimension, 
complementing  the  existing  bilateral  regional  and  national  interactions. 
The  European  Commission  will  not  replace  any  of  the  inputs  from  others.  The 
more support scientists in  Europe or Developing Countries receive or acquire from 
national or other sources,  the  more  European  programmes will  be  meaningful and 
give  room  for substantial cost efficient added value.  The  Commission functions on 
the  basis of subsidiarity,  a concept which  has  been  a matter of  debate  in  the  EU. 
At  the  European  level,  the  Commission  does what can  be  done only at this  level, 
and  most  importantly,  done  better  at  this  level.  The  Commission  builds  on  the 
valuable  contributions  to  health  research  of  the  individual  Member  States  of  the 
European Union.  Many agencies like the Institutions of the United Nations, such as 
WHO,  have  an  alternative  agenda focused  on  different  roles  and  responsibilities, 
although  often  in  support of common  goals. 
It  is  critical  that each  has their own  clearly defined  goals and  modes of operatipn. 
It  is  also important that all  operations are transparent so  that what  is  being  done, 
and  where,  can  be  precisely  established,  thus  avoiding  wasted  efforts  and 
unnecessary duplication.  What it boils  down  to,  is  the  need  to  establish  equitable 
partnerships which will facilitate the sharing of knowledge. Clearly with the financial 
and  human  resources  which  can  be  harnessed  from  within  the  European  Union 
the  opportunity can  be  provided  for  partnerships  to  be  established  within  Europe 
and  with  third  countries.  These  resources  are  not  an  objective  or  a  solution  in 
themselves.  They  simply  provide  the  appropriate  environment  and  the  means  to 
progress. 
For too  long  it  was  considered  that  ideas  and  practices  in  health  research  were 
"for''  Developing  Countries,  and  that  they  could  be  exported  from  Europe  to 
Developing Countries for direct application. While that attitude was  not exceptional 
in  times  gone  by,  it  is  now  certainly  no  longer  acceptable.  The  European  Union 
encourages  health  research  "with"  Developing  Countries. 
In  establishing  partnerships  in  health  research  with  Developing  Countries,  the 
criteria considered to  be  most important can  be  divided  in  three  parts.  The  first  is 
the scientific aspect.  It  is  essential that the  process of science  is  of a high  quality, 
indeed of international status,  and  respected  on  its own  merits and  rules.  There is 
only  one  science,  whether  it  is  classified  as  basic,  fundamental,  strategic,  opera-
tional  or  action  research.  What  matters  is  that  science  flourishes  in  a variety  of 
socio-economic  and  cultural  environments. 
364 The  second,  but  equally  important  consideration  is  the  mechanism  to  implement 
the  EU  policy  of  scientific  cooperation  in  health  research.  It  would  be  naive  to 
consider that any scientific interaction can  take  place  in  a vacuum,  insulated from 
other  aspects  of  life.  There  must  be  consideration  of  the  societal  aspects  of  the 
science.  In  other words there  must be  an  expectation  that the  scientific work will, 
at  one  time,  bring  tangible  benefits  for  society  as  a whole.  Therefore,  the  work 
supported  by  the  Commission  is  aimed  at  addressing  the  major health  problems 
faced  by  developing  countries.  New  practices  and  technologies  have  to  take 
account  of  the  context  in  which  they  may  be  applied  and  the  health  benefits  of 
their  application  have  to  be  clearly  established.  Public  health  concepts  are  a 
common  platform  for all  health  research. 
The third important point to consider is that health research partnerships cannot be 
established  unless  there  are  partners  to  establish  them  with.  Partners  within 
Europe  are  easier  to  find,  but  research  capacity  in  Developing  Countries  is 
relatively  scarce  and  cannot  be  created  overnight.  Although  the  inputs  from 
national  or  international  research  programmes can  help,  they  are  not the  solution 
in  themselves. 
What  is  needed  is  a prolonged  intensive  investment and  other support to  ensure 
capacity  and  capability  strengthening.  This  will  only  be  achieved  through  the 
political  will  and  the  economic  commitment  of  the  countries  themselves  together 
with  support from  other national and  international sources.  Fortunately the need for 
this  support  has  been  recognised  by  the  European  Union  through  its  economic 
and  development cooperation policy which  is mainly the responsibility of DGIB and 
DGVIII  within  the  Commission. 
Science  should  not  suffer from  any  unproductive  rivalry,  as  was  the  case  in  the 
early  years  of  this  century,  when  scientists  argued  over  whether  resistance  to 
disease was  dependent upon  cells  or serum.  Scientists  allied  themselves  on  one 
side  or  the  other  on  the  basis  of  their  nationality.  In  the  initial  stages  of  the 
European  Union's  Research  Programmes  even  the  prospect  of  uniting  two  Euro-
pean  research  institutions  or  laboratories  from  different  member  states  seemed 
daunting  to  less  receptive  scientists,  and  brought  some  opposition.  Scientists 
assumed,  falsely,  that their efficiency  or  competitiveness  would  be  diminished  by 
having  to  participate  in  what  was  considered  by  some  to  be  a  cumbersome 
interaction.  But the  imposition of this requirement of joint research  for eligibility for 
European  Union  support has  stood  the  test of time  and  is  helping  to  change  the 
paradigm  for  international cooperation  to  one  of  equitable partnerships. 
365 The  benefits  this  brings  are  many.  Now,  there  is  an  unprecedented  level  of 
European  cooperation  with  many  examples  of  the  EU  programme  providing  the 
initial contacts between labs which have blossomed and been extended to address 
many problems outside the  current programme.  Competition  between  laboratories 
remains a driving force for advances, but this has ensured that scientists tended to 
become  better specialists  in  their own  particular area.  There  is  now an  apprecia-
tion that the complexity of the problems and challenges being faced, can  be solved 
only through  cooperation  among  scientists with  expertise  in  complementary disci-
plines. 
If  establishing  links  between  scientists  in  Europe  needed  some  persuasion, 
European  scientists  found  establishing  links  with  developing  countries  even  more 
difficult  to  accept.  The  EC  is  not  interested  in  providing  strictly  pre-conceived 
"European"  solutions  to  problems  of  development.  There  is  an  acute  awareness 
that the  complex problems of development cannot be  contained  within  national  or 
regional  boundaries, they affect all  societies. The aim  is to find  a common  path  to 
achieving  improvements  in  development,  bringing  together  scientists  from  North 
and South who will  address the problems as an  integrated unit, each bringing their 
own expertise and experience to bear on the problem at hand.  If this is done in the 
right  way,  the  goal  of  learning  to  learn  will  be  achieved.  A culture  of  learning,  in 
which  scientific  rnethodology  becomes  an  intrinsic  part  of  society  will  be  estab-
lished.  Hypotheses  will  be  tested  and  development  programmes  modified  in  the 
light  of  the  results,  things  will  not  be  left  to  chance.  The  interactions  of  the 
scientists  in  the  Commission's programme leads to  the  establishment of a culture 
of  learning  across the  globe. 
The  Commission  continues  to  encourage  interactions  among  scientists.  Links 
between  European  laboratories are  stronger now than  they  have  ever been.  The 
same  can  be  said  for  links  between  European  scientists  and  their  colleagues  in 
Developing  countries. 
But  there  is  an  additional  benefit  from  the  requirements  of  the  programme, 
South-South cooperation,  and the sharing of knowledge among the third countries 
anxious  to  involve  their  regional  neighbours  in  their  quest  for  knowledge  of 
common  problems which  are  best addressed  in  partnership.  Of course  this  is  not 
a  unique  achievement  but  it  is  clear  that  the  Programme  has  done  much  to 
facilitate  additional  steps  in  this  direction. 
366 :. _-:...-
THE EUROPEAN UNION (EU) FOURTH FRAMEWORK PROGRAMME 
FOR RESEARCH AND TECHNOLOGICAL DEVELOPMENT (RTD) 
Collaborative  research  with  developing  countries  is  carried  out against the  back-
ground  of  the  Commission's  Fourth  Framework  Programme  for  Research  (FP4). 
The  basic  aim  of  FP4  is:  To  support  inter-Member State  scientific  collaboration, 
networking and concertation on issues of common concern. To  reach this goal FP4 
supports  multi-centre  research  projects,  concerted  actions  and  accompanying 
measures  which  help  to  improve  quality  of  life  and  increase  European  competi-
tiveness,  in  a  global  context.  More  than  this,  FP4  serves  to  support  other  EU 
policies,  such  as  economic and  development cooperation. 
The total budget of FP4 (1994-1998) is  12.31  billion  ECU  and is divided over four 
main  activities: 
I.  Research, Technological Development and Demonstration within the EU  Member 
States 
(10686  Million  ECU  (MECU)), 
II.  Cooperation with Third Countries and  International Organisations (540 MECU), 
Ill.  Dissemination  and  optimization  of results  (330  MECU)  and 
IV.  Training  and  Mobility of researchers within  the  EU  (740  MECU). 
Activity II,  Cooperation with Third Countries and  International Organisations has a 
pivotal role,  linking EU  policies in  science, economic cooperation and development 
through  coherent collaborative  research  activities with  third  countries. 
Health-related  research  can  take  place  in  activity  I and  in  activity  II  programmes. 
The  BIOMED  and  the  BIOTECH  programmes  of Activity  I have  a  budget  of 552 
MECU  and  336  MECU  respectively.  Many  aspects  of  health  research  which  are 
trans-disease,  can  be  covered  by these  programmes  and  might also  be  of great 
importance  for  collaboration  with  Developing  Countries  for  example,  malaria 
vaccine development. Within the activity II  INCO programme (540 MECU) there is 
also  a  health  component.  In  the  specific  Programme  for  developing  countries  a 
total budget of 63 MECU will be available for health between 1994-1998 and in the 
component geared towards Eastern and central Europe, health-related research  is 
also covered  (INCO-Copernicus). 
1  In  1996,  budgets of  specific programmes are  to  be  increased to the  new total  of  13.1 MECU. 
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Although  they may differ in  detail the Commission's research  programmes  in  FP4 
have  the  following  modes  of implementation: 
I Multilateral joint research  projects, 
II  Concerted Actions, covering the actual costs of concertation, such as the search 
for partners,  meetings,  common  publications 
Ill Accompanying Measures, such as contract holders meetings, networks, studies, 
targeted  research  training  and  mobility and  the  dissemination of  results  and 
IV  Concertation  through  consultation  with  the  Member states  and  in· the  case  of 
the  INCO-DC  programme consultation  with  developing countries. 
These  are  set  out  in  the  detailed  Work  Programme  together  with  the  main 
objectives  of  the  programme.  For  INCO-DC  these  are,  to  promote  the  role  of 
relevant  high  quality RTD  in  development in  economic cooperation,  to  encourage 
scientific collaboration between Europe and DCs,  between DCs and within Europe, 
to help reinforce and  maintain  RTD capacities,  including human capital,  in  DCs,  to 
contribute  to  maintaining  a competence  in  Europe  in  scientific  sectors  of  mutual 
interest and  in  those pertinent to problems of DCs,  to capitalise on  the experience 
gained  during  the  implementation  of  previous  Commission  S&  T  co-operation 
activities  and  to  take  into  consideration  the  political  obligations  of the  Union  and 
the  recommendations of international fora  such  as  the  Rio  conference concerning 
research  in  DCs. 
The  Work  Programme  is  implemented  through  Calls  for  Proposals  which  are 
updated from  year to year.  Details of research  themes which  are  to  be  supported 
are  provided  in  these  Calls for Proposals. 
The Call for Proposals 
The Call for Proposals (Anon  1996) contains detailed information on  criteria which 
have  to  be  fulfilled  by  applicants,  for  example  partnerships,  and  also  on  the 
specific  topic  areas  for  which  research  proposals  are  invited.  The  Call  for 
Proposals  is  updated  for  each  call  and  permits  the  Commission  to  direct  the 
research  programme on  the  basis of the  consultation  processes with  the  Member 
States,  developing countries  and  on  the  Commission's existing  research  portfolio. 
In  general  the Call  for Proposals  is  issued six  months  in  advance of the  deadline 
for  submission  of  proposals.  On  arrival  at the  Commission,  proposals  undergo  a 
stringent review  procedure. 
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In  addition to  scientific quality each  proposal  is  evaluated on  a variety of aspects, 
which  include: 
Is  the  health  problem  relevant to  developing  countries? 
Is  the  problem  of  national,  regional  or global  relevance? 
Is  the  problem  of  known,  documented  magnitude? 
Is  the  problem  vulnerable  (are  there  opportunities for cost-effective  impact)? 
Is  there  political  will  to  overcome the  problem? 
Will  the  research  be  induce changes  in  approach  or political  awareness? 
Does  the  research  build  on  existing  and  matching  capacities? 
Does the  research  partnership  have  a comparative  advantage  (including  DC) 
Is  there  a demonstration value  (spin-off  in  financial  or scientific terms)? 
Is  there  a likelihood  of  leverage for complementary funding  in  European  Member 
States  and/or DCs? 
Is  there  likelihood  of  sustainability of the  proposed  approaches? 
What  is  the  research  capability strengthening  aspect of the  proposal? 
What  is  the  training  and  mobility aspect of the  proposal? 
How is  the  integration  of the  DC  partner(s)  in  the  national  setting? 
How does the  project fit  in  the  international  funding  picture? 
The  evaluation  of  proposals  is  effectively done  in  four tranches: 
I.  Decision on  eligibility by the Commission's Services based on  partnership and 
documentation  of the  innovation  and  relevance  of the  project. 
II.  Scientific evaluation  by  selected  experts. 
Ill.  Evaluation of the highly-rated proposals from the second tranche by a regional 
panel  from  developing  countries 
IV.  Prioritisation  of  the  highly-rated  proposals  based  on  coherence  and  comple-
mentarity with the Commission's existing research  portfolio,  partnership value, 
research  capacity  strengthening  and  training  value  and  regional  versus 
national  relevance. 
Following  these  procedures  the  Programme  Committee  consisting  of  the  repre-
sentatives of the Member States and associated countries,  give an  opinion on  the 
proposals.  Finally the  Commission decides to implement the selected projects and 
activities. 
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LIST OF COLLABORATING INSTITUTES BY REGION/COUNTRIES 
AFRICA 
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